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Abstract 
 
Peripheral Vascular Disease (PVD) has a major morbidity and mortality in the general 
population. The spectrum of PVD ranges from intermittent claudication to critical limb 
ischaemia. There is a high prevalence of intermittent claudication in the general population, 
however only five to ten percent will progress to more severe disease. The progression of 
disease is at present unpredictable. 
 
There is a growing awareness that patients with intermittent claudication may have differing 
propensities for developing cardiovascular morbidity and mortality.  
This study aims to investigate the relationship between the endothelial response to exercise in 
the macro and microcirculation and correlate this with plasma inflammatory cytokine levels, 
plasma oxidative state and a marker of acute kidney injury in patients with peripheral 
vascular disease and healthy controls. 
This information may lead to a new screening test for patients with an increased risk of 
disease progression who once identified could be better managed to reduce their risk. 
Furthermore potential new cytokine targets for halting disease progression and potential 
treatment will be investigated. 
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1. INTRODUCTION 
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1.1 Overview 
 
Atherosclerosis is a widespread, chronic progressive disease that mainly involves medium-
sized arteries and clinically presents varyingly as ischaemic heart disease, cerebrovascular 
disease, reno-vascular disease or peripheral arterial occlusive disease (PAOD). 
 
This study has focussed on clinically manifest atherosclerosis of the lower extremity arteries; 
the local and systemic implications. The term PAOD is synonymous with peripheral artery 
disease (PAD) and peripheral vascular disease (PVD). The clinical manifestations of PAOD 
cause acute and chronic illness, and are associated with decrement in functional capacity and 
quality of life, limb amputation, and increase in the risk of death (Hirsch et al., 2006). 
 
Peripheral arterial occlusive disease frequently coexists with vascular disease in other parts of 
the body. (Serrano Hernando, 2007). Approximately 50,000 patients in England and Wales 
are admitted to hospital each year due to PAOD. Although PAOD is a manifestation of 
systemic atherosclerosis and associated with an increased risk of death and ischemic events, it 
may be under diagnosed in primary care practice (Braunwald, 1997). 
 
In view of its high prevalence, high rates of nonfatal cardiovascular ischaemic events, 
myocardial infarction, stroke and other thromboembolic events, increased mortality, and 
diminution of quality of life, the consequences of PAOD in the developed world are 
significant (Hirsch et al., 2006). 
 
Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, which 
develops in a limb during exercise and is relieved with rest. IC is the main symptom of 
peripheral arterial disease (Bendermacher BLW, 2006). 
 
Peripheral arterial disease affects 20% of people over 70 years of age and 4% to 12% of the 
population aged 55 to 70 years. Approximately 40% of those affected with peripheral arterial 
disease commonly complain of intermittent claudication. Peripheral arterial occlusive disease 
is a progressive disorder irrespective of symptomatic improvement in many patients (Robless 
P, 2008). In the United Kingdom, there is a five per cent prevalence of intermittent 
claudication over the fifth decade of life (Leng et al., 1996). 
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Patients with stable intermittent claudication, are usually managed conservatively by 
optimising the risk factors such as smoking cessation, exercise, pharmacological treatment of 
hypertension, diabetes mellitus, obesity and hypercholesterolemia (Norgren L, 2007).  
Studies suggest that exercise (walking to the level that causes pain, three times a week) can 
relieve intermittent claudication for many people (Smith et al., 1998).  In the general 
population, regular exercise is thought to decrease the risk of future cardiovascular disease 
and improve health. Supervised exercise therapy significantly increases pain-free and 
maximal walking distance in patients with intermittent claudication (Regensteiner and Hiatt, 
2002). 
 
Despite the relatively benign prognosis for the affected leg, intermittent claudication is an 
indicator for the development of systemic atherosclerosis (Criqui, 2001).  Atherosclerosis is 
considered a systemic disease; therefore patients with proven atherosclerotic disease are 
likely to have similar lesions in other vascular beds. Patients with peripheral arterial occlusive 
disease (PAOD) are especially prone to widespread atherosclerotic disease (Clement, 2000). 
Compared with age-matched controls, people with intermittent claudication have a three- to 
six- fold increased chance of dying as a result of cardiovascular events (Robless et al., 2007). 
 
Evidence is also accumulating that exercise itself may be responsible for the adverse 
inflammatory changes implicated in this significant cardiovascular mortality. In patients with 
intermittent claudication by exercise, provoked tissue ischaemia causes a local pathologic 
response followed by reperfusion and potentially deleterious systemic manifestations (Joras 
and Poredoš, 2008). Tissue ischaemia evokes anaerobic metabolism that enhances the 
formation and accumulation of anaerobic metabolites and synthesis of free oxygen radicals 
that cause functional damage to metabolic processes in ischaemic tissues.  
During reperfusion, these anaerobic metabolites are released into the circulatory system with 
possibility of distant organ damage (Coolen et al., 2002) 
 
Revascularisation is believed to have beneficial consequences for ischaemic tissue by 
improving the energy supply and removal of the accumulating anaerobic metabolites.  
However, reperfusion is associated with introduction of anaerobic metabolites from the 
region of local ischaemia to the systemic circulation, thus predisposing to serious metabolic 
derangement and further local tissue injury (Tisi and Shearman, 1998a). Revascularisation of 
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an ischaemic limb can result in a number of systemic problems characterized by metabolic 
acidosis, hyperkalaemia, myoglobulinaemia, myoglobulinuria and renal failure (Weitz et al., 
1996). 
 
1.1.1. Ischaemia-Reperfusion (IR) Injury 
The prompt reperfusion of ischemic tissue is critical for restoring normal function. However, 
this return of blood flow can paradoxically produce a progressive destruction of reversibly 
damaged cells, thereby leading to tissue dysfunction and infarction. This "reperfusion injury" 
has a multifactorial aetiology but appears to be strongly associated with an inflammatory 
response. With the return of blood flow, several inflammatory processes may occur to 
potentiate ischemic injury by leukocyte adhesion, infiltration and free radical release (Clark 
et al., 2007).  It has also been defined as the conversion of the reversibly injured to 
irreversibly injured tissues after restoration of blood supply (Parums, 1990). The IR injury is 
characterised clinically by leg pain, leg swelling, paraesthesia, tenderness and impaired limb 
movement. The basic pathophysiological process is most probably oxidative stress as a 
consequence of free radical generation. It occurs if the production of free radicals is excessive 
due to internal or external factors and if the protective mechanisms are exhausted. (Shearman 
and Simms, 1988) In patients with intermittent claudication, in every ischaemia – reperfusion 
cycle, there is an inflammatory response with an increase in the baseline of markers of 
chronic inflammation (Joras and Poredoš, 2008). 
 
The biochemical and microvascular features include free radical production, complement 
activation, leucocyte-endothelial cell adhesion, platelet aggregation, increased microvascular 
permeability and decreased endothelial relaxation (Weitz et al., 1996). During a period of 
ischaemia, a large fraction of cells will undergo biochemical and pathological changes 
associated with anoxia but remain potentially viable. These potentially viable cells are 
therefore the ‘battleground' in the reperfusion period. After reperfusion, it is difficult to know 
whether damaged cells were truly part of the ‘potentially viable' group. The concept of 
reperfusion injury can only be established if an intervention can unequivocally be 
demonstrated to salvage viable cells and improve outcome after reperfusion (Becker, 2004). 
 
The biochemical mediators generated in the ischaemic limb may be responsible for acute 
transient endothelial perturbation at distant sites. Indeed, in claudicants maximal exercise 
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induces increased intestinal permeability and urinary albumin excretion, which probably 
reflects a generalized increase in vascular permeability. It has been shown that there are 
increases in urinary microalbumin excretion, neutrophils and plasma thromboxane after 
exercise in claudicants. This low-grade ischemia-reperfusion in claudicants leads to damage 
of local tissues and remote organs (Wijnen et al., 2001). 
 
The results lend further support to the concept of ischaemia-reperfusion events in patients 
with intermittent claudication, leading to a systemic increase in vascular permeability as a 
result of endothelial dysfunction. (Khaira et al., 1995).  Acute impairment in endothelial 
function may be prevented by antioxidant treatment. It is noteworthy that antioxidant therapy 
has been linked to a reduction in cardiovascular events, although this beneficial effect was 
not observed in other studies (Boaz et al., 2000). 
 
Considering the systemic consequences of peripheral arterial occlusive disease, it is important 
to study the pathophysiological consequences of repeated ischaemia reperfusion injury in this 
group of patients.   At present, there is inadequate research on the effect on systemic 
endothelial function, the biochemical, immunological and inflammatory mediator profiles of 
repeated ischaemia reperfusion injury. The result of this study would improve our knowledge 
of PAOD, ischaemia reperfusion injury, and potentially inform future management strategies 
for patients with intermittent claudication. 
 
Preliminary studies in our department have demonstrated that patients who have PAOD 
develop I-R injury leading to local and systemic inflammatory response such as renal tubular 
injury. N-acetyl-β-D-Glucosaminidase (β-NAG), a sensitive and specific marker of renal 
injury was found to be elevated in the urine, suggesting renal tubular injury in claudicants 
(Morsey et al., 2003).   
1.1.2. Clinical Relevance of the Study 
The cumulative effect of repeated low-grade inflammatory responses during intermittent 
claudication may have an unfavourable effect on the progression of atherosclerosis. This may 
also explain why patients with intermittent claudication are subject to a massive increase in 
cardiovascular morbidity and mortality rates (Joras and Poredoš, 2008). These findings may 
also have important therapeutic implications in PAOD patients. By elimination of obstruction 
to flow in the circulation it is possible not only to prevent loss of an ischaemic leg and to 
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improve quality of life, but through elimination of transient episodes of ischaemia, it is 
theoretically possible to prevent progressive damage of local and remote organs. One study 
showed that percutaneous transluminal angioplasty (PTA) reduced the free oxygen radical 
challenge and decreased or eliminated oxidative stress (Lewis et al., 1999). 
  
Exercise training treatment modalities of PAOD patients have adverse systemic effects, 
however some studies indicated that prolonged training is associated with the reduction of 
inflammatory markers and symptomatic improvement. This may be caused by the exhausting 
of inflammatory potential during repeated exercise (Tisi et al., 1997). Some studies also 
suggest that vitamins and prostaglandins reduce oxidative stress in claudicants and can have 
therapeutic applications (Wijnen et al., 2001). Furthermore, preventive measures and drugs 
used in secondary prevention of PAOD can probably modify oxidative stress (O'Driscoll et 
al., 1997). It is not clear why most claudicants remain clinically stable or improve and some 
worsen in their clinical condition. It may be that there is a phenotype associated with 
peripheral vascular disease which is more prone to worsening of disease manifestation and in 
fact may even be more susceptible to sytemic effects. 
 
1.1.3. Justification of the Study 
 
Imprtant issues to address in investigating PAOD include why more PAOD patients succumb 
to myocardial infarction and develop multiple organ failure. Also: What is the role of 
inflammatory mediators and oxidative stress/ defense in the aetio-pathogenesis of the 
potentially systemic nature of PAOD.  
 
Much work has been done on coronary IR injury and revascularisation, however there has 
been far less investigation of PAOD patients at a clinically early stage when intermittent 
claudication is the only symptom in the majority of patients.  It may be that intervention, 
medical or surgical, at this stage may improve cardiovascular mobidity, end organ injury and 
limb loss before the terminal stages of the disease, characterized by critical limb ischaemia, 
manifest.  
 
Measures being taken to prevent PAOD appear ineffective because the major risk factors 
such as obesity, smoking, hyperlipidaemia, diabetes mellitus and hypertension are believed to 
be on the increase.  However, evidence is also accumulating that lipid hypothesis may not be 
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the sole pathologic basis of atherogenesis. Recent developments in immunology and cell 
biology have demonstrated the importance of inflammation in the pathogenesis of post-
ischemic organ dysfunction. Whereas prolonged ischemia causes anoxic cell death, recent 
evidence suggests that sub lethal injury may be amplified by inflammatory and cytotoxic 
injury cascades activated during the reperfusion period (Chamoun et al., 2000).  
 
 There is growing acceptance of the role of oxygen derived free radicalsfree radicals in 
atherogenesis, the nature of their involvement is less clear. A burst of reactive oxygen species 
(ROS) have been well described with the first moments of reperfusion of acute ischaemia and 
is associated with injury (Droge, 2002). ROS generation is appreciated to occur during 
ischemia despite the low oxygen tension, from a likely mitochondrial source, and ROS-
induced ROS release may amplify release. The burst of ROS seen during reperfusion may 
originate from a different cellular source than during ischemia and is not yet fully identified. 
ROS and cellular reduction-oxidation (redox) conditions regulate a large number of vital 
pathways (energy metabolism, survival/stress responses, apoptosis, inflammatory response, 
oxygen sensing) (Becker, 2004). 
 
 The main origin of oxygen derived free radicals (OFR) is from the uric acid pathway in 
which xanthine dehydrogenase in a two-stage reaction, converts hypoxanthine (generated 
from adenosine triphosphate (ATP) metabolism) via xanthine to uric acid under normal 
physiological conditions (Balaban et al., 2005).  However, during ischaemia, xanthine 
dehydrogenase is converted to xanthine oxidase enzyme (Error! Reference source not 
found.).   This process generates substantial amounts of OFR also known as reactive oxygen 
species (ROS), which may account for IR injury.  It is yet unclear if ROS is the initiator or 
the culprit for the entire consequences of IR injury both locally and systemically.   
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FIGURE 1-1. THE ROLE OF XANTHINE OXIDASE IN THE SYNTHESIS OF FREE RADICALS. 
 
An overview of xanthine metabolism leading to ischaemia reperfusion injury is shown in 
(Figure 1-2) During ischaemia, transmembrane ion gradients are dissipated, allowing 
cytosolic concentrations of calcium to rise, which in turn, activates protease that irreversibly 
converts XDH, predominant in vivo, into XO. At the same time, cellular ATP is catabolized 
to hypoxanthine, which accumulates. During the reperfusion, XO, using readmitted oxygen 
and hypoxanthine, generates superoxide and hydrogen peroxide (McCord and Fridovich, 
1968)..  
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FIGURE 1-2. ISCHAEMIA-REPERFUSION HYPOTHESIS 
 
During ischaemia, transmembrane ion gradients are dissipated, allowing cytosolic 
concentrations of calcium to rise, which in turn, activates protease that irreversibly converts 
XDH, predominant in vivo, into XO. At the same time, cellular ATP is catabolized to 
hypoxanthine, which accumulates. During the reperfusion, XO, using readmitted oxygen and 
hypoxanthine, generates superoxide and hydrogen peroxide (McCord and Fridovich, 1968). 
 
It is believed that the process of intermittent claudication evokes repetitive reperfusion. 
Angiogenesis is said to occur and patients over time are expected to develop collateral blood 
supplies and to improve symptoms as well as outcome. However, it is unclear why some 
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claudicants deteriorate with time to require intervention.  It is possible that exercise has an 
associated risk to patients with intermittent claudication via IR injury (Joras and Poredoš, 
2008). 
 
This study aims to address the effect of the ischemia reperfusion associated with exercise in 
claudaicanta and potentially provide possible direction for future management of peripheral 
arterial disease. Treadmill walking was used as a model to recreate intermittent claudication 
in patients and various parameters were assessed in order to assess its systemic effects 
focussing on endothelial function, oxidative stress and renal organ damage.  
 
1.1.4. Hypotheses 
Ischaemia reperfusion injury in peripheral arterial occlusive disease may cause differential 
responses in some patients with intermittent claudication compared to others. These 
differential responses may be systemic inflammatory responses associated with altered 
plasma oxidative state. The differential response to ischaemia reperfusion injury may 
manifest as altered systemic endothelial function and end organ injury. 
 
1.1.5. Study Objectives 
To establish whether there is a subgroup of claudicants who have a malignant form of 
atherosclerosis with impaired endothelial cell function and end organ function.  
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1.2 The circulatory system 
1.2.1. Introduction 
The circulatory system is composed of the cardiovascular and the lymphatic systems. The 
cardiovascular system consists of the heart, vessels and the blood. The lymphatic system 
consists of lymphatic capillaries and lymph vessels.  This is a very complex system, which 
comprises a large number of vessels that play an integral role in the movement of blood, but 
most of all, through this extensive network of arteries, capillaries, and veins is that cell 
homeostasis is maintained including cellular function, absorption of essential nutrients and 
removal of cellular and metabolic waste products (Pugsley and Tabrizchi, 2000). 
 
1.2.2. Structure of the vascular wall 
 
The arterial wall is composed of three layers (Figure 1-3). 
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These are the tunica intima (innermost layer), the tunica media (middle layer) and the tunica 
adventitia (outer layer) (Levick, 2003).  
 
The tunica intima, consists of a single layer of endothelial cells mounted on a basement 
membrane (or basal lamina). The endothelial layer is the principal barrier to plasma proteins 
and also secretes many vasoactive products, but it is mechanically weak. Below this there is a 
sub-endothelial fibro-elastic connective tissue layer and an organised layer of internal elastic 
lamina that provides flexibility and stability for endothelial cells. Also in close apposition to 
the endothelial cells are perivascular cells or pericytes. Pericytes are mesenchymal cells with 
cytoplasmic processes that surround the endothelial (Sims, 1986) . The pericytes are 
multipotential stem cells that are fully capable of differentiating into many types of cells 
including fibroblasts, osteoblasts, adipocytes, connective tissues cells, and vascular smooth 
muscle cells (Hirschi and D'Amore, 1996). They provide the endothelial cells, which lack 
their own blood supply, with a balanced cellular microenvironment. Pericytes also manifest 
contractile ability, suggesting that these cells possess the necessary actin and myosin proteins. 
Thus, they can therefore potentially modulate blood flow (Kelley et al., 1987). 
 
Endothelial cells perform a critical role in all aspects of tissue homeostasis. They regulate 
vascular tone by an interaction with components of the peripheral nervous system and are 
involved in thrombolysis and coagulation processes. They are also involved in inflammatory 
endothelium
smooth muscle
between elastic layersadventitia
basement membrane
artery arteriole capillary
FIGURE 1-3. LAYERS OF THE VESSEL WALL 
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and immunological processes and they have been implicated in atherosclerosis and occlusive 
vascular disorders (Pugsley and Tabrizchi, 2000). The endothelial cell surface consists of a 
layer of surface glycoprotein (glycocalyx), which provides not only a local charged barrier to 
the transendothelial migration of blood cells and plasma proteins under normal physiological 
conditions but is also very metabolically active. 
 
The tunica media contains predominantly smooth muscle cells and elastin fibers. These cell 
layers tend to be more highly organized in larger arteries owing to the function that these 
vessels play in the movement of large volumes of blood. The spindle-shaped smooth muscle 
cells are arranged circularly and embedded in a matrix of elastin and collagen fibres. Sheets 
of elastin (the internal and external elastic laminae) mark each boundary of the media. In 
some places, the endothelial cells project through gaps in the internal elastic lamina to make 
contact with smooth muscle cells in small arteries, but the exact significance of this contact 
remains unclear. The media supplies mechanical strength and contractile power. 
 
The last and outermost layer of the blood vessel is the tunica adventitia and  is almost entirely 
composed of fibro-elastic connective tissue with no distinct outer border. Both lymphatic and 
nerve plexi are observed in the adventitia along with the vasa vasorum, which are small blood 
vessels supplying the blood vessels themselves. In larger blood vessels, the simple diffusion 
of oxygen and carbon dioxide across the vessel wall is limited, so the vasa vasorum penetrate 
into the outer media too, thus they provide these larger arteries and veins with adequate 
nutrients and oxygen (Levick, 2003). 
1.2.3. Functional class of vessels 
 
The vessels of the arterial system are disposed into a hierarchy of functional classes. These 
classes are: Elastic arteries; Conduit (muscular) arteries; resistance arteries; exchange vessels; 
capacitance vessels. Each class has a specifically adapted vessel wall to suit its role. 
 
Elastic Arteries are the largest arteries (1-2 cm; eg aorta and iliac arteries) and receive the 
stroke volume. They act to smooth the pulsatile blood flow from the heart. Their media is rich 
in elastin – hence very distensible (up to ~10 %). Elastin is an extracellular protein six times 
more distensible than rubber. Collagen, also a protein in the media is 100 times stiffer than 
elastin. This forms a network and prevents over distension of the vessel. 
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Conduit (muscular) arteries are medium to small arteries (0.1-1 cm). The media contains 
more smooth muscle and is thicker relative to the lumen than in elastic arteries and has a rich 
autonomic innervation. Conduit arteries contract and relax in response to nervous and 
humoural factors (e.g. trauma, blood pressure, vasospastic angina) 
 
The mean drop in pressure from aorta to radial artery is only about 2mm Hg, the major 
pressure drop occurs across the resistance vessels. These include the terminal arteries (100 – 
500 µm diameter) and arterioles (< 100 µm diameter with a single layer of muscle). Terminal 
arteries are richly supplied by sympathetic vasoconstrictor fibres and have a thick muscular 
wall relative to the lumen. These vessels have a high resistance as the lumen is narrow and 
the number of vessels is relatively small. As they account for most resistance, they can act as 
regulators of local tissue perfusion with vasoconstriction increasing resistance and 
vasodilatation decreasing resistance. 
 
Exchange vessels are the site of gas and metabolite exchange; the capillaries are numerous 
and tiny (4-7µm). Most cells are within 10-20 µm of a capillary. The capillary wall is a single 
layer of endothelial cells (0.5 µm thick), which facilitates rapid diffusion. Although very 
narrow, they have a very large combined cross sectional area, hence a low resistance and 
modest pressure drop. Also as a result of larger area, flow slows; each red cell takes about 
0.2-2 seconds to traverse. 
 
Capacitance vessels act as blood reservoirs. Venules are 50 – 200 µm diameter and coalesce 
into veins. They have a thin intima containing collagen and smooth muscle. Intima of limb 
veins contains semi-lunar values to ensure directional flow. Venules and veins are far more 
numerous than arterioles and arteries, hence net resistance is low. Because of their large 
number and size they contain two thirds of the circulating blood volume. Many peripheral 
veins are innervated by vasoconstrictor nerve fibres and hence can regulate the volume in 
capacitance vessels in times of stress. 
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1.2.4. The endothelium and endothelial dysfunction 
The endothelium used to be thought of as an inert barrier, it is now known to be an active 
component of the vasculature, regulating vascular homeostasis and producing and being acted 
upon by a host of vaso-active compounds, some of which are listed below. (Table 1) 
 
TABLE 1. SUBSTANCES PRODUCED BY ENDOTHELIAL CELLS 
Substance Activity 
Prostacylin vasodilation, inhibits platelet aggregation 
Nitric oxide (EDRF) vasodilation, inhibits platelet adhesion and 
aggregation 
Endothelin Vasoconstriction 
Tissue plasminogen activator (tPA) regulates fibrinolysis 
Thrombomodulin anticoagulant activity 
Thromboplastin promotes blood coagulation 
Platelet activating factor (PAF) activation of platelets and neutrophils 
Von Willebrand Factor promotes platelet adhesion and activation of 
blood coagulation 
Endothelium-derived 
hyperpolarizing factor (EDHF) 
vasodilation (especially small resistance 
vessels) 
Prostanoid vasoconstriction (large arteries) 
 
The principal properties of endothelial cells have been thought to be maintaining proper fluid 
and solute flux and providing a barrier between the blood and tissues for a long time. 
However, with the development of novel techniques in molecular biology, immunological 
methods and non-invasive assessing methods have become clear that endothelium have 
several different and very important functions.  
 
 35 
 
Endothelial cells are able to sense changes in blood pressure, oxygen tension and blood flow 
by as yet unknown mechanisms. In response to changes in local conditions they respond by 
secreting substances which have powerful effects on the tone of vascular smooth muscle and 
haemostatic roles among others. Properties of endothelium may be defined as follows: 
1. Permeability and its regulation, creating an adjustable porous membrane, which permits 
the rapid transfer of metabolites and signalling molecules between blood and tissues. 
2. Local Vascular Control, because they are directly exposed to the shearing action of the 
bloodstream, endothelial cells are ideally situated to sense the local blood flow and to elicit 
local flow-regulating responses in the underlying vascular smooth muscle. They do this by 
synthesizing and secreting a number of vasoactive agents, including nitric oxide, prostacyclin 
and endothelin. 
3. Enzymatic actions on plasma, by means enzymes from the surface of the endothelium that 
act on certain plasma constituents. 
4. Antihaemostatic and haemostatic roles, through endothelial secretions such as nitric oxide 
and prostacyclin, which not only affect vascular tone but also inhibit the aggregation of 
platelets, and thus inhibit blood clotting. 
5. Defence against pathogens, by producing adhesion molecules induces circulating white 
cells to emigrate into the affected tissue. At the same time endothelial permeability to 
immunoglobulins is dramatically increased by the active formation of endothelial cell gaps. 
6. Angiogenic role, initiating the development of new blood vessels. 
7. Atherogenic role in arterial disease, because changes in endothelial function are important 
in the development of atheromatous plaques, which are a patchy thickening of the walls of 
large arteries by plasma-derived cholesterol, fibrin and cells. 
 
Many substances involved in several vascular functions are released or expressed at the cell 
surface of endothelial cells. For example, the primary cofactor for platelet adhesion to 
extracellular matrix components, von Willebrand factor (vWF), is synthesised and locally 
secreted by endothelial cells. vWF secretion is probably mediated by elevation of 
intracellular ionised calcium and/ or activation of protein kinases (Pearson, 1994). Levels of 
vWF in patients with vascular disease are elevated and this is a reliable marker of ongoing 
endothleial dysfunction (Poston and Taylor, 1995, Stehouwer et al., 1995, Petty and Pearson, 
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1989). Vane and colleagues in 1976 discovered that blood vessels secrete prostacyclin (PGI2), 
a vasodilator agent and an inhibitor of platelet aggregation. In 1980 Furchgott and Zadwadski 
discovered an endothelium-derived vasodilator agent and it was first called “endothelium-
derived relaxing factor” or EDRF, but it was soon identified as the simple molecule, nitric 
oxide (NO).  In 1989, molecular biology studies by workers in Japan led to the discovery of a 
third endothelium-generated vasoactive factor, endothelin, and this time a vasoconstrictor 
agent. All three substances, prostacyclin, nitric oxide and endothelin, are secreted as they are 
produced. There is no vesicular storage for later release. 
 
Physical or biochemical injury to the endothelium results in impaired production of 
homeostatic mediators such as nitric oxide. This results in an intima that is characterized 
by enhanced thrombus formation, aberrant vessel tone, and dysregulated vascular smooth 
muscle cell growth. (Figure 1-4) 
 
endothelial cell
hypertension
hypercholesterolaemia
diabetes mellitus
cigarette smoking
hyperhomocysteinemia
vasoconstriction
smooth muscle cell proliferation
platelet aggregation
inflamation
FIGURE 1-4. ENDOTHELIAL DYSFUNCTION AND NO (RUSSO ET AL., 2002). 
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In the setting of clinical conditions associated with endothelial dysfunction, a decrease in NO 
or an increase in reactive oxygen species will result in decreased NO bioavailability. This 
leads to vasoconstriction, vascular smooth muscle cell proliferation, platelet aggregation and 
inflammation. Worsening lesions of atherosclerosis are associated with progressive 
worsening of endothelial dependent relaxation of the vessel wall (Verbeuren et al., 1986). 
 
1.2.5. L-arginine metabolism and nitric oxide synthesis 
 
Arginine has been considered as a non-essential amino acid, which could become essential in 
some disease states. L-arginine is a cationic amino acid necessary for maintaining growth rate 
in the young animal; however low levels of arginine do not affect health, normal eating 
pattern, or reproductive capability as demonstrated in adult rats and dogs. System y+ is the 
primary carrier mediating facilitated transport of L-arginine, in which the negative membrane 
potential leads to an accumulation of cationic amino acids within the cell (Mann et al., 2003). 
Arginine synthesis in endothelial cells is increased in sepsis, infection and inflammation 
(Wagner et al., 1983). Conversely, L-arginine levels have been found to be significantly 
lower in adult rats with diabetes mellitus and some nephropathies. Also in humans 
intravenous or oral administration of L-arginine is associated with a reduction in vascular 
resistance (Reyes et al., 1994). 
 
A proposed model of L-arginine anabolism is shown in Figure 1-5. Via the constitutive or 
inducible forms of NO synthase (NOS) in endothelial cells ((Fleming et al., 1994, Moncada 
and Palmer, 1991), L-arginine is converted to L-citrulline giving NO as a coproduct. L-
citrulline is then converted to arginosuccinate via arginisuccinate synthetase in the presence 
of L-arginine, L-citrulline and ATP as a cofactor. Aginosuccinate lyase catalyses the 
conversion of arginosuccinate into L-arginine and fumarate which is recycled via the Krebbs 
cycle into aspartic acid to be used in the synthesis of arginosuccinate releasing ammonia. L-
citrulline may be converted directly into L-arginine via a transamination reaction. 
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The conversion of L-arginine to L-citrulline and the inorganic radical gas NO is catalysed by 
a family of isoenzymes called nitric oxide synthases (NOS; (Knowles and Moncada, 1994). 
In endothelial cells it is now known that NOS needs the substrate L-argninine, molecular 
oxygen and NADH as cosubstrates and tetrahydrobioptherin (BH4), flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN) and protoporphyrin IX haem as cofactors. 
The necessities of specific cofactors to catalyse the reaction is different depending on the 
source of the tissue. 
 
L-arginine
L-citrulline
arginosuccinate
L-ornithine
urea
NO
fumarate
Krebs
cycle
endothelial cell
L-citrulline
NH3
L-arginine
aspartic acid
glutamic acid
L-glutamine
-
a
b
c
d
e
FIGURE 1-5. L-ARGININE METABOLISM IN ENDOTHLEIAL CELLS. A NITRIC OXIDE 
SYNTHASES, B ARGINOSUCCINATE SYNTHASES, C ARGINOSUCCINATE LYASE, D ARGINASE, E 
TRANSAMINATION REACTION, - INHIBITION. 
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The most common and rapid way for NO catabolism is the reaction of NO with water to form 
nitrites and nitrates (Butler et al., 1995). No can also be released into the blood stream and 
instantly destroyed by haemoglobin (Anggard, 1990). However, in cells depleted of L-
arginine, or when L-arginine concentration becomes a rate limiting factor for NO synthase 
activity, cells can generate the reactive oxygen intermediate superoxide anion (02-) and 
hydrogen peroxide (H202; (Heinzel et al., 1992)).  
L-arginineL-citrulline
endothelial cell
L-arginine
L-citrulline
N -hydroxyarginine
NOL-citrulline ONOO- ONOOH
NO2 NO3
-
+ +
OH H+
a
b
O2
- H+
 
FIGURE 1-6. NITRIC OXIDE METABOLISM. NO NITRIC OXIDE, O2- SUPEROXIDE ANION, ONOO- 
PEROXYNITRITE, NO2 NITROGEN DIOXIDE, NO3- NITRATE, OH HYDROXYL RADICAL SPECIES, A NΩ-
HYDROXYARGININE MONO-OXYGENASE. 
 
Assaying neuroprotective and neurotoxic mechanisms in neurons, a mechanism has been 
proposed by which NO can be inactivated by O2- generating the alternative redox states of 
NO: NO and nitrosonium ion (Figure 1-6). These compounds lead to the formation of 
peroxynitrite which has been shown to be an initiator of lipid peroxidation and cytotoxicity in 
several cell types (Lipton et al., 1993). These reactions for NO catabolism are important in 
cells which release O2- in some pathological conditions such as hyperglycaemia in diabetes 
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(Poston and Taylor, 1995), hypercholesterolaemia or in hypoxic tissue (Olsson and Pearson, 
1990).  
 
NOS is a family of proteins which have been characterised, purified and cloned and act in a 
sequence of reactions with multiple physiological roles. At least three different NOS have 
been cloned and characterised: nNOS or type I, iNOS is type II and eNOS or type III. 
However, there are other NOS functionally distinct from these isoforms (Sessa, 1994). An 
inducible isoform of the constitutive eNOS has been found in endothelial cells (Forstermann 
et al., 1991). This enzyme is called eiNOS (or type Ib), is similar to eNOS but is cytosolic and 
not inhibited by calmodulin antagonists. The chromosomal localisation is unknown but it 
appears to be at the same location as eNOS (Knowles and Moncada, 1994). eiNOS can be 
activated by cytokines in bovine aortic endothelial cells (Lamas et al., 1991). The activation 
of this enzyme has a lag phase of two hours, reaching a maximum between six and 12 hours 
and is inhibited by glucocorticoids and protein synthesis inhibitors (Moncada et al., 1991) 
1.2.6. Nitric Oxide and the endothelial cell – smooth muscle cell 
unit. 
Nitric oxide (NO) is a lipophilic, freely diffusible, soluble gas. It has several important 
cardiovascular actions. It is a powerful vasodilator; it inhibits vascular smooth muscle 
contraction, and platelet aggregation. Also, it inhibits the nuclear transcription of leukocyte-
binding adhesion molecules, such as vascular cell adhesion molecules (VCAM), en 
endothelium. It inhibits vascular smooth muscle proliferation and loss of these various 
inhibitory effects contributes to arterial disease. 
 
The tissue half-life of NO is only seconds because it reacts very rapidly with oxygen-derived 
free radicals, namely superoxide anions, and with haemoglobin. Because its half-life is so 
short, NO must be generated continuously to be effective. It is produced from the amino acid 
L-arginine, which enters the cell via an amino-acid transporter in the cell membrane. NO is 
cleaved off L-arginine by an enzyme, nitric oxide synthase (NOS). Nitric oxide synthase 
occurs in three isoforms and requires tetrahydrobiopterin as a cofactor. Messenger RNA for 
the production of NOS is upregulated by chronic shear stress and by oestrogens. If NO 
production is interrupted, arteries constrict. NO production can be interrupted by giving 
analogues of arginine such as N-monomethyl-L-arginine or nitroarginine methyl ester. These 
enter the cell and block the synthase enzyme. 
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NO diffuses into the underlying vascular smooth muscle. There it has two actions, the first of 
which is more important. NO combines with the haem group in the enzyme guanylyl cyclase 
to activate the enzyme. The enzyme catalyses the production of cyclic guanosine 
monophosphate (cGMP) from guanosine triphosphate (GTP). The cGMP activates a protein 
kinase which by a number of phosphorylating actions, reduces the cytosolic Ca2+ 
concentration in the vascular myocyte. This leads to vasodilatation. 
 
The rate of production of NO is determined by the activity of NOS. Three main factors affect 
overall NOS activity: pharmacological agonists, shear stress due to blood flow, and inducible 
NOS formation. The isoform of NOS that is normally present in endothelium is called cNOS 
or NOS-III. It is bound to the cell membrane and is activated by calcium-calmodulin, a 
complex that is formed when cytosolic Ca2+ increases and reacts with the protein calmodulin. 
Ca2+
adensine
bradykinin
ATP
histamine
L-citrulline
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NO˙cGMPrelaxation
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FIGURE 1-7. ENDOTHELIAL CELL – SMOOTH MUSCLE CELL UNIT. VASOACTIVE AGONISTS SUCH AS 
BRADYKININ, ATP, AND HISTAMINE ELEVATE INTRACELLULAR CA2+ AND ACTIVATING ENOS AND 
CGMP-DEPENDENT CA2+-ACTIVATED K+ CHANNELS, WITH THE ENSUING MEMBRANE 
HYPERPOLARIZATION INCREASING THE DRIVING FORCE FOR ARGININE ENTRY VIA SYSTEM Y+ 
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Thus any external agent that raises cytosolic Ca2+ from its basal level of ≤ 0.1µM to ≥ 1 µM 
will enhance NOS-III activity and NO secretion. Such agonists agents include bradykinin, 
thrombin, substance P, ATP, ADP, acetylcholine, vasoactive intestinal polypeptide, insulin 
and in some tissues histamine. (Figure 1-7) However, not all vasodilator agents act via the 
endothelium. 
 
Shear stress is the force exerted on the vessel wall by the sliding action of flowing blood and 
it depends on the rate at which the blood is sliding along and on the blood viscosity. The 
shear stress created by flowing blood is probably the most important stimulus, normally, for 
the nuclear transcription of NOS and for a continuous, basal production of NO. Shear stress 
and NO give rise to an important form of vascular regulation called “flow-induced 
vasodilatation” in medium-sized arteries. During the exercise, dilatation of down-stream 
resistance vessels by other mechanisms causes an increase in blood velocity in the parent, 
conduit artery. The increased shear stress in the conduit artery causes it to dilate, due to 
endothelial secretion of NO. This helps the parent vessel to deliver blood to its dilated 
branches. Shear stress, not flow itself, is the stimulus for increased NO production, because if 
the blood viscosity is increased experimentally, to increase the wall shear stress, 
vasodilatation can occur at a fixed flow. 
 
Although shear stress-induced vasodilatation is due, at least in part, to increased nitric oxide 
secretion, the linking pathways are not yet clear. Activation of mechanosensitive ion channels 
has been suggested and a tyrosine kinase may also be involved. (Levick, 1997)  
 
Even when NO and prostacyclin production have been blocked pharamacologically, 
stimulation of small artery endothelium by agonists such as acetylcholine and bradykinin can 
still cause an initial hyperpolarization and relaxation of vascular myocytes. The 
hiperpolarization elicits vascular relaxation and it is caused by vasodilator product called 
endothelium derived hyperpolarizing factor (EDHF).  This is a small molecule whose 
importance relative to NO varies with vessel size. In large arteries, NO is the dominant 
endothelial-derived vasodilator, but in small resistance vessels EDHF may dominate. 
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As described above, not all cases of non-NO endothelium-dependent hyperpolarization of 
arterioles involve a released, humoral factor. In the small arterioles of some tissues, where the 
ratio of endothelium to vascular myocyte is high, acetylcholine hyperpolarize both the 
endothelial cell and vascular myocyte when the myoendothelial gap junctions are intact; but 
if the connexons are blocked chemically, acetylcholine causes hyperpolarization of the 
endothelial cell but not the vascular myocyte. This implies that the myoendothelial gap 
junctions can transmit either a hyperpolarizing potential or small molecular weight 
hyperpolarizing factor directly from the endothelial cell to myocyte. 
 
Prostacyclin has similar actions to NO, but its production is not well maintained in contrast 
with the well-sustained production of NO. Prostacyclin is considered to be less important 
than NO. 
 
Endothelium produces two known vasoconstrictor substances. One is a prostanoid and the 
other is endothelin. Prostanoid may mediate the contractile response of certain large arteries 
to hypoxia. Endothelin is a peptide which elicits a powerful and unusually persistent 
vasoconstriction (Strachan and Webb, 2002) lasting 2-3 hours. There is three isoforms of 
endothelin, the chief one in endothelium being endothelin-1. As with the dilator products, 
endothelin is not stored but is secreted as soon as synthetized. There is a low, basal rate of 
synthesis, and this can be enhanced by angiotensin II, vasopressin, thrombin and hypoxia. 
Plasma levels are normally very low, but it does contribute a little to the basal tone of 
resistance vessels, helping to counterbalance the tonic dilator action of basal NO release 
(Levick, 2003). 
 
1.2.7. The Cutaneous Microcirculation 
The cutaneous microvasculature is disposed into two transversely arranged plexi. The upper 
plexus lies 1-1.5 mm below the skin surface, and the lower one is at the junction between the 
dermis and subcutaneous tissue. Paired ascending arterioles and descending venules connect 
the two plexi. The lower plexus is fed by vessels which perforate from the underlying 
muscles and subcutaneous fat (Figure 1-8) 
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Interconnections exist between ascending arterioles and descending venules within the 
dermis. From the upper layer, arterial capillaries arise to form the dermal papillary loops, 
which are nutritive to the skin (Figure 1-9) Pre capillary sphincters exist where the ascending 
arterioles divide to form the arteriolar component of the upper horizontal plexus. At the 
dermal subcutaneous junction, there are collecting veins with 2-cusped valves that are 
oriented to prevent the retrograde flow of blood. (Braverman, 2000b).  
 
Most of the microvasculature is contained in the papillary dermis 1-2 mm below the 
epidermal surface. In areas where the dermal papillae are not well developed, arterioles 
connect with capillaries that course close to the dermal-epidermal junction before the latter 
move deeper into the dermis to join the postcapillary venules in the upper horizontal plexus. 
The superficial horizontal plexus is a thermal radiator however thermoregulation is primarily 
achieved by the arterio-venous anastomoses. The arteriolar and venular sides of the 
microvasculature can be identified by the ultrastructure of the mural basement membrane 
upper horizontal plexus
lower horizontal plexus
dermal papillary loops
ascending arterioles and
descending venules
FIGURE 1-8. SCHEMATIC OF THE CUTANEOUS MICROCIRCULATION 
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material by means of electron microscopy (Braverman and Yen, 1977). Arterioles can be 
identified with certainty by the presence of an internal elastic lamina, a homogeneous 
basement membrane; capillaries, on the basis of a thin vascular wall containing pericytes; and 
venules, on the basis of thicker walls without elastic fibers and a multilaminated basement 
membrane. The elastic lamina in the arterioles is a discontinuous layer which gradually 
disappears from the arteriolar wall to form an external sheath just before the arteriole 
connects with the arterial capillary segment.   
 
Periadventitial cells (veil cells) are present around all microvessels. Their size and number 
appear to correlate with the thickness of the basement membrane material found in cutaneous 
vessels in diabetes and chronological aging. The contractile cells of vascular wall surround 
the endothelial cell tube in a manner suggesting specific functions. The smooth muscle cells 
in the arteriolar segment form a sleeve, whereas each pericyte in the postcapillary venular 
simultaneously makes many contacts with several underlying endothelial cells (Braverman, 
1989). 
 
The arterioles in the papillary dermis function as resistance vessels in the skin. In these 
arterioles, the endothelial cells are surrounded by two layers of smooth muscle cells. The 
cells in the inner layer are longitudinally oriented and those in the outer layer form a spiral. 
The basement membrane completely surrounds and encompasses the elastic fibers and 
smooth muscle cells. The inner smooth muscle cells and endothelial cells send cytoplasmic 
processes toward each other to make tight junctions through breaks in the basement 
membrane. The subendothelial elastic lamina appears as an interrupted layer between the 
endothelial and smooth muscle cells in cross-section. In longitudinal sections and in three-
dimensional reconstructions, the elastic lamina can be seen to be made up of interwoven 
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longitudinal fibres resembling a wire mesh fence. As the diameter of the arteriole decreases, 
the elastic fibres assume a progressively more peripheral position in the vascular wall. At the 
15 µm level, the elastic fibres have disappeared from the vascular wall and are present only as 
an incomplete sheath between the wall and the surrounding adventitial (veil cell) layer. This 
external elastin sheath disappears at the 10-12 µm level, which corresponds to the beginning 
of the capillary bed. The arterial capillary has an outside diameter of 10-12 µm and an 
internal endothelial tube diameter of 4-6 µm. Pericytes form tight junctions with endothelial 
cells through breaks in the basement membrane.  The walls of these capillaries vary from 2 to 
3 µm in thickness, but in a few instances the endothelial tube is surrounded by a wall only 
0.5-1 µm wide, in contrast to capillaries elsewhere in the body, where the vascular wall is 
usually only 0.1 µm wide. The venous capillary connects with the postcapillary venule, a 
vessel whose external diameter increases from 12 to 35 µm and whose endothelial tube 
diameter enlarges from 8 to 26 µm. The vessels in the papillary dermis are composed entirely 
of terminal arterioles, arterial and venous capillaries, and postcapillary venules but the 
majority of vessels, however, are postcapillary venules, the physiologically most reactive 
segment of the microcirculation. Here the inflammatory cells migrate from the vascular space 
into the tissues, and endothelial cells often develop intercellular gaps that result in increased 
vascular permeability in response to acute inflammation. The ultrastructural differences in 
basement membrane material between the arterial and venous components of the 
microcirculation are present in all areas of the skin (Braverman, 2000b). 
 
There are skin sites which have a high density of arterioles and venules and sites with 
predominantly nutritive capillary perfusion (Rendell et al., 1998), and skin areas 
predominantly arteriolar in composition, venular in composition, or essentially devoid of all 
microvascular elements, so skin microvasculature is not uniformly distributed. 
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Each dermal papilla is supplied by a single capillary loop, which has an intrapapillary and 
extrapapillary portion. The ascending limb of the loop arises from the horizontal plexus and 
passes either directly to a papilla or subdivides once t three times before giving rise to the 
final ascending limbs that enters individual papillae. The capillary loops of normal forearm 
and elbow skin can be divided into two segments: an intrapapillary and extrapapillary 
portion. The intrapapillary portion have the ultrastructural characteristics of an arterial 
capillary homogeneous appearing basement membrane without bridged fenestrations. The 
ascending limb in the extrapapillary portion is also an arterial capillary and the descending 
limb in the same portion has venous characteristics multilayered basement membrane. The 
intrapapillary arterial loop develops venous characteristics abruptly after the vessel left the 
dermal papilla proper. (Braverman and Yen, 1977). 
There are no ultrastructural differences between the capillary loops at different sites in the 
skin, including the lower leg; only their density varies. The ultrastructure of the arterioles and 
venules in the mid and lower dermis and in the lower horizontal plexus differ from the 
ultrastructure of comparable vessels in the superficial horizontal plexus in several ways: the 
FIGURE 1-9. PHOTOMICROGRAPH OF DERMAL PAPILLARY LOOPS 
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diameter are wider, the walls are thicker, smooth muscle cells or pericytes are present as 4-5 
layers in contrast to 1-2 layers in similar vessels of the superficial plexus and bundles of 
collagen fibrils in arterioles are present in subendothelial positions rather than in the 
periphery of the vascular wall. The arterioles and venules in the fat lobules are identical in 
structure and size to those of the lower horizontal plexus. Valve-containing vessels pass from 
the deep dermis into the superficial layer of the fat. Postcapillary venules join these large 
vessels from all directions. 
 
Direct canulation of human finger nailfold capillaries has demonstrated that the blood 
pressure is pulsatile in both the arteriolar and the venular limbs. Valves in collecting veins at 
the dermal-fat interface would seem to be appropriately placed to insure the forward motion 
of the blood. 
 
Smooth muscle cells and pericytes comprise the contractile elements of the microvascular 
wall. In the arteriolar segment just before the capillary bed, the contractile cells resemble 
pericytes more than smooth muscle cells.  A single cell with multiple circumferential arms 
completely or almost completely encircles the endothelial tube. The cell has multiple arms 
that overlap each other slightly, and exhibits multiple junctional contacts with the endothelial 
cell. 
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1.2.8. Oxidative Stress and anti-oxidant Defence 
 
Free radicals 
 
A free radical is an atom with an unpaired electron in the outer ring. Since electrons have a 
very strong tendency to exist in a paired rather than an unpaired state, free radicals 
indiscriminately pick up electrons from other atoms, which in turn converts these atoms into 
secondary free radicals, thus setting up a chain reaction which can cause substantial 
biological damage. 
 
Free radicals contribute to many different diseases. Chemically, a substance is oxidized when 
electrons are removed and reduced when electrons are added.  
 
The highly reactive properties of free radicals arise from their unstable electron 
configurations. They can readily donate or extract electrons from other molecules with which 
they collide. This second molecule becomes a free radical capable of reacting and hence a 
chain reaction is established (Cheeseman and Slater, 1993).  
 
Cell membranes are made of unsaturated lipids. The unsaturated lipid molecules of cell 
membranes are particularly susceptible to this damaging free radicals process and readily 
contribute to the uncontrolled chain reaction. Oxidative damage, caused by free radicals can 
lead to a breakdown or hardening of cell wall lipids. If the cell wall is hardened (lipid 
peroxidation) normal cellular respiration may be affected. Addition, other biological 
molecules are also susceptible to damage, including RNA, DNA and protein. 
 
The production of radical oxygen, the most common radical in biological systems (ROS, 
reactive oxygen species), occurs mostly within the mitochondria of cells. Mitochondria are 
small membrane enclosed regions of a cell that produce the chemicals a cell uses for energy. 
Mitochondria accomplish this task through the "electron transport chain." In this mechanism, 
electrons are passed between different molecules, with each pass producing useful chemical 
energy. Oxygen occupies the final position in the electron transport chain. Occasionally, the 
passed electron incorrectly interacts with oxygen, producing oxygen in radical form. 
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The primary site of free radical damage is the DNA found in the mitochondria. Cells 
automatically repair much of the damage done to nuclear DNA. However, mitochondrial 
DNA cannot be readily fixed. Therefore, extensive DNA damage accumulates over time and 
shuts down mitochondria, causing the cells to die and the organism to age. 
 
Various disease states correlate with free radical damages: Coronary artery disease, gout, 
obesity, chronic obstructive pulmonary disease, cancer, Parkinson’s disease, arthritis, 
diabetes, ageing, infections, chronic kidney disease, and many others. 
 
It has been suggested that reactive oxygen species (ROS) are involved in several pathological 
processes underlying cardiovascular diseases, particularly in the development of ischemia-
induced myocardial reperfusion injury. When the balance between the cellular sources of 
ROS and the defence system is disturbed, ROS may react with cellular components like 
phospholipids and proteins. These reactions lead to lipid peroxidation and the oxidation of 
thiol groups resulting in the impaired function of both the cell membranes and various 
cellular proteins that influence responses to cardiac cell injury. Such responses include cell 
death, apoptosis and inflammation (Ceconi et al., 1991, Hirasawa et al., 1997). Therefore, 
understanding the role of oxidative stress in the development and initiation of 
atherothrombotic complications remains paramount.  
 
Direct measurement of ROS is difficult because many are present in low concentrations and 
have short half-lives. In general, the action of ROS is assessed indirectly by studying the 
effects of substances involved in the production or elimination of these species 
 
Oxidative stress and Cardiovascular disease 
 
The first direct evidence that free radicals were produced in living cells was published in 
1954 (Commoner et al., 1954). Reactive Oxygen/Nitrogen Species (ROS/RNS) include 
several oxygen-nitrogen-derived free radicals and oxidants, superoxide (O2●-), hydrogen 
peroxide (H2O2), hypochlorite (HOCl), nitric oxide (NO), hydroxyl radical (●OH), nitrogen 
dioxide (NO2), peroxynitrite (ONOO-), and other amino acid- and lipid-derived radicals. 
Although ROS/RNS play an important role in immune-mediated defence against invading 
microorganisms and serve as cell-signalling molecules, at high concentrations, ROS/RNS are 
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capable of damaging host tissues, i.e., ROS/RNS can modify or damage DNA, lipids, and 
proteins. 
 
ROS/RNS levels are controlled through an intricate network of enzymes and endogenous and 
exogenous antioxidant molecules that are responsible for scavenging and consumption of 
specific reactive species. In this regard, intake of dietary antioxidants has received much 
attention, with the concept being that these molecules can affect disease by modulating the 
biological reactivity of ROS and RNS. 
 
Cardiovascular Diseases 
Traditional vascular risk factors, including hyperlipidemia (cholesterol, LDL, etc.), 
hypertension, cigarette smoking, diabetes, overweight, physical inactivity, age, male sex and 
familial predisposition, only partly explain the excess risk of developing cerebrovascular and 
Coronary Heart Disease (CHD), and many studies support today the role of oxidative stress 
in their pathogenesis. 
 
Paradoxically, although moderate exercise poses an acute oxidant stress, regular endurance 
exercise is associated with improved cardiovascular function and a reduction in traditional 
CHD risk factors. These findings are consistent with the hypothesis that adaptations induced 
by acute exposures to exercise-induced oxidative stress lead to long-term vascular protection. 
This occurs through activation of signalling pathways that lead to increased synthesis of 
intracellular antioxidants and antioxidant enzymes and decreased ROS production during 
exercise.  
 
Since nitric oxide (NO) is a cell-signalling molecule that plays a central role in the regulation 
of vasomotor tone and blood flow, in the context of vascular diseases NO is of particular 
interest, and a decrease in NO bioactivity has been associated with impaired endothelial 
function. Endothelial cells generate NO in response to several stimuli, including shear stress, 
acetylcholine, bradykinin, and circulating factors in plasma such as oestrogen, insulin, and 
lipids. NO, in turn, diffuses to neighbouring smooth muscle cells and platelets, where NO 
induces vasorelaxation, inhibits platelet activation and adhesiveness, and regulates 
inflammatory responses. An increase in ROS results in a decrease in NO bioactivity by 
diverting NO away from anti-inflammatory reactions to those that promote injury. 
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Atherosclerosis 
Atherosclerosis is a complex process involving the deposition of plasma lipoproteins and the 
proliferation of cellular elements in the artery wall. This chronic condition advances through 
a series of stages leading to the atherosclerotic plaques formation that provide a barrier to 
arterial blood flow and may precipitate clinical events. Considerable evidence has been 
gathered in support of the hypothesis that free-radical-mediated oxidative processes and 
specific products arising therefore play a key role in atherogenesis (Bhunia et al., 1997).  
 
Oxidative processes are proposed to play a role in lesion maturation and the precipitation of 
clinical events, causing myocardial infarction and stroke (Devasagayam et al., 2004). The 
oxidation theory is supported by the presence of oxidised LDL (oxLDL) within 
atherosclerotic lesions and the correlation between the sensitivity of LDL to oxidation and 
risk of CVD. Moreover, LDL oxidization can be inhibited by nutritional antioxidants. Several 
epidemiological evidences and interventional studies correlate higher level of antioxidantrich 
food uptake with lower incidence of CHD (Kanani et al., 1999). 
 
LDL can leave the antioxidantreplete plasma, entering the sub-endothelial space of arteries. 
Here LDL is oxidized. oxLDL is capable of initiating processes that contribute to the 
formation of atherosclerotic lesions. It is taken up by macrophages and induces the release of 
factors that recruit other cells and stimulate smooth muscle cell proliferation. oxLDL may 
also up-regulate expression of cellular adhesion molecules that facilitate leukocyte binding. 
High levels of oxLDL can also down-regulate the expression of endothelial nitric oxide 
synthase (eNOS), the enzyme that synthesizes the majority of vascular NO. 
 
A scavenger enzyme, superoxide dismutase, protects against this kind of harmful reaction by 
converting superoxide to hydrogen peroxide, which is then degraded by catalase and 
glutathione peroxidase. Sufficient O2- survives, however, to destroy NO quite rapidly. The 
reaction between NO and O2- creates peroxynitrite.  
 
Peroxynitrite gives rise to highly reactive hydroxyl radicals, which readily oxidize lipids and 
thereby damage the cell membrane. In support of this, it has been shown that superoxide 
dismutase, an enzyme that scavenges free oxygen radicals, improves the vasodilator response 
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of atheromatous vessels to agonists. Superoxide is generated by a number of oxidases 
involved in cellular metabolism, and increased superoxide production closely parallels 
hypercholesterolemia, which is a cardinal risk factor for atherogenesis.  Superoxide 
production is also increased by hyperglycaemia in diabetes, another major risk factor for 
atheroma (Levick, 2003). 
 
 
Low NO levels could explain several features of atheroma, as follows (Levick, 2003): 
1. Inhibitors of NOS increase LDL and fibrinogen uptake by the artery wall, and conversely 
stimulation of NO production by L-arginine reduces atheroma formation in 
hypercholesterolaemic rabbits. NO and cGMP may have a barrier-enhancing effect in arterial 
endothelium, as they do in monolayer cultures but not in microvessels. 
2. Low NO levels increase cell-surface VCAM, which promotes monocyte adhesion. 
3. NO inhibits vascular smooth muscle growth and migration in cultures. 
4. NO strongly inhibits platelet aggregation. 
 
It is well documented that endothelium-mediated vasodilatation is impaired in atheromatous 
arteries. These arteries often constrict in response to acetylcholine, in contrast to the usual 
vasodilator response, but NO generation degradation product have been found even raised in 
atheromatous animals, suggesting that the abnormal response of atheromatous vessels may 
not be due to a failure of NO synthesis. It has been proposed that impaired NO-mediated 
responses in atheroma may be due to an increased inactivation of the NO by superoxide 
radicals, so that less NO reaches the vascular myocytes (Levick, 2003). 
 
Stroke/ Ischemia-Reperfusion 
Stroke is the main cause of disability and mortality in Western countries. Especially the 
condition of ischemia and reperfusion occurring after stroke has been shown to be associated 
with free radical-mediated reactions potentially leading to cell death (Alexandrova et al., 
2004). Although ischemic and hemorrhagic stroke have different risk factors and patho-
physiological mechanisms, there is evidence of an increased generation of free radicals and 
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other reactive species in both conditions, leading to oxidative stress. Ischemic stroke is the 
consequence of the interruption or severe reduction of blood flow in arteries followed by 
physiological and metabolic changes that appear within seconds of the cessation of blood 
flow. When anoxia is followed promptly by reperfusion, tissue can be saved but reperfusion 
might potentially have negative consequences: upon reoxygenation, OS is rapidly built up 
and numerous non-enzymatic oxidation reactions take place both in the cytosol and/or in 
cellular organelles. Independent of the mechanisms responsible for ischemic stroke, ischemia 
causes a cascade of events that can increase free radical production via several different 
pathways, including inflammatory cells, xanthine oxidase, cyclooxygenase, and 
mitochondria. Also the large increases in glutamate and aspartate that accompany ischemia 
may contribute to free radical generation by cytotoxic mechanisms (Piantadosi and Zhang, 
1996). During ischemia and reperfusion the altered function of the mitochondrial electron 
transport chain is a likely source of OS. Upon reperfusion, the accumulation of blood borne 
inflammatory cells, such as neutrophils and monocytes/macrophages might further promote 
oxidative stress. Consequently, a large excess of O2-derived free radicals appears during the 
first minute of reperfusion and peaks some 4 to 7 minutes after the onset of reperfusion. In 
ischemic tissues, numerous studies have established a direct role for ROS in oxidative 
damage to lipids, proteins, and nucleic acids. 
 
Antioxidants 
The radical-scavenging antioxidants in human serum represent a heterogeneous group of 
substances, some synthesized in the body and some derived exclusively from the diet. 
Individual members of the antioxidant defense team are deployed to prevent generation of 
ROS, to destroy potential oxidants, and to scavenge ROS. A deficiency in any of these 
components can cause a reduction in the overall antioxidant status of an individual. 
 
Antioxidants work in different ways: Prevent free radicals formation; slow or stop oxidative 
processes after they begin or by scavenging and quenching the chain-carrying radicals. 
Oxidative stress induced tissue damage is then minimized. However, a deficiency of 
antioxidant defenses or an overproduction of ROS may lead to a dangerous imbalance in the 
organism and to an “oxidative stress condition”.  
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Plasma antioxidant status is the result of the interaction of many different compounds and 
systemic metabolic interactions. Plasma antioxidant capacity is principally represented by: 
water-soluble antioxidants (protein/SH-group/albumin (800-1000 mmol/l) uric acid (150-450 
mmol/l) ascorbic acid (30-150 mmol/l)); and fat-soluble antioxidants (tocopherols (20-50 
mmol/l) carotenoids (0.5-3 mmol/l)). Plasma antioxidant capacity is modulated either by 
radical overload or by intake of dietary antioxidants and can therefore be regarded as more 
representative of the in vivo balance between oxidizing species and antioxidant compounds 
(known and unknown, measurable and not measurable) than the concentration of a single, 
selected antioxidant.  
The interplay between pro and antioxidative forces and resultant oxidative state from a 
variety of cardiovascular risk factors may result in elevated expression of atherogenic gene 
products such as adhesion molecules and other vascular inflammatory gene products (Figure 
1-10). 
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FIGURE 1-10. THE ASSOCIATION OF ATHEROSCLEROTIC RISK FACTORS, OXIDATIVE STRESS, AND REDOX-
SENSITIVE GENE EXPRESSION. REDRAWN FROM (KUNSCH AND MEDFORD, 1999B). 
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1.2.9. Blood Flow in The Circulatory System 
1.2.9.1. General organisation of the circulatory system 
The aorta and pulmonary artery divide into smaller arteries, which progressively form smaller 
arteries, then high-resistance vessels called arterioles and then branch into innumerable 
capillaries which  converge to form venules and veins. Basic fluid dynamics describes how 
the velocity of blood flow decreases as the radius of the vessel decreases (Pugsley and 
Tabrizchi, 2000). However, because of the increase in vessel number with branching, the 
total cross-sectional area of the vascular system increases despite the progressive fall in 
vessel size. This slows the velocity of the blood, because of velocity (cm/s) is flow (cm3/s) 
divided by cross-sectional area (cm2). Thus, in the capillaries the blood velocity is < 1/200th 
of that in the aorta (Figure 1-11) failitating time to exchange O2, CO2 and others with the 
tissue (Nichols et al., 1985). 
  
The highest resistance of the arterioles and smallest arteries is caused by their narrow lumen 
and because they dominate resistance to flow, they act as regulators of the circulation turning 
local blood flow up or down to match local needs. When they dilate (vasodilatation) the 
resistance to flow falls, so blood flow increases. Vasoconstriction has the reverse effect 
(Levick, 2003). 
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FIGURE 1-11. VESSEL DIAMETER, CROSS-SECTIONAL AREA, BLOOD PRESSURE AND 
VELOCITY. 
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Three different patterns of flow occur in the circulation: laminar flow, turbulent flow and 
single-file flow. Laminar flow occurs in normal arteries, arterioles, venules and veins, 
turbulent flow in the ventricles and single-file flow in capillaries. 
 
In laminar flow, fluid follows smooth, parallel streamlines. In a cylindrical tube like a vessel, 
the liquid behave like a set of thin concentric shells, or laminae, which slide past each other 
during flow. The lamina in direct contact with the vessel wall is fixed by molecular cohesive 
forces and has zero velocity. The adjacent lamina slides slowly past the non-slip lamina. The 
next lamina slides past the second lamina. Since the second lamina is itself moving, the third 
lamina has a higher velocity relative to the tube wall and so on until maximum velocity is 
reached at the centre of the tube in parabolic manner (Figure 1-12).  
 
FIGURE 1-12. A) PARABOLIC FLOW PROFILE AND VELOCITY; B) CONCENTRIC FLOW PATTERN WITH 
MAXIMAL VELOCITY CENTRE STREAM. 
 
For a Newtonion fluid like water, the transverse velocity profile is a perfect parabola, 
however, with a particulate suspension like blood, the velocity profile is more blunted than a 
parabola (Figure 1-13) (Nichols et al., 1985, Levick, 2003). 
 
A B 
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FIGURE 1-13. BLOOD FLOW PATTERNS IN A LARGE VESSEL 
 
The shearing of lamina against lamina causes the red cells to tend to orientate themselves 
parallel to the direction of flow at high shear rates. Shear rate is the change in fluid velocity 
per unit distance across the tube. Another effect of the shear is that the cells are displaced a 
little towards the central axis leaving a thin cell-deficient layer of plasma at the margins. The 
marginal layer is only 2-4 µm thick, but it is important in arterioles, where it helps to ease the 
blood along. 
 
The shearing of one lamina on an adjacent lamina has a tugging effect on the second lamina, 
in much the same way that dragging one sheet of paper over a second one tends to move the 
second sheet. The tugging force exerted by one layer on the other is called the shear stress. 
The size of the shear stress depends on the shear rate and on the viscosity of the liquid. In 
fact, viscosity is defined as the ratio of shear stress to shear rate: and is in effect the friction 
between two layers of fluid. 
 
The diameter of most capillaries (5-6 µm) is less than the width of the human red cell (8 µm). 
Red cells are therefore compelled to proceed through capillaries in single-file, and to deform 
themselves. Since the cell spans the full width of the tube, parabolic flow is impossible and 
the bolus of plasma trapped between the cells is compelled to move along at uniform 
velocity, albeit with some internal eddying (‘bolus’ or ‘plug’ flow). Bolus flow eliminates 
some of the internal friction associated with lamina sliding against lamina and friction 
between the cell and capillary wall is thought to be minimized by a thin film of plasma and/ 
or by the endothelial glycocalyx, a cell surface coating of mucopolysaccharides. The 
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glycocalix is rich in negatively charged sialic acid residue, and since the red cell surface is 
negatively charged too, electrostatic repulsion contributes to the difficulty red cells 
experience in entering a capillary. The efficiency of bolus flow depends critically on the 
deformability of the red cell, and this is impaired in many clinical conditions (Levick, 2003). 
 
The control of tissue blood flow is a dynamic process exemplified by the interaction among 
physical, chemical, and electrical events occurring within the vessel wall and between the 
vasculature and tissue parenchyma. Blood flow control is integrated among many vessel 
segments and coordinated throughout the resistance network. The interaction within and 
among vascular segments can be explained by chemical and electrical signals to smooth 
muscle cells and endothelial cells in response to changes in transmural pressure as well as 
luminal shear stress. Increasing pressure results in smooth muscle cells contraction via the 
myogenic response. Increasing flow stimulates endothelial cells to release autacoids (eg, NO) 
which relax smooth muscle cells (Segal, 1994). 
 
The behaviour of the heart and blood vessels has to be constantly adjusted in order to deal 
with varying environmental and internal demands. This is achieved by nervous and 
neuroendocrine reflexes, which are coordinated by the brain. One of the most important 
cardiovascular reflexes is the arterial baroreceptor reflex, which safeguards blood flow to the 
brain by maintaining a stable blood pressure. The reflex is initiated by baroreceptors in the 
walls of major arteries, which sense changes in blood pressure. Nerve impulses are sent to the 
brainstem and reflexly after the activity of autonomic nerves that control the heart and blood 
vessels and thus it results in changes in cardiac output, peripheral resistance and venous 
capacitance which restores blood pressure to normal (Levick, 2003). 
 
1.2.9.2. Blood flow in the cutaneous micro-circulation 
The skin of an average 70kg adult weighs 2-3kg and has an approximate area of 1.8m2. It is 
the largest organ of the human body but has modest metabolic requirements to provide many 
important functions. It is composed of dermis and epidermis.  
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The superficial epidermis is histologically divided into 5 discrete layers (4 on the hands and 
feet). It varies in thickness from 0.5mm on the eyelids, to 1.5-4mm on the palms of the hands 
(Whitton and Everall, 1973). The epidermis is an avascular, keratinous layer and therefore, is 
only of significance in LDF when considering laser depth penetration.  
 
The dermis is the deeper portion of the skin and measures 0.3 on the eyelid to 3 mm on the 
back. It is divided into the deep ‘reticular’ dermis and the superficial ‘papillary’ dermis. 
Unlike the epidermis, it is highly vascular and contains many organs (hair, nerves, glands 
etc). Vessels within the dermis run parallel to the skin surface and branch vertically to give 
capillaries, which perfuse the papillary dermis, and epidermis by diffusion.  
 
Subdermal arterioles (40 - 70 µm) form dermal arterioles (40 - 60 µm in diameter) which 
enter the skin from a variety of sources. Dermal arterioles may communicate by either true 
(no change in vessel calibre) or choke anasatmoses, as shown in Figure 1-14. Capillaries 
(~10µm in diameter) regularly branch from arterioles, where perfusion is controlled by pre-
capillary smooth muscle sphincters. Capillaries travel towards the skin surface to form hair-
pin loops in the papillary dermis, which drain into venous plexi. Together, these capillary 
networks comprise the superficial plexus. The dominance and types of each type of network 
within areas of the skin (subdermal vs. dermal vs. superficial plexus) depends on the 
anatomical location (C, 1983, W, 1893, M, 1988) and is highly pertinent to LDF 
measurements (see later).  
  
 
 
FIGURE 1-14. SCHEMATIC DEMONSTRATING TYPES OF ANASTOMOSES. A) CHOKE; B) TRUE. 
 
There is enormous temporal and spatial heterogeneity in the microvasculature of the skin. Of 
importance, the skin of the hands, feet, ears and nose are all rich in arteriovenous 
A B 
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anastomoses (AVA)(Grant RT). AVAs have a wider maximal diameter than most capillaries 
(50-70µm) and therefore have a high surface area to volume ratio. They play an important 
role in skin perfusion & temperature regulation. For these reasons, LDF measurements of 
skin should be on recognised areas with well defined vascularity. 
 
 
 
 
 
 
Skin blood flow is primarily controlled by sympathetic nerve fibres whose activity is linked 
to temperature regulation. Sympathetic neural control of the skin blood flow includes the 
noradrenergic vasoconstrictor system and a sympathetic active vasodilator system, the latter 
of which is responsible for 80 % to 90% of the substantial cutaneous vasodilatation that 
occurs  with whole body heat stress (Charkoudian, 2003). In a thermoneutral environment, 
namely 27-28oC for a naked man, skin temperature is around 33oC and core temperature is 
37-37.5oC .Under these conditions the blood vessels of the hands and feet are subject to a 
high degree of tonic, sympathetic vasoconstrictor tone. In the skin of the limbs and trunk, by 
contrast, there is only very slight sympathetic vasoconstrictor activity when the subject is 
comfortably warm. This is proved by the hyperaemia of the extremities but not the limbs that 
follow surgical sympathectomy or a local nerve block. 
 
Subtle changes in the activity of this system during most daily activities are responsible for 
maintenance of normal body temperature with slight changes in activity or ambient 
temperature. This is possible because small changes in skin blood flow can cause relatively 
large changes in heat dissipation. For example, a change in skin blood flow from resting 
neutral levels of a little as 8 ml per 100 mL/min over the entire body surface results in a 
doubling of heat transfer to the environment. This allows for a zone of thermoregulation 
(referred to as the “neutral” or “vasomotor” zone) that is accomplished solely via changes in 
cutaneous vasomotor tone (Charkoudian, 2003). The active vasodilator system is responsible 
 
   Flow in a thermoneutral environment (27o C): 10-20 ml min -1100g -1 
 
   Minimal flow: 1 ml min -1 100 g -1 
 
   Maximal flow: 150-200 ml min -1 100 g -1 
                                                                                                                                      (Levick, 1997) 
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for most of the vasodilatory response to heat stress and can increase skin blood flow > 10 fold 
(Pierzga et al., 2003). 
 
The human cutaneous circulation is unique in that it is controlled by two populations of 
sympathetic nerves. Sympathetic vasoconstrictor and vasodilator nerves innervate all areas of 
nonglarous skin, whereas areas of glaborous skin (palms, soles, lips) are innervated only by 
sympathetic vasoconstrictor nerves. Another important distinction between glabrous and non-
glabrous skin is the existence of AVAs, which are thick-walled, low-resistance conduits that 
allow high flow rates directly from arterioles to venules. In glabrous skin, AVA are numerous 
and richly innervated by sympathetic vasoconstrictor nerves. Therefore, in these areas, 
opening or closing of these AVA can cause substantial changes in skin blood flow. In 
contrast, nonglabrous skin has few if any AVAs and is innervated by both sympathetic 
vasoconstrictor and vasodilator nerves (Charkoudian, 2003) 
 
Human skin has several special tasks. A very important one is regulation for internal 
temperature, which is normally kept within a degree or so of 37oC. This is achieved by 
balancing the internal heat production with the heat loss from the surface. Certain areas 
termed acral skin, possess abundant direct connections between dermal arterioles and 
venules. These AVAs occur at exposed sites with a high surface area/volume ratio such as 
fingers and toes, palm and sole, lips, nose and ears. AVAs have little basal tone and are 
controlled almost exclusively by sympathetic vasoconstrictor fibres, whose activity is 
controlled by a temperature-regulating centre in the hypothalamus. When core temperature is 
high, vasomotor drive is reduced and the AVAs offer a low-resistance shunt pathway, which 
increases the cutaneous blood flow and delivers more heat to the skin. Heat readily crosses 
the walls of the dermal venous plexus that is fed by the AVAs, so skin temperature rises and 
heat loss increases. Conversely, AVAs are constricted to conserve heat under cold conditions. 
Indeed, dilatation of AVAs increases heat loss (Figure 1-15) (Levick, 2003). 
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FIGURE 1-15. VARIATIONS IN THE BLOOD SUPPLY TO THE SKIN UNDER: A) COLD AND; B) WARM CONDITIONS 
 
Skin blood flow in humans can increase substantially in response to thermal stress: 
thermoregulatory vasodilatation can increase skin blood flow to 6 to 8 L/min during severe 
hyperthermia. Such response in skin circulation represents a vital aspect of normal 
thermoregulation in humans. Cutaneous sympathetic vasoconstrictor and vasodilatator 
systems also participate in baroreflex control of blood pressure; this is particularly important 
during heat stress, when such a large percentage of cardiac output is directed to the skin. 
Local thermal control of cutaneous blood vessels also contributes importantly; local warming 
of the skin can cause maximal vasodilatation in healthy humans and includes roles for both 
local sensory nerves and NO. Local cooling of the skin can decrease skin blood flow to 
minimal levels (Charkoudian, 2003). 
 
During menopause, changes in reproductive hormones level substantially alter 
thermoregulatory control of skin blood flow. This altered control might contribute to the 
occurrence of hot flashes. In type 2 diabetes mellitus, the ability of skin blood vessels to 
dilate is impaired. This impaired vasodilatation likely contributes to elevated ambient 
temperatures (Charkoudian, 2003). 
A B 
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1.2.10. Vascular Control 
The active tension of smooth muscle cells arranged in a circumferential pattern in blood 
vessels controls the radius of the vessel. Vasoconstriction is brought about by contraction of 
the smooth muscle cells. Vasodilatation, by contrast, is a passive, not active process, being 
powered by blood pressure as vascular smooth muscle relaxes. Local arteriolar resistance 
regulates blood flow to the tissue down-stream of the arteriole. Capillary recruitment and 
capillary filtration pressure are both regulated by local arteriolar tone. Thus, arteriolar radius 
exerts both local effects (control of nutritive supply and organ fluid balance) and central 
effects (homeostasis of blood pressure and plasma volume). 
 
The active tension exerted by vascular smooth muscle in a segment of wall is called vessel 
tone.  The arterioles and some larger arteries retain a degree of tone even when their 
sympathetic innervation is interrupted, that means, remain partially contracted, and this is 
called the basal tone. The geometric organization and control of microbed varies with 
different organs and tissue elements. The moment-to-moment regulation of local blood flow 
occurs without dominant control by the extrinsic nervous system; this enhances the exchange 
of fluids, solutes and blood gases, and allows rapid redistribution of blood flow during states 
of stress and high metabolic demand (Huether, 1983). The tone of a vessel is actively 
controlled by numerous factors which fall into two broad categories: intrinsic control 
mechanisms and extrinsic control mechanisms. Intrinsic local control is brought about by 
mechanisms that are wholly located within the organ itself and the extrinsic control is brought 
about by mechanisms that influence the organ from outside itself (Table 2). 
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1.2.10.1. Rhythmic Vasomotion 
 
Cutaneous vessels undergo autonomous rhythmic contraction & relaxation. This phenomenon 
produce periodic fluctuations in cutaneous blood flow and has been teemed period 
fluctuations(J, 1988), rhythmic variations (Creutzig A, 1987) and rhythmic vasomotion 
(Engelhart M, 1986, Goldstein DS, 1986, Cochrane T, 1986), which is the term we will 
adopt. Rhythmic vasomotion was first described by Haumschild in 1986 (DJ, 1986) after he 
observed a negative correlation between the tissue partial pressure of oxygen (tcPO2) and 
LDF flux. More recently, vasomotion has been shown to be a function of the endothelium 
(Gustafsson H, 1993).  
 
The physiological role of vasomotion remains a topic of debate. The leading hypothesis that 
is vasomotion aids the control of tissue oxygenation, especially in situations where perfusion 
is critically limited. This theory is supported by mathematical models showing that 
TABLE 2. FACTORS CONTROLLING THE TONE OF A VESSEL. 
CATEGORIES      FACTORS OF THIS MECHANISM 
 
 
INTRINSIC 
CONTROL 
MECHANISMS 
 
• Physical factors (temperature and pressure). 
• The Bayliss myogenic response 
• Endothelial secretions (NO, EDHF and endothelin) 
• Metabolites (lactate, adenosine) 
• Vasoactive chemicals (histamine) 
 
 
EXTRINSIC 
CONTROL 
MECHANISMS 
 
• Sympathetic, parasympathetic and other vasoactive 
nerves 
• Circulating hormones (adrenaline, angiotensin and 
vasopressin). 
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multibranched micovascular networks (Ursino M, 1992, Ursino M, 1996) experience an 
increased frequency of vasomotion and increased blood flow (of up to 60%) in response to 
tissue hypoxia, acidosis and hypotension (Schmidt-Lucke C, 2002). 
 
There is wide variation in the frequency and amplitude of vasomotions from 2-17 cycles per 
minute on various areas of skin, amongst individuals (Goldstein DS, 1986). It has been 
shown to be unrelated to heart rate or respiratory rate (Goldstein DS, 1986) but linked to 
tcPO2, pH, perfusion pressure and a number of other factors, including: 
 
• Vessel diameter – there is a maximum frequency of 9-15 cycles per minute in small 
arterioles (8-15µm) and 1-3 cycles per minute in larger arterioles (70-100µm). 
Therefore, the smaller the vessel, the greater the frequency of vasomotion. In fact, 
there is a linear relationship between arteriole diameter and the velocity of red blood 
cells. (Le-Chong P, 1979) 
• Vessel integrity – when the endothelium is damaged or removed entirely, vasomotion 
ceases (Gustafsson H, 1993). 
• Local mediators – Ca2+ dependent K+ channels(Mauban JR, 2004) are vital in 
controlling the production of NO (Gustafsson H, 1993, Stefanovska A, 1999, Peng H, 
2001, Ursino M, 1998) and therefore, the degree of contraction of smooth muscles in 
cutaneous vessels. 
• Temperature –the temperature of a tissue is directly proportional to the frequency and 
amplitude of waves of vasomotion (Salerud EG, 1983, Kastrup J, 1989).  
• Sympathetic innervation – in the absence of all other mediators, local sympathetic 
nerve activity contributes to the membrane potential for vasomotor oscillations 
(Haddock RE, 2002, Kastrup J, 1989). 
• Local anaesthetic – administration of local anaesthetics eliminated vasomotion 
entirely, leaving the vessel flaccid (Colantuoni A, 1984). 
 
The degree of vasomotion also changes according to body site. There is limited human data 
in this field other than measurements made on the nail fold capillary bed, which shows 
periodic fluctuations in flow velocity of 0.5mm/s. 
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Temperature 
High ambient temperatures cause cutaneous arterioles and veins to dilate. Conversely, skin 
temperatures down to 10-15 o C cause vasoconstriction which conserves heat and safeguards 
core temperature. The vasoconstrictor response of skin vessels to cold contrasts with the 
behaviour of most other tissues, where vessels relax in response to cold. This appears to be 
related to the relative abundance of α2 – type adrenoreceptors in skin vessels, in contrast to α1 
in other tissues. The affinity of α2 adrenoreceptors for noradrenaline, the sympathetic 
vasoconstrictor neurotransmitter, increases as temperature falls towards 10o C. In support of 
this explanation, it is found that blockers of α2-adrenoreceptors such as yohimbine and 
rauwolscine inhibit the cutaneous vasoconstrictor respond to cold. Cooling skin below 
approximately 12oC by contrast, leads to paradoxical cold vasodilatation, which is caused by 
the impairment of neurotransmitter release and by the release of vasodilator substances like 
prostaglandins from the tissue (Levick, 2003). 
1.2.11. Pressure And The Myogenic Response 
Transmural pressure is the difference in pressure across the wall of a vessel that means, the 
internal blood pressure minus the external pressure acting on the vessel. A high external 
pressure compresses vessels and impairs blood flow. This happens in skeletal muscle and 
myocardium during their contraction phase. Flow through the skin is impaired by 
compression during sitting, kneeling, lying, etc.  
 
When internal pressure is raised in an artery or arteriole, the immediate, purely mechanical 
effect is to distend the vessel slightly and reduce its resistance. Most systemic arterioles and 
some arteries then react to the distension by contracting. This is called the myogenic response 
and it is important because it stabilizes blood flow and capillary filtration pressure during 
changes in blood pressure. It also contributes to basal tone, which is a prerequisite for the 
capacity to vasodilate (Levick, 2003). 
 
Almost 80 percent of blood volume lies in veins and venules, representing a large capacitance 
reservoir. Veins are thinner-walled than arteries and can therefore expand greatly. This 
explains why veins are much more complaint than arteries at low pressures. Despite this, 
there is sufficient smooth muscle in the walls of all but the smallest venules to actively 
modulate venous tone. It therefore follows even small changes in venous tone are capable of 
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translocating large amounts of blood to and from the central compartment. Cardiac 
performance is exquisitely sensitive to the state of cardiac filling such that stroke volume may 
change as much as 50% in response to a change in filling pressure of as little as 1 cm H2O if 
buffering reflexes are blocked or exhausted (Schmitt et al., 2002). 
1.2.12. Cellular Mechanisms 
When pressure rises, stretching of the myocites activates their stretch-sensitive, non-selective 
cation channels and chloride channels. The resulting ionic currents depolarize the myocyte, 
which increases the open probability of L-type Ca2+ channels. The ensuing rise in cytosolic 
Ca2+ activates the contractile machinery. In support of this simplified scheme, it is found that 
the myogenic response is often impaired by blockers of L-type Ca2+ channels such as 
nifedipine, by blockers of stretch-activated cation channels such as gadolinium ions (Gd3+), 
and by blockers of chloride channels. There is evidence of other factors at work too, 
including activation of protein kinase C, which enhances the sensitivity of the contractile 
apparatus to Ca2+. A puzzling feature of the myogenic response is that the vessel wall is only 
stretched temporarly, when the pressure is first raised. Stretch cannot explain the sustained 
contraction, because the myocytes are actually shortened. A possible explanation could be 
that the microscopic regions of the myocyte membrane are in a state of stress due to the 
contractile tension, and that the stretch-sensitive ion channels are located in these 
microscopically stretched regions. 
 
Raising arterial pressure evokes myogenic constriction; and vessel constriction raises arterial 
pressure, but this mechanism does not continue operating until total closure of the vessel. 
This may be partially that the KCa channels act as a brake on the process. As cytosolic Ca2+ 
rises, the calcium-activated potassium channels open, and their hyperpolarizing effect 
attenuates the depolarization that is driving the myogenic response. A further brake on 
myogenic constriction is provided by shear-induced production of the vasodilator agent NO 
by endothelium (Levick, 2003). 
 
The microcirculation is controlled partly by sympathetic vasoconstrictor impulses from the 
brain and partly by vasoactive substances secreted locally by the endothelial cells. These all 
act very locally, immediately adjacent vascular myocytes in order to modulate the local 
vascular tone. For example, the continuous production of endothelin contributes to local basal 
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tone, and the continuous production of NO partially counterbalances this. The nitric oxide 
facilitates flow by causing relaxation of vascular smooth muscle. Neural and endothelial 
controls of blood flow are impaired by illness. Neurological disease and vascular disease 
which affect the microcirculation predispose patients to develop ischaemic organ damage, 
including pressure sores. Severe sepsis or trauma may cause irreversible microcirculatory 
dysfunction resulting in multi-organ failure and death (Bliss, 1998). 
 
The vasodilator activity may predominate in small arterioles whereas the neural control may 
be directed to the small arteries and large arterioles. Thus, physiological, pharmacological 
and pathological influences may affect the control of blood flow and/or pressure at one or 
both of these sites (Joyner and Davis, 1987). 
 
The principal stimulus to the continuous production of NO under physiological conditions is 
the shear stress exerted by flowing blood on the vessel endothelium. The resulting low but 
sustained output of endothelial NO reduces that basal tone of adjacent myocytes and thereby 
reduces blood pressure and shear stress. Tonic production of NO in man has already been 
confirmed by infusing a blocker of NO synthesis into the human arm. This causes basal tone 
to increase and arm blood flow to decrease((Vallance et al., 1989). Thus, at rest, human 
vascular tone represents a balance between opposing factors, namely the vasodilator effect of 
tonically produced NO, and the vasoconstrictor effect of the myogenic response, endothelin, 
tonic sympathetic nerve activity and circulating hormones. For instance, during pregnancy, 
oestrogen levels upregulate the mRNA for constitutive NO synthase. The resulting increase 
in NO production causes a large fall in vascular tone, and blood pressure falls despite a 50% 
increase in cardiac output.  
 
Shear stress at the endothelial vessel surface is known to influence both smooth muscle tone 
(acutely) and vessel wall structure (chronically). Such mechanisms have provided the basis 
for the concept of vascular shear stress autoregulation and fairly constant shear rates were 
reported for arterial vessel trees in several tissues. Blood vessels are exposed not only to 
shear stress but also to the distending intravascular or transmural pressure. Like shear stress, 
intravascular pressure affects vessel diameter both acutely (through the myogenic response to 
vessel distension) and chronically (via remodelling of the vessel wall), (Johnson et al., 1980) 
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(Mulvany and Aalkjaer, 1990) (Bund et al., 1991)and intravascular pressure is thus likely to 
modulate the shear-dependent responses of blood vessels. (Price and Skalak, 1994) (Griffith 
and Edwards, 1990) (Griffith et al., 1987)  
 
Endothelial cells are known respond to changes of wall shear stress, which act as a direct 
stimulus. By contrast, the nature of mechanical signal sensed at the cellular level upon 
changes of transmural pressure is not known. Such mechanisms, operating in parallel with 
vascular responses to biochemical (metabolic) stimuli, would control haemodynamic features 
and arteriovenous asymmetry of vascular beds. 
 
The circulating hormone insulin is a further physiological stimulus to endothelial NO 
production. (Levick, 2003)  Since oestrogen augments nitric oxide-dependent vasodilation, 
these results are consistent with previous demonstrations that local warming vasodilation is 
nitric oxide dependent. On the contrary, it has not been found effect of hormone status on 
vasoconstrictor responsiveness to local cooling of the skin (Charkoudian, 2003). 
 
The existence of sympathetic active vasodilatation in human skin has been recognized since 
the 1930s and the role for nitric oxide is moderate. Recent investigations used local cutaneous 
microdialysis of N-nitro-L-arginine methyl ester (L-NAME) either before or during whole 
body heat stress to test whether local pharmacologic blockade of nitric oxide synthesis would 
inhibit active vasodilatation. On average, nitric oxide was found to contribute approximately 
30 % to the active vasodilator response to whole body heat stress. (Kellogg et al., 1998, 
Shastry et al., 2000)  
1.2.13. Flow-Induced Vasodilatation Of Arteries 
This is a second important function of shear-induced, endothelial NO production. When flow 
through an isolated artery is increased in vitro, the artery dilates, so that hardly any increase 
in pressure gradient is needed to maintain the higher flow. Such dilatation is endothelium-
dependent. 
 
Hyperaemia of the human forearm can evoke an increase in brachial artery diameter by up to 
50%. Flow-induced vasodilatation is important because arterial resistance, though small, 
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could become a limiting factor for blood flow once the downstream resistance vessels have 
dilated. Endothelial NO thus serves to couple arterial resistance to arteriolar resistance. 
Endothelial NO also enables vessels to adapt actively to changes in shear stress caused by 
changes in blood viscosity, such as occur in anaemia and polycythaemia. 
 
Flow-induced vasodilation of arteries is to some degree offset in vivo by the myogenic 
constrictor response to increased internal pressure. Under physiological conditions such as 
muscular exercise, the flow through the local artery increases by several hundred per cent but 
pressure increases by only 10-20%. The two opposing effects interact to produce a stable 
reduction in artery tone. (Levick, 2003)  
1.2.14. Hyperaemia 
Hyperaemia is the process by which the body adjusts blood flow to meet the metabolic needs 
of its different tissues in health and disease. Meticulous control of the microcirculation, the 
arterioles, capillaries and venules is essential to life. There are several types of hyperaemia, 
playing an essential role each (Table 3). 
Reactive Hyperaemia 
 
If the blood flow to a tissue is stopped for a while by compressing the supplying artery, or is 
slowed to the point where it is inadequate for tissue nutrition (ischaemia), the blood flow 
immediately after releasing the compression is much higher than normal, and then decays 
exponentially. This is called reactive hyperaemia or post-ischaemic hyperaemia.  
 
TABLE 3. TYPES OF HYPERAEMIA. ((BLISS, 1998);(LEVICK, 2003)) 
TYPES OF 
HYPERAEMIA 
DEFINITION 
Reactive hyperaemia 
 
Local vasodilatation which occurs in response to 
oxygen debt and accumulation of metabolic waste 
products due to interruption of blood flow. 
Active hyperaemia 
 
Increased blood flow in an organ during a period of 
activity. Also called metabolic hyperaemia. 
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Metabolic hyperaemia 
 
Increased blood flow by the release of a number of 
chemical substances into the interstitial fluid. The 
amount of vasodilator factors released by the active 
tissue is closely related to the metabolic rate of the 
tissue. 
Hyperaemic response to 
infection and trauma 
A number of inflammatory autacoids and cytokines 
stimulate the synthesis of inducible NO synthase 
producing vasodilator effect indirectly and hypotension 
by excessive production of NO. 
 
It is particularly obvious in the skin, which flushes a bright pink after a period of compression 
(Levick, 2003). For a 2 min occlusion on a healthy subject, the radius of the vessel is initially 
15 microns, increasing to 24.6 microns at the peak, reached 14 s after the release of the 
occlusion (Humeau et al., 2000).  
 
The myogenic response probably contributes significantly to the hyperaemia following brief 
arterial occlusions (<30 s); the arterioles dilate in response to the fall in transmural pressure. 
With no longer periods of occlusion, vasodilator metabolites accumulate and after 3 min of 
occlusion the vasodilatation is near-maximal in human limbs. Prostaglandins must contribute 
too, because the hyperaemia is reduced (but no abolished) by indomethacin. A minor 
contribution by NO has also been reported for some tissues. The longer the ischaemic period, 
the greater is the accumulation of vasodilator substances and the greater the total cumulative 
blood flow afterwards. As a result, a hyperaemic plateau precedes the exponential decay after 
long occlusions. The functional importance of reactive hyperaemia lies in resupplying oxygen 
and nutrients to ischaemic tissue as rapidly as possible. (Levick, 2003) As it was 
demonstrated by (Humeau et al., 2000) the high value of the LDF signal during the initial 
phase of reactive hyperaemia is produced by an increasing number of erythrocytes in a cross-
section, due to vasodilatation rather than an increase in moving blood cell velocities. 
Moreover, the rapidity of the vasodilatation and vasoconstriction effects determines the 
rapidity of the signal variations. 
Postischaemic reactive hyperaemia in the forearm is a marker of resistance vessel function. 
Several studies have proposed that the time to reach peak hyperaemic flux recorded with laser 
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Doppler is a simple and accurate method of evaluating ischaemic limbs and a method of 
estimating the peripheral vascular resistance. (Wahlberg et al., 1994) 
Dysfunction of resistance arteries by means of reduced endothelium-dependent or metabolic 
vasodilatation or reduced flow reverse is thought to constitute an early reversible stage in the 
development of vascular disease. Such vascular dysfunction is found in patients with 
hypercholesterolaemia or diabetes prone to premature vascular disease. Recently, several 
studies have confirmed the reversibility of such vascular dysfunction by pharmacological 
treatment. However, studies in experimental animals as well in humans have monitored 
dysfunction of resistance vessels, mostly by using invasive techniques with intra-arterial or 
intracoronary drug delivery. Non-invasive testing of vascular function by measurement of 
post-ischaemic reactive hyperaemia in the human forearm is suggested to represent an 
alternatively to intracoronary or intra-arterial drug infusion. Reactive hyperaemia is 
determined by a variety of metabolic factors, such as Nitric Oxide, or ATP-dependent 
potassium channels and also by adenosine, cyclo-oxygenase products and most importantly, 
myogenic response (Wascher et al., 1998). 
 
Reactive hyperaemia is so, a protective adaptive phenomenon, dynamic and dose dependent, 
which involves the vascular tone regulation mechanisms of the ischaemic distal territory as a 
whole, but also its proximal control (flow-mediated dilation). The resulting vasodilatation 
differs from one vascular bed to another, and also between the large proximal arteries and the 
distal arterioles in the microcirculation. Thus, although both are elicited by a similar transient 
occlusion of brachial blood flow, non-invasive investigation of reactive hyperaemia in the 
humeral circulation differs from assessment of endothelial function with the flow-mediated 
arterial dilation. Indeed, whereas NO plays the key-role in the later, several mediators are 
involved in the former, including myogenic and metabolic factors, prostaglandins, K + ATP 
channels, adenosine and NO which is only one of the many components of this complex 
regulation mechanism (Monsuez, 2001). 
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1.3 Cardiovascular disease 
1.3.1. Introduction 
Atherosclerotic cardiovascular diseases (CVD) in general represents a major cause of global 
morbidity and mortality, particularly in Western Countries (Jolly and Gill, 2008). The disease 
affects individuals in their most productive mid-life period, and requiring expensive and 
prolonged treatment (Gillum, 1990, Drummond, 1997). 
 Manifestations of CVD include peripheral arterial disease (PAD), coronary heart disease 
(CHD) and thrombotic stroke (TS) (Hackam and Anand, 2003). People with PAD have a two 
to three-fold higher coronary event rate than those without PAD (Fowkes et al., 1991)  
Three patterns of arteriosclerotic vascular disease are recognised. They cause thickening and 
hardening of arteries.  
1) Atherosclerosis (formation of atheroma): this is more common in males that females, is 
age related; affects intima of elastic and muscular arteries. 
2) Monckeberg’s medial calcification: This is a rare, age related degenerative disease 
affecting muscular arteries. 
3) Arteriosclerosis: Two forms of this disease are recognised:  
Hyaline form: this is the small vessel disease of diabetes and hypertension. Arterioles have a 
pink glassy appearance on H&E 
Hyperplastic: This is the proliferation of smoother muscle cells in an onion skin pattern. 
Subsequent luminal narrowing occurs. 
 
Previous studies had suggested that approximately 15% of the middle-aged and elderly male 
population had PAD, but modern ultrasound techniques and autopsy studies showed that 
prevalence of asymptomatic PAD can be much higher. (Beard, 2000)  In addition, most 
recent studies have shown a prevalence of 30% in eldest individuals, bearing in mind that the 
principal symptom, intermittent claudication, occurs only rarely in those under 50 years of 
age, but increases dramatically in older individuals. (Fowkes, 1997)  Besides, the Edinburgh 
Artery Study estimated that for every claudicant in the community, there are at least two 
individuals with asymptomatic disease of sufficient severity to produce a reduction in the 
ankle brachial pressure index (ABPI). (Fowkes et al., 1991)  
1.3.2. Risk factors for atherosclerosis 
A variety of factors have been associated with an increased risk of developing atherosclerotic 
disease. These are generally described as constitutional factors and acquired. 
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Constitutional factors: immutable 
Age: Age has a dominant influence on the occurrence of atherosclerotic disease. Early lesions 
appear in childhood, disease rises with each decade 
Gender: Males more prone than females. Females are protected till the menopause. Between 
the age of 35 and 55 years, men are five times more prone. 
Familial predisposition: This includes derangements in lipoprotein metabolism 
 
Acquired risk factors: modifiable 
Hyperlipidaemia: High levels of high density lipoprotein (HDL) – lower the risk of 
ischaemia heart disease (transports cholesterol from tissue to liver for excretion). High levels 
of low density lipoprotein (LDL) and total cholesterol increases the risk of ischaemic heart 
disease. Also high triglycerides (VLDL) has some increased risk 
Hypertension: Represents a major risk factor at all ages. 
Cigarette smoking: when >= 1 pack a day per day smoked for a number of years, risk of 
ischaemic heart disease increases by 200 percent. Cessation reduces risk in time.  
Diabetes: Diabetes induces hypercholesterolaemia which is itself a risk factor. Incidence of 
myocardial infarction is twice that in non diabetics. The occurrence of atherosclerotic related 
lower limb gangrene is rare in absence of diabetes.  
 
A number of emerging risk factors for atherosclerosis have recently been proposed to help 
identify high-risk individuals, and it is considered now that these novel factors are associated 
with vascular disease risk. Those factors are C-reactive protein, lipoprotein (a), fibrinogen 
and homocysteine (Hackam and Anand, 2003). 
 
1.3.3. Pathogenesis of Atherosclerosis 
The response to injury hypothesis is one widely accepted theory as to the pathogenesis of 
atherosclerotic lesions in the vasculature. This theory suggests a sequential ordering of events 
it the formation of an atherosclerotic lesion.  
 
1) Focal areas of endothelial injury (Figure 1-16) 
Focal areas of injury to the endothelium result in endothelial dysfunction. Endothelial 
changes precede changes of atherosclerosis. Causes of endothelial injury include:  
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• Circulating endotoxins, hypoxia, products from cigarette smoke, viruses, hyper- 
homocyteinemia 
• Haemodynamic disturbances (sheer stress, turbulent flow) – ostia and branch points 
• Hypercholesterolaemia 
 
 
 
 
 
2) Deposition of lipoproteins into vessel wall.  
As a consequence of endothelial dysfunction, lipoproteins are deposited in the vessel wall. 
 
3) Cellular interaction in these foci involving endothelial cells, monocytes/ macrophages, 
T lymphocytes and smooth muscle cells (Figure 1-17). 
After endothelial injury, monocytes adhere and migrate between endothelial cells to localise 
subendothelially These monocytes transform into macrophages and engulf lipoproteins (ox-
LDL) to become foam cells. LDL previously deposited in the vessel wall is chemotactic to 
monocytes. 
  
FIGURE 1-16. SCHEMATIC SHOWING CONSEQUENCES OF ENDOTHELIAL DYSFUNCTION. FROM 
(ROSS, 1999) 
fibrous cap formation
formation of necrotic core
macrophage accumulation
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4) Proliferation of smooth muscle cells in intima with formation of extracellular matrix 
(Figure 1-18). 
Macrophages in the vessel wall proliferate and secrete cytokines. Smooth muscle cells (SMC) 
migrate from media to intima, engulf LDL and also proliferate to become foam cells as well. 
Aggregates of foam cells form fatty streaks. These may regress if LDL levels reduced or may 
continue to evolve. 
 
Proliferation of SMCs about the focus of foam cells converts a fatty streak to a mature 
fibrofatty atheroma. Arterial SMCs can synthesise collagen, elastin and glycoproteins. 
Growth factors eg PDGF and TGFα have been implicated in SMC proliferation. 
 
 
 
FIGURE 1-18. ACTIVATING EFFECT OF LDL INFILTRATION ON INFLAMMATION IN THE ARTERY. FROM 
(HANSSON, 2005) 
FIGURE 1-17. CELLULAR INTERACTION IN THE VESSEL WALL 
endothelial permeability
leukocyte migration
smooth muscle migration
foam cell formation
adherence and aggregation
 of platelets
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5. Formation of fibrous cap (Figure 1-19)  
Further deposition of collagen, elastin and proteoglycans especially on intimal aspect.  
 
6. Thrombosis 
A complication of late stage atherosclerosis. Platelet normally do not adhere to endothelium, 
but denudation or biochemical disruption can lead it to become thrombogenic. 
 
 
 
1.3.4. Prevalence and prognosis of Peripheral Arterial disease 
(PAD) 
PAD is a common manifestation of atherosclerosis. It may be asymptomatic at first but is 
associated with shortened survival due to coronary, cerebral and carotid disease. 
Incidence: UK assessment of the femoral artery found that 64 % of patients aged 56 -77y had 
significant atherosclerosis. Only 10% of these were symptomatic. (Leng et al., 2000) 
 
1.3.4.1. Spectrum and Progression of Peripheral Vascular 
Disease (PVD) 
Asymptomatic disease 
FIGURE 1-19. UNSTABLE FIBROUS PLAQUES IN ATHEROSCLEROSIS. FROM (ROSS, 1999) 
thinning of fibrous cap
haemorrhage from plaque
microvessels
plaque rupture
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Screening of patients has revealed a significant preponderance of peripheral vascular disease 
in the asymptomatic population. The ankle-brachial pressure index (ABPI) has been shown to 
be a reliable method of screening for peripheral vascular disease (Baxter and Polak, 1993). 
Seven to fifteen percent of patients with an abnormal ABPI developed intermittent 
claudication over 5 years. These people also had an increased risk of AMI and stroke. There 
has been shown to be a relationship between lower ABPI and overall survival.(Figure 1-20) 
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FIGURE 1-20. SURVIVAL CURVE FOR PATIENTS WITH PERIPHERAL VASCULAR DISEASE GROUPED ACCORDING 
TO ABPI DEMONSTATING RELATIONSHIP BETWEEN ABPI AND REDUCED SURVIVAL. FROM (MCKENNA ET 
AL., 1991) 
 
 
Intermittent claudication 
This is characterised clinically by cramping, fatigue or aching in the calf of the leg, induced 
by walking which is relieved by standing still. Of these patients, 50 % remain stable, 25 % 
develop significant worsening in symptoms (Fowkes et al., 1991). Five percent deteriorate to 
merit revascularisation and 1-2 % require major amputations (Dormandy and Rutherford, 
2000). 
 
Critical Limb Ischaemia (CLI) 
CLI is defined as more than two weeks of recurrent foot pain at rest that requires regular 
analgesics (with an ankle systolic pressure of 50 mm Hg or less, or a toe systolic pressure of 
30 mm Hg or less); Or a non-healing wound or gangrene of the foot or toes, with similar 
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pressure. In CLI, 40% will lose their leg within 6 months if no revascularisation is done 
(Dormandy et al., 1989). 
1.3.5. Effect of Exercise and Endothelial function 
Duplex ultrasound quantified flow mediated dilation (FMD) has been used to quantify 
endothelial function in patients with intermittent claudication. A cross sectional study has 
shown that reduced FMD was associated with an increased serum concentration of the serum 
inflammatory marker highly sensitive c-reactive protein (hs-crp) (De et al., 2007). 
 
It is thought that long term exercise training is a good anti-atherogenic and anti-oxidant 
therapy. Exercise is also known to be associated with short term oxidative stress around the 
period of exercise (Kojda and Hambrecht, 2005). Suvorava and Kojda hypothesise that these 
repeated short terms bouts of oxidative stress are important in that they may cause the up-
regulation of anti-oxidant protein expression in the vascular wall eventually increasing its 
antioxidant capacity (Suvorava and Kojda, 2007). Vitamin C administration to patients with 
intermittent claudication has been found to abolish the exercise induced changes in 
endothelial function supporting the redox nature of the acute changes (Silvestro et al., 2002b). 
 
Recently, a case control study compared pro-inflammatory cytokine levels in patients with 
moderate and severe intermittent claudication to healthy controls before and after exercise. 
This study showed that in all groups there was a rise in cytokine levels post exercise, which 
was higher in the severe group than the moderate group. Also, most in the severe group and 
some in the moderate group exhibited a continued rise in cytokine levels in the resting period 
(Andreozzi et al., 2007b). This inflammatory response may be involved in the evolution of 
the disease.  
 
A separate study from the previous group has shown that maximal exercise on a treadmill 
causes a worsening in the FMD assessed endothelial function. Interestingly, the both pre and 
post exercise endothelial function were found to be improved following six weeks of 
supervised exercise (Andreozzi et al., 2007a).  
A single blinded trial of 28 days of aspirin versus a nitric oxide releasing aspirin treatment 
showed that nitroaspirin was able to abolish the exercise induced FMD assessed endothelial 
dysfunction seen in the aspirin group. There was no basal effect on endothelial function and 
the effect was mirrored in exercise induced levels of serum  elastase and VCAM-1 levels 
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(Gresele et al., 2007b). A study examining the effect of both acute and 6 weeks of exercise 
training on VEGF levels did not find any differential expression (Wood et al., 2006). 
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1.4 Ischaemia reperfusion injury 
1.4.1. Introduction  
IR injury has much in common with the responses of the body to physical injury. It is 
generally agreed that the condition is caused by the immune system, and is related to the 
sudden restoration of blood flow which reperfusion generates. Resulting damage provokes 
microvascular organ, inflammation, activation of platelets and blood coagulation. (Carden 
and Granger, 2000, Esmon, 2004).  
 
Considering inflammation first, generally, this is a local immune response which eliminates 
necrotic cells by phagocytosis or lysis. It is initiated by innate immune responses principally 
organized first by neutrophil (polymorphic nuclear (PMN) white blood cell), and 
subsequently by monocyte. (Friedewald and Rabb, 2004) In recent years, however, it has 
been discovered that inflammation is also associated with systemic immune responses (SIRs). 
(Grace PA, 1998) Evidence suggests that proinflammatory cytokines such as IL-1, IL-6, 
TNF, eicasanoids, complement and cell-adhesion-molecules (CAMs) are responsible for 
these global effects.  
 
IR injury considered at the cellular level also has some similarities to the systemic 
inflammatory responses associated with sepsis (Annane et al., 2005). In both disease entities, 
despite adequate oxygen to cells, mitochondria are unable to perform normal aerobic 
respiration (Brealey et al., 2002). Of note is the presumably mitochondrial origin of increased 
levels of reactive oxygen species (ROS), which have been detected in IR injury (Becker et al., 
2000). This abnormality arises from at least two factors: first, increased oxygen due to 
increased blood flow together with less endogenous anti-oxidant activity in ischaemic injured 
cells; and second, NADPH oxidase enzyme activities due to the infiltration of inflammatory 
cells particularly PMN (Kaminski et al., 2002). These two factors suggest that this injury type 
may be distinct from other forms of inflammation in that it is also associated with non-
inflamed cell death or apoptosis. 
 
As a result of reperfusion of acute ischaemia, massive apoptosis in the microcirculatory 
environment has been shown to occur (Eefting et al., 2004). Even if immediate apoptosis 
does not occur, cells experience an exaggerated intracellular Ca2+ response (Salomonsson et 
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al., 2004). This, in turn, leads to mitochondrial dysfunction including reactive oxygen species 
produced at harmful levels, electron transport chain failure resulting in ATP deficiency and 
(mitochondrial) permeability transition pore (MPTP) opening, all of which can generate 
intracellular signals leading to apoptosis (Zoratti M, 2005). It seems likely that this damage is 
related to a state of competition between the need to allow blood into the microcirculation to 
revive the ischaemic tissues and to retard the blood surge which is responsible for the risk of 
apoptosis. (Pries and Secomb, 2000). Normal vasomotion is replaced by vasoconstriction, 
due to imbalance in vasoconstrictor to vasodilator production. Endothelial derived nitric 
oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF) are vasodilators which 
have been shown to decline in IR injury (de Wit et al., 2000, Coleman et al., 2004). This 
failure of the normal vasomotion reflex may lead to tissue ischaemia being extended. 
 
In addition to the effects discussed above reperfusion may also causes an increase in 
microvascular permeability and simultaneously activates the clotting system, which in turn 
reinforces this increase in microvascular permeability (Bogatcheva et al., 2002). The key 
coagulation factor in haemostasis is thrombin (factor IIa) which has a number of vital effects, 
including inducing vasoconstriction, coagulation (via converting fibrinogen to fibrin), 
enhancing vascular permeability and eventually as an endogenous anticoagulant arresting the 
process of clotting which activates thrombomodulin together with protein C and protein S 
(Dahlback, 2005). The leakage of plasma protein into interstitium due to the increase in 
vascular permeability can cause tissue oedema (that compresses blood vessels, both arteriole 
and venule), leading to further tissue ischaemia. This may also result in haemoconcentration 
in the microvascular lumen, especially within the postcapillary venule (where PMN cells 
migrate from vessel lumen), increasing the potential for inflammation and clotting (Habazettl 
et al., 2000, Christ et al., 1998). Because the process of inflammation can prolong vascular 
permeability, the increase of capillary filtration rate may be an indication of the extension 
phase of IR injury (Christ et al., 1998, Molitoris and Sutton, 2004). 
 
1.4.2. Mechanisms of Ischaemia Reperfusion Injury 
 
Reperfusion following a previous period of ischaemia takes place in various organs as a result 
of a number of surgical procedures, and as a physiological response to certain pathological 
conditions. Surgical/medical procedures in which IR injury following revascularisation is an 
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identified complication include coronary (CAOD) and peripheral arterial occlusive disease 
(PAOD) interventions, using both conventional bypass and minimal invasive percutaneous 
transluminal angioplasty (PTA) techniques. The pathophysiological consequence of IR may 
also be considered as iatrogenic complications. Patients with intermitted claudication are 
often exposed to repetitive IR injury events. PAOD patients with claudication symptom 
initially are generally advised to do walking exercise; however intense exercise can cause an 
ischaemic event followed by reperfusion in the recovery period. The surgical approach to 
PAOD patients is another typical model of IRI due to the fact that revascularisation is 
regarded as the optimal treatment for moderate and severe degrees of PAOD. The 
revascularisation itself results in a reperfusion phase, which can be both curative and 
injurious. 
 
Collaborative studies focused on all medical models of IRI would advance our understanding 
of its mechanisms. IRI research has also extended into the field of operations involving free 
tissue transfer or flap and organ transplantation. These are the good models for IRI studies. 
The ischaemic event takes place when the donor tissues have been totally cut off from arterial 
supply and venous flushing flows; the reanastomosis of the blood vessel then initiates the 
reperfusion event. Likewise, bloodless procedures, using tourniquets to stop excessive blood 
loss during surgery, particularly of the limbs, commonly employed in orthopedic surgery is 
also an IRI model. Abdominal aortic aneurysm (AAA) repair procedures are another typical 
case in which IRI is induced. These include aortic clamping, causing tissue ischaemia in a 
widely affected area in the distal parts, including the intra-abdominal region and all of lower 
extremities; followed by releasing of the clamp producing the reperfusion insult. 
 
Physiological autonaomic vasoconstriction of the splanchnic circulation in response to injury, 
shifting the splanchnic blood pool to vital organs, may result in a pre-renal renal failure and 
intestinal ischaemia. Perturbation of the splanchnic circulation can sometimes occur due to 
systemic homeostatic responses to certain kinds of injury, like trauma, infection, and as a 
result of several chronic illnesses (e.g. chronic cardiac, renal or liver failure) all of which can 
lead to acute renal failure. Renal hypoperfusion (ischaemic) and return of blood flow 
(reperfusion) is believed at present to be the major mechanism of acute renal failure (ARF) in 
over 50% of ARF events affecting about 5% of all hospitalized patients (Ysebaert et al., 
2004, Thadhani et al., 1996). Intestinal IR injury is believed to cause the pattern of increased 
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gut permeability, gut hypoperfusion, hypoxia and reperfusion injury all of which appear to be 
a source of bacterial translocation and endotoxin into the circulation (Asimakopoulos, 1999). 
1.4.3. Essential Mechanisms of IRI 
 
IR injury events require prior local cell injury caused by ischaemia, and further cell injury 
associated with reperfusion. IR injury basically results from the pathophysiological 
consequences of an ischaemic condition followed by reperfusion damaging the local affected 
cells. These mechanisms are considered to originate from cell homeostasis derangement and 
microvascular disruption in the local tissue. It may be possible to classify the mechanisms 
generating the pathophysiological consequences of IR injury into local and global effects. 
The local mechanisms may be categorised into pathophysiological consequences as follows. 
 
1.4.3.1. Local Tissue Ischaemia 
Deterioration in cellular homeostasis and microcirculatory blood flow regulation is a 
consequence of ischaemia. Cells are starved of nutrients and are hypoxic. The prolongation of 
tissue ischaemia causes massive cell loss and leads to excessive intensity of local tissue 
injury. In the ischaemic cell, lack of O2 interrupts mitochondrial respiration and anaerobic 
respiration results, which is less effective than aerobic. Energy generation is lacking for 
necessary cellular functions especially ion channel control mechanisms, in particular the Na+-
K+ pump (Figure 1-21). This results in Na+ accumulation, subsequent cell swelling and 
eventual necrosis. 
 
 
 
 
FIGURE 1-21. A) NA+-GLUCOSE SYMPORT; B) NA+- CA2+ ANTIPORT (EXCHANGER) WITH NA+-K+ ACTIVE 
PUMP PROVIDING NA+ GRADIENT (ELLIOTT, 2001). 
 
A B 
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CO2 is the waste product of glucose utilization in the aerobic route while lactate is generated 
in the anaerobic. In a cell which has glycogen storage, when cells lose their glucose supply, 
glycogen storage has to be used for glucose and ATP. During ischaemia, the clearance of 
waste products is inadequate and this leads to an accumulation of lactate which causes 
intracellular acidosis or low pH. Under these conditions, H+ tends to move out, from 
mitochondria, then cytoplasm and subsequently into the interstitial space. The interstitial 
fluid becomes acidotic, and this leads to Na+ influx into the cell by Na+-H+ antiport 
(exchanger) as shown in Figure 1-22. Prolongation of ischaemia affects Ca2+ homeostasis 
because the Na+ influx affects the Na+-Ca2+ exchanger and high Na+ in cytosol is pumped out 
in exchange for Ca2+. In ischaemic conditions, the antiport Na+-Ca2+ exchanger has been 
shown to work in the opposite way to normal i.e. as a reverse Na+-Ca2+ antiport. This reverse 
action of the Na+-Ca2+ exchanger leads to an increase in intracellular calcium [Ca2+i] and a 
great increase in intracellular Ca2+ [Ca2+i], which subsequently triggers apoptotic signals 
mediated by mitochondria. 
 
 
 
Ischaemic conditions produce cascades of stress signaling as shown in Figure 1-23. It is 
suggested that ischaemia activates the production of nitric oxide, which leads to 
vasodilatation in the microvasculature. On the other hand, HIF-1α up-regulates vascular 
endothelial growth factor (VEGF) and erythropoietin (EPO). VEGF causes a microvascular 
permeability increase, which results in tissue edema. Erythropoietin leads to an increased 
production of RBC in bone marrow (Cao et al., 2005). 
 
FIGURE 1-22. NORMAL ANTIPORT EXCHANGE BETWEEN 
NA+ AND CA2+ AND BETWEEN NA+ AND H+ (COOPER, 2000) 
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FIGURE 1-23. TISSUE RESPONSES TO ISCHAEMIA (NO, NITRIC OXIDE; HIF-1Α, HYPOXIA INDUCIBLE FACTOR; 
EPO, ERYTHROPOIETIN; VEGF, VASCULAR ENDOTHELIAL GROWTH FACTOR; RBC, RED BLOOD CELLS) 
(CAO ET AL., 2005). 
 
Prolonged ischaemia with massive cell necrosis intensifies inflammation. Some endothelium 
may die as a result of ischaemia, and may detach from the basement membrane. Other 
endothelial cells may not function properly. In addition, ischaemia activates certain genes that 
lead to an increase in cellular respiration in mitochondria, especially in tissue that has a high 
metabolic rate such as heart or skeletal muscle. This is dangerous when the tissue is 
reperfused because it results in elevated cellular respiration, ATP manufacture, and a high 
production of ROS.  
 
No Re-flow Phenomenon 
Ischaemia can be caused by obstruction of tissue arterial perfusion and/or obstruction of the 
venous outflow that is required for drainage of waste products such as lactate, urea and CO2. 
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The presence of venous obstruction followed by its removal may be considered as another 
model of IR injury. However, most commonly studied models of IR injury involve the 
arterial supply. A number of studies have pointed out that IR injury often cause other 
episodes of ischaemia or arterial obstruction in the local tissue, even after successful 
reperfusion. This is known as the no re-flow phenomenon.   
 
Historically, the no re-flow concept was first described in ischaemic rabbit brains. These 
studies showed that if ischaemia was brief (2.5 minutes), normal blood flow was restored 
when the ischaemia was relieved. However, in the case of longer ischaemic periods, normal 
flow to brain tissues was not restored, even after relief of the vessel obstruction. This shows 
that prolonged ischaemia can result in significant changes in the microvasculature or no re-
flow after reperfusion. This phenomenon has been confirmed in a variety of both human and 
animal models of brain, heart and other tissue (Rezkalla and Kloner, 2002). 
 
The no re-flow phenomenon is recognised as inadequate tissue perfusion. There is strong 
evidence that it occurs after coronary intervention for acute myocardial infarction. In patients 
with total coronary occlusion undergoing catheterization, it has been shown by using contrast 
imaging and coronary Doppler flow that after coronary revascularisation, blood flow may 
slow down or cease in some areas. This slow down of blood flow can be categorised into four 
grades defined by the Thrombolysis in Myocardial Infarction (TIMI) group in the early 
1980s; Grade 0 refers to no flow at all after the obstruction point; Grade 1, the contrast 
material flows beyond the area of obstruction but fails to opacify the entire artery; Grade 2 
refers to opacification of the entire artery distal to the occlusion site but at a slower rate than 
normal; and Grade 3 refers to normal coronary flow (Rezkalla and Kloner, 2002). 
 
The no re-flow phenomenon is believed to occur immediately after reperfusion or shortly 
thereafter (Rezkalla and Kloner, 2002). It is believed that the etiological factor causing the no 
re-flow phenomenon is multifactorial involving the blood endothelial interface, end organ 
injury and coagulation. 
 
Calcium 
Increase of intracellular Ca2+ is a characteristic feature of IR. It is believed that Ca2+ overload 
may be the key explanation of massive cell death association with IR injury. Normally, Ca2+ 
is pumped out in exchange for Na+ influx (as shown in previous Figure 1-22), however, 
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following IR injury, the Na+/Ca2+ exchanger works in the reverse manner. The cytosolic Na+ 
overload leads to a reverse exchange of Na+ and Ca2+.  
 
As long as ischaemic-reperfused cells are unable to regenerate ATP to reactivate the function 
of Na+-K+ ATPase, Ca2+ continues to persistently move into the cytoplasm and as a result, the 
intracellular Ca2+ overload precipitates apoptosis.  
 
In the early period, after successful reperfusion, although there is a gradual availability of 
ATP, Ca2+ may still increase by the sequestration of Ca2+ from endoplasmic reticulum (ER) 
and this may be another reason of apoptosis induction by reperfusion (Piper et al., 2004). 
 
Mitochondrion 
The activities of Na+/Ca2+ and Na+/H+ antiports on the mitochondrial membrane are 
influenced by IR events similarly to those of the plasma sarcollema (Duchen, 2004b). 
Intracellular calcium concentration has been found to be one pivotal factor that shapes the 
future of cell in IR related events. Intra-mitochondrial calicium ([Ca2+m]) is generally low 
under ‘resting' conditions, regulated largely through the activity of a Na+/Ca2+ exchanger on 
the mitochondrial membrane. During the ischaemic state, anaerobic respiration occurs 
normally in the mitochondrial matrix and this leads to lactate accumulation, mitochondrial 
acidosis and then cytoplasm acidosis. The acidification in the mitochondria leads to a gradual 
increase in levels of Na+ and Ca2+, successively. Cytoplasmic calcium has a strong influence 
on influx of calcium into mitochondria and causing change in the mitochondrial electrical 
potential affecting ATP synthesis. It is likely that as long as an accumulation of lactic 
acidosis from anaerobic respiration occur in mitochondrion, mitochondrial potential will 
remain de-polarised (Duchen, 2004a). At reperfusion, mitochondrial potential will abruptly 
recover as mitochondria begin to respire again. However, the repolarisation of mitochondria 
membrane (Na+ flowing out) occurs at a time in which cytosolic [Ca2+] is high and may be 
injurious as this may cause further loading of mitochondria with calcium (Duchen, 2004a). 
 
Na+ inflow in exchange for H+ creating membrane depolarizing can occur from the luminal 
surface of endothelial, this Na+ flow is believed to produce succesive mitochondrial 
membrane depolarising. With reports that there is a persistent lactate production in cells after 
reperfusion, it is supposed that there is a persistent problem insofar as cells cannot reverse 
anaerobic to aerobic respiration despite restoration of oxygen supply. Mitochondrial 
 91 
 
membrane depolarisation may be associated with this inability of the cell to immediately 
reverse anaerobic to aerobic respiration. This is supported by reports demonstrating delayed 
recovery of several enzymes, previously downregulated during ischaemia (Wernly, 2004). 
Reoxygenation of mitochondria may lead to rapid or slow recovery of oxidative energy 
production, depending on the length of ischaemia, the extent of mitochondrial injury and 
mitochondrial Ca2+ ([Ca2+m]) overload (Piper et al., 2004). Long periods of ischaemia can 
alter the electron transport complexes in mitochondrion, all the complexes show a reduction 
in activity with structural damage (Siemionow and Arslan, 2004). 
 
Mitochondrial membrane electropotential, based on the proton gradients and the high H+ 
outside and low H+ inside, is necessary for function of ATP synthase and the respiratory 
complexes to produce ATP. At the moment of change from ischaemia to reperfusion, there is 
an additional energy consumption to translocate protons (H+) out of the mitochondria for 
repolarisation of the mitochondrial membrane (Duchen, 2004a). If there is not enough ATP 
available, mitochondrial membrane ion pumps will not be able to provide an adequate H+ 
gradient to restart aerobic ATP synthesis in mitochondria. 
 
In case that mitochondria can convert from anaerobic to aerobic respiration after the 
reintroduction of O2, the mitochondrial electron transport chain complexes may still be 
damaged from ischaemia, causing a leak of electrons that react with oxygen to generate 
reactive oxygen species (ROS), resulting in oxidative burst (Siemionow and Arslan, 2004). 
 
Mitochondria represent not only a major source of ROS generation, but also a major target of 
ROS induced damage. ROS have been indicated to be the cause of lipid peroxidation and 
damage to cell membranes and to DNA. Because of no coverage of histones, mitochondrial 
DNA is less protected from ROS damage than nuclear DNA.  The leaking of mitochondrial 
ROS into several cellular compartments is possible due to the incompetence of the natural 
course of detoxification action for ROS in mitochondria. It is believed that the combination 
of a high mitochondrial calcium concentration, ATP depletion with a high phosphate (due to 
ATP consumption), and oxidative stress, favor opening of the mitochondrial permeability 
transition pore  (MPTP) and caspases (cysteine aspartate-specific proteases) activation which 
are central to the course of mitochondrial mediated cell apoptosis (Duchen, 2004a). 
 
Oxidative Stress 
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During ischaemia, the tissues lack oxygen supply and the cells respond to the situation in at 
least three ways: an increase of respiratory elementary units in mitochondria, accumulation of 
anaerobic respiration products particularly xanthine (adenosine related chemical products) 
and impairment of several oxidative buffering enzymes. In the early period of reperfusion, it 
is believed that mitochondria become one of the major sources of ROS. Anaerobic respiration 
results in the consumption of ATP and this lead to hypoxantine generation as a final product 
(Figure 1-24) (Mallick et al., 2004).  
 
Endothelial xanthine oxidase (XO) is one of the major producers of ROS in IR injury. The 
degradation of ATP to ADP and then to AMP takes place, and this results in the intracellular 
accumulation of adenosine, inosine and free phosphated groups. These free phosphated 
groups are believed to facilitate apoptosis mediated by mitochondria. In contrast to the 
phosphorylated nucleotides, which cannot diffuse from the cellular cytoplasm into the 
extracellular matrix, both adenosine and inosine can pass into the extracellular space, where 
they are further degraded to hypoxanthine (Wernly, 2004).  
 
It has been shown that the attraction and adhesion of inflammatory cells to the endothelial 
microvasculature in response to damage is caused by free radicals generated by xanthine 
oxidase (Wernly, 2004). The infiltration of PMN also causes ROS to be ejected from the 
NADPH oxidase enzyme. It is believed that in the later stage of reperfusion, the major source 
of oxidative stress comes from this PMN-NADPH oxidase activity. 
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FIGURE 1-24. CA2+ FLUX AND THE UPREGULATION OF XANTHINE OXIDASE AND THEIR ROLES IN ROS 
OVERPRODUCTION (MALLICK ET AL., 2004). 
 
 
   
The ROS include both radical and non-radical biomolecules. A radical is defined as an 
atomic biomolecule containing unpaired electrons. Free radicals of oxygen include 
superoxide (O2●-) and hydroxyl radical (OH-) while non-radicals are generated from radical 
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molecules, the archetypical example being hydrogen peroxide (H2O2). The catalyst is 
superoxide dismutase (SOD):  
 
The process of ROS reacting with other biomolecules might be considered as the result of the 
action of NADPH, XO and other sources, which generate free single electrons; these 
electrons subsequently react with oxygen to form superoxide. These reactions are rapid, so it 
may be impossible to measure accurately the quantity of each radical and non-radical 
directly. In addition to ROS, reactive nitrogen species (RNS) also occur. The non-radical of 
these is nitric oxide (NO). Peroxynitrite (ONOO-) is a free radical RNS formed by NO and 
O2●- (Figure 1-25). The toxicity of ROS and RNS is a result of the formation of peroxynitrite 
(ONOO-) and hydrogen peroxide (H2O2). Unlike superoxide (O2●-), H2O2 can rapidly diffuse 
across cell membranes to other cellular compartments and to adjacent cells and therefore, it 
distributes the damaging effects to a wide area (Glantzounis et al., 2005). The Fenton reaction 
is a well-characterised toxic mechanism in which H2O2 reacts with trace amounts of metal 
ions (principally iron (Fe2+) and Copper (Cu+) as shown in the equation below to produce the 
toxic hydroxyl radical.  
 
 
Meanwhile, peroxynitrite can cause cell injury through multiple pathways: initiation of lipid 
peroxidation, direct inhibition of mitochondrial respiratory chain enzymes, inhibition of 
membrane Na+/ K+ ATPase activity, or oxidative protein modification such as formation of 
nitrotyrosine (Glantzounis et al., 2005). 
 
 
2 O2
	- + 2H+   H2O2 + O2
SOD
Fe2+ or Cu+ + H2O2 Fe
3+ or Cu2+ + OH- + OH-
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ROS toxicity is not solely caused by an increase in the line of free radical and non-radical 
bimolecular production; it is also due to the fact that ROS elimination is not fully functional 
after reperfusion. Normally, the cell has natural or endogenous antioxidant defense 
mechanisms to protect it from damage by free radicals. An endogenous antioxidant is defined 
as any substance that, when present at low concentration compared with an oxidizable 
substrate significantly delays or prevents oxidation of the substrate. Although ROS and RNS 
have an important role in signal transduction pathways coordinating the body's inflammatory 
response after injury, the production of both at such high levels that they cannot be 
counteracted by these endogenous antioxidant systems, can lead to damage of lipids, proteins, 
carbohydrates, and nucleic acids. This imbalance due to overproduction within the buffer 
system is termed as oxidative stress (Glantzounis et al., 2005).  
 
The buffering system begins with the conversion of free radical O2●- to H2O2 by SOD; 
catalase or glutathione then detoxifies the H2O2 to water. Metal binding proteins, such as 
transferrin and ceruloplasmin, bind free metal ions and prevent the progress of Fenton 
2O2 2O2
¯ H2O2 H2O + O2
ONOO¯ 2OH¯
catalase
NO
+
Fe2+
Fe3+
+
Oxidation
Glutathione peroxidase
Thioredoxin
FIGURE 1-25. FREE RADICAL AND NON-RADICAL ELEMENTS OF ROSS AND RNSS CYCLES. (TOUYZ, 2004) 
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formation of free radicals. SOD is the main counterbalance to the free radicals of the ROS. It 
converts superoxide to hydrogen peroxide and oxygen as show in equation below.  
 
There are several well-characterised SOD isoforms including SOD-1 (or SODCu), SOD-2 or 
(SODZn) and SOD-3 or (SODMn). SOD 1 and 2 locate in cytosol while SOD-3 resides at the 
mitochondrial and extracellular levels. The buffer mechanisms for ROS and RNS can be 
categorised by their location as, either intracellular or extracellular, and by their actions as 
counteracting either free radicals or non-radicals. The intracellular group consists of SOD, 
catalase, glutathione peroxidase and gluthathione reductase, peroxidase, thioredoxin and 
haem oxidase system, while the extracellular group includes metal binding protein-
transferrin, lactoferrin, glutathione, SODMn, and ceruloplasmin (Urban et al., 1995). 
 
Hemoglobin and myoglobulin are intracellular, however under conditions of oxidative stress, 
these proteins are degraded and release haem and free metal ions such as Fe2+ into the 
extracellular space. It is believed that free metal iron and copper can promote the free radical 
toxic effect, accelerating plasma membrane lipid peroxidation by converting H2O2 (hydrogen 
peroxide, diffused from inside cells) to the free radical OH- via the Fenton reaction. 
 
There are three well known buffering systems for detoxifying hydrogen peroxide to water 
and oxygen. Catalase and gluthione peroxidase act as follows: 
 
 
2O2- + 2H+ H2O2 + O2
SOD
2H2O2 O2 + 2H2O
2GSH +2H2O2 GSSG +2H2O
Catalase reaction
Glutathione 
peroxidase (GSH)
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Glutathione reductase recycles GSSG (the oxidized form of GSH) to GSH, which can be 
reused. The GSH/GSSG ratio also identifies the excitation state of the cell. The third H2O2 
detoxification system is peroxidase; it reduces hydrogen peroxide and alkyl hydroperoxides 
to water and alcohol. There are several other intracellular antioxidants, one of which is 
thioredoxin. This polypeptide is mainly located in endoplasmic recticulum and partially in 
mitochnodria. Its mechanism is similar to gluthathione; the detoxification of ROS is driven 
by the conversion of its sulfhydryl group (reduced form) to disulphide (oxidized form) 
(Glantzounis et al., 2005). 
 
Another widely studied factor is haeme oxygenase (HO); this is an enzyme found in the 
endoplasmic reticulum that catalyses the breakdown of haem to biliverdin with the release of 
free iron ions (pro-oxidant) and carbon monoxide. Three isoforms of HO have been 
characterized: HO-1, which is highly inducible in conditions of inflammation and oxidative 
stress, and HO-2 and HO-3, which are constitutively expressed. Induction of HO-1 protects 
the cell against oxidative injury by controlling intracellular levels of free heme Fe2+ (pro-
oxidant), producing biliverdin (antioxidant), and improving microcirculation via carbon 
monoxide release (Glantzounis et al., 2005). 
 
Cells in different organs contain different concentrations of endogenous antioxidants and also 
a varied level of both amount and kind of the buffering system. This means that some tissues 
can tolerate IRI better than others. 
 
Blood / Endothelium Interactions 
Blood/endothelial interaction in the normal physiology is complex and includes the exchange 
of plasma, temperature, lower pH, and different of ionic concentration from local interstitial 
fluid, the the resupply of nutrients, oxygen, plasma proteins and coagulation factors (Tedesco 
et al., 1999) and interaction of blood cells. Mainly of these responses if disrupted may result 
in pathological consequences (Molitoris and Sutton, 2004, Ward and McCarthy, 1995, 
Mazzoni et al., 1995). The increase of blood flow into the ischaemic and inflamed 
microcirculation results in pathophysiology because WBC numbers will increase in this low 
blood supply. WBC/ endothelial interaction will result in end organ injury, high level of ROS 
and endothelial dysfunction (Becker et al., 2000, Granger, 1999, Harris et al., 1997). The 
reintroducing of blood cells especially PMN therefore, intensify the inflammatory by PMN 
activation and transmigration. 
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Intense Inflammation 
Inflammation results from local events which occur between injured cells in one area 
interacting with the immune system including immune cells and plasma inflammatory-related 
proteins (most synthesized in liver). Mediated by production of a variety of mediators, the 
interplay may be local in nature or, under more intense condition, may be systemic.  
 
Inflammatory mediators present in the circulation are employed to recruit elements of the 
systemic immune system. Recently, the detection of inflammatory mediators in the 
circulating blood informed the term systemic inflammatory response syndrome (SIRS). These 
molecules represent the messages sent from the local microcirculation to the remote immune 
system including bone marrow and secondary lymphatic organs like lymph nodes, liver and 
spleen to react to the injury. Inflammation is the interplay of immune elements and injured 
cells which constitutes a destructive step followed by a reparative stage. The first stage is to 
eliminate foreign elements, abnormal cells and debris while the following step is to heal the 
damage. 
 
The innate system comprises the majority of the inflammation that is manipulated by innate 
immune cells, and plasma inflammatory related proteins in particular complement. Acute 
inflammation is different from chronic inflammation as it eradicates the injury caused in a 
short period and the tissue can start to repair. In contrast, chronic inflammation shows 
prolonged activity of the immune elements and implies a persistent injury which causes 
continuous cell injury. Therefore, the tissue repairing process in chronic inflammation can 
start but may not reach a conclusion. 
 
In local tissue injury, IRI causes an active inflammatory response. The triggered 
inflammatory signals from injured parenchymal cells and activated endothelial cells result in 
the release of proinflammatory mediators including cytokines, chemokines, and eicasanoids 
and the activation of complement, and coagulation proteins. Up-regulation of 
proinflammatory cytokines, like tumor necrosis factor (TNF), interferon (INF), interleukin 
(IL)-1, IL-2, and IL-8, cause an increase in vascular permeability resulting in tissue edema 
and microcirculatory haemodynamic stasis. In addition, it is believed that the inflammatory 
signals and the releasing of the pro-inflammatory mediators stimulate the endothelial cell to 
relax VSMC and cause microvasculature increase of blood flow and vessel diameter. These 
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changes in the microvasculature result in recruitment of peripheral leukocytes into the 
microvasculature which then migrate into the interstitial space.  
 
The combined effects of inflammatory signals, proinflammatory mediators and tissue edema 
provides a possible mechanism of up-regulation of cellular adhesion molecules on the 
endothelial luminal surface, initiating a series of WBC attraction coordinated steps including 
tethering, triggering, strong adhesion, and trans-endothelial migration of PMN and monocyte 
(Ysebaert et al., 2004).  
 
One of common inflammatory signals initiating these local pathophysiological consequences 
is regarded to activation of NF-κB. The common sources activating NF-κB in endothelial 
cytoplasm leading to an expression of CAMs include proinflammatory cytokines, oxidants 
and gram negative bacterial wall, lipopolysaccharides (LPS) (As shown in Figure 1-26) 
(Mallick et al., 2004). Following IR injury, tissue damage activates endothelial cell up-
regulation of adhesion molecules which promotes endothelial-leukocyte interactions. These 
adhesion molecules include integrins, members of the immunoglobulin superfamily, 
including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 
(VCAM), and P&E-selectin (Bonventre and Zuk, 2004).  
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FIGURE 1-26. STRESS SIGNALS AND EXPRESSIONS OF CELLULAR ADHESION MOLECULES (CAMS)(MALLICK 
ET AL., 2004) 
 
Clearly, endothelium plays a crucial role in the crosstalk between the immune cells 
circulating in the blood, and the tissue. Indeed, endothelial cells can initiate both primary 
innate and secondary specific immunity responses. Because of the ability of these cells to 
provide costimulatory signals to circulating T cells and other cells, they may serve as the 
initial antigen presenting cell in the immune responses in peripheral tissues (Ysebaert et al., 
2004).  
 
Endothelial cells express CAMs on their surface glycosalyx when it is necessary to attract the 
immune cells to infiltrate the tissue that are exposed to attack or need phagocytocyte to 
scavenger cell debris. Generally, selectin is believed to play a predominant role in early 
WBC/ endothelium interaction while intregrin plays an important role later (Figure 1-27) 
(Mallick et al., 2004). PMN is the primary and crucial immune cell that triggers acute and 
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intensive inflammatory processes. The infiltration of PMN promotes injury of tissue and the 
emigration of PMN into the injured tissue is the hallmark of acute inflammation.  
 
p-selectin PGSL-1 CD11/CD18ICAM-1 PECAM-1
blood flow
selectins
integrins
loose adhesion (rolling) firm adhesion diapedesis
 
FIGURE 1-27. TRANSMIGRATION OF PMN (MALLICK ET AL., 2004) 
 
 
The infiltrated PMN generate intense inflammatory processes by degranulation and releasing 
several enzymes including NADPH oxidase, myeloperoxidase (MPO), elastase, collagenase 
and phospholipase (Kaminski et al., 2002). These enzymes further mediate and amplify 
inflammatory processes. NADPH oxidase produces ROS while myeloperoxidase (MPO) 
content of postischaemic tissue reflects presence of PMN, activated residential interstitial 
macrophages and freshly migrated monocytes in inflamed tissue (Ysebaert et al., 2004). 
 
1.4.3.2. Global Effects 
 
Reperfusion may cause systemic spill-over of local inflammatory mediators into the systemic 
circulation. This may subsequently activate processes which impair the remote 
microcirculation. IR injury may cause inappropriate immune responses which result in a wide 
range of homeostasis derangement with cellular, tissue level and systemic consequences. 
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Exposure of proinflammatory cytokines like IL-1 and TNF in remote tissues can result in the 
induction of inflammatory signalling pathways, PKC and NF-κB. The activation of PKC on 
endothelial cells by the inflammatory mediators can result in alternation of microvascular 
vasopermeability (Stevens et al., 2000, Konstantoulaki et al., 2003).  
 
The NF-κB transcription factor family, discovered in 1986, induces the expression of many 
genes that play a critical role in both the regulation of immune and inflammatory responses 
and in the protection of cells from variant insults. NF-κB factors can be activated by a wide 
variety of stimuli such as proinflammatory cytokines, bacterial lipopolysaccharide (LPS), 
viruses, radiation and oxidative stress. NF-κB therefore initiates a coordinated and rapid 
response in multiple cell types (Carlsen et al., 2004). The transduction stimulation of NF-κB 
are initially activated in the cytoplasm through phosphorylation IκB reaction which 
consequently upregulate a transcription protein NF-κB in the nucleus. NF-κB later generates 
signals transduction cascading to upregulate several chemotaxis factors, cellular adhesion 
molecules (CAMs) and pro-inflammatory cytokines. There are also several inflammatory 
enzymes generated through the NF-κB activation including cyclooxygenase (COX), 
lipooxygenease (LOX) and cytochrome P450, and inducible nitric oxide synthase (iNOS) as 
shown in Table 4 
 
 
TABLE 4. INFLAMMATORY MEDIATORS IN ASSOCIATED TO NF-ΚB ACTIVATION (BARNES AND KARIN, 1997) 
Inflammatory 
Enzymes 
Chemokines Adhesion 
molecules 
Proinflammatory 
Cytokines 
Inducible nitric 
oxide synthase 
(iNOS) 
Interleukin-8 Vascular-cell 
adhesion molecule 
1 (VCAM-1) 
Interleukin-1 
Inducible 
cyclooxygenase-2 
(COX-2) 
Macrophage 
inflammatory 
protein 1 (MIP-1) 
Intercellular 
adhesion molecule 
(ICAM-1) 
Tumor necrosis 
factor (TNF) 
5-Lipoxygenase 
(LOX) 
Macrophage 
chemotactic protein 
1 (MCP-1) 
E-selectin Interleukin-2 
Cytosolic   Interleukin-6 
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phospholipase A2  
Cytochrome P450   Granulocyte-
macrophage 
colony-stimulating 
factor (GMCSF) 
   Macrophage 
colony-stimulating 
factor (MCSF) 
 
 
The expression of iNOS is regulated by the transcriptional factors gene in nucleus. It is 
believed that the upregulation of the promoter regions of iNOS genes as well as several 
inflammatory enzymes are associated to NF-κB binding sequences. High levels of NO 
through the iNOS pathway can result in high formation of peroxynitrite which is a potent free 
radical nitrogen oxidant and may exacerbate tissue injury and inflammation (Alderton et al., 
2001).  
 
The sustained plasma levels of proinflammatory cytokines are associated with consequent 
activation of cells in tissue through the NF-κB pathway and iNOS reaction. This may disturb 
or induce a loss of biologic activity of endothelium-derived nitric oxide in remote vulnerable 
organs like lung and kidney (Carden and Granger, 2000, Huang and Vita, 2006).  
 
The disturbance of eNOS-NO biosynthesis pathway leads to the alternation of endothelial 
function which further impairs local control of vasomotor tone, promotes procoagulants and 
local thrombosis, and accelerates inflammation by releasing chemotactic factors and the 
upregulation of CAMs expression on the endothelial luminal surface resulting in an 
enhancement of PMN sequestration (as shown in Figure 1-28) (Carden and Granger, 2000, 
Huang and Vita, 2006). 
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FIGURE 1-28. GLOBAL EFFECTS OF IR INJURY IN THE REMOTE MICROCIRCULATION (CARDEN AND 
GRANGER, 2000), 
 
 
The severity of IRI and its local and systemic consequences may be influenced by: 
 
• The intensity of local tissue inflammation that would cause a proportional release of 
inflammatory mediators. 
• The prolongation of local tissue loss and inflammatory processes will have a tendency 
to cause remote organ injury more frequently and more organs will be affected. 
• The vulnerability of the individual person due to previous presence of exposure to 
CVD risk factors which cause a different degree of endothelial dysfunction  
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• The susceptibility of remote organs to inflammation that would occur, influenced by 
pre-existing endothelial dysfunction and the type of tissues. 
 
In summary, the IRI mechanisms can be considered as changes occurring at the cellular level 
from ischaemia injury of cells to oxidative stress injury of cells. Restoring blood flow to 
ischaemic cells generate considerable alterations in cellular homeostasis with overproduction 
of toxic ROS. The change of blood flow also affects organs at a microvascular levels. 
Revascularisation in the microvasculature results in an increase of vascular permeability, 
expression of cellular adhesion molecules (CAMs), and infiltration of WBCs. Circulating 
immune cells from the blood adhere to activated endothelium and transmigrate through 
vascular wall resulting in increased cell injury.  
 
1.4.4. Clinical Manifestations Of Ischaemia Reperfusion Injury 
 
Certain organs are recognised to be associated with IR injury in two ways; firstly as a primary 
injured organ and subsequently producing an effect to other distant organs and secondly as a 
secondary targeted organ affected from the massive tissue injury in the primary organ 
together with the systemic responses effects.  
 
The following sections examine the damage to cell homeostasis in the heart while the 
microvascular dysfunction is discussed with respect to revascularisation of the lower limbs.  
 
1.4.4.1. Local effects 
Heart  
Coronary artery occlusive disease (CAOD) has the same risk factors as the peripheral arterial 
occlusive disease (PAOD).  
 
In the heart, IR injury following revascularisation of the coronary arteries disease (CAD) and 
acute coronary syndrome (ACS) may limit to small local areas or result in extensive loss of 
myocardial cells leading to further circulatory system failure Heyndrickx, GR et al. (1975) 
(cited in (Wernly, 2004)). It is seen in the clinical setting after reperfusion, where many areas 
in myocardial tissue are not functional after successful reperfusion and termed ‘stunned’ 
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which show lack of contractility but generally are not associated with cardiocyte death. An 
analogous phenomenon has been termed hibernation. 
 
The consequences of cells injured from IR injury may be reversible or. Cells which are 
successfully reperfused, and replenish ATP can stabilize their cell membrane and may not 
progress to necrosis. However, reperfusion can make high degree of metabolic change that 
leads to mitochondrial dysfunction causing MPTP opening and eventually activating 
apoptosis. In IRI, as the mitochondrion is related not only to cellular respiration but also ion 
concentration in the cell. The dramatic loss of intracellular ions, especially potassium 
together with the prompt loading of calcium can progress the apoptotic process (Norwood et 
al., 2004). Mitochondria are the core compartment that play significant role in driving the 
apoptosis program including the release of cytochrome C from the mitochondrial 
intermembrane space (MIMS) (Duchen, 2004a) , and a series of  enzyme cascades activation 
resulting in organized and coordinated cell destruction. (Figure 1-29) 
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FIGURE 1-29. MITOCHONDRIAL PERMEABILITY TRANSITION (MPT)-DEPENDENT MODES OF CELL DEATH 
FATE IN IRI: CSA; CYCLOSPORIN A, DEVD; CASPASE 3 INHIBITOR (KIM ET AL., 2004) 
 
Prolongation of ischaemia results in the running out of ATP; the ion homeostasis is 
deteriorated; cell subsequently swell and are likely to necrose. During reperfusion, calcium 
loading, mitochondria quandary and ROSs toxicity are supposed to be triggers for the 
induction of apoptosis program (Siemionow and Arslan, 2004). Apoptosis may occur during 
ischaemia, but majority of cell death occurs after reperfusion (Eefting et al., 2004). Therefore 
the mode of cell death during ischaemia is likely to be cell necrosis while the apoptosis is 
expected to be the major mode of programmed cell death when the tissue is reperfused. In the 
heart, apoptosis may not result in inflammation but massive but acute organ dysfunction, 
circulatory failure and shock (Eefting et al., 2004, Thompson, 1998). 
 
Lower Extremities 
Interestingly, it has been repororted that patient with PAOD are not disease free in the upper 
extremities (Labs et al., 1999, Dormandy and Rutherford, 2000, Hirsch and Hiatt, 2001). 
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Indeed, peripheral arterial disease has long been known as a marker of lesion of coronary 
artery occlusive disease (CAOD). Conversely, in patients with CAOD, it is possible to find 
PAOD lesions in the lower limbs.  
 
One of the obvious clinical manifestations of the lower extremities after revascularisation 
regarding IR injury is prolonged postoperative leg oedema indicating microcirculatory 
perterbance. In terms of the micro-circulation, the pre-capillary arteriole is affected by 
ischaemic and reperfusion events as the vascular smooth muscle cells can not relax as normal 
physiological process, conducted by the regulation of the endothelial-related vasodilatation 
mechanism because of the overproduction of superoxide that interfere with the nitric oxide 
synthesis from eNOS pathway (Figure 1-30).  
 
arterioles capillaries venules
 
  
 
Primary 
pathology 
Impaired 
vasodilatation 
Decreased perfusion 
and fluid leakage 
Increased 
permeability 
    
 Varied response Non reflow phenomenon Leukocyte adhesion 
 Vessel size and tissue type Platelet and leukocyte  Endothelial expression 
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FIGURE 1-30. RHEOLOGICAL PHENOMENA AND CHANGES IN MICROVASCULAR CALIBER FOLLOWING IR 
INJURY (ADAPTED FROM (SEAL AND GEWERTZ, 2005)). 
 
Next, in the capillary anastomosis, the combined effects of ischaemia, reperfusion and 
overproduction of ROS result in endothelial activation, endothelial dysfunction and necrosis 
of the endothelium, leading to platelet aggregation, activation of complements and 
coagulation factors, and hydraulic fluid leakage. 
 
In the post-capillary venule, expression of adhesion molecules on endothelial apical lining 
promoting leukocyte plugging and this lead to neutrophil sequestration which subsequently 
cause massive inflammatory processes and ROS generation. The plugging retards blood flow, 
increasing the interaction between activated platelet and leukocyte. This causes the release of 
inflammatory mediators and coagulation factors which activate endothelial signal pathways 
leading to endothelial gap formation, predominantly in venules. This further increases 
vascular permeability and promotes plasma protein extravasation causing intra-luminal 
haemoconcentration and extra-luminal tissue edema, both reinforcing haemodynamic 
stagnation.  
 
In comparison to the other organs, the lower limbs occupy a wide surface area of the body, 
and a high percentage of blood supply, accounted by the percentage of cardiac output 
(Levick, 2003). Following IR injury, the local tissue injury taking place in the lower limb 
extends to a wide area: therefore, causing the release of large amount of inflammatory 
mediators.  
Plasma interleukin (IL)-6 has been found to elevate following lower limb IR injury, an 
important marker of systemic inflammation (Cesari et al., 2003). IL-6 can further induce an 
increase of plasma acute phase protein, CRP synthesized in the liver. The elevation of plasma 
IL-6 in lower limbs IR injury may be associated with a disturbance on adipose tissue and 
muscle cells mass. Adipose tissue is one of the main sources of IL-6 during the rest condition 
adhesion of adhesion molecules 
Mechanisms Decreased  endothelial  derived NO synthesis 
 
Compression 
 
Leukocyte migration 
 Depletion of precursors  
and co-factors 
Increased hydraulic 
conductivity 
 
Oxidative injury 
 
 Direct effect of ROSs Interstitial edema Leukocyte oxidative   
burst & ROSs formation 
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(Coppack, 2001) while muscular contraction is the main source of IL-6 during exercise 
(Pedersen et al., 2004). In addition, IL-6 is also a reliable indicator of muscular damage 
(Pedersen et al., 2001, Febbraio and Pedersen, 2002).  
 
1.4.4.2. Systemic Considerations 
 
The pathophysiological consequences as a result of IR injury, occurring in the remote organs 
is believed to be mediated by the high level of circulating inflammatory mediators, the 
circulating of activated blood cells. Reperfusion not only delivers those inflammatory 
mediators but also re-circulates activated cells including endothelial cells, activated platelets 
and activated PMNs. 
 
 The activated neutrophil can be caught by activated endothelial cells elsewhere in the remote 
microcirculation as a result of high concentration of proinflammatory mediators in the 
systemic circulation. And this can result in the sequestration of PMN in the vulnerable site for 
instance of pulmonary microcirculation.  
 
It is notable that the diverse responses of the end-organs to inflammatory stimuli possibly 
differ due to the individualised nature of the tissue and its microcirculatory homeostasis 
(Stevens et al., 2001). In vulnerable organs like lung, intestine and kidney, the endothelial 
cells are likely to be activated and the WBC-endothelial interactions are exaggerated. At the 
same time, coagulation and platelets are likely to be stimulated as well. 
 
Acute Respiratory Distress Syndrome (ARDS)  
The lung microcirculation is the primary organ where venous blood returns loaded with 
proinflammatory mediators in particular TXA2 and LTB4 (Grace PA, 1998). The lung is a 
highly vascularized organ. Because the lung's water content depends on the integrity of the 
endothelial barrier, the alveolar–capillary barrier is not firmly secluded; the airspace side is 
very thin, with minimal interstitial space, while the capillary side contains a substantial 
interstitial space that allows fluid influx from the capillary.  
 
The pathogenesis of ARDS is believed to be mediated by the compound effect of 
inflammatory mediators in the plasma and by the increased reactiviy to both inflammation 
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and coagulation processes. As a result, plasma leaks though the capillary endothelium and 
readily enters into the alveolar space, causing ARDS, which reduces the efficiency of blood-
gas exchange. 
 
Neuro-Endrocrinal System 
The neuroendocrinal system functions exists throughout the whole body as well as the 
immune system and these systems work co-operatively in responding to IR injury.  
 
The neuro-endocrinal system regulates the immune system locally and systemically by the 
network connections of nerve pathways and circulatory hormonal cascades. The neuro-
endocrinal system cooperates and regulates the immune system through two major 
mechanisms: (a) the hormonal stress response and the production of glucocorticoid through 
hypothalamic-pituitary-adrenal axis (HPA axis), and (b) the autonomic nervous system 
primarily via sympathetic adrenergic neurotransmitters released through neuronal routes 
(Elenkov et al., 2000, Webster et al., 2002, Sternberg, 2001).  
 
Firstly, regarding glucocorticoid, the main down-regulator of the immune system by the 
neuro-endocrinal system is supposed to be through the hypothalamic-pituitary-adrenal axis 
(HPA axis), which leads to the secretion of the corticotropin releasing factor (CRF) or 
corticotropin-releasing hormone (CRH). The components of the HPA axis begin with the 
production of corticotropin-releasing hormone (CRH or CRF) by the paraventricular nucleus 
(PVN) in the hypothalamus and then secreted into the hypophyseal portal blood supply, 
which lead to the production of the adrenocorticotropin hormone (ACTH) in the anterior 
pituitary gland. ACTH then circulates in the bloodstream to the adrenal glands where the 
glucocorticoid is generated. The stimulation of the neuro-endocrine regulation together with 
the immune function responses is essential for survival during stress conditions like trauma 
and infection. Exercise and the circadian rhythms are associated with the changes in the 
levels of circulating glucocorticoids. 
 
Secondly, the sympathetic nervous system is also another key system regulating and 
modulating the function of the immune system in responding to IRI (Elenkov et al., 2000, 
Webster et al., 2002, Sternberg, 2001). Sympathetic nerve stimulation causes several organs 
to respond to injury and this leads to the uprising of catabolic and the downfall of the 
anabolic hormones during stress conditions including adrenaline increasing and insulin 
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decreasing. The increase of the hormone due to sympathetic stimulation may be termed as 
sympathtomimetic hormones.  
 
Catecholamines are released from adrenal gland medulla, pass through the endothelial lining 
into the circulation. They stimulate β1-adrenergic receptor mainly located in the heart and 
result in tachycardia and increase in cardiac contractility; both also activate α-adrenergic 
receptor distributed in the general tissue resulting in widespread vasoconstriction and 
increasing the peripheral resistance (Levick, 2003, Elenkov et al., 2000).  
 
However, there is exception for skeletal muscle, myocardium and liver which have an 
abundance of β2-adrenergic receptor in their arterioles; adrenaline with higher production 
than noradrenalin has a higher affinity to this receptor than noradrenaline (which has a high 
affinity to α-adrenergic receptor) and the activation result in vasodilatation (Levick, 2003, 
Elenkov et al., 2000). 
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In turn, through similar connections, the immune system also regulates the neuroendocrinal 
system. During inflammation, proinflammatory cytokines produced at the inflammatory site 
can signal to the brain and produce the symptoms of sickness (Webster et al., 2002, 
Sternberg, 2001). The hypothalamus, temperature setting part of the body is modulated by 
inflammatory mediators and fever is a commonplace in SIRS. The increased levels of IL-1 
and TNF have long been recognised in association with neuro-endocrinal secretions from the 
brain (Figure 1-31). These proinflammatory cytokines can pass through the blood-brain 
barrier at leaky points, for example at the organum vasculosum lamina terminalis (OVLT) or 
median eminence and can influence the brain by activation of second messengers, such as 
nitric oxide and prostaglandins. In addition, they can also rapidly signal the CNS through the 
vagus nerve (Webster et al., 2002, Sternberg, 2001). Despite the small amounts, they can lead 
to high production of glucocorticoid and the stimulation of sympathetic autonomous reflex to 
several pivotal organs through the releasing of noradrenaline in postganglionic synapses. 
 
The Reticulo-Endothelial (RE) System 
The RE system is the cooperated network of endothelial lining and certain tissues including 
lymphoid organs, the spleen, bone marrow and liver all of which regulate the production and 
elimination of the blood elements. The capillaries of most recticulo-endothelial organs 
Interleukin 1, 
TNF
Substance P, 
Noradrenaline
fever, 
sleep 
anorexia
MSH
Adrenocorticotropic 
hormone
Glucocorticoids
Adrenaline, VIP, PACAP, Acetylcholine
pro-inflammatory 
cytokines
CRF
FIGURE 1-31. CROSSTALK BETWEEN THE IMMUNE AND NEURO-ENDOCRINAL RESPONSES: 
CRF=CORTICOTROPIN RELEASING FACTOR. PACAP=PITUITARY ADENYLATE CYCLASE 
ACTIVATING PEPTIDE. VIP=VASOACTIVE INTESTINAL POLYPEPTIDE. MSH=MELANOCYTE 
STIMULATING HORMONE (ANNANE ET AL., 2005) 
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including liver, lymph node, spleen and bone marrow are sinusoidal in type (Levick, 2003), 
and parenchymal cells are readily exposed to circulating mediators.  
 
In tissue ischaemia, HIF-1 signalling causes generation of circulating vascular endothelial 
growth factor (VEGF) from ischaemia cells and erythropoietin (EPO) from liver and kidney 
resulting in attraction of endothelial precursor cell (EPCs) to ischaemic sites and the 
increased production of red blood cells in bone marrow, respectively. 
 
 
The Systemic Inflammatory Response Syndrome (SIRS) 
 
The endothelium principally controls vascular permeabilities and transcapillary exchange 
both transcellular and paracellular transport (Stevens et al., 2000). The endothelial cell 
surface consists of a layer of surface glycoprotein (glycocalyx) that is capable of expressing 
cellular adhesion molecules (CAMs). It is believed that CAMs play a central role in bringing 
circulating cells into the parenchymal tissue (WBC infiltration/migration or sequestration).  
 
Therefore, endothelial surface site is the pivotal locations modulating blood-parenchymal 
communication signals. Under physiologic conditions, endothelial lining exert several 
elemental functions that are essential for normal homeostasis of the microcirculation 
including: preventing unwanted coagulation, controlling the migration of blood cells into the 
tissues by expression of adhesion molecules and production of chemotactic factors, dictating 
the tone of the arterioles, and regulating vasopermeability (Figure 1-32) (Hack and Zeerleder, 
2001). 
protein c activated protein c
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FIGURE 1-32. ENDOTHELIAL FUNCTIONS UNDER NORMAL CONDITIONS (LEFT) AND UPON ACTIVATION 
(RIGHT): TM, THROMBOMODULIN; PC, PROTEIN C; APC, ACTIVATED PROTEIN C; FIIA, THROMBIN; TFPI, 
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TISSUE FACTOR PATHWAY INHIBITOR; NO, NITRIC OXIDE; PGI2, PROSTAGLANDIN-I2; ATIII, ANTITROMBIN 
III 
 
The control of coagulative state and inflammatory condition in the microcirculation have 
been linked to the consumption of protein C (Esmon, 2004). In SIRS uncontrolled endothelial 
activation is associated protein C levels (Joyce et al., 2004). 
 
Clinical manifestation suggesting the possible occurrence of SIRs is defined by the presence 
of at least two or more of this following criteria (Norwood et al., 2004): 
 
• A white cell count of > 12,000 cells/mm3, or < 4000 cells/mm3, or  > 10 % immature 
(band) forms 
• A temperature of > 38 or, < 36 0C 
• A heart rate of > 90 beats per minute 
• A respiratory rate of > 20 breaths per minute, or PaCO2 > 4.3 kPa 
 
SIRS may be considered as a generalised immune response caused by the activation of the, 
neuron-endocrinal, respiratory, circulatory and RE systems. While producing acute phase 
protein like CRP by the liver is well recognised in SIRS following IR injury as well as 
following sepsis. In sepsis, the bone marrow response is in line with that mediated by the 
neuro-endocrinal pathway in IR injury (Figure 1-33). 
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FIGURE 1-33. ACUTE PHASE RESPONSES OF THE IMMUNE SYSTEM AND SYSTEM INFLAMMATION IN 
ASSOCIATION TO SEPSIS SYNDROME. ADAPTED FROM (ANNANE ET AL., 2005). 
 
 
The liver is central to regulating coagulation factor and complement proteins and is a central 
player in mediating the global effects of IRI injury(Arumugam et al., 2004, Riedemann and 
Ward, 2003). When the liver is the primary injured organ, the complement and coagulation 
systems are key mechanism generating the IR injury pathophysiology and inhibition of both 
systems activation is highly beneficial (Teoh and Farrell, 2003). 
 
Intestine and Splanchnic Circulation 
 
Liver blood flow may not be affected from the circulatory stress as much as intestinal and 
renal blood flow because it receives dual blood supply from hepatic portal vein and hepatic 
arteries. In addition, hepatic arterioles possess abundant of β2-adrenergic receptors which in 
stress, stimulated by the sympathetic system exert vasodilatation.  
 
In contrast, the intestinal and renal vessels react by vasoconstriction. Cardiovascular stress 
can cause intestinal ischaemia which results in failure of the intestinal mucosal barrier and the 
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consequent escape of bacteria into the splanchnic microcirculation (Mallick et al., 2004, 
Norwood et al., 2004).  
 
Gram negative endotoxaemia is elieved to mediate the intense systemic immune responses 
associated with sepsis. Intestinal ischaemia and bacterial translocation may result both as 
aspect of a direct organ injury or as a secondary insults to cardiovascular stress (Figure 1-34) 
(Mallick et al., 2004, Norwood et al., 2004). 
 
Abdominal aortic aneurysm repair is an example where intestinal and lower limbs IR injury 
occur and the generating inflammation especially the activation of complement and blood 
coagulation similar to sepsis, resulting in splanchnic microvascular mal-perfusion, associated 
with renal insufficiency, intestinal mucosal ischaemia, systemic bacterial translocation 
together with the release of endotoxin into the blood circulation (Norwood et al., 2004). 
 
Acute Renal Failure  
Acute renal failure is characterized by a deterioration of renal function to excrete nitrogenous 
waste products and to maintain fluid and electrolyte homeostasis (Thadhani et al., 1996). 
Acute renal failure can be induced by several factors compromising renal perfusion.  
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FIGURE 1-34. IRI OF THE LOWER PARTS OF THE BODY IN ACCOMPANY WITH MESENTERIC 
ISCHAEMIA AND LEAKAGE OF ENDOTOXIN FUELING SIRS IN AAA REPARATIVE 
PROCEDURE (MALLICK ET AL., 2004) (NORWOOD ET AL., 2004) 
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Failure of renal function without major renal tubular cell damage is termed prerenal failure, 
while acute renal failure due to a primary intra-renal cause where there is an renal cell injury 
e.g. tubular necrosis due to prolonged ischaemia, is termed intrinsic renal failure. Acute renal 
failure related to obstruction of the urinary outflow tract is termed as postrenal failure. The 
kidney is highly vulnerable to the deleterious effects of renal hypoperfusion and to many 
toxic substances (Figure 1-35) (Thadhani et al., 1996). Renal hypoperfusion is a cause of 
renal tubular dysfunction by both prerenal and intrinsic renal routes and is responsible for 
most episodes of acute renal failure. 
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FIGURE 1-35. CONDITIONS PREDISPOSING TO ISCHAEMIC ACUTE RENAL FAILURE (THADHANI ET AL., 1996) 
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Several hormones influence renal circulation physiological and pathological responses: 
Sympathomimetic hormones, including catecholamine from adrenal medulla (previously 
discussed), antidiuretic hormone (ADH, or vasopressin) from pituitary and the renin-
angiotesin-aldosterone (RAA) system from justaglomerular complex in kidney, regarding the 
responses after stress conditions. ADH is a vasoconstrictor, produced from the hypothalamus 
and secreted through endothelial lining in posterior pituitary gland. It is mainly sensed to a 
rise in blood osmolarity when the body dehydrates and a fall in blood pressure and volume, 
instance of blood loss. The role of ADH is i) principally to decrease or draw back the water 
excretion from renal tubule and ii) partially vasoconstriction (Levick, 2003). Renal 
hypoperfusion affects the justaglomerular apparatus and triggering the RAA system (Figure 
1-36).  
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After ischaemia and reperfusion, the renal tubule has been reported to show morphologic 
changes indicating cell death either a result of necrosis or apoptosis. The apoptosis pathway 
in renal IR injury is influnced by the gene p53 and guanosine triphosphate (GTP) cell 
signaling. This is evidenced by the importance of GTP depletion in apoptosis (versus ATP in 
necrosis) and the ability of guanosine and p53 inhibitors (pifithrin) to protect against 
apoptosis and renal dysfunction (Figure 1-37) (Dagher, 2004). 
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FIGURE 1-36. THE RENIN-ANGIOTENSIN SYSTEM (TOUYZ AND SCHIFFRIN, 2000) 
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FIGURE 1-37. IRI LEADING TO GTP DEPLETION AND THE ACTIVATION OF P53 SIGNALS AND LINKING 
TO MITOCHONDRIA MEDIATED APOPTOSIS (DAGHER, 2004) 
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1.5 Cytokines and Inflammation 
 
1.5.1. Introduction 
The cytokines are a large family of polypeptide signalling molecules that are released by 
various cells of the body as a response to an activating stimulus. They are small proteins of 
approximately 25kDa (range: 6-51) in size. They effect response by binding to specific 
receptors. They can act in an autocrine or paracrine manner and some are stable enough to 
have endocrine function. 
The number of cytokine molecules identified is large and ever increasing. Also the precise 
mechanisms of action of these molecules and the complex inter-relationships between them is 
far from being clearly elucidated. Both pro and anti-inflammatory cytokine level aberrations 
have been associated with the progression of localised inflammation to the systemic 
inflammatory response syndrome (Figure 1-38). Systemic inflammation in the setting of 
peripheral vascular disease related to cytokine level aberrations may be important in the 
progression of peripheral vascular disease. 
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FIGURE 1-38 BALANCE BETWEEN PRO- AND ANTI-INFLAMMATORY CYTOKINES 
 
1.5.2. Pro-inflammatory cytokines 
 
TNF-alpha, IL-6, IL-8, and MIP-1 alpha have been found to correlate well with the severity 
and mortality in patients with sepsis. The same study found that in patients with inhalation 
injury the high IL-8 levels in bronchoalveolar lavage fluid on admission predicted the 
development of respiratory insufficiency (Cavaillon et al., 2001, Aikawa et al., 1996). A 
study of 52 intensive care patients in shock demonstrated that persistence of elevated TNF 
and IL-6 levels in the serum correlated with poor outcome for these patients (Pinsky et al., 
1993). Another study of 20 ICU patients in shock revealed that TNF levels correlated well 
with outcome and that IL-6 levels were elevated in patients with shock. 
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1.5.2.1. Proximal pro-inflammatory cytokines 
 
Tumour Necrosis Factor α (TNFα) 
 
TNF α is a 17-kDa protein produced primarily by monocytes with pleiotropic effects. 
Infusion of recombinant TNF α in humans results in SIRS with fever, haemodynamic 
abnormality, leukopaenia, elevated liver enzymes and coagulopathy (Spriggs et al., 1987). 
 
TNFα has a significant regulatory role in the development of SIRS. A number of studies 
involving infusing endotoxin have shown that peak levels are reached in 60-90 mins of 
infusion (Michie et al., 1988, Suffredini et al., 1989). In light of the fact that TNFα appears 
rapidly in the plasma, it is in a prime position to facilitate the activation of other mediators of 
inflammation. 
 
Together with CRP and IL-6, TNF α  production has been shown to correlate well between 
atherosclerotic parents and their children(Haddy et al., 2003). There is also evidence 
reporting association of TNF α levels with atherosclerotic progression and severity (Ziegler et 
al., 2005, DePalma et al., 2003) 
 
Interleukin-1 (IL-1) 
 
IL-1 encompasses two related proteins, IL-1α and IL-1β both of which act on the same IL-1 
receptors. IL-1 is synthesised by monocytes, neutrophils and other cell types. Infusion of IL-1 
into humans also causes fever, haemodynamic abnormalities, anorexia, malaise, arthralgia, 
headache and neutrophilia; endotoxin infusion also causes an elevation of its levels 
(Dinarello, 2005). IL-1’s effects on leucocyte recruitment and trasnmigration facilitate it 
perpetuating the inflammatory process once initiated. IL-1 levels have also been reported to 
be associated with plaque rupture (Libby et al., 1995) 
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Although the pro-inflammatory cytokines are generally thought of as deleterious in excess, 
their low levels may also contribute to the development of the SIRS. In an  ex vivo model of 
sepsis LPS induced TNFα, IL-1 beta and IL-6 secretion from monocytes harvested from 
controls and patients in sepsis. The release of TNF-alpha, IL-1 beta and IL-6 was markedly 
reduced, and effect lasting up to 10 days following onset of sepsis (Kremer et al., 1996). 
1.5.2.2. Distal pro-inflammatory cytokines 
 
Interleukin 6 (IL-6) 
 
IL-6 is a 21 kDa glycoprotein produced by many cell types including lymphocytes, fibroblast 
and monocytes. 
 
An observational study of 25 patients with severe sepsis of less than 48 hours evolution 
showed that there is a tight correlation between the elevation of IL-6 and the severity of the 
Systemic Inflammatory Response and mortality (Dougnac et al., 2001). 
 
In an observational study of 30 patients who underwent major surgery for cancer, IL-6 levels 
were found to be persistently elevated in those patients who developed sepsis, severe sepsis 
or septic shock (Mokart et al., 2002). And in elective cardiac surgery, post pump IL-6 levels 
were found to predict reduced lung function post pump (Halter et al., 2005). 
 
In an animal model, mice were subjected to a standard contact burn followed by intra-
peritoneal LPS to simulate SIRS. Treatment with a combination of anti-IL-6 and anti-IL-6R 
antibodies caused a significant reduction in inflammation. Anti-IL-6R antibody monotherapy 
had no effect. A significant reduction in mortality was seen in both antibody groups (Pallua et 
al., 2003). This data suggests that the inflammatory potential of IL-6 independently is low, 
however as mortality was significantly altered by both antibodies, that the inflammatory and 
lethal potential of IL-6 are not the same. 
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Also, IL-6 infused into anaesthetised dogs did not cause any significant haemodynamic 
abnormality which would suggest that a primary role in cardiovascular abnormality in sepsis 
unlikely (Preiser et al., 1991).  
 
IL-6 has consistently been associated with and the severity of peripheral vascular disease 
(Tzoulaki et al., 2005, McDermott et al., 2005, Allison et al., 2006, Nylaende et al., 2006) 
 
Interleukin 8 (IL-8) 
 
IL-8 is a small basic protein. It is produced by monocytes, neutrophils, endothelial and 
epithelial cells and a variety of mesothelial cells in response to stimuli including endotoxin, 
IL-1 and TNF α. 
 
In vitro experiments with microvascular endothelial cells stimulated by LPS produced a rise 
in IL-8 in line with IL-6 rise (Schneider et al., 2003). 
 
MCP-1 
 
The protein MCP-1 directs leucocytes to sites of inflammation, a chemokine. It is associated 
with atherosclerosis and is involved in monocyte recruitment into the precursor of the 
atherosclerotic plaque (Shin et al., 2002). Plasma MCP-1 has been reported to be an 
independent risk factor for peripheral vascular disease and was also elevated in association 
with coronary artery disease (Hoogeveen et al., 2005). MCP-1 has also been shown to 
correlate with the severity of peripheral vascular disease as assessed by angiogram as well as 
maximum treadmill walking distance (Nylaende et al., 2006). Interestingly, statins have been 
found to have an independent effect on reducing MCP-1 levels (Leu et al., 2004) 
 
1.5.3. Cytokines of the anti-inflammatory response and 
immunosuppression 
Evidence supporting pro- anti-inflammatory cytokine imbalance as being part of the 
pathogenesis of SIRS was provided by Rodriguez-Gaspar et al. in their study of 174 patients 
with SIRS criteria. They found that serum TNF-α, IL-6, IL-8 and IL-10 levels were raised in 
SIRS patients. Furthermore, they found that the slope of the regression line between IL-10 
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and TNF-alpha was sharper in patients with severe sepsis and in those who died (Rodriguez-
Gaspar et al., 2001). 
 
It is well established that major operative intervention as well as the systemic inflammatory 
response from sepsis and major trauma is associated with immunosuppression of both cell 
mediated and humoral systems (Slade et al., 1975, Iwasaka and Noguchi, 2004, Hirota et al., 
2004, Giannoudis, 2003, Reddy et al., 2001, Cheadle et al., 1996) 
 
Interleukin-10 (IL-10) 
 
A Japanese case control study of 12 patients with SIRS compared to healthy volunteers 
showed that levels of TNF and IL-10 were higher in patients with SIRS as compared to the 
healthy volunteers, also levels of both were higher in patients with MOF as compared to 
patients without MOF. The same Japanese paper reports that in a murine model, intra-
peritoneal loading of IL-10 attenuates the serum TNF response to LPS injection and 
furthermore, similar IL-10 mediated inhibition was reported in a cell culture environment 
with murine macrophage LPS stimulated TNF production (Sander et al., 1997, Kawai et al., 
1995). 
 
Interleukin 13 (IL-13) 
 
A cohort study of ICU patients demonstrated that IL-13 was elevated in patients with SIRS 
and that the increase was greater in sepsis patients compared to those with non-infective 
SIRS. In SIRS, the elevation of IL-13 was associated with a greater increase in TNF and a 
leukopaenia (Socha et al., 2006) 
 
It has been suggested that the anti-inflammatory response may be mediated by proximal pro-
inflammatory cytokines themselves. In vitro experiments using cord blood monocytes show 
that cells exposed to TNFα and LPS produced lower levels of TNF α and IL-6 at re-exposure 
compared to TNF α naïve cells. The effect was abolished by TNF α antibodies. TNF α pre-
treatment had no effect on IL-8 and IL-10 levels (Hassett et al., 2006). 
1.5.4. Cytokine receptor antagonists 
In a previously mentioned observational study of 30 cancer patients undergoing major 
surgery, post-operative immunosuppression measured as the incidence of septic shock 
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correlated well with circulating levels of IL1-ra. The levels of IL-1ra also correlated well to 
levels of IL-6 (Mokart et al., 2002). Also, IL-1ra has been shown to be correlate with the 
severity of peripheral vascular disease in number of small cohort studies (Fiotti et al., 1999, 
McDermott et al., 2005). 
 
Confusingly, in an observational study of 20 paediatric cardiac patients pre-bypass soluble 
TNF receptor I (p55 sR) was found to be a good predictor of subsequent hypercytokinaemia 
and complications including SIRS and MODS. (el-Barbary and Khabar, 2002). 
 
IL-10 has been shown to inhibit monocyte adherence to human aortic endothelial cells in 
vitro (Pinderski Oslund et al., 1999). 
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1.6 Genetic factors predisposing to systemic inflammatory 
response syndrome 
1.6.1. Introduction 
 
The extent of the inflammatory response is variable and unpredictable in patients who 
experience similar levels of operative or infective insult or trauma. The systemic 
inflammatory Response Syndrome may shed light on the interesting gentic dichotomy which 
seems to exists between individuals who are able to appropriately suppress systemic 
inflammation and those who are not able to withstand this systemic stress. It is as yet unclear, 
although data is accumulating, whether inflammatory variability is associated with genetic 
variations. The data to date is summarised in tabular form below (Table 5). 
 
1.6.2. Studies suggesting Genetic Predilection for Systemic 
Inflammation 
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TABLE 5. PUBLISHED LITERATURE REGARDING GENETIC FACTORS AFFECTING SIRS. 
Author, date 
and country 
Patient group 
Study type 
(level of 
evidence) 
Outcomes Key results 
(Watanabe et 
al., 2005) 
113 ICU patients with sequential 
organ failure score of ≥ 5 
Prospective 
cohort study 
IL-6 max, survival, and septic 
complications were compared between 
carriers and non-carriers of less frequent 
alleles 
Carriers of less frequent alleles in IL-1-related 
polymorphisms appear to have significant 
vulnerability to production of excessive IL-6 blood 
levels and to deterioration in septic shock 
(Hildebrand et 
al., 2005) 
97 injured patients. Injury 
Severity Score >16, age 18 to 60 
years, and a survival >48 h after 
injury 
Prospective 
cohort study 
Four different polymorphisms (TNF-
Nco1, IL-1-Taq1, IL-6-174G/C, and IL-
8-251A/T) were determined in patients 
who did and did not develop SIRS 
The IL-6-174G/C polymorphism was associated 
with the severity of posttraumatic SIRS 
(Sutherland et 
al., 2005b) 
252 patients with SIRS 
Prospective 
cohort study 
C-159T CD14, the X/Y and B, C, and D 
polymorphisms of mannose-binding 
lectin, and T-16933A Toll-like receptor-
2 were genotyped. tested for association 
Mannose-binding lectin haplotype pairs XO/O and 
O/O were also associated with increased 
prevalence of positive bacterial cultures. Toll-like 
receptor-2 -16933AA was associated with 
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of genotype with prevalence of positive 
bacterial cultures, type of organism 
(Gram-positive, Gram-negative, other), 
sepsis and septic shock at admission to 
the intensive care unit, and 28-day 
survival. 
increased prevalence of sepsis and with Gram-
positive bacteria. 
(Watanabe et 
al., 2005) 
150 ICU patients with IL-6 
levels > or =10,000 pg/mL and 
150 healthy subjects 
Case control 
Allelic frequencies of polmorphisms of  
IL6, IL1β and TNF of patients with IL-6 
peak levels of > or =10,000 pg/mL 
(group A) were compared with those of 
patients with IL-6 peak levels of 
<10,000 pg/mL (group B) 
The IL-6 peak levels were significantly correlated 
with simultaneously measured TNF. 
TNF-308*A, IL1RN*2, and IL1RN*3 alleles were 
associated with the prevalence of the extremely 
high IL-6 blood level in the critically ill, their 
uncontrollable blood IL-6 kinetics, and outcome 
(Sutherland et 
al., 2005a) 
228 critically ill white patients 
who met at least 2 of 4 SIRS 
criteria 
Cohort study 
28-day mortality and multi-organ 
dysfunction 
Patients who had 2 copies of haplotypes from 
within the IL6 haplotype clades -
174C/1753C/2954G (C/C/G), G/G/G, or G/C/C 
had a greater 28-day mortality compared with 
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patients who carried 1 or no copies of these 
haplotypes (40.0% vs 26.0%; P = .02) 
(Fidler et al., 
2004) 
One hundred consecutive 
admissions to a PICU with at 
least one organ system failure 
longer than 12 h 
Cohort study Development of SIRS 
Variant Mannose Binding Lectin (MBL) alleles 
were significantly over-represented amongst the 
59 patients that developed SIRS 
(Garred et al., 
2003) 
272 patients with systemic 
inflammatory response 
syndrome 
Prospective 
cohort 
different MBL genotypes were 
compared, with respect to microbiology, 
sepsis development, and survival 
MBL variant alleles was associated with the 
development of sepsis, severe sepsis, and septic 
shock. An increased risk of fatal outcome was 
observed in patients carrying variant alleles 
(Dumon et al., 
1998) 
Surgical ITU patients with SIRS 
and sepsis 
Cohort 
 
determined the TNFA polymorphism 
(position--308) and related these data to 
plasma cytokine levels of TNF alpha, 
IL6, IL6R and IL8 
clear risk group could not be determined 
(Calvano et al., 
2003) 
44 surgical ITU patients 
Prospective 
cohort 
incidence of sepsis, septic shock, or 
mortality between patients bearing the 
There was no difference in the  
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various alleles 
     
(Child et al., 
2003) 
 cohort severity of SIRS 
A trend between the minor allele of TLR4 and 
mortality in SIRS (odds ratio of 4.3; P =0.076),  
(Schroeder et 
al., 2003) 
Cardiac patients, 47 with CPB 
and 36 without 
Case control 
 
TNF alpha plasma level and TNF 
genotype 
Patients homozygous for the TNF-B2 allele 
showed significantly higher TNF-alpha plasma 
levels after termination of CPB compared with 
non-CPB patients 
(Gallagher et 
al., 2003) 
Patient with community 
acquired pneumonia (CAP) 
Cohort study 
TNF alpha and IL-10 gene 
polymorphisms and SIRS score (1-4) 
There was a higher frequency of the GG genotype 
of IL-10 with increasing severity from non-SIRS 
through to SIRS 4. IL-10 G allele frequency was 
also increased in patients who died as a result of 
CAP (n=11) compared with CAP survivors (n=82) 
(p=0.01) 
(Schroder et 
al., 2003) 
80 consecutive severe trauma 
patients 
cohort 
Plasma concentrations of interleukin-6 
and tumour necrosis factor-alpha were 
Patients carrying the genotypes HSPA1B AG or 
HSPA1L CT had significantly higher plasma 
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measured over a 5 days. The genotypes 
of the polymorphisms HSPA1B (HSP70-
2) G1538A and HSPA1L (HSP70-Hom) 
C2437T were determined. 
concentrations of tumour necrosis factor-alpha and 
interleukin-6 compared with those with genotype 
GG or TT 
(Reid et al., 
2002) 
83 patients with MODS  
prevalence of genetic variation for 
cytokine production (tumour necrosis 
factor [TNF]-alpha, interleukin-10, 
transforming growth factor-beta1 
compared to clinical outcome. 
A genetic predisposition to high interleukin-10 
production or intermediate TNF-alpha production 
may be protective of admission to the intensive 
care unit, although once admitted, any protection 
provided by these genotypes seems to be lost. 
TNF-beta genotype conferred no advantage to 
patients with multiple organ dysfunction 
syndrome, the TNFB2 allele being associated with 
increased mortality 
(Waterer et al., 
2001) 
280 patients with CAP cohort 
LTalpha+250 (TNFbeta+250) and 
TNFalpha-308 gene polymorphisms and 
development of septic shock and 
Carrying at least one AA (tumour necrosis factor 
[TNF] high secretor) genotype had an 18.0% risk 
of SS versus 6.8% (p = 0.006). GG homozygotes 
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respiratory failure. (TNF low secretors) at both loci had only a 2.9% 
risk of SS. Septic shock was associated with the 
LTalpha+250:TNFalpha-308 A:G haplotype but 
not the A:A haplotype, suggesting that 
LTalpha+250 is a marker, rather than a causative 
polymorphism. Carriage of the G:G haplotype had 
a significant protective effect against the 
development of septic shock (p = 0.011). T1RF 
was not associated with LTalpha+250 AA 
genotype. In the absence of septic shock, there was 
a significant trend to greater T1RF in patients with 
LTalpha+250 GG (TNFα hyposecretor) genotype 
(p = 0.03). 
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1.7 Peripheral vascular disease and systemic inflammation 
1.7.1. Introduction  
Cardiovascular disease (CVD) associated with atherosclerosis is a common condition 
particularly in older patients. The lower limbs are among the most common sites for 
atheroma development or plaque obstructive lesions. By the nature of atherogenesis, it is 
believed that patients with PAOD have a prolong period of chronic inflammation in the 
arterial wall preceding the presence of ischaemic symptoms like claudication. Investigators 
found evidence of chronic inflammation associated with an elevation of circulatory pro-
inflammatory cytokines.  (Petersen and Pedersen, 2005) have suggested the term “chronic 
low-grade systemic inflammation” for conditions in which a typically two- to threefold 
increase in the systemic concentrations of TNF-α, IL-1β, IL-6, IL-10, IL-1ra, sTNF-R, and 
CRP are present in individuals with obese, aging, smokers, insulin resistance, type 2 diabetes 
mellitus and atherosclerosis. 
 
Ischaemia reperfusion injury is one of the main problems encountered in the management of 
CVD, which is one of the most common and debilitating modern illnesses. New approaches 
to the management of CVD have been developed, reperfusion therapeutic strategies including 
percutaneous transluminal angioplasty (PTA) and bypass surgery have become widely 
available both for CAD and PAOD and reduce morbidity and mortality for CVD patients. 
Presently, reperfusion therapy (revascularisation) has been accepted to benefit patients and 
effectively decrease the rate of mortality and morbidity for CVD disease. However, 
revascularisation that has achieved restoration of blood flow into ischaemic area, may also 
create an ischaemia reperfusion injury (IRI). Restoration of blood supply to previously 
ischaemic tissue can paradoxically injure these tissues by means of oxidative stress and acute 
inflammation. ROSs toxicity and neutrophil hypersensitivity have been suggested as the two 
keystones mediating the pathophysiological mechanisms of IRI (Kaminski et al., 2002). The 
ischaemic condition contributes to a low flow haemodynamic state and inadequate tissue 
oxygen supply, these lead to activation of PMN by means of parenchymal cells necrosis, 
haemoconcentration, blood cell packing. Once the ischaemic condition is relieved, the 
reperfusion increases oxygen supply to the previously ischaemic tissues which may result in 
oxidative stress. ROSs can further exacerbate PMN activation which are recruited to the 
tissue by restoration of blood flow which in turn amplifies oxidative stress by generating 
ROSs through their NADPH activity.  
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Another distinctive feature of IRI is a possible relationship between local IRI events and a 
systemic response, which can if unchecked lead to multi-organ pathologies and in some 
cases, even death. The immuno-reactive activities in the inflammatory processes are 
supposed to take place in the local region, however, local intense inflammation is presently 
accepted to be able to generate systemic immunoreactions due to the generation of circulating 
inflammatory mediators. Propagated through a number of molecular and cellular mediators, 
this local IRI can result in a systemic condition known as systemic immune responses (SIRs) 
(Grace PA, 1998). Evidence suggests that pro-inflammatory cytokines such as IL-1, IL-6, IL-
8, TNF, eicasanoids, complement and cell-adhesion-molecules (CAMs) are responsible for 
the global effects. The details of common proinflammatory mediators implicated in IRI are 
shown in Table 6. 
 
TABLE 6. BROAD GROUPINGS OF INFLAMMATORY MEDIATORS (WOOLF, 1998) 
Source  Mediators  
   
Activated plasma protein cascades Complement system 
Kinin system 
  Blood clotting activation 
  Fibrinolytic system such as plasmin 
   
Stored within cells and released on 
demand 
Histamine  
5- Hydroxytryptamine (seratonin) 
  Lysosomal components  such as MPO 
   
Newly synthesized in and released 
from cells on demand 
Eicasanoids such as prostaglandins, 
thromboxane and leukotriens 
  Platelet-activating factor 
  Cytokines such as IL-l, IL-6 and TNF 
   
 
The common source of the common proinflammatory cytokine IL-1 is produced by 
macrophage, endothelial cells, and activated PMN while the major sources of IL-6 are 
macrophage, endothelial cells as well as IL-8. The major sources of TNF are macrophage and 
PMN but not endothelial cells while the sources of IL-10 are macrophage and lymphocyte (as 
shown in Table 7) (Gallin, 1999). 
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TABLE 7. THE MAJOR SOURCES OF COMMON CYTOKINES (ADAPTED FROM (NORWOOD ET AL., 2004)) 
   
Cytokines Main sources and Cells of 
origin 
Effects 
   
IL-1β Macrophages, Neutrophil, 
Endothelium 
Endothelial activation, fever 
and neutrophil release 
  
   
TNF-α Macrophage, Neutrophil Endothelial activation, 
interfering endothelial nitric 
oxide synthesis, fever,  
neutrophil and macrophage 
activation and 
chemoattraction 
  
  
   
IL-6  Macrophage, Neutrophil,  
Endothelium and Monocytes 
Endothelial activation, Fever, 
neutrophil release and  acute 
phase protein synthesis 
   
IL-8 Macrophage, Neutrophil and 
Endothelium 
Neutrophil chemoattraction 
and activation 
   
IL-10 Macrophage and T-cells Inhibition of macrophage and 
T-cell function (anti-
inflammatory) 
  
 
It is accepted that the local tissue I/R condition is a resource of these inflammatory mediators, 
produced in large volumes and then secreted into the circulation. Therefore, IRI can lead to 
remote organs injury by a mechanism similar to SIRs seen in sepsis, burns and other kinds of 
severe injuries. 
 
Obviously, the derivative molecules of ROSs and RNSs have been suggested as a cause of 
oxidative injury. However, there are several inflammatory mediators responsible for 
generating the local and global effects and it is not possible to definitely identify one of those 
mediators as a single responsible cause. The aims of this study were to investigate IRI 
mechanisms and elucidated the progression of the pathophysiological consequences of IRI at 
the cellular level, in the microcirculation and to investigate the relationship between 
microcirculation of locally injured tissues and microcirculation of distant organs. 
Furthermore, it is an aim of this study to determine the relationship between mediators of IRI 
and the clinical outcome. 
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1.8 Molecular mechanisms of cytokines in ischaemia reperfusion 
injury 
1.8.1. Redox responsive transcriptional pathways 
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FIGURE 1-39. DIAGRAMMATIC REPRESENTATION OF THE ROLE OF NF-κB IN INFLAMMATORY PATHWAY 
SIGNALLING 
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1.8.2. Redox sensitive transcription factors 
 
Transcription factors are the nuclear components that are modulated by upstream signaling 
events. They interact with transcription factor specific DNA in the regulatory regions of 
genes, transcription factors to modulate the magnitude of gene expression. Redox-sensitive 
modulation of transcription factor activity may occur via direct oxidative modification of the 
transcription factor itself by intracellular ROS or by post-translational modifications (ie, 
phosphorylation/dephosphorylation), as a result of redox- regulated intracellular signaling 
cascades. 
 
Hypoxia inducible factor-1 (HIF-1) 
 
HIF-1 is a nuclear transcription factor important in the cellular response to ischaemia. It may 
confer protection against IR injury by triggering the activation of specific protective genes. 
iNOS is a known downstream target of HIF-1, and has been shown to be cardioprotective in 
acute and chronic heart disease (Tang Xq Fau - Yu et al., Bulhak Aa Fau - Sjoquist et al., 
Cuong Dv Fau - Kim et al., Jones Sp Fau - Bolli and Bolli). In murine microvascular 
endothelial cells, induction of HIF-1 expression produced a time- and dose-dependent 
increase in iNOS mRNA. These mice experienced a decrease in infarct size and cardiac 
dysfunction following global myocardial IR. The improved functional recovery was lost in 
iNOS knockout mice (Natarajan R Fau - Salloum et al.). 
 
Its expression and activation in cultured human intestinal type epithelial cells was compared 
in response to hypoxia and also a cytomix, (IFNγ, TNF, and IL-1β). Incubation of normoxic 
cells with cytomix, as well as hypoxia for 48 h both markedly increased HIF-1 DNA binding 
(Fink, 2002, Scharte et al., 2003). 
 
NFκB 
 
NFκB is a DNA binding protein, which is thought to play a pivotal role in activation of 
inflammatory pathways (Figure 1-39). In septic patients, NFκB activation in peripheral 
monocytes was shown to correlate well with mortality (Bohrer et al., 1997). Its mechanism of 
activation has recently been elucidated and is well reviewed elsewhere (Christman et al., 
1998). TNFα activates NFκB via binding to the type 1 TNF receptor (TNFR1), which then 
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through a series of signal transducing proteins activates NFκB inducing kinase (NIK). 
Activation of NIK results in phosphorylation of IκB kinases (IKK) which binds to and 
phosphorylates IκBα at serines 32 and 36. Phosphorylation of IκBα is targeted for destruction 
by the ubiquitinisation/ proteosome (26S) degradation pathway, allowing translocation of 
NFκB to the nucleus. 
 
IL-1β binding to the type 1 IL-1 receptor (IL-1R1) and IL-1 receptor accessory protein (IL-
1RacP), which facilitates an interaction between IL-1 receptor associated kinase (IRAK) and 
TNF receptor associated factor 6 (TRAF-6), which subsequently results in NIK, IKK and 
NFκB.  
 
Studies on neonatal rat cardiac cells have demonstrated that TNF α enhances the IL-2 
induced expression of iNOS mRNA, iNOS proteins and increased production of NO. The 
TNF α effects also included enhancement of the transcription factor NFκB activity. Both 
effects was blocked by a selective inhibitor of mitogen activated protein kinase (Kan et al., 
1999). Thus there is evidence to support elevation of NFκB activity and upregulation of NO 
production may be important pathways in the cytokine response in SIRS. 
 
Common to all of the activation mechanisms that lead to IκB degradation and NF-κB nuclear 
translocation has been suggested to involve ROS. The evidence for this is that inhibition of 
NF-kB activation is achieved by several chemically distinct antioxidants (Schreck R Fau - 
Rieber et al., Schreck R Fau - Albermann et al., Schreck R Fau - Meier et al.) (Suzuki and 
Packer, 1993). 
 
AP-1 
 
AP-1 behaves as a redox- sensitive transcription factor in several cell types and is 
activated, to different extents, under pro-oxidant conditions generated by treatment 
with agents such as superoxide, H2O2, and cytokines (Amstad et al., 1990, Shibanuma 
et al., 1990, Nose et al., 1991).  
 
In endothelial cells, agents such as H2O2  LDL, and oxLDL have been found to activate AP-1 
DNA binding activity. In smooth muscle cells, oxLDL, H2O2, and the lipid peroxidation 
 145 
 
product 4-hydroxy-2-nonenal have been shown to increase AP-1 expression or DNA binding 
activity (Kunsch and Medford, 1999a).  
 
Interestingly, regulation of the vascular inflammatory genes MCP-1 and ICAM-1 by H2O2 is 
mediated by AP-1 binding elements in the promoters of these genes (Wung et al., 1996, 
Roebuck et al., 1995). 
 
In terms of the mechanism of redox mediated activation of AP-1; H2O2-induced AP-1 
activation requires both tyrosine and serine/threonine phosphorylation (Barchowsky et al., 
1995), and it has been suggested that AP-1 activation under oxidative conditions may be, at 
least in part, mediated by phosphorylation of Jun proteins (Gomez del Arco P Fau - Martinez-
Martinez et al.).Therefore, it appears that posttranslational modifications after oxidative stress 
may modulate AP-1 activity. 
 
Peroxisome Proliferator-Activated Receptors 
 
The PPARs are composed of members of the nuclear hormone receptor superfamily of 
transcription factors. This large and diverse group of proteins, mediate ligand-dependent 
transcriptional activation and repression (Mangelsdorf et al., 1995). PPARs are key control 
elements in lipid and glucose metabolism. Reports suggest that PPARs may play a role in 
inflammatory processes involved in the pathogenesis of atherosclerosis and restenosis due to 
their ability to modulate monocyte gene expression(Nagy et al., 1998, Jiang et al., 1998, 
Ricote M Fau - Li et al.). Also, PPAR expression and functional activity have recently been 
observed in endothelial cells (Marx et al., 1999) and smooth muscle cells (Marx et al., 1998). 
These studies suggest that PPARs may have a role as redox- sensitive transcription factors in 
the vasculature by being selectively activated by oxidised fatty acids. 
 
 
 
 
 
 
 
 
 
 146 
 
2. Methods  
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2.1 Methods Used To Measure Blood Flow And Vessel Function 
 
2.1.1. Introduction 
 
Advancement in medical imaging and biotechnology has made it possible to undertake 
detailed investigation of the anatomy, physiology, cellular, molecular and metabolic 
processes of the circulatory system. 
 
The imaging technologies in the radiological field has been technically improved leading to 
an ability to display anatomy of the blood vessels in three dimensional view and physiology 
of the blood flow as an animated motion. In addition, using well-advanced contrast media in 
nanotechnology such as micro-bubbles, microspheres and nanoparticles, it is possible to 
acquire precise detail of molecular and metabolic detail of the elementary cells in the 
microcirculation (Maier, 2005) (Fan et al., 2005). It also provides a novel avenue of 
delivering drug for treatment at the cellular level (Blomley et al., 2001) (Lindner, 2002) 
(Averkiou et al., 2003) (Jain, 2005) (Moshfeghi and Peyman, 2005) (Fortina et al., 2005). 
 
The advancement in vascular imaging technology has broadened and has been integrated with 
intelligent computer software programs to emerge as a powerful technique such as spiral CT 
and high frequency cutting plane MRI, which are capable of providing real-time trimensional 
images of the vascular structure. Digital subtraction angiography can display vascular images 
without interference from the surrounding tissue while echocardiogram and color Doppler 
imaging ultrasound can assess physiology of the blood flow and displays the information as a 
real time motion-animation show. 
 
A major advancement in the field of circulatory assessment has been the development of flow 
probes for blood flow assessment. The flow probes or sensors are non invasive and therefore 
are commonly employed techniques in vivo for the measurement of arterial blood flow in 
several organs. Two of the commercially available systems for blood flow assessment include 
ultrasound (1-50 MHz) and electromagnetic flow probes (Figure 2-1). The ultrasound and 
Doppler ultrasound techniques are basically noninvasive tools while the electromagnetic 
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probe is invasive as it is necessary to dissect the vessels and apply the probe directly over the 
blood vessels. 
 
audible range ultrasound
20 Hz 20 kHz
1MHz 50 MHz
vascular: 4 to 10 MHz  
 
FIGURE 2-1. RANGE OF ULTRASOUND FREQUENCIES USED IN MEDICAL IMAGING (ALLAN, 1997) 
 
 
There are two types of ultrasonic modalities, conventional ultrasound and Doppler 
ultrasound. The Doppler ultrasound is an extension of conventional grey scale ultrasound. 
The Doppler ultrasound was established in 1960s and it is one of the dominant tools in 
vascular assessment. The Doppler principle has been well known for many years. Christian 
Doppler (1842) formulated his theory in regard to light. He was the first to observe that the 
frequency of a wave signal change, depending on the relative velocity of the source and the 
detector: the so called “Doppler shift”. His theory later can applied to both light and sound 
waves (Tabrizchi and Pugsley, 2000).  
 
The Doppler ultrasound probe measures the blood flow by calculating the “transit time” of 
the emitted ultrasound wave to traverse the vessel. The transducers emit higher than normal 
frequency sound (ultrasonic waves) traversing the blood vessel, which are then reflected by a 
fixed acoustic reflector and subsequently detected by a sensor in the body of the probe 
(Tabrizchi and Pugsley, 2000). The Doppler ultrasound basically measures RBC movement 
as an object creating the “Doppler shifts” signals. For advanced and accurate measurement of 
blood flow, microbubbles, microspheres and nanoparticles are used as a contrast to enhance 
the image information. 
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The principle of Doppler shift has been used with both ultrasound and light. Laser light from 
an optic fibre is used as a photodetector which can measure and translate the scatter effect 
transmitted back from the vessel of interest. Laser Doppler technique is capable of resolving 
images of very small/micoscopic scale objects, whereas Doppler ultrasound is used for 
imaging larger structures. And therefore the laser Doppler is frequently used for assessing 
microcirculation while Doppler ultrasound is generally reserved for medium to large arteries 
(Tabrizchi and Pugsley, 2000).  
 
Common techniques for the assessment of the cardiovascular system are demonstrated in the 
Table 8 below 
 
TABLE 8. COMMON TECHNIQUES FOR THE ASSESSMENT OF THE CARDIOVASCULAR SYSTEM (PUGSLEY AND 
TABRIZCHI, 2000) 
In vivo tools and modalities In vitro tools and modalities 
• Vascular imaging  • Dissected tissue preparations 
Arteries   
Veins 
• Angiography  • Isolated cell and cultured methods  
Smooth muscle cells 
Cultured endothelial cells 
• Flow probes or sensors  
Conventional ultrasound 
Doppler-ultrasound / laser 
Electromagnetic 
Sonomicrometry – Microbubles, 
Microspheres and 
Nanoparticles 
Intravascular ultrasound 
• Biochemical and Molecular 
• Sphygmomanometer 
     Plethysmography  
• Genetic recombinant 
 § Immunohistochemical (IHC) 
 § ELISA 
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Currently, the application of molecular biology, usually in vitro, is the way forward to study 
the cardiovascular system (Table 8). Using molecular biology technologies, arterial or venous 
tissue can be examined at molecular level, while the microvascular cells such as endothelium 
or vascular smooth muscle cell (VSMC) can be isolated, cultured and replicated. The modern 
development in molecular biomedical technologies for the assessment of circulatory system, 
have been integrated into preexisting basic methodologies such as microscopy, to produce 
ideal investigative tools.  
 
Sub-cellular fractionation and centrifugation have long been utilized for separating the cells 
from the secretions and tissues while the techniques of fluorescence facilitate cell sorting 
(FACS) and flow cytometry can detect and purify the cells with the specific phenotypes 
(Rose, 2002). As well as the methods to retrieve specific cells for study, a variety of methods 
to extract the biomolecules have been crafted. Column chromatography and electrophoresis 
are commonly used for protein separation by using the fundamental of the different molecular 
mass of the substances for extracting the protein. These two techniques have evolved into 
sophisticated technologies of electro-blotting for separating protein, DNA and RNA (Rose, 
2002). 
 
One of the major innovations has been the development of the immunochemistry technique 
based on a simple principle of specific binding between antigen and its specific antibody. 
Enzyme-linked immunosorbent assay (ELISA) was initially a tool for diagnosing infectious 
diseases by using either polyclonal or monoclonal antibodies in immunological methods 
(Rose, 2002). Advances in ELISA technique has made it possible to show gene-protein 
expression or the phenotype of the cell in the body secretions and tissues. Advances in 
immunocytochemistry, staining the antigen-antibody with coloring substances like DAB, has 
expanded to the technique of radioimmunoassay (RIA) method (Rose, 2002) in which the 
binding of antigens-antibody complexes can be seen by tagging the samples with radioactive 
substance such as I131. The integration of chromatography, electrophoresis and 
immunochemistry have resulted in the development of immunoprecipitation techniques 
which use chromatography-electrophoresis to extract the  proteins by  their electric charges 
and molecular mass, and then can be retrieved with a high specificity by using the 
antigenicity properties of  these proteins for separation. This method of specific proteins 
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separation is known as Western blotting, immunoblotting or enzyme-assisted 
immunoelectroblotting (Rose, 2002). 
 
Another major advancement in the field of molecular biology has been the development of 
genetic recombinants technology. These techniques include gene cloning and DNA 
sequencing, polymerase chain reaction (PCR) for amplifying the DNA and RNA, and 
Southern blotting for DNA separation (Rose, 2002). In addition, genetic engineering together 
with immunochemistry have become power tools to study gene expression, including 
Northern blotting for separation of  active RNA, Quantitative PCR- Reverse Transcriptase 
PCR (RT-PCR: the most sensitive tool for detection of mRNA) and in-situ hybridization 
(Rose, 2002). Ankle Brachial Pressure Index (ABPI) 
 
A distinguished German physiologist and physician, and a pioneer in finding method to 
record the blood pressure, Otto Frank (1865–1944) is well known to circulatory physiologists 
as one of the discoverers of the Frank-Starling law (Levick, 2003). In medicine, physician 
routinely compare right and left to detect abnormalities. Blood pressure is the simplest 
method that is still used. Therefore, in PAOD, ABPI test uses this principle to detect a decline 
of blood flow in the lower limb by comparing blood pressure in the ankle to the forearms. 
Sphygmomanometer is the universal tool used for measuring blood pressure. The 
measurement is done by applying the cuff and measuring the blood pressure from the brachial 
arteries in the arm. The ankle brachial pressure index (ABPI) is the formula for the 
comparison of ankle systolic blood pressure to the forearm (brachial) pressure. For the 
measurement of ankle blood pressure, Doppler ultrasound probe and sphygmomanometer are 
used to record the value of blood pressure. 
 
ABPI is chiefly employed in the lower extremities in patients with the symptom of leg pain 
on walking and clinical signs of arterial occlusion in the lower extremities. To grade the 
severity of the atherosclerosis lesion, ABPI ratio of more than 0.95 is considered to be normal 
while the range 0.5-0.95 indicates mild to moderate lesion classified as intermittent 
claudication (IC), a value of less than 0.5 is classified as severe obstructive lesion and termed 
as critical ischaemia (CI). (Table 9) 
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TABLE 9 ABPI GRADING AND CLINICAL PROGRESSION OF THE PATIENTS WITH PAOD 
ABPI Range Clinical Grouping 
More than 0.95 Normal 
0.5 - 0.95 Intermittent Claudication (IC) 
Less than 0.5 Critical Ischaemia (CI) 
 
ABPI is also the tool used for assessing the success of the revascularisation operation in the 
PAOD patients. Continuous wave Doppler ultrasound is a basic tool used to provide the early 
assessment of ABPI postoperatively. An increase of ABPI by 0.15 following 
revascularisation indicates successful procedure (Anderson, 2002) (Murabito et al., 2003) 
(Ramanathan et al., 2003). 
2.1.2. Continuous Wave Doppler Ultrasound 
 
The ultrasound devices for vascular testing are equipped with various facilities including 
continuous wave Doppler (CWD), pulse wave Doppler (PWD), duplex Doppler (DD), colour 
Doppler imaging (CDI) and power Doppler imaging (PDI) ultrasound (Allan, 1997). All 
these functions are usually present in the expensive laboratory based machines whereas 
smaller devices have only one or two functions. CWD ultrasound is a small common 
inexpensive basic bedside device capable of displaying the sound and the Doppler wave of a 
blood vessel being examined.  
 
CWD ultrasound is commonly used for testing peripheral arterial occlusive disease as it can 
reveal the early pathology by detecting attenuation of triphasic Doppler signal, which 
deteriorates, to biphasic and monophasic waves representing the progression of 
atherosclerosis lesion. The early plaque lesion is difficult to detect with angiography, as there 
is a reflex vasodilatation, which does not allow narrowing of the arterial lumen in early 
atherosclerosis. However, the stiffness of the arterial wall can cause changes in the normal 
laminar flow and the resulting changes in the parabolic velocity can be detected with CWD 
ultrasound. This modality is sensitive enough to detect small changes in velocity thereby 
providing information about the early phase of the occlusive disease.   
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The tri-phasic velocity graph is the normal graph illustrating the systolic blood pressure with 
the highest average velocity during cardiac contraction shown as a first phase, while the 
second phase shown as the negative velocity are produced due to the cardiac relaxation 
during the diastolic period. Finally the third phase is the compliance without the stiffness of 
normal arteries which generate a small increase of velocity. (Figure 2-2) 
 
 
The atherosclerosis causing a stiffness of arterial wall leads to the change of blood flow to 
become biphasic feature. When the atherosclerosis disease progresses with a partial or nearly 
complete obstruction, the velocity profile will change to monophasic and attenuated 
monophasic, respectively. This is because of the massive reflex vasodilatation and the blood 
flow of collateral circulation distal to the obstructive point (Thrush, 2004). The highlight of 
the early pathology of atheroma or plaques by continuous wave ultrasound is the support 
velocity
systole diastole
normal triphasic flow profile
biphasic monophasic attenuated monophasic
FIGURE 2-2 TRI-PHASIC, BI-PHASIC, MONO-PHASIC AND ATTENUATED (DAMPED) MONO-PHASIC GRAPH OF 
THE VELOCITY GRAPH DISPLAYED BY CWD U/S 
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confirmation of the diagnosis of the unseen plaque lesion and also proclaims the possible 
concurrence of the lesion in the other arteries and the risk of forthcoming atheromatous 
complications. 
 
2.1.3. Imaging Duplex Doppler Ultrasound  
 
Although the CWD ultrasound can measure the velocity of the blood flow and show as a 
wave sign, it has limitations as it reveals only the average of blood flow and can not identify 
the true variation of velocity termed as a parabolic laminar flow as shown in Figure 2-3. 
 
 
plaque
plaque
 
FIGURE 2-3 NORMAL LAMINAR FLOW (AS A PARABOLIC CURVE) AND ABNORMAL DISTURBED FLOW 
 
Both CWD and PWD ultrasound cannot show blood flow as an animated image. The 
combination of CWD and PWD ultrasound leads to the Duplex Doppler (DD) ultrasound.  
 
The DD ultrasound is the technology that transforms the information of blood flow and vessel 
structure into image (Allan, 1997). The mode of imaging Doppler ultrasound, therefore, 
includes  
• Simple duplex Doppler (DD) mode 
• Colour Doppler imaging (CDI) mode  
• Power Doppler imaging (PDI) mode.  
 
And these modes are presently combined into the single one device. 
 
The sonographer can select mode of Duplex Doppler ultrasound combination instrument 
which can display the information obtained either from mode of simple DD, CDI and PDI 
ultrasound. By inserting the different colour fixed to the direction of blood flow, the CDI 
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ultrasound can discriminate basically the artery and vein as the blood flow usually travel in 
the opposite direction in one anatomical area. In addition, by the same principal, it can 
demonstrate the turbulence effect. The PDI ultrasound is the mode of duplex Doppler 
imaging designed for detecting the flow that is very low and difficult for other modes to 
sense. 
 
Imaging with duplex Doppler ultrasound is superior to CWD ultrasound, it can demonstrate 
different velocities (parabolic wave) from the highest in the center of arterial lumen to the 
lowest in the tangential area nearest to the wall as a display of Doppler spectra. 
 
2.1.4. Angiography  
 
Angiography is the technique that is performed by inserting a catheter into blood vessel and 
then injecting radio opaque contrast media into blood circulation. Afterwards, the X-ray is 
shot and an image is obtained. Generally, there are two modes of angiography, conventional 
and digital subtraction which is conducted by taking X-ray as a background firstly and then 
after the injection the contrast media (Beard, 2004). Thereafter, subtracting the image of the 
background will display only contrast media in the examined arteries. Nonetheless, the 
contrast media used in angiography vascular imaging carries the acceptable risk of allergic 
anaphylaxis and there is contraindication of this technique in renal failure patients 
predisposing them to renal tubule toxicity. The high dose of contrast media used in digital 
subtraction angiography has to be weighed between a clearer image and unfavourable risks 
(Beard, 2004). 
 
Angiography is a standard intra-operative assessment for evaluating successful  operation not 
only in the revascularisation of the coronary arteries in CAOD and lower limb arteries in 
PAOD but also in the reanastomosis of arteries in the field of traumatic surgery and in the 
procedures regarding thrombolytic therapy (Beard, 2004). Their displays of the contrast 
media refilling distal to previous obstruction confirms the successful reperfusion as shown in 
Figure 2-4. 
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FIGURE 2-4 A) PRE PROCEDURE AND B) POST REVASCULARISATION ANGIOGRAPHY AS A CONFIRMATIVE 
ASSESSMENT OF SUCCESSFUL REVASCULARISATION 
 
Although the intraoperative assessment indicates the success of the operation, there may be 
secondary causes of the obstruction due to certain factors regarding non-reflow phenomenon 
which may progress to complete blockage by the development of thrombo-embolic events. 
 
In the heart, it is important to make sure the success of a reperfusion therapy. Therefore, 
many centers have certain guidelines for intra-operative measurement of certain physiological 
responses such as 12-lead ECGs etc where in coronary angioplasties, the ST-segment 
elevation should gradually return to baseline (Rezkalla and Kloner, 2002). The monitoring of 
the successful tissue perfusion after revascularisation, have been integrated as an aid for the 
diagnosis and an early detection of the failure of  PTA and CABG interventions and the 
identification of non-reflow phenomenon (Rezkalla and Kloner, 2002). With the advances of 
radio-imaging technology, the techniques including coronary Doppler flow wire, digital 
coronary angiography, nuclear imaging, contrast-enhanced magnetic resonance, and positron 
emission tomography (PET) scan can confirmed the non-reflow phenomenon that may occur 
immediately after reperfusion or shortly thereafter (Rezkalla and Kloner, 2002). 
Nevertheless, the availability of these techniques is varied in each center. 
 
On the other hand, in the lower limbs of PAOD patients, ABPI is accepted as the initial 
assessment for the post-operative evaluation for the outcome of the revascularisation and the 
increase of ABPI of more than 0.15 is accepted to be an indicator of successful 
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revascularisation. In case the symptoms are not relieved and the ABPI is not increased, 
further investigation using simple DD, CDI and PDI ultrasound and repeated angiography are 
performed. 
2.1.5. Non Invasive Measurement of Endothelial Function – Macro-
circulation 
 
Brachial Artery Flow mediated dilation (FMD) 
 
Flow mediated dilatation is well established as a technique to assess endothelial function in 
human arteries. The technique relies on the creation of increased flow in the vessel being 
assessed and the resulting changes in vessel size measured with duplex ultrasound. Ischaemia 
in the distal vascular bed caused by tourniquet inflation is often used to cause increased flow 
in the vessel being assessed (Pyke and Tschakovsky, 2005). 
 
As discussed previously, blood vessels have the ability to self-regulate vasomotor tone. An 
increase in blood flow will result in an increase in ‘shear stress’ to the local endothelium. The 
vessel responds to this by dilating – flow mediated dilation (FMD; Figure 2-5). 
 
 158 
 
Ca2+
blood flow
shear stress
Kc
hyperpolarisation
eNOS
NO
phosphorylation
eNOS
eNOS gene
transcription
PGI2 EDHF
FMD
Ca2+
entry
endothelial cell
smooth muscle cell
 
FIGURE 2-5 DIAGRAM ILLUSTRATING PRINCIPLE OF FLOW MEDIATED DILATION 
 
Recently, increasing effort has been made assessing brachial artery vasodilator response in 
order to establish a correlation with presence of atherosclerotic disease in coronary and 
carotid vascular beds as well as predicting the risk of restenosis following coronary artery 
restenosis (Akcakoyun et al., 2008).  
 
Furthermore it has been found in an autopsy study (Sorensen et al., 1997) that the grade of 
atherosclerotic lesion in the brachial, carotid and coronary arteries are significantly 
correlated, as was severity in the brachial and carotid arteries and the carotid and coronary 
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arteries. This provides morphological corroboration to the findings from non-invasive studies 
of endothelial function.  
 
Technique for Flow mediated dilation (FMD) for endothelial function assessment. 
Flow mediated dilatation is well established as a technique to assess endothelial function in 
human arteries. The technique relies on the creation of increased flow in the vessel being 
assessed and the resulting changes in vessel size measured with duplex ultrasound. Ischaemia 
in the distal vascular bed caused by tourniquet inflation is often used to cause increased flow 
in the vessel being assessed (Pyke and Tschakovsky, 2005). Duplex ultrasound quantified 
flow mediated dilation (FMD) has been used to quantify endothelial function in patients with 
intermittent claudication. A cross sectional study has shown that reduced FMD was 
associated with an increased serum concentration of the serum inflammatory marker highly 
sensitive c-reactive protein (hs-crp) (De Haro et al., 2008). 
A study has shown that maximal exercise on a treadmill causes a worsening in the FMD 
assessed endothelial function. Interestingly, the both pre and post exercise endothelial 
function were found to be improved following six weeks of supervised exercise (Andreozzi et 
al., 2007a).  
A single blinded trial of 28 days of aspirin versus a nitric oxide releasing aspirin treatment 
showed that nitroaspirin was able to abolish the exercise induced FMD assessed endothelial 
dysfunction seen in the aspirin group. There was no basal effect on endothelial function and 
the effect was mirrored in exercise induced levels of serum elastase and VCAM-1 levels 
(Gresele et al., 2007a). A study examining the effect of both acute and 6 weeks of exercise 
training on VEGF levels did not find any differential expression (Wood et al., 2006). 
Using a high resolution ultrasound scanner it is possible to monitor changes in vessel 
diameter resulting from FMD and thus non-invasively determine endothelial function (Alam 
et al., 2005).  
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The acquisition of images whilst maintaining the anatomical location of the transducer is 
technically difficult and some investigators insist on a stereo tactic probe holding device 
(Corretti et al., 2002). Also the necessity of gating image acquisition to the R-wave of the 
ECG recording has been discussed. Some authors suggest that ECG gating is essential to the 
accurate acquisition of brachial artery images (Alam et al., 2005). R-wave gating will ensure 
that all images are acquired in the end diastole phase of the cardiac cycle.  
 
Previously it was thought that ECG gating of the brachial artery measurements was essential 
to accurate measurement of brachial artery diameter for FMD assessment (Alam et al., 2005, 
Corretti et al., 2002). Such gating relies on the R-wave of the ECG coinciding with the end-
diastolic phase of the cardiac cycle.  
 
Vessel diameter is larger at peak diastole compared to end-diastole, and the degree of this 
difference may be related to vessel compliance which itself may be related to availability of 
NO. Thus R wave gating may act to mask the effects of endothelial dysfunction, potentially 
resulting in reduced sensitivity. Also, automated computer based analysis of brachial artery 
size has been shown to reduce variability in measurement (Preik et al., 2000). 
ECG R-waves
pre-distal ischaemia post distal ischaemia
brachial artery
diameter
ECG trace
time time
A
B C
FIGURE 2-6 EXPLANATION OF ECG R-WAVE GATING OF BRACHIAL ARTERY DIAMETER MEASUREMENT FOR 
FMD. A) B MODE US IMAGE OF BRACHIAL ARTERY SHOWING EDGE DETECTION OF INTIMA-MEDIA 
INTERFACE. B) PRE-ISCHAEMIA CONTINUOUS RECORDING OF BRACHIAL ARTERY DIAMETER WITH 
CONCOMITANT RECORDING OF ECG TRACE BELOW. R WAVES ARE INDICATED BY ARROWS. C) POST-
ISCHAEMIA RECORDING SHOWING INCREASED BRACHIAL ARTERY DIAMETERS. 
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We have previously demonstrated that with automated image registering software, there is 
good correlation and good agreement between R-wave gated and non-gated ultrasound 
brachial artery measurements. (Jaffer and Aslam) (Figure 2-7and Figure 2-8). 
 
 
 
FIGURE 2-7 SCATTER PLOT OF R-WAVE GATED VERSUS NON-GATED BRACHIAL ARTERY DIAMETER SHOWING 
CORRELATION LINE. 
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FIGURE 2-8 BLAND AND ALTMAN PLOT OF DIFFERENCE IN R-WAVE GATED AND UN-GATED BRACHIAL ARTERY 
DIAMETERS AND MEAN OF TWO DIAMETERS. SOLID LINES DENOTED MEAN DIFFERENCE ± TWO STANDARD 
DEVIATIONS. 
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FMD patient testing protocol 
 
1) Following taking informed consent from a participant, the participant was asked to lie 
down on a couch for a period of approximately 45 minutes. 
 
2) A blood pressure cuff was placed around the participant’s upper right arm after confirming 
that this site was not painful or tender.  
 
3) The participant’s right brachial artery was scanned in longitudinal section approximately 2 
to 3 cm above the elbow joint. The arm was positioned on an arm board attached to the 
examination couch. The arm was stabilised using a vacuum beanbag attached to the arm 
board (Figure 2-9). 
 
 
FIGURE 2-9 PHOTOGRAPHS OF A) PROBE HOLDER ATTACHED TO COUCH AND B) ARM HELD IN POSITION ON 
VACUUM BEANBAG ON ARM BOARD. 
 
4) The blood pressure cuff will be inflated to 30 mmHg above the systolic blood pressure. 
Inflation was maintained for a period of three minutes. 
 
5) Following release of the blood pressure cuff, the brachial artery scan was repeated. 
 
6) The participant was then asked to walk briskly on a treadmill (10 per cent incline; 4 miles/ 
hour) until they could not tolerate their typical claudication pain.  
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7) Steps 3, 4 and 5 were then repeated following exercise in order to assess endothelial 
function again. 
 
Image Analysis 
 
Images were acquired using the M7 portable ultrasound machine (Shenzhen, China) using a 
40mm 5-10 MHz broadband linear array transducer. 
 
Images were transferred from the S-video output via a digital image recording device to a 
personal computer, Dazzle video creator (Pinnacle Systems GMBH, Braunschweig, 
Germany). Images were stored as AVI files and analysed off line. 
 
Brachial artery diameter and carotid intima-media thickness measurements were performed 
using automated edge detection software, Vascular Research Tools 5 (Medical Imaging 
Applications, Coralville, Iowa, USA; Figure 2-10).  
 
ECG R-wave gated measurements were obtained by frame by frame examination of the 
captured video clips and recording those which corresponded to the simultaneously recorded 
ECG R-wave at the bottom of the ultrasound scanner display.   
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2.1.6. Non Invasive Measurement of Endothelial Function - 
Microcirculation 
2.1.6.1. Introduction 
The use of techniques to monitor the microcirculation or the blood flow through small vessels 
at the capillary level is a more recent development of the last two decades. The various 
options that are available for monitoring the microcirculation are included in table 5.1 with a 
brief description about each one. The technique employed in this work is Laser Doppler 
flowmetry. 
Propelled by the work of Stern (Stern, 1975b) who first demonstrated the use of Doppler 
shifted light to quantify red blood cell movement in the skin, the laser Doppler technique has 
since become the focus of numerous studies, particularly in the fields of dermatology and 
microvascular surgery. Growing use of this technique was facilitated by linking the laser 
Doppler flowmeter (LDF) to a computer in order to store and analyze the acquired data. 
Although given credit for its ability to make non-invasive and continuous measurements, the 
laser Doppler has yet to gain universal acceptance for any one of its many potential 
applications as it will be explained further in this document. 
FIGURE 2-10 AUTOMATED IMAGE ANALYSIS OF BRACHIAL ARTERY NEAR TO FAR INTIMAL DIAMETER IN 
DEFINED REGION OF INTEREST. RESULTS PANE ON RIGHT OF IMAGE RECORDS INDIVIDUAL 
MEASUREMENTS. 
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2.1.6.2. Optics 
 
Light is a form electromagnetic radiation. Electromagnetic radiation has a sinusoidal 
waveform and is capable of travelling in a vacuum. White light is composed of many 
different wavelengths both visible and invisible to the human eye; when broken down, each 
component of white light has it’s own unique properties which we perceive as colour. In 
1901, Max Planck showed that light exists in small packets or units and he termed these 
“quanta”(M, 1901). The word photon (γ) derives from the Greek for light and was coined by 
Gilbert Lewis 1926(G, 1926). Einstein and others demonstrate that photons exhibit both 
wave-like and particle-like properties. Photons have wave-like properties because they may 
be refracted, reflected, dispersed, diffracted, polarised and be subject to interference. Photons 
also have particle-like properties because they interact with other elementary particles by 
being absorbed and emitted as a whole: it is this theory of photons reacting in discrete units 
or as a whole, which gives the photon its particle-like property. Photon are thus said to have 
wave-particle duality. The study of light is known as optics. 
 
The main properties of photons can be described in terms of: 
• Intensity 
• Frequency (f) 
• Energy (E) 
• Wavelength (λ) 
• Phase 
• Speed (c) 
• Polarisation 
 
Intensity 
In optics, light intensity refers to the timed-average energy flux, per unit volume and may be 
denoted by many symbols and calculated in many ways which are irrelevant to this book. 
Intensity of light can be broadly found by taking the energy per unit volume of light and 
multiplying it by the velocity, to give vector of intensity per unit volume. It describes the 
energy transferred by a population of photons, within a given volume. Medical lasers may be 
of high or low intensity depending on their purpose. Diagnostic lasers are normally of low 
intensity because they aim to leave tissues intact. The intensity (I) of light can be calculated 
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from the speed of light (c), the energy of the light (E), refractive index (RI) of the medium 
and the electric constant E0: 
 
 I = E2 [(cE0 RI) / 2] 
 
Frequency (f) 
In optics, frequency refers to the number of cycles of a wave, per unit time. The unit of time 
is usually 1 second and often measured in Hertz (Hz). For reasons of pragmatism, we will 
denote frequency by the letter (f) but normally, in optics, the frequency of a photon is denoted 
by the Greek letter nu (ν). Of note, the frequency of any given photon never changes. 
 
Energy 
A photon has a constant energy which is proportional to the frequency (f) multiplied by 
Planck’s constant (h). Planck’s constant is simply the numerical relationship between the 
energy of a photon and its frequency. The energy of a photon is also inversely proportional to 
the wavelength (λ), whereby: 
 
 E = hf= hc / λ 
 
Wavelength (λ) 
The wavelength of a sinusoidal wave is a measure of the special period over which it repeats. 
The point of repetition is usually taken as a peak, trough or zero crossing. The wavelength of 
a sinusoidal wave of light is equal to the speed (c) divided, by the frequency (f) and so given 
by the equation: 
 
λ = c / f 
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Phase 
Phase is a function of frequency and refers to the relative time taken for a sinusoidal wave to 
be formed and complete a single cycle. In optics, phase is an important term which conveys 
information about the timing of wave production. For example, photons are said to have the 
same phase if they have been produced at the same time or complete a cycle at the same time. 
If photons are produced at different time points then are said to have different phases, or have 
under gone a phase-shift. Figure 2-11 shows two identical waveforms for a photon of light; 
one produced at t = 0 and the other at t > 0; therefore, the photons have a different phase. If 
both were produced or to cross the x-axis at the same value of t, they would be said to have 
the same phase.  
 
 
t
FIGURE 2-11 SHOWS THE 2 PHASES OF 2 IDENTICAL WAVES 
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The idea of phase becomes important when we superimpose 2 (or more) waves upon each 
other. Consider 2 photons with the same frequency; they will always have the same phase if 
produced at the same time but never be in phase if produced at different times (as in Figure 
2-12). Now consider 2 photons with different frequencies (and therefore wavelengths); one 
with wavelength λ1 and the other with wavelength λ2. If these photons are produced at the 
same time, then they will have the same phase at creation but fall out of phase thereafter. 
They will travel in unison, and cancel/add with one-another until they (if at all) come back 
into phase again. The overall frequency of these 2 waves can then be calculated, based on the 
principle of phase and give a measure known as “beats”, which will be covered in the 
Doppler effect section. 
 
Speed 
Light has a constant speed in a vacuum of 299 792 458 metres/second and is denoted by the 
letter c (“the speed of light in a vacuum”). The speed of light varies depending on the 
medium in which the photon travels (e.g., in a vacuum it is faster than in a solid) due to 
alterations in wavelength. The speed of a photon(c) can be calculated from the wavelength (λ) 
and frequency (f), with the formula: 
 
 c =λ f 
 
Light travelling in a medium may be slower that c because photons are continuously absorbed 
and re-emitted from elementary particles within the medium. Some photons (of specific 
t
FIGURE 2-12 SHOWS 2 DIFFERENT WAVES (OF WAVELENGTH Λ1 
AND Λ2) COMING IN AND OUT OF PHASE. 
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wavelengths) may also be absorbed & re-emitted more than others and thus, emerge from the 
medium at different times; this is known as dispersion and occurs when light is split into its 
component colours by a prism. For this reason, in optics, the discussion of the speed of light 
in a medium, is often described in terms of phase velocity (v).  
 
Phase velocity (v) describes the effect of a given medium, on the relative speed of light. The 
degree to which photons are absorbed & re-emitted in a medium dictates the “speed” of 
conduction because this process takes time. This absorption and re-emission phenomenon is 
also termed refraction because of the macroscipc effect that this process has on bending light 
and slowing portions of it. So, if a material is highly refractive (e.g., plastic) it is less 
“permeable” to light and so, will slow the passage of light: it is slowed because the matrial is 
more dense, therefore absorbs and re-emits more photons. If a material (e.g., air) is highly 
permeable to light, it will not slow its passage because there are few particles to absorb & re-
emit photons. It is the “permeability” of a substance to light which determines how refractive 
it is, and this property is quantified by the refractive index (RI).  
 
 
 
 
 
 
 
photon photon
time
FIGURE 2-13 PHASE VELOCITY – PHOTON A 
TRAVELLING THROUGH A SUBSTANCE WITH LOW 
REFRACTIVE INDEX WILL EMERGE SOONER THAN 
PHOTON B, BECAUSE IT HAS TRAVELLED LESS 
DISTANCE AND THE SPEED OF LIGHT IS CONSTANT. 
THUS, THE PHASE VELOCITY OF A > B. 
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Refraction occurs because when a photon interacts with an atom (i.e. it is absorbed), the 
electron fields are energised and disturbed, causing them to oscillate. The wavelength of the 
oscillating electrons is generally slightly out of sync (phase) with the wavelength of the 
photon. Therefore, when the photon is re-emitted (as the electron is de-energised and falls to 
a lower shell) it too becomes disturbed; more specifically, the wavelength is reduced and so, 
the velocity reduces in the medium. The photon is now said to have undergone a phase shift.  
 
To relate refraction to velocity: if the RI of a medium is high, light travels slowly through the 
material and vice versa. Photons travelling an equal distance through a substance with a high 
refractive index will emerge at a relatively later time than photons travelling through a 
substance of low refractive index. It is this relative velocity which we term phase velocity and 
is shown pictorially in Figure 2-13. This relationship between phase velocity of a photon (v) 
and the refractive index (RI) of a medium, is given by the equation: 
 
v = c / RI 
 
Sometimes it is more practical to talk in terms of the velocity of groups of photons (vg) in a 
medium and the affect of a refractive index on the passage of grouped light (RIg). This 
relationship between the phase velocity for grouped photons and the RI is inferred from the 
equation above but still based on a velocity of a single photon. The equation is: 
 
RIg = c / vg 
  
The importance being that the grouped refractive index (RIg) can now be related to the 
wavelength of a particular photon in a vacuum (λ), by differentiation/ integration: 
 
 RIg = RI – λ [dRI / dλ] 
 
Or the  group velocity (vg) may be calculated for a known refractive index of a homologous 
medium: 
 
vg = 1 / c [RI – λ (dRI / dλ)] 
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In summary, the speed of photons (c) in a vacuum is proportional to the frequency (f) 
multiplied by the wavelength (λ). However, the velocity of a photon is not constant and 
depends upon the RI of the medium in which it is travelling or the velocity of a moving object 
which it encounters. The wavelength (therefore velocity) of a photon decreases when it 
travels in a medium. The relationship between the original velocity and the new velocity 
(phase velocity), when a photon is slowed by a medium or moving object, is known as a 
phase shift. This relationship is given by the formula: 
 
λ = c / RI f 
 
This pivotal principle linking the velocity of a photon in a medium with wavelength and 
frequency, is the basis of the Doppler effect in laser technology. 
 
Polarisation 
The polarity of a wave describes the plane in which a wave travels. In general, light (as an 
electromagnetic wave), is made up of mutually perpendicular, fluctuating electric and 
magnetic fields; thus, the photons are travelling in the same direction but in any and all 
number of planes. White light is made up of many waves of different polarity. When waves 
are travelling perpendicular to one another, they cancel out, otherwise, they add. Diagnostic 
medical lasers may or may not have a polarising filter to allow the passage of selected 
photons, of parallel waveforms. 
 
2.1.6.3. Lasers 
 
The first working laser was demonstrated by Maiman et al (Maiman, 1966) and four years 
after this, a laser was used to measure the velocity of particles in solution by interpreting the 
Doppler frequency-shifted light which was backscattered (Yeh H, 1964). Some years later  
(Riva et al., 1972) used the principle of the Doppler shift to measure the velocities of red 
blood cells using lasers, in a glass tube. The birth of laser Doppler blood perfusion 
measurement however, is attributed to  (Stern, 1975a) for his description of ‘In vivo 
evaluation of microcirculation by coherent light scattering’: He postulated that when 
coherent light impinges on the skin, some of it will be backscattered by moving red blood 
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cells and some by static tissue. If the reflected light is brought to the surface of a sensitive 
photodetector, optical beating will produce an audio-frequency photocurrent output.  
 
A laser (light amplification by stimulated emission of radiation) is a mechanism for emitting 
light from the electromagnetic radiation region of the spectrum. Light emitted from a laser is 
spatially coherent and has narrow low-divergence, but can be manipulated by a lens. Most 
lasers are “coherent” which means that all the light produced is of the same frequency & 
phase; however, some can be configured to produce a broad beam of light, with varying 
wavelengths and differing phases (“incoherent”). In medicine, most lasers are monochromatic 
and thus, coherent. 
 
A laser can emit light of any frequency from gamma waves to radio waves. A laser is 
constructed from three principle parts and sometimes may also have a lens (the 4th part) 
(Figure 2-14): 
1. The pump (energy source) 
2. The gain/laser medium 
3. Two or more mirrors that form an “optical resonator” 
4. Lens 
 
  
 
 
 
FIGURE 2-14 LASER CONSTRUCT SHOWING THAT LIGHT PRODUCED FROM THE PUMP ENTERS THE MEDIUM 
TO ENERGISE IT. PHOTONS OF VARYING FREQUENCIES ARE LIBERATED. PHOTONS OF UNDESIRED FREQUENCY 
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ARE REFLECTED BACK INTO THE MEDIUM FROM THE HIGHLY OF PARTIALLY REFLECTIVE MIRRORS (TO 
“GAIN” FURTHER PHOTON EMISSION). PHOTONS OF DESIRED FREQUENCY PASS THROUGH THE PARTIALLY 
REFLECTIVE MIRROR, FOCUSED BY A LENS AND THUS, A LASER IS PRODUCED. 
 
 
The Pump 
This part produces the energy for the laser system. The energy (photons( may be produced 
from electrical discharges, flash-lamps, arc lamps, chemical reactions or even another laser. 
A historic energy source is a Helium-Neon (HeNe) gas mixture which emits light of 
wavelength of 632 nm, when a charge is applied to it. The most commonly used pump in 
current medical laser systems is a laser diode, because it is small, safe, energy efficient and 
cheap to produce. A laser diode is a semiconductor which converts alternating current into 
direct current (rectification), and passes this current across a specific and microscopic gap-
junction, with the aid a carrier substance (e.g., gallium arsenide). When the carrier substance 
delivers the charge to the other side of the gap-junction, a photon is produced. The frequency 
of the photon corresponds to the composition of the semiconductor. Laser diodes produce 
incoherent photons, therefore, modulation is required (by the gain medium and optical 
resonator) to make the laser coherent. 
 
The Gain/Laser Medium 
A gain medium is a substance designed to absorbed and re-emit photons of specific 
frequencies. It may be principally composed of: 
• Gases:  these lasers normally use electricity from the pump to discharge light  
from gases such as: HeNe, CO2 and Krypton 
• Liquids: normally composed of a solvent and a dye, these lasers use a variety of 
energy sources. 
• Solids (such as crystals or glasses). Solid mediums are usually laced with an 
impurity (e.g., Neodymium) and the pump/energy source is often a laser diode or 
flash lamp. 
• Semiconductors: formed from a conductor and an insulator, which allows 
direction of current through pores. They can be configured to produce photons of 
 175 
 
different frequencies according to the concentration of ‘impurities’ or crystals 
(dopant level), when electrons pass through the micro gap-junctions. 
 
When light from the pump interacts with the gain medium, the molecules become excited and 
undergo population inversion. Population inversion describes the situation where groups of 
atoms (N), in ground energy state (E1), absorbs light energy and thus become energised to a 
higher energy state (E2). This ascension of atoms to a higher state of energy occurs through 
the promotion of electrons to an outer and higher order shell. When an electron(s) ascends 
shells it absorbs energy and when it returns/falls back to its original shell, it emits a photon of 
light. Some atoms within the molecule will be energised (N2) whilst others will not (N1), 
giving the relationship:  
 
N = N1 + N2 
 
The difference between the ground energy state (E1) and the new higher energy state (E2) of 
atoms, is denoted by the symbol (ΔE) and given by the equation: 
 
ΔE = E2 – E1 = hfχ 
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Where h is Planck’s constant, describing the relationship between the frequency and energy 
of a photon and fχ is the characteristic frequency of light which will interact maximally with 
an atom. Any number of photons of any frequency can promote an electron (in many steps or 
one) to a higher energy state, as shown in Figure 2-15. However, the frequency of light 
proportional to the energy gap ΔE is determine by the chemical composition of the gain 
medium and so χ can take many values. It is this value of χ which determines the frequency 
of light emitted from the gain medium and therefore, the frequency of the laser light 
produced, when an electron falls back down to its original shell and the atom returns to 
ground energy state (E1).  
 
When atoms in the gain medium (N) are saturated with energy, some groups of atoms will 
become energised and decompose to emit photons of light: these photons are randomly 
generated and are of differing frequencies, hence incoherent. This is known as spontaneous 
emission. If an atom is in a higher energy state (E2), then it may be disturbed by another 
photon of light with a frequency equal to the energy gap ΔE. In this case, if another photon of 
frequency fχ interacts with the atom in energy state E2, then the atom relaxes back to the 
ground energy state (E1) and emits a photon of identical frequency (fχ) and phase to the 
disturbing photon. Interestingly, the disturbing photon is not absorbed and thus escapes the 
medium. This has the effect of producing 2 photons of identical phase & frequency; the 
hf = E
E2; higher energy state
E1; ground energy state
FIGURE 2-15 WHEN A PHOTON (OF FΧ) IS 
ABSORBED BY A GROUND ENERGY STATE ATOM 
(E1) AND ASCENDS TO A HIGHER ENERGY STATE 
(E2) 
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output photon from the relaxing atom and the original photon. This is the process of 
stimulated emission and illustrated in Figure 2-16. 
 
It follows then, that to produce more laser light than one puts in (through the pump), the ratio 
of atoms in the ground energy state (N1) and higher energy state (N2) cannot be equal, 
because then the photons would simply be reabsorbed into the medium. In order to ensure net 
output of laser light, the population of atoms must be N2>N1. 
 
The Optical Resonator 
In order to attain more atoms in a higher energy state (E2) than ground energy state (E1), 
photons of undesired frequency can be recycled. Recall that the photons emerging from the 
decomposing gain medium are of multiple frequencies and phases. These photons can either 
be allowed to escape out of the system (if they are of the desired frequency) or they can 
otherwise be redirected into the medium, and thus reabsorbed.  The reabsorbed photons of 
unwanted frequency aid the promotion of other atoms in a ground energy state (E1) to a 
higher energy state (E2). Therefore, by inputting light (from the pump) of the desired 
frequency & phase, more identical light is produced than input. This phenomenon is known 
as optical gain or amplification, and is the crux of laser production. 
 
hf = E
E2; higher energy state
E1; ground energy state
in: 1 photon (hf)
out: two photons of 
identical frequency 
(hf) and phase 
FIGURE 2-16. WHEN A PHOTON (OF FΧ) PASSES AN ATOM IN A HIGHER ENERGY STATE 
(E2) WITH AN EQUIVOCAL ΔE, THE PASSING PHOTON CAUSES THE ATOM TO RELAX 
BACK TO GROUND ENERGY STATE (E1) AND EMIT A PHOTON OF IDENTICAL FREQUENCY 
& PHASE 
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The optical resonator is a system of mirrors within the device, which reflects light of 
unwanted frequencies back into the gain medium. Traditionally, the optical resonator is 
composed of multiple mirrors flanking the gain medium; one mirror is a partial reflector and 
the other(s) high reflector(s). High reflectors reflect all light and partial reflectors only 
permits photons of the desired frequency through to form the output laser beam, while 
reflecting all other frequencies back into the gain medium, in order to drive the production of 
more photons. 
 
Lens 
 
According to Snell’s Law (Rashed, 1990), when a wave (or photon in this case) passes from 
one medium to another, it undergoes refraction. This means that the normal wave’s direction 
of travel is altered (because the wavelength changes) and the incident wave takes a new 
direction of travel. This is relationship is given by the equation: 
 
 RI1 sin θ1 = RI2 sin θ2 
 
Where RI1 and RI2 are the refractive indices of the two mediums, and θ1 and θ2 are the angles 
between the normal and incident wave respectively (Figure 2-17). This phenomenon is also 
associated with the change in the speed of light (as the RI of a medium affects the wavelength 
and speed) and so, based on the equation linking the velocity of a photon wave in a medium 
(v) and the RI, we can infer: 
v1
v2
1
2
medium with RI1 medium with RI2
FIGURE 2-17 SNELL’S LAW OF THE CASE OF A 
WAVE MOVING FROM AIR (RI1) TO A MEDIUM 
(E.G., SKIN) WITH RI2. 
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 V1 sin θ2 = v2 sin θ1 
 
This principle of refraction holds strong for uniformly dens medium, with a constant RI. Lens 
can either focus (converge) light to a narrow beam with a convex lens or disperse (diverge) 
light with a concave lens. Lenses of medical lasers normally to converge laser light and use 
the Lensmaker’s equation (E, 1987) (Figure 2-18) to determine the focal length and required 
properties of the lens. This is given by the equation: 
 
(1 / S1) + (1 / S2) = 1 / FL 
 
Where FL is the desired focal length, S1 is the object difference and S2 is the virtual image. 
 
Lenses also have many other properties which can be exploited (such as chromatic 
aberration) but they are not pertinent to LDV. 
 
photon B
photon A
object
image
S1
S2
F
FIGURE 2-18 THE LENSMAKER’S EQUATION APPLIED TO TWO PHOTONS, 
ONE BEING REFRACTED BY A CONVERGING LENS (A), THE OTHER NOT. THE 
OBJECT IS WHERE THE INCIDENT BEAMS MEET AND IS MOST INTENSE. 
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In LDV, it is not just the mechanisms behind laser production which are important, but also 
the focussing of the beam and measurement of what is reflected back. Diagnostic medical 
also have a: 
1. Photodetector 
2. HP filter 
3. Nomaliser 
4. Differential Amplitude Detector 
 
Photodetector 
Photons returning from the illuminated tissue interact with each other (adding or cancelling) 
and strike the surface of the photodetector attached to the surface of the skin. The 
photodetector measures the difference in frequency between the interacting photons in Hz 
and converts this into a DC current with a fast Fourier Transformation. The range of Hz 
detected is proportional to the intensity of light striking the detector and thus, DC amplitude. 
The DC current, defining the flow rate, is then passed through a filter. 
 
Laser
skin
photodetector HP filter Normaliser
Differential 
aplitude 
detector
photodetector HP filter Normaliser
processing 
unit
output 
graph
 
FIGURE 2-19 SHOWS A MULTI-CHANNEL SETUP FOR A LDF, MEASURING THE BACK SCATTERED LIGHT FROM 
MULTIPLE LOCATIONS TO REDUCE THE SIGNAL-TO-NOISE RATIO AND GAIN A HIGHER QUALITY RECORDING 
 
Low Pass (LP) High Pass (HP) filter 
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Filters only allow DC photocurrents corresponding to a specific Hz range to continue through 
the system. A LP filter cuts of frequencies below a certain value whilst a HP filter removes 
high frequencies. For example, low frequency lasers (~633nm) have a tight HP filter which 
permits only 0~12Hz current through, compared to HP filters of high frequency lasers 
(~780nm) which permit a range of 0~30Hz through. The range permissible depends on the 
depth of measurement the investigators wants because higher frequencies will penetrate into 
deeper tissue and thus undergo a greater Doppler shift, which must be allowed for the 
measurement. The HP filter differs between machines and is sometimes changeable, but 
dictates the range of flux detectable. This range of detectable flux is often termed the 
“Bandwidth” and some authors advise that higher bandwidths should be used, in order to 
measure as deeply as possible and detect higher average velocities of red blood cells. The 
filtered DC current is then passed to the Normaliser. 
 
Normaliser 
DC charge passed into the normaliser can be plotted in a graphical form. At this point, the 
distribution of DC charge is exponential and only useful to a skin depth of 0.6mm9-10. The 
distribution of the DC photocurrent should be normal (Gaussian) because Brownian motion  
and tissue light scattering is random, therefore, the distribution of the residuals should also be 
normal. For this reason, the photocurrent and thus, LDF flux trace can be considered to have 
2 main portions; The heterodyne signal (iS) and homodyne signal (iR) as shown in Figure 
homodyne
‘noise’
heterodyne
‘signal ’
I
0 f∆f
FIGURE 2-20 SHOWS THE HOMODYNE TRACE (“NOISE”) OF 
BACKSCATTERED LIGHT FROM STATIC TISSUES AND THE 
HETERODYNE TRACE (“SIGNAL”) ARISING FROM DOPPLER SHIFTED 
PHOTONS FROM MOVING OBJECTS, PLOT AGAINST INTENSITY (I) 
AND IN FREQUENCY (F). 
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2-20. 
The heterodyne trace (iS) arises from photons backscattered from moving objects (“signal”) 
and shows the only true variation in measured flux which is due to flowing blood cells. The 
heterodyne signal is often simply termed “signal” an is the portion of the LDF trace which we 
are interested in. The homodyne trace (iR) arises from photons backscattered from static 
tissue and/or the reference beam: due to the fact that scattering from static tissue is random 
and constant (provided there is no motion artefact and experimental conditions eg. 
temperature, TcO2 etc are kept constant), we can disregard this trace as background noise. 
The ratio heterodyne to homodyne signal is termed “signal-to-noise ratio”. 
 
The signal-to-noise ratio is determined by the number of channels in the device and their 
mathematical algorithms. Each channel measures backscattered light from a separate area of 
skin, allowing assimilation and comparison. Usually there are multiple channels arranged 
around a central laser which identify homodyne patterns signifying background noise and 
remove them from the trace. Some noise patterns however cannot be removed, despite 
improving hardware and software, therefore, the resultant DC photocurrent is still expressed 
in terms of signal (iS) and irrevocable noise (iR): 
 
DC photocurrent = iR + iS  
 
As described, the distribution of the photocurrent is exponential, therefore to normalise it the 
DC photocurrent is often squared – [DC]2. Due to this transformation, the flow measurement 
is now defined in arbitrary units of flux and given by the formula: 
 
Flux = [iR + iS]2  
 
Newer LDF machines can measure flux relative to overall flow and alter the output signal by 
using the root-mean-square (RMS) of the DC current which is more contextualised and offers 
some advantages for measuring flow continuously in one specific location, because it better 
removes the effect of tissue light scattering. It is given by the formula: 
Relative flux = [√µDC]2  
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We advise authors to express reported LDF measurements in flux units and define which 
normalising algorithm was used. 
 
Differential Amplitude Detector 
This portion of the detector measures the difference in DC photocurrent and simply plots it 
on a graph against time (x-axis). The output of more recent machines is digital and can be to 
PC software, for keeping and later statistical analysis. 
2.1.6.4. The Doppler Effect: Lasers 
 
Johan Christian Doppler originally described the Doppler effect in 1842 (C, 1842), as a 
change in the frequency of a wave for an observer moving relative to the source wave. In 
other words, the frequency of a wave changes depending on the relative velocities of the 
source and the detector. It occurs because the waves emitted by the source are either 
compressed (if the source and detector are moving towards each other) or dispersed if the 
source and detector are moving in opposite directions. This principle allows us to calculate 
the velocity of a moving object, based on the frequency (Doppler; Figure 2-21) shift which it 
produces.  
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epidermis
dermis
blood vessel wall
red blood cells
non Doppler shifted laser light
Doppler shifted laser light
 
FIGURE 2-21 DOPPLER EFFECT. 
 
 
To understand how LDV is clinically applicable, 3 particular facts are of importance: 
1. If a photon is absorbed and re-emitted it is refracted but continues travelling away 
from the source 
2. If a photon is reflected from a static tissue, it’s wavelength is unchanged and so its 
phase velocity remains constant 
3. If a photon is reflected from a moving object, it’s wavelength is reduced and so is 
its phase velocity: ie. the wave undergoes a Doppler shift. 
 
Most photons are either absorbed & re-emitted by static tissues or reflected back unchanged 
[Nilsson GE. Perimed's LDV flowmeter.  In: (Shepherd 1990)]. Only a very small number of 
photons undergo a Doppler shift and are backscattered for measurement, but it is this small 
sample of photons from which we can discern the speed and concentration of blood flow 
(Leahy MJ, 1999) (Figure 2-22). 
 
Over time, the term “Doppler Effect” has become synonymous with “velocity measurement” 
in medicine, however, the methods by which velocity is inferred in the field of medical lasers 
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is different. Unlike sound waves, photons have very high frequencies which are difficult to 
measure directly. As previously eluded to, the issue of measuring a photon’s frequency can 
be circumvented by using the phenomenon of ‘beats’.  
 
When photons come in and out of phase, their frequencies synchronously add (if the 
polarities is the same) or cancel (if the polarities are different), respectively. Therefore, when 
two photons of slightly different frequencies are superimposed, we can simply measure the 
difference in frequency between them as this value will be much smaller and more readily 
quantifiable. Take a photon of frequency=3 and one of frequency=2: the maximum range of 
difference is -1 to 5 units. Again, take a photon of frequency 10,000 and one of frequency 
20,000. The maximum range of difference is -10,000 to +30,000. When a photon undergoes a 
Doppler shift, the frequency drops (because the wavelength is reduced), therefore, we are not 
interested in the high end of the range of differences, but only the lower end. This 
conveniently makes measuring the frequency of Doppler shifted photons much easier. The 
difference in frequency between 2 photons is measured in terms of amplitude and called a 
‘beat’(Yeh H, 1964). The frequency of each ‘beat’ is exactly proportional to the frequency 
shift produced by the Doppler effect and therefore, allows us to calculate velocity.  
 
First, consider these scenarios to explain how the Doppler effect is applied to lasers: 
1. Two identical photons are produced from a source and reflected directly back 
from a mirror, to the detector.  The difference in frequencies is nothing because 
they had the same phase at emission and detection. The measured amplitude 
therefore is zero. 
2. Now make the 2 photons of slightly different frequency but keep all other 
conditions the same. As the photons travel to the mirror they come in and out of 
phase slightly, before returning to the detector in a different relative phase to that 
which they left. The difference in frequencies will be small and so the measure 
amplitude will be small also. 
3. Finally, take 2 photons of different frequencies and emit them from the source, 
and make the mirror static human tissue. Call one photon the reference wave (R) 
and the other, the effector wave (Z). Allow the reference photon (Z) to be 
reflected directly back from static tissue to the detector, but the other photon (R) 
to be affected by a moving object e.g., a red blood cell. The frequency of the 2nd 
photon (Z) will be reduced, because the movement of a photon in a medium is 
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relatively slowed due to absorption and re-emission, therefore its wavelength is 
reduced and so is its frequency. This means that the effecter photon (Z) will have 
undergone a Doppler shift and strike the detector well after the reference photon 
(R). The difference in frequencies between the reference photon (R) and the 
effected photon (Z) will now be greater than the when they were emitted, so the 
difference measured amplitude will be large.  
 
 
 
 
 
 
By mixing a Doppler-shifted wave with a reference wave, a ‘beat’ is produced. The 
frequency of each beat is much lower than either of the two constituent waves and is thus 
much easier to measure.  
 
In simplicity, the relationship between the frequency change (a ‘beat’) between a reference 
wave and Doppler shifted wave can now be expressed in the equation: 
 
 f ' – f = f [v(c – v)] 
 
FIGURE 2-22. SHOWS	  A	  PHOTON	  TRAVELLING	  IN	  DIRECTION	  K1	  AT	  ANGLE	  TO	  THE	  
NORMAL	  AND	  COLLIDING	  WITH	  A	  RED	  BLOOD	  CELL.	  THE	  INCIDENT	  PHOTON	  THEN	  
TRAVELS	  IN	  DIRECTION	  (K2)	  AT	  ANGLE	  AFTER	  UNDERGOING	  A	  DOPPLER	  SHIFT.	  NOTE:	  
THE	  ANGLES	  ARE	  HIGHLY	  EXAGGERATED.	  SCATTERING	  IS	  USUALLY	  IN	  THE	  FORWARD	  
DIRECTION	  WITH	  THE	  MEAN	  ANGLE	  BEING	  5.4O 
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Where f ' is the Doppler shifted frequency, f is the reference frequency, v is the relative 
velocity of the source/detector and c is the velocity of the photon. In the case of laser 
Doppler, the velocity of light (c) is usually much larger than the velocities we are interested 
in and so the subtraction of measured velocities would make no difference to the observed f ’, 
therefore, we ignore it and simply the equation to: 
 
f ' – f = f (v/c) 
 
To express this in terms of change in frequency (Δf) we have the equation: 
 
 Δf = f – f ‘ = 2v / λ 
 
These equations hold true only for the detection of photons travelling perpendicular to the 
source and do not consider the angulations of the normal beam (θ) and moving objects. 
Therefore, a more practical equation in common use is: 
 
 Δf = 2v sin θ / λ 
 
If the returning photon is detected after a single Doppler shift and without further scattering 
from moving objects, then the resultant Δf can be considered in terms of the angle of 
incidence (φ) also: 
 
 Δf = cos φ (2v sin θ / λ) 
 
This is still impractical because in a system of moving particles such as skin, it is clear that 
photons will interact with more than just one single structure (moving or static) and so 
undergo more than one Doppler shift. Therefore, the detected frequency is written in terms of 
the sum (Σ) of individual events (i): 
 
 Δf = Σi cos φi (2vi sin θi / λ) 
 
Now that we can measure the Doppler shift of a laser by calculating the difference in 
frequencies, which produce a ‘beat’, we can translate this into a useful measurement to 
quantify flow. This value of frequency change is an arbitrary figure and usually termed ‘flux’. 
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2.1.6.5. Biological Zero 
 
Measurement of flow with Laser Doppler flux is still not perfect; even after total vessel 
occlusion, tissues can remain metabolically active for several hours and the contained 
molecules will continue to move in space & time. Therefore, in the absence of flow and even 
in death, tissues have a detectable Doppler signal (Tenland T, 1983b, Caspary L, 1988).  This 
signals primarily seems to originate from Brownian movement of the interstitium (Tenland T, 
1983b, Caspary L, 1988) and movement of red blood cells in the vascular compartment 
(Parpart A, 1956). Brownian movement is the mathematical model which describes the 
seemingly random movement of particles suspended in a liquid/gas (R, 1828). In relationship 
to laser Doppler measurements, it is particularly the movements of macromolecules within 
the interstitium of skin that generates measurable Doppler shift on photons and therefore, a 
flux signal. It is this measurable baseline signal, which is always present and independent of 
regional flow, which was termed “Biological Zero” (BZ) by Tenland et al (Tenland T, 
1983b). 
 
Many authors believe that the BZ signal should be subtracted from measurements, in order to 
get the “true” flux value and thus, the “true” flow (ref). Although BZ is clinically only 
influenced by temperature, the value for BZ is very small and usually consistent between and 
within subjects, therefore, it rarely (if ever) changes the results of any study. Furthermore, 
subtracting BZ from measured results has been shown to be detrimental to the reproducibility 
of measurements (S Jadhav, 2007). 
 
The question still remains, does BZ change in normal versus disease tissue and during 
occlusion? Until this question is answered, it is advised that experimental conditions be kept 
constant, the BZ is not subtracted from flux measurements but all factors and readings clearly 
stated in the write up; (Rajan et al., 2009). 
 
2.1.6.6. Types of Laser Doppler measuring devices 
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There are two main types of laser Doppler measuring devices: the probe and the 
scanner/imager. The first to be developed was the conventional laser Doppler probe or 
flowmeter (LDF). After LDF, the laser Doppler imager (LDI) emerged predictably in 
response to several limitations of the conventional flowmeter. One complaint about the probe, 
which is applied directly to the skin, was that it restricted measurements to an area of 1 mm2 
at a time. A single reading could misrepresent the spatial heterogeneity of blood perfusion in 
the surrounding area of interest. The probe was also found to be extremely sensitive to 
motion and vibration and it was considered to have poor reproducibility of readings. Finally, 
it was suggested that direct contact of the probe with the skin surface could itself alter skin 
blood flow.  
 
Laser Doppler imaging is based on the same principle of measuring blood flow as 
conventional laser Doppler flowmetry, except that a system of mirrors and light- collecting 
lenses performs the function of the fiber optics in the probe device. The laser beam is focused 
on the skin by a mirror that is maneuvered by microprocessor-controlled stepping motors. 
The instrument scans the given area (from 5 5 cm up to 50 50 cm) in a systematic, 
rectilinear manner. Light reflected back from the skin is detected by a photodetector, which is 
positioned approximately 200 mm above the skin surface. Unlike the laser Doppler probe, the 
photodetector is not placed in contact with the skin. Measurements are made sequentially at 
65,536 points and are processed and stored. Once scanning is complete, a color-coded 
perfusion image can be displayed on a connected computer screen along-side a corresponding 
"photo image". This research used the laser Doppler flowmeter technique.  
2.1.6.7. Laser Doppler Flowmeter 
The laser Doppler technique measures blood flow in the very small blood vessels of the 
microvasculature, such as the low-speed flows associated with nutritional blood flow in 
capillaries close to the skin surface and flow in the underlying arterioles and venules involved 
in regulation of skin temperature. It consists of a 2-mW helium-neon gas laser, which 
transmits light (usually of visible red wavelength=632.8 nm) to the skin surface via optical 
fibers running through a probe head; the probe head is placed directly on the skin. Once the 
transmitted incident light is reflected and scattered from both stationary structures and 
moving red blood cells, a portion of this backscattered light is collected by another optical 
fiber at the skin surface. This blended sample of nonshifted and Doppler shifted components 
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is transferred to a photodetector for processing and conversion to a voltage output. Normal 
fibre separations in the probe head are a few tenths of a mm so consequently blood flow is 
measured in a tissue volume of typically 1mm3 or smaller. The tissue thickness sampled is 
typically 1mm, the capillary diameters 10 microns and the velocity spectrum measurement 
typically 0.01 to 10mm/s. This depth reaches the arterioles, capillaries, and postcapillary 
venules of the upper horizontal plexus but does not extend beyond these vessels to the deep 
horizontal plexus below the dermis, so the capillary blood supply to the sweat glands and hair 
follicles does not contribute to the LDF signal because these structures are 3-5 mm below the 
skin surface.  Ultimately, however, the depth of tissue penetrated by the laser is dependent on 
factors such as laser light wavelength, skin pigmentation, and probe type. 
 
As it was said before the technique depends on the Doppler principle whereby low power 
light from a monochromatic stable laser; e.g. a Helium Neon gas laser or a single mode near 
infra-red laser diode, incident on tissue is scattered by moving red blood cells and as a 
consequence is frequency broadened. The frequency broadened light, together with laser light 
scattered from static tissue, is photodetected and the resulting photocurrent processed to 
provide a blood flow measurement. Doppler shift frequency range is typically 20Hz to 20 
KHz for a well perfused region of the microcirculation. e.g. finger tips. 
 
(Braverman, 2000b) constructed a topographic map of the skin areas using Laser Doppler 
flowmetry and correlative skin biopsies and defined whether these areas were predominantly 
arteriolar in composition, venular in composition or essentially devoid of all microvascular 
elements. He recorded simultaneously by laser Doppler flowmetry red cell flux and the 
concentration of moving red blood cells (CMRBC). He found that high amplitude red cell 
flux waves exhibiting vasomotion correspond to an underlying ascending arteriole and low 
amplitude waves without vasomotor activity corresponded to venular predominance under the 
1 mm diameter LDF detecting probe (Table 10). 
 
These LDF studies have demonstrated that the ascending arterioles are randomly spaced at 
intervals of 1.5-7 mm (Braverman and Schechner, 1991), thus explaining the basis for the 
spatial heterogeneity of LDF measurements (Tenland T, 1983a). Each ascending arteriole 
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divides into 4-5 branches to form a portion of the upper horizontal plexus. The ascending 
arteriole is accompanied by a post-capillary venule that is formed from the confluence of 8-
10 branches within the upper plexus. Each vascular unit is attached to its neighbours along a 
portion of their respective peripheries. In three dimensions, the vascular unit resembles an 
umbrella: the handle is represented by the paired ascending arteriole and descending venule. 
The umbrella proper is formed by the arteriolar and venular branches, with the arterioles 
being predominant in the center and the venules predominant in the periphery. The phasic 
(vasomotor) variation in red cell flux amplitude is greatest over the ascending arteriole and its 
immediate branches, suggesting that these vessels are the morphologic site for the generation 
of vasomotor activity detected by LDF in the skin. The putative sphincter, formed by a single 
encircling smooth muscle cell at the site where the elastic containing arteriole branches to 
form the arterioles of the upper plexus, may be the origin of the vasomotion detected by LDF. 
When a single arteriolar site is continuously monitored for 1-2 h, the red cell flux changes 
from minimum to maximum and vice versa at intervals of 12-20 min at some sites and 70-90 
min at other sites, thus explaining in part the temporal heterogeneity of LDF measurements. 
 
TABLE 10 TOPOGRAPHIC MAPPING OF THE CUTANEOUS MICROCIRCULATION BY MEANS OF LASER-DOPPLER 
FLOWMETRY. ((BRAVERMAN, 2000A, BRAVERMAN ET AL., 1992) 
 
 
The strategy based on LDF-morphologic correlation provides a way to determine the 
approximate mixture o microvascular elements beneath the 1 mm diameter probe. Density of 
ascending arterioles in a defined area of skin can be determined  
FLUX CMRBC* STRUCTURE 
High High Ascending arteriole + descending venule 
High High to Medium Ascending arteriole entering upper plexus 
High Low Arteriolar predominance 
Medium/Low Medium 
Medium to low 
Peripheral part of the vascular unit that was 
fed by the ascending arteriole 
Low High Venular predominance 
Low Low Avascular Areas 
 192 
 
as well as the areas of capillary and postcapillary predominance between the arterioles may 
be defined, and the areas of relative avascularity in both experimental designs and pathologic 
states. The vascular islands with attachments at their peripheries coupled with intervening 
avascular spaces explains the livedo pattern in skin following heat stress and impaired blood 
flow for other reasons  (Braverman, 2000b). 
 
          *CMRBC= Concentration of moving red blood cells. 
. 
 
The pattern of LDF oscillations is peculiar for each type of vessels, and the total power is 
greater in larger arterioles than in venules. In other words, the flux motion is fundamentally 
dependent on the type of vessel from which it originates and is directly related to the 
vasomotion of the arterioles (Colantuoni A, 1984). 
 
As it was demonstrated by (Wahlberg and Fagrell, 1994) the time to reach peak hyperaemic 
flux recorded with laser Doppler is a simple and accurate method of evaluating ischaemic 
limbs since it does reflect limb vascular resistance in an experimental model. Thus, LDF may 
be used as a quantitative indicator of overall blood flow impairment and it may be useful in 
patients with lower-limb atherosclerosis. Laser Doppler flowmetry has a list of applications 
in experimental medicine but also in clinical medicine measuring certain inflammatory 
reactions, monitoring inflammation, monitoring flaps and monitoring burn depth (Eun, 1995). 
In experimental medicine, laser-Doppler flowmetry has been used in the study of 
spontaneous rhythmical variations as well as in the study of spatial and temporal fluctuations 
in human skin blood flow and in a variety of tissues (Oberg, 1990). Rhytmic variations in 
blood flow are called oscillatory flow activity and are due to variations in the myogenics 
activity of the smooth muscle cells of the arteries and arterioles. Oscillatory flow patterns are 
composed of waves with several different frequencies (Colantuoni A, 1984). Although early 
studies suggested that LDF had substantial difficulties with sampling, stability, and 
reproducibility, subsequent refinements in equipment and application have led to technical 
acceptability (Schabauer and Rooke, 1994). 
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2.1.6.8. Post-occlusive Reactive Hyperaemia  
The smooth muscle of distal vascular networks displays an inherent property of periodical 
contraction and relaxation. This is known as rhythmical vasomotion, a process thought to be 
part of active microvascular autoregulation (reviewed by (Nilsson and Aalkjaer, 2003)).  
Laser Doppler flowmetry (LDF) is a non-invasive measure of tissue perfusion and reliably 
assesses cutaneous blood flow (Stern, 1975a). LDF measurements have been shown to 
reliably differentiate patients with peripheral arterial occlusive disease from controls 
(Morales et al., 2005). 
Laser Doppler perfusion monitoring is a well know technique for assessing tissue 
microcirculation in a continuous and non-invasive way (Stern et al., 1977). A typical Laser 
Doppler flowmeter makes use of two optical fibres, the illuminating or source fibre and a 
detecting or collecting fibre. Diode laser light of wavelength 780 nm is commonly used as the 
illuminating light source. The degree of the Doppler shift n frequency from the reflected light 
represents the degree of flux of the moving elements in the sample volume. 
 
A number of studies have shown that resting flux measurements are of questionable value 
(Kvernebo et al., 1988).  However the use of provocative tests such as the post-occlusive 
reactive hyperaemia test as described for brachial artery flow mediated dilation has been 
shown to differentiate between patients with peripheral vascular disease and normal controls 
(Del et al., 1986) (Wahlberg et al., 1990). 
 
One of the most well-known tests in clinical practice for evaluating the functional aspects of 
the arterial blood flow in a limb is the reactive hyperaemic response to a certain period of 
arterial occlusion, also called postocclusive reactive hyperemia (PORH; Table 11 and Figure 
2-23).  
TABLE 11 PARAMETERS FOR LDF EVALUATION OF SKIN MICROCIRCULATION DURING POSTOCCLUSIVE 
REACTIVE HYPERAEMIA (PRH). 
PARAMETERS DEFINITION 
rLDF Resting LD flux value 
pLDF (peak flow) Highest LD value after occlusion 
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tpLDF Time to peak flow 
FRT (time of 
latency) 
Time after occlusion until start of hyperaemic response 
Time of recovery Time after occlusion until rest LD flux value is reached 
Time of hyperaemia Time to total duration of the hyperaemic response 
 
FIGURE 2-23 SCHEMATIC TRACING OF AN LD FLUX RECORDING IN PRH 
 
This test is based on the response to an ischaemic insult. If the blood flow to a tissue is 
stopped for a while by compressing the supplying artery, or is slowed to the point where it is 
inadequate for tissue nutrition (a state called “ischaemia”), the blood flow immediately after 
releasing the compression is much higher than normal, and then decays exponentially. The 
table 5.2 shows the various parameters used for LDF evaluation of skin circulation during 
postocclusive reactive hyperaemia (PRH) (Bongard and Fagrell, 1990).  
 
2.1.6.9. Problems Of Evaluating The LDF Signal Measurements 
Of The Skin 
 
Signal composition 
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It is still uncertain what actually generates the signal recorded from the skin because all 
moving objects of a certain structure within the measuring volume are recorded, and in the 
skin of healthy subjects most of the signal is made up by the movement of red blood cells. 
However, during pathological conditions, e.g., in patients with leukaemia or 
thrombocythemia, a portion of the signal could possibly be produced also by the movements 
of white cells and platelets, respectively. Consequently, in order to be accurate, it can only be 
stated that the major part of the signal is produced by the movements of all blood cells in the 
vascular bed of the measuring volume (Bongard and Fagrell, 1990). 
Penetration depth and measuring volume 
 
The penetration depth has been said to be approximately 1.5 mm, but this value cannot be 
fixed since it must vary with factors like the amount of blood and the composition of the skin 
in the region investigated. Also, the measuring volume must change with these factors. 
Consequently, a quantification of flow in ml min -1 100 g -1 can be obtained only if certain 
specific considerations are fulfilled, which is not the case for the human skin (Bongard and 
Fagrell, 1990). 
 
Instrumental and biological zero values 
 
According to the instructions of the manufacturer, the zero value for the instrument is 
obtained by applying the flow probe to a white surface. This zero value has been found to be 
reasonably stable and can be referred to as the instrument zero. However, it cannot be used as 
zero value for a biological tissue, since marked variations in this value, i.e., the biological 
zero, can be seen from one tissue, and from one area to another (Bongard and Fagrell, 1990). 
 
2.1.6.10. Protocol for Laser Doppler Flowmetry Measurement  
 
A laser-Doppler blood flow monitor DRT4 (Moor Instruments Limited Axminster, Devon) 
with compatible DRTSOFT V3.5 hardware (copyright Moors Instruments Ltd) was used for 
this study (Figure 2-24) and two optical probes previously calibrated were adhered onto the 
forearm skin surface and hand skin surface using double sided adhesive discs (PAD) to 
transmit and collect the light.  The probes were DP1T of a dual fibre design with a fibre 
separation of 0.5 mm (centre to centre) and fibre total diameter of 500 µm which is a dual 
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channel system capable of measuring flux from two different areas simultaneously. A cuff 
was placed in the same arm. The optic connectors from the glass fibres were attached to the 
front panel of the laser Doppler instrument. 
Initially baseline blood flow was recorded for 3 minutes and reactive hyperaemic response 
was obtained after a 3 minutes occlusion period blocking the circulation into the arm by 
having inflated the cuff over systolic pressure and after that exact period time measured by 
the computer the cuff was released. The cuff pressure was reached using air pumps to achieve 
the maximum cuff pressure in a very short time (within 0.1 second). The flow (flux) was 
recorded then continuously until it reached baseline again or for a minimum 3 minutes 
period. 
 
Definition Of Parameters Of Measurements 
 
FLUX: This parameter is related to the product of average speed and concentration of moving 
red blood cells in the tissue sample volume.  
CONCENTRATION: This parameter gives an indication of the number of moving red blood 
cells in the tissue sample volume. 
 
SPEED: This parameter gives an indication of the average speed of red blood cells moving in 
the tissue sample volume. 
 
FIGURE 2-24 DRT4 LASER DOPPLER BLOOD FLOW 
MONITOR (MOOR INSTRUMENTS LIMITED, UK). OPTICAL 
FIBRES TRANSMIT LASER LIGHT TO THE TISSUE. 
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DC: This parameter gives an indication of the backscattered laser light intensity. It can be 
used to check the efficiency of light collection by the laser Doppler probes. 
 
TEMPERATURE: This is measured by probe and where there is good thermal conduction 
between probe and tissue it reaches tissue temperature. 
 
FLOW UNITS: It is generally agreed by researchers and manufacturers that because of the 
nature of the flow in capillaries and connecting small blood vessels, and the effect of varying 
skin colour and structure, it is not appropriate to use absolute flow units such as ml/100 
gm/minute. So, flux was measured in arbitrary units (AU). 
 
Optical Probe Calibration 
 
Probes were calibrated individually in a room with stable temperature (20-22 degrees 
centigrade) and on a surface free from oscillation. Five ml of Flux standard was poured into 
the calibration pot after shaking it. Using a clamp, the probe head was positioned in the 
calibration pot making sure that the surface of the probe was near the centre of the fluid 
volume and finally a stable reading was checked on the screen in run mode. 
 
Laser-Doppler Flowmetry Measurements 
 
For all measurements performed, the probe on the forearm was identified with the number 1 
and the one on the hand was identified with the number two. The following measurements 
were performed in all groups of subjects: 
Baseline flux 1 (BL Flux 1) 
Baseline flux 2 (BL Flux 2) 
Baseline red cells concentration 1 (BL conc. 1) 
Baseline red cells concentration 2 (BL conc. 2) 
Baseline dc 1 (BL dc 1) 
Baseline temperature 1 (BL temp. 1) 
Baseline temperature 2 (BL temp. 2) 
Maximum flux 1 (Max. Flux 1) 
Maximum flux 2 (Max. Flux 2) 
Maximum concentration 1 (Max. conc. 1) 
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Maximum concentration 2 (Max. conc. 2) 
Maximum dc 1 (Max. dc 1) 
Maximum dc 2 (Max. dc 2) 
Maximum temperature 1 (Max. temp. 1) 
Maximum temperature 2 (Max. temp. 2) 
Minimum flux 1 (Min. Flux 1) 
Minimum flux 2 (Min. Flux 2) 
Minimum concentration 1 (Min. conc. 1) 
Minimum concentration 2 (Min. conc. 2) 
Minimum dc 1 (Min. dc 1) 
Minimum dc 2 (Min. dc 2) 
Minimum temperature 1 (Min. temp. 1) 
Minimum temperature 2 (Min. temp. 2) 
Time from the peak to baseline flux 1 (seconds) (Peak-BL1) 
Time from the peak to baseline flux 2 (seconds) (Peak-BL2) 
Time to reach maximum hyperaemic response 1 (seconds) (time-MHR1) 
Time to reach maximum hyperaemic response 2 (seconds) (time-MHR2) 
Time from baseline to minimum flux 1 (seconds) (time BL-Min.Flux1) 
Time from baseline to minimum flux 2 (seconds) (time BL-Min. Flux 2) 
Percentage of increase on baseline flux 1 during maximum hyperaemic response (% MHR1) 
Percentage of increase on baseline flux 2 during maximum hyperaemic response (% MHR2) 
Delta Flux (Δ Flux): Difference between peak at maximum hyperaemic response and baseline 
flux. 
 
 
Laser Doppler flowmetry traces were analysed using the Moorsoft/ DRT4 version 2 software 
(Axminster, UK). Basal, blood pressure cuff inflation and maximal post deflation 
measurements were recorded. 
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FIGURE 2-25 SCREEN SHOT OF MOOR/ DRT4 ANALYSIS SOFTWARE FOR LASER DOPPLER FLOWMETER. 
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2.2 Methods for Cellular and Molecular Analysis 
 
2.2.1. Circulatory Inflammatory Biomarkers 
 
Biomarkers are the tools that have arisen from the technology of the new genetics. Abnormal 
genes and their respective products, and other organic chemicals made by these abnormal or 
pathological cells are identifiers that make up the molecular signals of a cell. Biomarkers are 
cellular indicators of the physiological state and of changes during a pathogenesis of certain 
chronic diseases. For instance, researchers have saught to indetify biomarkers indicating the 
presence of the risk of CVD, and to pursuit early detection or prognosis (Fichtlscherer et al., 
2004) (Srinivas et al., 2001) (Lind, 2003).  
 
Blood testing which encompasses analyses of the haematocrit, platelet counting, erythrocyte 
sedimentation rate (ESR), function of blood cells and their precursors in bone marrow (e.g. 
staining blood films), and chemical constituents of blood serum and plasma (e.g. 
coagulation), are basically biochemical markers (Henry, 2001)[(Morris, 2001) cited in  
(Henry, 2001)]. In addition, the inflammatory markers are currently become promising 
predictor as biochemical markers of atherosclerosis and its complications.  
 
The plasma CRP, fibrinogen and IL-6 are important as they both are used as systemic 
markers of inflammation and these markers provide satisfactory correlation between analysis 
of their level and incidence of thrombo-embolic events. This might be because the high 
inflammation in the vascular wall is associated to the high possibility of fibrous cap rupture 
of the plaques. Furthermore, the onset of myocardial infarction (MI) is sudden and can be a 
fatal event. The initial diagnosis of MI is performed by serial measurement of the cardiac 
enzymes as biomarkers, namely troponin and CK-MB. These biomarkers have become a 
reliable indicator to support the diagnosis of MI and assist the management of these patients 
(Fichtlscherer et al., 2004) (Srinivas et al., 2001) (Lind, 2003).  
 
In IRI, blood test can identify the presence of inflammatory mediators like cytokines and the 
other inflammatory mediators, deriving from the injured parenchymal cells, endothelial cells, 
infiltrated immune cells and the reactions of complement and hemostatic processes on the BE 
interface. The studies of biomarkers of inflammation is essential in the field of  IRI  because 
the pathophysiological consequences of IRI start to occur from the cell injury within the 
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locally affected microcirculation of the tissue causing generation of inflammatory mediators 
which are subsequently released into the circulation and eventually have effects on the 
microcirculation of the remote organs. 
 
Immuno-hematology basically refers to hematology regarding the immunological properties 
and reactions of all blood components and its constituents (Henry, 2001, Beadling, 
Immunohepatology). It plays an integral part in transfusion medicine (since the testing 
reactions of the antigen on RBC surface and the antibody in plasma is necessary for blood 
grouping) and in the transplantation medicine (since the testing of the major 
histocompatibility complex (MHC) on the WBC surface is required for the compatibility 
between the donor and the recipient).  
 
Hormones, cytokines and other inflammatory mediators represent less than 1% of blood 
plasma. Although the amount of these substances in blood is small, their influences on the 
whole body are massive. 
 
Haemapheresis is the process of separating blood serum into its constituent components, 
generally by centrifugation. It includes cytapheresis and plasmapheresis, which aim to take 
blood cells and to use plasma component of serum, respectively (Henry, 2001) (Winters). It is 
widely used in transfusion medicine to prepare blood component for transfusion purposes, 
but is also useful in the study of cytokine concentration in plasma. 
 
Assays for the cytokines quantification / characterization fall into two categories (Remick, 
2002) :  
 
• Bioassay  
• Immunoassay  
 
The purpose of the bioassay is to validate the biological functions of the cytokines typified 
into four areas: i) measuring their cytotoxicity, ii) measuring the cell proliferation they induce 
iii) measuring their action in regard to specific cell function, iv) measuring the amount of 
cellular protein production they induce. On the other hand, immunoassay is mainly used to 
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monitor the level of cytokines in plasma regardless of their biological actions (Remick, 
2002).  
 
Although bioassays are the best way to assess the cytokine activity, they are time-consuming, 
as cells have to be cultured before the cytokines can be inserted into them. The technique is 
usually unmanageable for clinical purposes in a hospital setting (Massey) in (Henry, 2001). 
 
The concept of biological ligand is interesting in immuno-hematology as it is based on the 
affinity between a two specific molecules such as an enzyme and substrate, a hormone and 
receptor, or an antigen and antibody. Immunoassay is an analytical tool, which estimates the 
frequency of specific binding between an antibody and an antigen. There are at least six well-
recognised immunoassays: i) radioimmunoassay (RIA), ii) enzyme-linked immunosorbent 
assay (ELISA), iii) precipitation immunoassays iv) particles immunoassays, v) fluorescent 
immunoassays and vi) chemi-luminescent immunoassays (Ashihara) in (Henry, 2001).  
 
2.2.2. Enzyme-linked Immunosorbent Assay (ELISA) 
 
Immunoassays can be devided into liquid phase and solid phase, also sometimes termed 
homogeneous and heterogeneous (Remick, 2002). First, in the homogeneous immunoassay, 
all stages are conducted in the liquid phase, which means that the studied substance is 
homogeneously mixed in the solution all the time, so no washing is required. In contrast, the 
solid phase or heterogeneous methods necessitate washing an unbound antibody out at some 
stages of the procedure.  
 
The solid-phase immunoassay is ubiquitous in the modern biological laboratory providing 
decisive information for use in both clinical medicine and basic molecular biological science 
(Carpenter) in (Rose, 2002). There are a variety of matching sets of the immunoassay 
technique available to appropriately quantify each of the circulating inflammatory mediators 
in the plasma, for instance cytokines, cellular adhesion molecules (CAMs), complements and 
coagulation factors. 
 
The radioimmunoassay RIA and ELISA are the two commonest methodologies employed in 
clinical practice to quantitatively measure the plasma level of cytokines. The former uses 
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radioisotope and proton counting (e.g. 125I, 3H) while the latter uses an enzyme as a label, 
which can be quantified by a variety of spectrophotometries, which measure the absorption of 
light by color created by the enzyme label (Henry, 2001) (Remick, 2002) [(Ashihara) in 
(Henry, 2001)] 
They are both of the heterogeneous or solid phase type. Although RIA is superior in its 
rapidity and high sensitivity, the radioactive agents used to label the immune complex 
possess a certain amount of radio-toxicity. ELISA, which was initially introduced in the 
1970s, has largely replaced earlier techniques, such as immuno-fluorescence and 
agglutination. This technique has outstanding efficiency, objectivity and capability to run 
large numbers of samples with less hands-on technician time. It has been acknowledged to be 
the most appropriate tool for the assessment of circulating cytokines in plasma. 
 
Enzyme-linked immunosorbent assay (ELISA) is the immunochemistry technique based on 
the principle of specific binding of the antigen and the antibody. 
 
The antigen and its associated antibody are conjugated to an enzyme, and then deposited on a 
substrate to form a coloured product (labelling step). Commonly used enzymes are 
horseradish peroxidase (HRP) and alkaline phosphatase (AP). Substrates used for HRP 
include o-phenlenediamine (OPD), 5-aminosalicylic acid, 2,2-azino-di (3-ethyl-
benzthiazoline sulfonate-6 (ABTS) and 3,3’,5,5’-tetramethylbenzidine (TMB) while ρ-
nitrophenyl phosphate (NPP) is commonly used with AP (Carpenter) in (Rose, 2002).  
 
The technique can be divided into two major methodological categories: direct and indirect 
(or sandwich). Both methods are illustrated in Figure 2-26.  
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FIGURE 2-26 DIRECT AND INDIRECT CONJUGATION OF AG-AB AND ENZYME IN ELISA (ADAPTED FROM 
(REMICK, 2002)) 
 
ELISA is routinely performed in 96-well-plate and in both direct and indirect procedures, the 
initial step (step 1) is to fix the cytokine (antigen) or the antibody to the well plate base. The 
antigen (cytokine) is titrated and prepared by diluting in coating buffer. In the direct method, 
the second step involves adding antibody to form immune complex, which is then incubated 
and washing out the unbounds, successively. In the indirect method, there is an additional 
step. The sandwiched antibody is added, incubated and washed out. The following steps 
involve conjugation which is performed by adding enzyme to conjugate the immune complex 
and afterward the pouring of the substrate to generate a color. 
 
Washing requires the use of the different buffers at each step of washing out; the buffer 
commonly employed for cytokine assessment is phosphate buffer solution (PBS). Incubation 
is important to bind antigen-antibody securely to form the immune complex and to bind the 
complex to the conjugated enzyme. Normally, the incubation period is 1-2 hour, at room 
temperature (250c).  
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In the final step, the measurement of the cytokine concentration is calibrated by 
spectrophotometer, measuring the optical density of the color created by the enzyme. The 
optical density (color intensity) is done first at one wavelength (492 nm) and then at another 
wavelength (620 nm). By subtracting these two values, the concentration of cytokine apart 
from other substances can be estimated. The spectrophotometer is interfaced with a dedicated 
computer which processes the results. 
 
The degree of intensity of the color reaction is directly proportional to i) the ability of Ag or 
Ab to bind well with the well plate, ii) the amount of the binding of the Ag-Ab which 
subsequently determines iii) the quantity of the combination of enzyme to the Ag-Ab 
complex. In the direct method, the accuracy is sometimes low because it binding with the 
plastic plate is poor due to competition by several other proteins in plasma (other cytokines). 
Therefore, indirect method claims to overcome this problem and was chosen for this study. 
 
Indirect ELISA has been modified into two types: competitive and noncompetitive. The 
advantage of the competitive method is cost as it uses less expensive antibody commercial 
kit. The non-competitive indirect method is lower in specificity but higher in sensitivity. 
 
In this study, venous blood was taken from PAOD patients undergoing revascularisation 
preoperatively and postoperatively at one hour and one day. Blood samples taken from the 
patients were centrifuged at 10,000 rounds (revolutions) per minute for 15 minutes. The 
plasma in the sample tube was subsequently separated from blood cells and kept frozen at -
700C until the sample size was sufficient to be analysed in a statistically significant way. The 
technique for quantifying the mediators was an indirect non-competitive ELISA technique 
using an available commercial kit. The detail of this technique is detailed in Appendix A.   
 
 
2.2.3. Assessment the Remote Organ Injury: Urine NAG (N-acetyl-
β-D-glucosaminidase) 
 
Normally, 25% of cardiac output passes through the kidneys every minute, amounting to, 
around 180 litre of blood filtrate, of which only 1-2 litre/day is excreted as urine through 
renal glomeruli (Henry, 2001)]. Urinalysis basically investigates urine by three approaches: 
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the examination of its physical properties; the qualitative and quantitative assessment of its 
chemical components and the microscopic examination of urine sediment. 
 
The physical examination of urine inspects the colour, clarity, odor, osmolarity and volume 
(urine output). The chemical analysis includes the measurement of urine pH and electrolytes 
and the identification of a wide range of bioorganic components, including proteins, glucose 
and other sugars, ketones, hemoglobin, myoglobin, bilirubin, urobilinogen, using a variety of 
biomedical laboratory techniques.  
 
The examination of the urine sediment uses centrifugation to retrieve insoluble constituents. 
Microscopic examination of the solid constituents is carried out, which includes cells 
(desquamated/exfoliated epithelial lining cell of urinary tract, hematogneous origin:WBC, 
RBC and neoplastic cells), casts (cellular element originated from kidney), crystals and 
microorganisms (Henry, 2001)]. Nowadays, automated urinalysis is widely available. 
 
The investigation of proteins in the urine has been refined over the years in order to diagnose 
pathologies in the body. The biomarker for renal tubule impairment can be identified in this 
way. Urine enzyme activity has been acknowledged as a reliable indicator of renal tubule 
damage (Bosomworth et al., 1999). IRI is a major mechanism causing acute renal failure 
(Hauet et al., 2000), and several urine enzymes, such as  urine N-acetyl-b-D-glucosaminidase 
(NAG),  trimethylamine-N-oxide (TMAO), dimethylamine (DMA) and acetate have been 
used as biomarkers of renal tubule exposure to it. 
 
Urine N-acetyl-b-D-glucosaminidase (NAG) is an enzyme protein and is one of 200 kinds of 
proteins that can be found in urine. It is one of the most commonly used diagnostic markers 
for early indication of renal tubular damage and dysfunction due to insults by nephrotoxic 
substances or renal diseases (Hauet et al., 2000) (Price, 1992b). The ELISA of urinary N-
acetyl-beta-D-glucosaminidase (NAG) is a reliable test with few false positives since the 
NAG level remains high during active disease or a sustained insult and it falls to normal 
levels quickly during the period of recovery or the removal of toxic substances (Bosomworth 
et al., 1999) (Hauet et al., 2000) (Price, 1992b) (Rabb, 1998) (Price, 1992a). The ELISA 
method used for qualitative analysis urine NAG has been previously described (Yuen et al., 
1984) and its use in this study is detailed in Appendix B.   
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2.3 Assays of Oxidative Stress and Anti-oxidant defence (FORT 
and FORD) 
 
 
2.3.1. Oxidative Stress 
 
The FORT test (Callegari, Parma, Italy) is a colourimetric test based on the ability of 
transition metals, such as iron, to catalyse the breakdown of hydroperoxides into derivative 
radicals (ROOH), according to Fenton’s reaction. Once they are formed in cells, ROOH 
maintain their chemical reactivity and oxidative capacity to generate proportional amounts of 
alkoxyl (RO·) and peroxyl (ROO·) radicals (Figure 2-29, reactions A and B).  
 
These derivative radicals are then preferentially trapped by a suitably buffered chromogen (an 
amine derivative, reagents R1 of the FORT kit; CrNH2) and develop, in a linear kinetic based 
reaction at 37°C, a coloured fairly long-lived cation photometrically detectable radical (fig. 5, 
reaction C).  
FIGURE 2-27 THE CR3000 ANALYSER (CALLEGARI, PARMA, ITALY) FOR USE 
WITH FORT AND FORD TESTS. 
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The intensity of the colour correlates directly with the quantity of radical compounds, 
according to the Lambert-Beer’s law, and it can be related to the oxidative status of the 
sample. 
 
R-OOH Fe2+ R-O OH- Fe3+
R-OOH Fe3+ R-OO H+ Fe2+
R-O ROO 2CrNH2 RO- ROO-
+ + +
+ + +
+ + +
A
B
C
 
FIGURE 2-28 REACTIONS CHARACTERISING THE FORT TEST (FENTON’S EQUATIONS). A: ALKOXYL RADICAL 
FORMATION; B: PEROXYL RADICAL FORMATION; C: COLOURED COMPOUND FORMATION 
 
Interpretation of FORT test results 
Due to the chemical heterogeneity of the secondary radical species deriving from the iron-
dependent breakdown of ROOH during the FORT test (RO· and ROO·), the 
spectrophotometer absorbency readings are converted into arbitrary units (FORT units). The 
transformation is automatically performed by the instrument. Results are also expressed as 
equivalent concentrations of H2O2 as reference hydroperoxide. One FORT unit corresponds 
to approx.7.6 mmol/l equivalent to 0.26 mg/l of H2O2. 
 
The higher the result obtained, the higher the level of oxidative stress. Normal values are up 
to 310 FORT units. 
 
Reagents 
All reagents are ready to use, and stored at room temperature. 
The test kit contains: 
 
• R1 reagent: a solid chromogen contained in disposable square based cuvettes. 
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• R2 reagent: a buffer stabilised and preserved in disposable conical tubes. 
• 20 ml heparinised capillaries. 
 
The testing procedure is described in Appendix C. 
2.3.2. Antioxidant Defence 
 
The FORD (Callegari, Parma, Italy) test is a near patient plasma antioxidant capacity test. 
The assay measures the combined effect of the overall plasma water-soluble antioxidant 
defenses in blood thus enabling assessment of the integrated antioxidant system which 
encompasses biological components with antioxidant activity.  
 
Antioxidants measured by FORD test include: 
 
• Vitamin C  
• Vitamin E (water soluble part) 
• Plasma proteins (albumin, ferritin, metallothionine, transferrin)  
• Thiol group containing compounds (Glutatione, cysteine, lipoic acid, N-acetyl-cysteine, 
mercaptopropionylglycine (MPG)).  
• Bilirubin  
• Polyphenolic compounds (ie flavonoids and tannins).  
 
FORD is a colourimetric test based on the ability of antioxidants present in plasma to reduce 
a preformed radical cation. A stable coloured cation (photometrically detectable at 505 nm) is 
formed in the presence of an acidic buffer (pH 5.2) and an oxidant (FeCl3). Antioxidant 
compounds (AO) present in the sample analysed, reduce the radical cation of the chromogen 
quenching the color and producing a decolouration of the solution, which is proportional to 
their amount in the sample (Figure 2-29).  
 
chomogen+ 
(purple)
AOH chromogen
+ 
uncoloured) AO+ +
 
FIGURE 2-29. COLOURIMETRIC REACTION USED IN THE FORD TEST 
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The UV-visible spectrum of the FORD chromogen radical cation shows a maximum of 
absorbance at 505nm.  Absorbance reading between 0.80 and 1.00 is reached after 3-4 
minutes when a stable coloured solution is formed. This provides an assay based on the 
extent of radical reduction at a fixed time point, namely 4 minutes, and not on the rate of 
reduction. This feature rules out complications owing to monitoring the time course of colour 
inhibition, which is common to other methods such a crocin based assays ((Pryor et al., 1993, 
Tubaro et al., 1996)and ABTS based assays (Miller and Rice-Evans, 1997). 
 
Colour quenching is determined especially by contribution of antioxidants like proteins such 
as albumin, reduced glutathione, Vitamin C, Trolox (water soluble analogue of Vitamin E). 
These antioxidants (together with uric acid which is purposely not detected by the FORD test, 
see later) are among the most important contributors to plasma antioxidant function. FORD 
results are obtained from the capacity of plasmatic antioxidants to inhibit the chromogen 
radical, relative to Trolox. 
 
Results are expressed as Trolox equivalents (mmol/l). A calibration curve is performed using 
a Trolox standard solution. 
 
Interpretation of FORD test results 
Based on a preliminary number (Unpublished data; Callegari, Italy) of 70 human blood 
donors (male/female ratio, 37/33; aged 20-70 years, mean age 36 years) and the values cited 
in scientific literature (Miller and Rice-Evans, 1997, Re et al., 1999, Wayner et al., 1987, 
Yeum et al., 2004, Cao and Prior, 1998), the reference values of FORD were established to 
be within the 1.07-1.53 mmol/l Trolox range (mean value = 1.23 mmol/l Trolox). 
 
Reagents 
All reagents are ready to use, and stored at room temperature. 
 
C1 reagent: a solid chromogen contained in disposable square based cuvettes. 
S1 reagent: a NaCl solution preserved in disposable conical tubes. 
S2 reagent: a buffer stabilised and preserved in disposable conical tubes. 
S3 solution (FeCl3). 
 
The testing process is described in Appendix D. 
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2.4 Hypothesis, Aims and Objectives 
2.4.1. Hypotheses 
 
There is a relationship between plasma oxidative stress, endothelial function and kidney 
injury in claudicants undergoing maximal walking exercise. 
 
There is a subgroup of patients with intermittent claudication who are more susceptible to 
acute kidney injury when undergoing maximal walking exercise. 
 
2.4.2. Aims 
 
§ To investigate relationship between endothelial function, oxidative stress, oxidative 
defence and acute kidney injury in patients with intermittent claudication in response 
to maximal walking exercise. 
§ To identify a potential screening strategy to identify claudicants who are vulnerable to 
acute kidney injury when undergoing maximal walking exercise.  
§ To investigate the relationship between the cytokine MCP-1 with oxidative stress, 
endothelial function and acute kidney injury. 
2.5 Participant Recruitment 
Potential participants were identified from the arterial database maintained at the vascular 
laboratory at the Hammersmith Hospital, London. All patients with intermittent claudication 
were invited to participate. Patients with leg pain when at rest and/or skin ulceration were 
excluded. 
Inclusion criteria:  
§ Patients with peripheral vascular disease experiencing intermittent claudication. 
 
Exclusion criteria: Concomitant disease precluding treadmill exercise: 
§ Active heart disease 
§ Active renal failure 
§ Active lung disease 
§ Musculoskeletal pain 
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2.6 Study Design 
 
The study design is shown in the following flow diagram (Figure 2-30). 
 
Testing protocol for claudicant patient 
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Patients with intermittent 
claudication
Arrive, empty bladder and rest 
for 90 mins
Treadmill stress test till 
maximum walking distance 
achieved (4km/h, 10% incline)
Post exercise FMD and blood 
sample
Free radicals and anti-
oxidative capacity (near 
patient test)
Urinary NAG test
Free radicals and anti-
oxidative capacity (near 
patient test)
Urinary NAG test
plasma MCP-1
plasma MCP-1
FIGURE 2-30 STUDY DESIGN FOR INVESTIGATION OF SYSTEMIC INFLUENCE OF EXERCISE IN 
PATIENT WITH INTERMITTENT CLAUDICATION 
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2.7 Data Analysis 
Data was analysed using Microsoft Excel (2010 edition) and SPSS (version 20). Data will be 
plotted and parametric or non-parametric tests were used appropriately.  
 
2.8 Study Administration; Ethical Issues; Dissemination And 
Outcomes 
 
Patients’ interests were safeguarded by providing contact points for clarification or 
complaints. All contact details were provided in the Patient Information Leaflet. 
 
Supervision and sponsorship for the study was provided by Imperial College London, with Dr 
Aslam (Hammersmith Hospital) being responsible.  
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3. Results 
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3.1 Demographic data 
 
 
 
 
 
 
 
 
 
 
 
2250 patients identified from 
vascular lab database with 
lower limb ABPI 
measurements between 
2004 and 2011 
114 patients identified 
with ABPI % 0.9 and 
invited to participate
20 patients agreed to 
partipate
No records not found for 
3 patients
Vascular lab reports 
reviewed to identify 
patients with intermittent 
claudication
9 female 11 male
94 patients not available 
for study or with very 
limited mobility
FIGURE 3-1 FLOW CHART DEMONSTRATING RECRUITMENT OF PATIENTS FROM VASCULAR 
LABORATORY DATABASE. 
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Demographic data is summarised in the Table 12 below. Details of individual participants are 
included in Appendix E 
 
TABLE 12. DEMOGRAPHIC DATA OF ALL PARTICPANTS. 
Number of participants 20 
Age (years)  (median, IQR) 71.5, 65.75 to 80 
Male (n, %) 11 (55%) 
Lowest ABPI (median, IQR) 0.7, 0.6 to 0.8 
Mean ABPI (median, IQR) 0.8, 0.66 to 0.9 
Maximum walking distance (m; median, IQR) 265, 155 to 450 
Height (m) (median, IQR) 1.695, 1.5725 to 1.7525 
Weight (kg) (median, IQR) 70, 63.5 to 88 
BMI (kg/ m2) (median, IQR) 26.35, 23.675 to 29.95 
 
TABLE 13. MEDICATION USAGE IN PARTICIPANTS 
Particpant 
number 
Statin Antiplatelet Other drugs 
1 Atorvastatin Aspirin Lansoprazole, Tamsulosin, 
Finasteride, Amlodipine, Irbesartan 
2 simvastatin Aspirin Spiriva inhaler, salbutamol inhaler,  
3  Aspirin Tolterodine 
4 simvastatin Aspirin,Clopidogrel Bisoprolol 
5 Simvastatin Aspirin  
6  Aspirin Ramipril 
7 simvastatin Aspirin Metformin, , Insulin, Gliclazide, 
Enalapril, Amlodipine, and 
Bendrofluazide 
8 Atorvastin Aspirin Omeprazole and Atenolol 
9   Amiodarone, Warfarin 
10 Simvastatin   
11   Metformin, Ramipril 
12   None 
13 Rosuvastatin Aspirin Omeprazole, Carvedilol 
14   Enalapril, Cilostasol 
15 Pravastatin Aspirin Amlodipine 
16 Simvastatin  Bendrofluazide, Irbesartan, Metformin, 
Insulin, Omeprazole, Ursodeoxycholic acid 
17   Bendrofluazide 
18 Simvastatin Aspirin , Clopidogrel  
19 Simvastatin Aspirin Metformin,  
20 Simvastatin Aspirin Quinine, Bendrofluazide 
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3.2 Endothelial function changes in claudicants following 
exercise  
 
 
3.2.1. Comparison of Brachial artery diameter in claudicants pre- 
and post-exercise 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
Brachial artery 
diameter (cm; 
median, IQR, range) 
4.49; 4.15 to 5.03, 
2.86 to 5.80 
4.35; 3.94 to 
4.99, 2.86 to 5.22 
p = 0.147, Mann 
Whitney U test 
 
 
FIGURE 3-2. A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
BRACHIAL ARTERY DIAMETER IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.2.2. Comparison of FMD in claudicants pre- and post-exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
FMD (% change; 
median, IQR, range) 
1.91; 3.55 to 3.87,  -
17.48 to 13.39  
3.75; 1.29 to 
7.45, -17.43 to 
13.99 
p = 0.313, Mann 
Whitney U test 
 
FIGURE 3-3. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING ENDOTHELIAL FUNCTION (FMD) IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.2.3. Comparison of resting LDF in claudicants pre- and post-
exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 12 12  
Resting LDF 
(median, IQR, 
range) 
154.25, 154.25 to 
265.05, 24 to 887 
209.40, 142.83 to 
768.03, 115 to 
945 
p = 0.06, Mann 
Whitney U test 
 
FIGURE 3-4. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING LASER DOPPLER FLOWMETRY FLUX IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.2.4. Post occlusion reactive hyperaemia (LDF) for claudicants 
pre- and post-exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 12 12  
PORH - LDF 
(median, IQR, 
range) 
59, 25.74 to 260.43, 
-70 to 786 
11.2, -9.85 to 
218.9, -64 to 303 
p = 0.388, Mann 
Whitney U test 
 
FIGURE 3-5. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING LASER DOPPLER FLOWMETRY POST OCCLUSION HYPERAEMIA RESPONSE IN 
CLAUDICANTS PRE AND POST EXERCISE. 
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3.3 Oxidative stress in claudicants 
 
3.3.1. Plasma oxidative stress in claudicants pre- and post exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
FORT (FORT units; 
median, IQR, range) 
296.50, 243.25 to 
425.50, 160 to 600 
303.5, 263 to 
401.25, 160 to 
600 
p = 0.888, Mann 
Whitney U test 
 
FIGURE 3-6. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING PLASMA OXIDATIVE STRESS (FORT) IN CLAUDICANTS PRE AND POST EXERCISE. 
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 Pre-exercise Post-exercise p value 
n 20 20  
H2O2 (mmol/l; 
median, IQR, range) 
2.19, 1.81 to 3.02, 
0.83 to 4.56 
2.31, 2 – 3.1, 
1.22 to 1.56 
p = 0.825, Mann 
Whitney U test 
 
FIGURE 3-7. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING PLASMA OXIDATIVE STRESS (H2O2) IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.3.2. Antioxidant defence in claudicants pre- and post-exercise 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
FORD (Trolox 
equivalents; median, 
IQR, range) 
0.96, 0.84 
 to 1.22, 0.25 to 
1.53 
1, 0.43 to 1.32, 
0.25 to 4.55 
p = 0.575, Mann 
Whitney U test 
 
FIGURE 3-8. BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
PLASMA OXIDATIVE DEFENCE (FORD) IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.4 Urinary N-acetyl-β-D-glucosaminase/ Creatinine ratio in 
claudicants pre- and post-exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 17 17  
Urinary NAG/ 
creatinine; 
µmol/L/mmol Cr, 
median, IQR, range) 
8.94, 6.73 to 14.27, 
4.4 to 23.25 
 
12.90, 9.07 to 
17.72, 7.16 to 
36.98 
p = 0.000293, Mann 
Whitney U test 
 
FIGURE 3-9. BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
URINARY NAG/ CREATININE RATIO IN CLAUDICANTS PRE AND POST EXERCISE. 
 
 
 
 
 
 
 
 226 
 
 
 
 
 
 
 
 
 
 
3.5 Plasma MCP-1 concentration in claudicants pre- and post-
exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
Plasma MCP-1; 
pg/ml, median, IQR, 
range) 
88.41, 69.34 to 
119.43, 47.45 to 
178.84 
 
93.31, 70.6 to 
48.49, 70.6 to 
126.41 
p = 0.601, Mann 
Whitney U test 
 
FIGURE 3-10. BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
PLASMA MCP-1 IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.6 Effects of lowest ABPI on oxidative stress and defence, 
endothelial function, MCP-1 and kidney injury 
 
3.6.1. Correlation of lowest ABPI with oxidative stress in 
claudicants 
 
 
FIGURE 3-11. SCATTER GRAPH OF LOWEST ABPI VERSUS PRE- EXERCISE PLASMA OXIDATIVE STRESS 
MEASURED BY FORT TEST (FORT UNITS) 
 
 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
pre-exercise plasma oxidative stress as measured by the FORT test (Rs = 0.544, p = 0.013; 
Spearman’s rank correlation; Figure 3-11). 
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FIGURE 3-12. SCATTER GRAPH OF LOWEST ABPI VERSUS POST- EXERCISE OXIDATIVE STRESS MEASURED BY 
FORT TEST (FORT UNITS) 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
post-exercise plasma oxidative stress as measured by the FORT test (Rs = 0.736, p = 
0.000218; Spearman’s rank correlation; Figure 3-12). 
 
There was no association between lowest ABPI with percentage change (post-pre) of FORT 
(Rs = 0.164, p = 0.490)   
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FIGURE 3-13. SCATTER GRAPH OF LOWEST ABPI VERSUS PLASMA OXIDATIVE STRESS AS MEASURED IN H2O2 
(MMOL/L). 
 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
pre-exercise plasma H2O2 (Rs = 0.444, p = 0.05; Spearman’s rank correlation; Figure 3-13). 
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FIGURE 3-14. SCATTER GRAPH OF LOWEST ABPI VERSUS POST- EXERCISE PLASMA OXIDATIVE STRESS AS 
MEASURED IN H2O2 (MMOL/ L).  
 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
post-exercise plasma H2O2 (Rs = 0.736, p = 0.000218; Spearman’s rank correlation; Figure 
3-14). 
 
There was no association between lowest ABPI with percentage change (post-pre) of H2O2 
(Rs = 0.175, p = 0.462)   
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3.6.2. Correlation of lowest ABPI with anti-oxidant defense 
 
There was no correlation between lowest ABPI and the antioxidant defense as measured by 
FORD (pre: Rs = -0.3, p = 0.199; post: Rs = -0.124, p = 0.601; percent change post exercise: 
Rs = 0.06, p = 0.801). 
 
3.6.3. Correlation of lowest ABPI with macro-vascular endothelial 
function 
There was no correlation found between FMD (per cent change) either pre (Rs = 0.273, p = 
0.244) or post exercise (Rs = 0.286, p = 0.222) nor FMD per cent change (post – pre; Rs = -
0.181, p = 0.444) exercise with lowest ABPI. 
 
3.6.4. Correlation of lowest ABPI With micro-vascular endothelial 
function 
There was no correlation of LDF PORH response (per cent change) either pre (Rs = -0.343, p 
= 0.275) or post (Rs = 0.2, p = 0.534) nor per cent change (post – pre; Rs = 0.173, p = 0.465) 
with lowest ABPI. 
 
3.6.5. Correlation of lowest ABPI with kidney injury 
Similarly there was no correlation of NAG/ Creatinine ratio neither pre (Rs = -0.108, p = 
0.680) or post (Rs = -0.125, p = 0.633) nor per cent change (post – pre; Rs = -0.326, p = 
0.202) with lowest ABPI. 
 
3.6.6. Correlation of lowest ABPI with plasma MCP-1 
There was no correlation of lowest ABPI with MCP-1 pre- (Rs = 0.105, p = 0.661); post-: Rs 
= 0.163, p = 0.494; or percent change post-exercise: Rs = 0.167, p = 0.481). 
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3.7 Effect of average ABPI on oxidative stress and defence, 
endothelial function, MCP-1 and kidney injury 
3.7.1. Correlation of average ABPI with oxidative stress 
There was a significant correlation between average ABPI with the plasma FORT pre-
exercise (Rs = 0.475, p = 0.043; Spearman’s rank correlation; Figure 3-15). 
 
 
 
 
There was a significant correlation between average ABPI and plasma FORT post-exercise 
(Rs = 0.554, p = 0.011; Spearman’s rank correlation; Figure 3-16). 
 
FIGURE 3-15. SCATTER GRAPH OF AVERAGE ABPI VERSUS PRE- EXERCISE OXIDATIVE STRESS AS MEASURED 
BY FORT (FORT UNITS) 
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There was no significant correlation between average ABPI and plasma FORT change post 
exercise (Rs = 0.220, p = 0.352) 
 
There was no correlation between average ABPI and plasma H2O2 pre-exercise (Rs = 0.223, 
p = 0.346). 
 
There was a significant correlation between average ABPI and plasma H2O2 post-exercise 
(Rs = 0.554, p = 0.011; Spearman’s rank correlation; Figure 3-16). 
 
 
FIGURE 3-16. SCATTER GRAPH OF AVERAGE ABPI VERSUS POST- EXERCISE PLASMA OXIDATIVE STRESS AS 
MEASURED IN FORT UNITS. 
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There was no significant correlation between average ABPI and plasma H2O2 percentage 
change post exercise (Rs = 0.283, p = 0.227). 
 
3.7.2. Correlation of average ABPI with oxidative defence 
There was no significant correlation between average ABPI and FORD: pre (Rs = -0.235, p = 
0.319); post (Rs = 0.160, p = 0.501); and percent change, post – pre (Rs = 0.220, p = 0.352). 
 
 
 
 
 
 
FIGURE 3-17. SCATTER GRAPH OF AVERAGE ABPI VERSUS POST-EXERCISE PLASMA OXIDATIVE STRESS AS 
MEASURED BY H2O2 
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3.7.3. Correlation of average ABPI with macro-vascular endothelial 
function 
 
 
There was a significant correlation between average ABPI And FMD post-exercise (Rs = 
0.466, p = 0.038; Spearman’s rank correlation; Figure 3-18). There was no correlation 
between average ABPI and pre-exercise FMD (Rs = 0.337, p = 0.146). There was no 
association between average ABPI and percent change (post – pre) FMD (Rs = -0.026, p = 
0.915). 
 
 
 
FIGURE 3-18. SCATTER GRAPH OF AVEAGE ABPI VERSUS POST EXERCISE ENDOTHELIAL FUNCTION. 
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3.7.4. Correlation of average ABPI with micro-vascular endothelial 
function 
 
There was no correlation between average ABPI and LDF: Pre- (Rs = -0.364, p = 0.245); 
post- (Rs = 0.301, p = 0.342) or percent change post – pre LDF (Rs = 0.197, p = 0.406). 
 
3.7.5. Correlation of average ABPI with kidney injury 
 
There was no correlation between average ABPI and kidney injury (NAG/ Creatinine ratio): 
Pre- (Rs = -0.174, p = 0.504); post- (Rs = 0.015, p = 0.955) or percent change post – pre LDF 
(Rs = -0.230, p = 0.374). 
3.7.6. Correlation of average ABPI with MCP-1 
 
There was no correlation between average ABPI and MCP-1: Pre- (Rs = 0.232, p = 0.326); 
post- (Rs = 0.155, p = 0.514) or percent change post – pre LDF (Rs = 0.026, p = 0.915). 
 
3.8 Effects of resting oxidative stress on endothelial function, 
MCP-1 and kidney injury 
 
3.8.1. Correlation of pre exercise oxidative stress with macro-
vascular endothelial function in claudicants 
 
There was no association between FORT (pre) and FMD (% change) pre exercise (Rs = 
0.301, p = 0.198). Similarly, there was no association between FORT (pre-exercise) and 
FMD % change (post exercise) R =0.259, p = 0.271. 
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FIGURE 3-19. SCATTER GRAPH OF PRE EXERCISE OXIDATIVE STRESS (FORT) VERSUS PERCENTAGE CHANGE 
IN ENDOTHEIAL FUNCTION (FMD) POST EXERCISE. 
 
There was a negative correlation between the post – pre change in FMD with pre-exercise 
FORT test in claudicants (Rs =  -0.468, p = 0.038; Spearman’s rank correlation; Figure 3-19). 
There was no association between H2O2 (pre) and FMD % change pre exercise (Rs = 0.120, 
p = 0.613).  
 
Similarly there was no association between H2O2 (pre) and FMD % change post exercise R 
=0.044, p = 0.855. 
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There was a negative correlation between the post – pre change in FMD with pre-exercise 
H2O2 in claudicants (Rs =  -0.537, p = 0.026; Spearman’s rank correlation; Figure 3-20). 
 
3.8.2. Correlation of pre exercise oxidative stress with micro-
vascular endothelial function in claudicants 
There was no correlation between pre-exercise FORT with the LDF post-occlusion 
hyperaemia response: Pre- (Rs = -0.161, p = 0.618); post- (Rs = -0.091, p = 0.779) or percent 
change post-exercise (Rs = 0.049, p = 0.838). 
 
There was no correlation between pre-exercise H2O2 with the LDF post-occlusion 
hyperaemia response: Pre- (Rs = -0.161, p = 0.618); post- (Rs = -0.091, p = 0.779) or percent 
change post-exercise (Rs = -0.003, p = 0.990). 
FIGURE 3-20. SCATTER GRAPH OF PRE-EXERCISE OXIDATIVE STRESS (H2O2) VERSUS PERCENTAGE CHANGE 
IN ENDOTHELIAL FUNCTION (FMD) POST EXERCISE. 
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3.8.3. Correlation of pre exercise oxidative stress with kidney 
injury in claudicants 
There was no association between FORT (pre) and NAG/creat ratio pre exercise (Rs = 0.002, 
p = 0.993). Similarly there was no association between FORT (pre) Nag/creat (post) R 
=0.181, p = 0.486. There was no association between FORT  (pre) with NAG/creat ratio (post 
– pre) Rs = -0.390, p = 0.122 
 
There was no association between H2O2 (pre) and NAG/creat ratio pre exercise (Rs = 0.279, 
p = 0.277). Similarly there was no association between H2O2 (pre) and Nag/creat (post) R 
=0.086, p = 0.743. There was a negative correlation between the per cent change (post – pre) 
of NAG/ Creatinine with pre-exercise H2O2 in claudicants (Rs =  -0.468, p = 0.038; 
Spearman’s rank correlation; Figure 3-21). 
 
 
 
FIGURE 3-21. SCATTER GRAPH OF PRE-EXERCISE OXIDATIVE STRESS (H2O2) VERSUS PERCENTAGE CHANGE 
IN NAG/ CREATININE RATIO POST EXERCISE. 
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3.8.4. Correlation of pre exercise oxidative stress with MCP-1 
 
There was no association between pre exercise FORT with pre exercise MCP-1 (R = -0.271, 
p = 0.248). There was no association between pre exercise FORT with post exercise MCP-1 
(R = -0.039, p = 0.870). There was no association between pre exercise FORT with % change 
post- pre exercise MCP-1 (R = 0.232, p = 0.326). 
 
There was no association between pre exercise H2O2 with pre exercise MCP-1 (R = -0.418, p 
= 0.067). There was no association between pre exercise H2O2 with post exercise MCP-1 (R 
= -0.080, p = 0.738). There was no association between pre exercise H2O2 with % change 
post- pre exercise MCP-1 (R = 0.371, p = 0.107). 
 
3.9 Effect of post exercise oxidative stress on endothelial 
function, kidney injury and MCP-1 
 
3.9.1. Correlation of post exercise oxidative stress with macro-
vascular endothelial function in claudicants 
 
There was no association between FORT (post) and FMD % change pre exercise (Rs = 0.252, 
p = 0.285). Similarly there was no association between FORT (post) with FMD % change 
(post) R =0.063, p = 0.793. 
 
There was no association between H2O2 (post) and FMD % change pre exercise (Rs = 0.252, 
p = 0.285). Similarly there was no association between H2O2 (post) and FMD % change 
(post) R =0.063, p = 0.793. 
 
3.9.2. Correlation of post exercise oxidative stress with micro-
vascular endothelial function in claudicants 
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There was no correlation between the post exercise FORT with the post-occlusion 
hyperaemia response pre- (Rs = -0.165, p = 0.609), post- (Rs = 0.025, p = 0.940) or 
percentage change post-exercise (Rs = 0.215, p = 0.362). 
 
There was no correlation between the post exercise H2O2 with the post-occlusion 
hyperaemia response pre- (Rs = -0.165, p = 0.609), post- (Rs = 0.025, p = 0.940) or 
percentage change post-exercise (Rs = 0.215, p = 0.362). 
 
3.9.3. Correlation of post exercise oxidative stress with kidney 
injury in claudicants 
There was no association between FORT (post) and NaG/creat pre exercise (Rs = -0.229, p = 
0.377). Similarly there was no association between FORT (post) with NaG/creat (post) R =-
0.052, p = 0.844. 
 
There was no association between H2O2 (post) and NaG/creat pre exercise (Rs = -0.229, p = 
0.377). Similarly there was no association between H2O2 (post) with NaG/creat (post) R =-
0.052, p = 0.844. 
 
3.9.4. Correlation of post exercise oxidative stress with MCP-1 
There was no association between post exercise FORT with pre exercise MCP-1 (R = -0.243, 
p = 0.303). There was no association between post exercise FORT with post exercise MCP-1 
(R = -0.283, p = 0.226). There was no association between post exercise FORT with % 
change post- pre exercise MCP-1 (R = 0.156, p = 0.512). 
 
There was no association between post exercise H2O2 with pre exercise MCP-1 (R = -0.243, 
p = 0.303). There was no association between post exercise H2O2 with post exercise MCP-1 
(R = 0.283, p = 0.226). There was no association between post exercise H2O2 with % change 
post- pre exercise MCP-1 (R = 0.156, p = 0.512). 
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3.10 Effect of change in oxidative stress post exercise on 
endothelial function, kidney injury and MCP-1 
3.10.1. Correlation of post-pre exercise change in oxidative 
stress with antioxidant defence 
There was no association between percentage change post exercise FORT with FORD: Pre 
(Rs = -0.012, p = 0.960); post- (Rs = -0.179, p = 0.449); or percentage change post-exercise 
(Rs = -0.165, p = 0.486). 
 
There was no association between percentage change post exercise H2O2 with FORD: Pre 
(Rs = -0.020, p = 0.932); post- (Rs = -0.024, p = 0.919); or percentage change post-exercise 
(Rs = -0.046, p = 0.847). 
 
3.10.2. Correlation of post – pre exercise oxidative stress with 
macro-vascular endothelial function in claudicants 
There was no association between FORT percent change (post - pre) and FMD % change pre 
exercise (Rs = -0.003, p = 0.990). Similarly there was no association between FORT (post - 
pre) with FMD % change (post) R =-0.099, p = 0.677.  
 
Also, there was association between FORT (post - pre) with FMD % change (post - pre) (Rs 
= 0.477, p = 0.034; Spearman’s rank correlation; Figure 3-22). 
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FIGURE 3-22. SCATTER GRAPH OF PERCETNAGE CHANGE IN OXIDATIVE STRESS (FORT) POST EXERCISE 
VERSUS PERCENTGAE CHANGE IN ENDOTHELIAL FUNCTION (FMD) POST EXERCISE. 
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There was a correlation between the percent change (post – pre) of plasma oxidative stress as 
measured by the FORT test with per cent change (post – pre) in FMD in claudicants (Rs = 
0.477, p = 0.034; Spearman’s rank correlation). 
 
 
 
There was no association between H2O2 (post - pre) and FMD % change pre exercise (Rs = 
0.071, p = 0.767). Similarly there was no association between H2O2 (post - pre) and FMD % 
change (post) R =-0.003, p = 0.990. 
 
Also, there was association between H2O2 (post - pre) with FMD % change (post - pre) R 
=0.520, p = 0.019; Spearman’s rank correlation; Figure 3-23).  
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FIGURE 3-23. SCATTER GRAPH OF PERCENTGAE CHANGE IN OXIDATIVE STRESS (H2O2) POST EXERCISE 
VERSUS PERCENTAGE CHANGE IN ENDOTHEIAL FUNCTION (FMD) POST EXERCISE. 
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3.10.3. Correlation of post – pre oxidative stress with micro-
vascular endothelial function in claudicants 
 
There was no association between the percentage change FORT post – pre with the post 
occlusion reactive hyperaemia test pre- (Rs = 0.217, p =0.499), post- (Rs = 0.112, p = 0.729) 
or percent change post exercise (Rs = 0.098, p = 0.681). 
 
There was no association between the percentage change H2O2 post – pre with the post 
occlusion reactive hyperaemia test pre- (Rs = 0.224, p = 0.484), post- (Rs = 0.119, p = 0.713) 
or percent change post exercise (Rs = 0.106, p = 0.658). 
 
3.10.4. Correlation of post – pre exercise oxidative stress with 
kidney injury in claudicants 
 
There was no association between FORT percent change (post - pre) and NAG/ creat ratio 
pre exercise (Rs = -0.402, p = 0.109). Similarly there was no association between FORT (post 
- pre) with NAG/ creat ratio (post) R =-0.167, p = 0.522.  
 
Also, there was no association between FORT (post - pre) with NAG/ creat ratio (post - pre) 
Rs =0.450, p = 0.070. 
 
 
There was no association between H2O2 percent change (post - pre) and NAG/ creat ratio pre 
exercise (Rs = -0.422, p = 0.092). Similarly there was no association between H2O2 (post - 
pre) with NAG/ creat ratio (post) R =-0.074, p = 0.779.  
 
Also, there was a significant association between H2O2 (post - pre) with NAG/ creat ratio 
(post - pre) R =0.507, p = 0.038; Spearman’s rank correlation; Figure 3-24). 
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3.10.5. Correlation of post - pre exercise oxidative stress with 
MCP-1 
 
There was a correlation between the per cent change (post – pre) of plasma oxidative stress as 
measured by the FORT test with pre-exercise plasma MCP-1 levels in claudicants (Rs = 
0.687, p = 0.000815; Spearman’s rank correlation; Figure 3-25). 
 
FIGURE 3-24. SCATTER GRAPH OF PERCENTAGE CHANGE IN OXIDATIVE STRESS (H2O2) POST EXERCISE 
VERSUS PERCENTAGE CHANGE IN NAG/ CREATININE RATIO POST EXERCISE. 
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There was no association between post - pre exercise FORT with post exercise MCP-1 (R = 
0.260, p = 0.268). 
 
 
There was no association between post - pre exercise FORT with % change post- pre exercise 
MCP-1 (R = -0.301, p = 0.198). 
 
 
There was an association between post - pre exercise H2O2 with pre exercise MCP-1 (R = 
0.701, p = 0.000579; Figure 3-26). 
 
 
 
 
FIGURE 3-25. SCATTER GRAPH OF PERCENTGAE CHANGE IN OXIDATIVE STRESS (FORT) POST EXERCISE 
VERSUS MCP-1 PRE EXERCISE. 
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FIGURE 3-26. SCATTER GRAPH OF PERCENTAGE CHANGE IN OXIDATIVE SRTESS (H2O2) POST EXERCISE 
VERSUS MCP-1 PRE EXERCISE. 
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There was no association between post - pre exercise H2O2 with post exercise MCP-1 (R = 
0.256, p = 0.277). 
 
There was no association between post - pre exercise H2O2 with % change post- pre exercise 
MCP-1 (R = -0.329, p = 0.156). 
 
3.11 Effect of resting antioxidant defense on oxidative stress, 
endothelial function, kidney injury and MCP-1 
3.11.1. Correlation resting antioxidant defense with oxidative 
stress 
There was no correlation between resting FORD and FORT: pre- (Rs = -0.090, p = 0.707); 
post- (Rs = -0.020, p = 0.932) and percentage change post-exercise (Rs = -0.012, p = 0.960). 
 
There was no correlation between resting FORD and H2O2: pre- (Rs = 0.05, p = 0.818); post- 
(Rs = -0.020, p = 0.932) and percentage change post-exercise (Rs = -0.053, p = 0.823). 
 
3.11.2. Correlation of resting antioxidant defence with macro-
vascular endothelial function 
There was no correlation between resting FORD and FMD: pre- (Rs = -0.258, p = 0.272); 
post- (Rs = -0.169, p = 0.475) and percentage change post-exercise (Rs = -0.161, p = 0.497). 
 
 
3.11.3. Correlation of resting antioxidant defence with micro-
vascular endothelial function 
There was no correlation between resting FORD and LDF: pre- (Rs = -0.245, p = 0.442); 
post- (Rs = 0.438, p = 0.155) and percentage change post-exercise (Rs = 0.392, p = 0.088). 
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3.11.4. Correlation of resting antioxidant defence with kidney 
injury 
 
There was no correlation between resting FORD and NAG/ Creatinine ratio: pre- (Rs = -
0.206, p = 0.428); post- (Rs = 0.392, p = 0.088) and percentage change post-exercise (Rs = 
0.260, p = 0.314). 
 
3.11.5. Correlation of resting antioxidant defence with MCP-1 
There was no correlation between resting FORD and MCP-1: pre- (Rs = 0.061, p = 0.798); 
post- (Rs = -0.173, p = 0.465) and percentage change post-exercise (Rs = -0.152, p = 0.522). 
 
3.12 Effect of post-exercise antioxidant defense on oxidative 
stress, endothelial function, kidney injury and MCP-1 
3.12.1. Correlation of post-exercise antioxidant defense with 
oxidative stress 
There was no correlation between post-exercise FORD and FORT: pre- (Rs = 0.285, p = 
0.222); post- (Rs = -0.024, p =0.919) and percentage change post-exercise (Rs = -0.179, p = 
0.449). 
 
There was no correlation between post-exercise FORD and H2O2: pre- (Rs = 0.008, p = 
0.972); post- (Rs = -0.024, p = 0.919) and percentage change post-exercise (Rs = -0.066, p = 
0.784). 
 
3.12.2. Correlation of post exercise antioxidant defence with 
macro-vascular endothelial function 
There was no correlation between post-exercise FORD and FMD: pre- (Rs = 0.066, p = 
0.781); post- (Rs = 0.329, p = 0.156) and percentage change post-exercise (Rs = 0.268, p = 
0.253). 
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3.12.3. Correlation of post exercise antioxidant defence with 
micro-vascular endothelial function 
There was no correlation between post-exercise FORD and LDF: pre- (Rs = -0.417, p = 
0.178); post- (Rs = 0.417, p = 0.178) and percentage change post-exercise (Rs = 0.283, p = 
0.227). 
 
3.12.4. Correlation of post exercise antioxidant defence with 
kidney injury 
There was no correlation between post-exercise FORD and NAG/ Creatinine ratio: pre- (Rs = 
-0.301, p = 0.240); post- (Rs = 0.144, p = 0.582) and percentage change post-exercise (Rs = -
0.015, p = 0.955). 
 
3.12.5. Correlation of post exercise antioxidant defence with 
MCP-1 
There was no significant correlation between post-exercise FORD and pre-exercise (Rs = -
0.148, p = 0.532) or percentage change MCP-1 post exercise (Rs = -0.314, p = 0.177). 
However, there was a significant correlation between post-exercise FORD and post-exercise 
MCP-1 (Rs = -0.481, p = 0.032; Spearman’s rank correlation; Figure 3-27).  
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FIGURE 3-27. SCATTER GRAPH OF OXIDATIVE DEFENSE POST EXERCISE VERSUS MCP-1 POST EXERCISE. 
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3.13 Effect of change in antioxidant defense post exercise on 
oxidative stress, endothelial function, kidney injury and MCP-
1 
3.13.1. Correlation of percent change post-exercise in 
antioxidant defense with oxidative stress 
There was no correlation between percentage change post-exercise FORD and FORT: pre- 
(Rs = 0.236, p = 0.316); post- (Rs = -0.046, p = 0.847) and percentage change post-exercise 
(Rs = -0.165, p = 0.486). 
 
There was no correlation between percentage change post-exercise FORD and H2O2: pre- 
(Rs = -0.032, p = 0.895); post- (Rs = -0.046, p = 0.847) and percentage change post-exercise 
(Rs = -0.068, p = 0.777). 
 
3.13.2. Correlation of post exercise change in antioxidant 
defence with macro-vascular endothelial function 
There was no correlation between percentage change post-exercise FORD and FMD: pre- (Rs 
= 0.174, p = 0.462); post- (Rs = 0.296, p = 0.205) and percentage change post-exercise (Rs = 
0.176, p = 0.458). 
 
3.13.3. Correlation of post exercise change in antioxidant 
defence with micro-vascular endothelial function 
There was no correlation between percentage change post-exercise FORD and LDF: pre- (Rs 
= -0.371, p = 0.236); post- (Rs = 0.189, p = 0.557) and percentage change post-exercise (Rs = 
0.098, p = 0.681). 
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3.13.4. Correlation of post exercise change in antioxidant 
defence with kidney injury 
There was no correlation between percentage change post-exercise FORD and NAG/ 
Creatinine ratio: pre- (Rs = -0.086, p = 0.743); post- (Rs = 0.248, p = 0.338) and percentage 
change post-exercise (Rs = -0.233, p = 0.368). 
 
3.13.5. Correlation of post-exercise antioxidant defence with 
MCP-1 
There was no correlation between percentage change post-exercise FORD and MCP-1: pre- 
(Rs = -0.247, p = 0.295); post- (Rs = -0.382, p = 0.097) and percentage change post-exercise 
(Rs = -0.161, p = 0.498). 
 
3.14 Effect of maximum walking distance on endothelial 
function, oxidative stress and defense, kidney injury and 
MCP-1 
3.14.1. Correlation of maximal walking distance with macro-
vascular endothelial function in claudicants  
There was a significant association between the maximum walking distance and the percent 
change in endothelial function post exercise in FMD (Rs = 0.515, p = 0.020; Spearman’s rank 
correlation; Figure 3-28). There was no correlation between distance traveled and pre-
exercise FMD (0.148, p = 0.533). There was no association between distance travelled and 
post-exercise FMD (0.033, p = 0.890). 
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FIGURE 3-28. SCATTER GRAPH OF MAXIMUM WALKING DISTANCE VERSUS PERCENTGAE CHANGE IN 
ENDOTHEILA FUNCTION (FMD) POST EXERCISE. 
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3.14.2. Correlation of maximal walking distance with micro-
vascular endothelial function in claudicants  
There was no correlation between maximum walking distance and post occlusion hyperaemia 
response of LDF: pre- (Rs = -0.042, p = 0.897); post- (Rs = -0.182, p = 0.570) and percentage 
change post-exercise (Rs = 0.128, p = 0.592). 
 
3.14.3. Correlation of maximal walking distance with oxidative 
stress in claudicants 
There was no correlation between maximum walking distance and FORT: pre- (Rs = 0.036, p 
= 0.880); post- (Rs = -0.032, p = 0.892) and percentage change post-exercise (Rs = -0.115, p 
= 0.629). 
 
There was no correlation between maximum walking distance and H2O2: pre- (Rs = -0.148, 
p = 0.533); post- (Rs = -0.032, p = 0.892) and percentage change post-exercise (Rs = -0.023, 
p = 0.925). 
 
3.14.4. Correlation of maximal walking distance with 
antioxidant defense in claudicants  
There was no correlation between maximum walking distance and FORD: pre- (Rs = 0.255, p 
= 0.278); post- (Rs = 0.152, p = 0.524) and percentage change post-exercise (Rs = -0.110, p = 
0.645). 
 
3.14.5. Correlation of maximal walking distance with kidney 
injury in claudicants  
There was no correlation between maximum walking distance and NAG/ Creatinine ratio: 
pre- (Rs = -0.136, p = 0.062); post- (Rs = 0.153, p = 0.556) and percentage change post-
exercise (Rs = 0.471, p = 0.056). 
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3.14.6. Correlation of maximal walking distance with MCP-1 in 
claudicants  
There was no correlation between maximum walking distance and MCP-1: pre- (Rs = -0.273, 
p = 0.244); post- (Rs = 0.029, p = 0.905) and percentage change post-exercise (Rs = 0.389, p 
= 0.090). 
 
3.15 Effect of resting FMD on post exercise endothelial 
function, oxidative stress and defence, kidney injury and 
MCP-1 
3.15.1. Correlation of resting macro-vascular endothelial 
function with post exercise and percent change in macro-
vascular endothelial function 
There was no correlation between resting FMD and FMD: post- (Rs = 0.143, p = 0.548); and 
percentage change post-exercise (Rs = 0.247, p = 0.295). 
 
3.15.2. Effect of resting macro-vascular endothelial function 
on resting, post exercise and percent change in microvacular 
endothelial function following exercise 
There was no correlation between resting FMD and LDF post occlusion hyperaemia 
response: pre- (Rs = 0.035, p = 0.914); post- (Rs = -0.231, p =0.471) and percentage change 
post-exercise (Rs = -0.028, p = 0.907). 
 
3.15.3. Effect of resting macro-vascular endothelial function 
on oxidative stress 
There was no correlation between resting FMD and FORT: pre- (Rs = 0.301, p = 0.198); 
post- (Rs = 0.252, p = 0.285) and percentage change post-exercise (Rs = -0.003, p = 0.990). 
 
There was no correlation between resting FMD and H2O2: pre- (Rs = 0.120, p = 0.613); post- 
(Rs = 0.252, p = 0.285) and percentage change post-exercise (Rs = 0.071, p = 0.767). 
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3.15.4. Effect of resting macro-vascular endothelial function 
on oxidative defence 
There was no correlation between resting FMD and FORD: pre- (Rs = -0.258, p = 0.272); 
post- (Rs = 0.066, p = 0.781) and percentage change post-exercise (Rs = 0.174, p =0.462). 
 
3.15.5. Effect of resting macro-vascular endothelial function 
on kidney injury 
There was no correlation between resting FMD and NAG/ Creatinine ratio: pre- (Rs = 0.029, 
p = 0.911); post- (Rs = 0.194, p = 0.456) and percentage change post-exercise (Rs = -0.007, p 
= 0.978). 
 
3.15.6. Effect of resting macro-vascular endothelial function 
on MCP-1 
There was no correlation between resting FMD and MCP-1: pre- (Rs = 0.167, p = 0.482); 
post- (Rs = 0.093, p = 0.696) and percentage change post-exercise (Rs = -0.021, p =0.930). 
 
3.16 Effect of post exercise FMD on oxidative stress and 
defence, kidney injury and MCP-1 
3.16.1. Correlation of post-exercise macro-vascular 
endothelial function with percent change in macro-vascular 
endothelial function 
There was no correlation between post exercise FMD and percent change in FMD post-
exercise (Rs = -0.027, p = 0.910). 
 
 261 
 
3.16.2. Effect of post-exercise macro-vascular endothelial 
function on percent change in micro-vacular endothelial 
function following exercise 
There was no correlation between post exercise FMD and percent change in LDF post 
occlusion hyperaemia response (Rs = 0.070, p =0.770). 
 
3.16.3. Effect of post-exercise macro-vascular endothelial 
function on oxidative stress 
There was no correlation between post exercise FMD and FORT: pre- (Rs = 0.259, p = 
0.271); post- (Rs = 0.063, p = 0.793) and percentage change post-exercise (Rs = -0.099, p = 
0.677). 
 
There was no correlation between post exercise FMD and H2O2: pre- (Rs = 0.044, p =0.855); 
post- (Rs = 0.063, p = 0.793) and percentage change post-exercise (Rs = -0.099, p = 0.677). 
 
3.16.4. Effect of post-exercise macro-vascular endothelial 
function on oxidative defence 
There was no correlation between post exercise FMD and FORD: pre- (Rs = -0 .169, p = 
0.475); post- (Rs = 0.329, p =0.156) and percentage change post-exercise (Rs = 0.296, p 
=0.205). 
 
3.16.5. Effect of post-exercise macro-vascular endothelial 
function on kidney injury 
There was no correlation between post exercise FMD and NAG/ Creatinine ratio: pre- (Rs = 
0.069, p =0.794); post- (Rs = 0.363 p = 0.152) and percentage change post-exercise (Rs = -
0.199, p = 0.445). 
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3.16.6. Effect of post-exercise macro-vascular endothelial 
function on MCP-1 
There was no correlation between post exercise FMD and MCP-1: pre- (Rs = 0.092, p = 
0.701); post- (Rs = -0.071, p =0.767) and percentage change post-exercise (Rs = -0.104, p = 
0.663). 
 
3.17 Effect of post – pre exercise FMD on micro-vascular 
FMD, oxidative stress and defence, kidney injury and MCP-1 
 
3.17.1. Effect of post-exercise macro-vascular endothelial 
function on percent change in micro-vascular endothelial 
function following exercise 
There was no correlation between percentage change in FMD post exercise and LDF post-
occlusion hyperaemia response: Pre- (Rs = -0.238, p =0.457); post- (Rs = 0.168, p = 0.602) 
and percentage change post-exercise (Rs = 0.178, p = 0.453). 
 
3.17.2. Effect of post- pre-exercise macro-vascular endothelial 
function on oxidative stress 
There were significant correlations between percentage change in FMD post exercise and 
FORT: Pre- (Rs = -0.468, p = 0.038); and percentage change post-exercise (Rs = 0.477, p 
=0.034). There was no correlation between percentage change in FMD post exercise and 
FORT post-exercise (Rs = -0.0124, p =0.062). 
 
There were significant correlations between percentage change in FMD post exercise and 
H2O2: Pre- (Rs = -0.558, p = 0.011; Spearman’s rank correlation; Figure 3-29); and 
percentage change post-exercise (Rs = 0.520, p = 0.019). There was no correlation between 
percentage change in FMD post exercise and H2O2 post-exercise (Rs = -0.124, p = 0.602). 
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FIGURE 3-29. SCATTER GRAPH OF PERCENTAGE CHANGE IN ENDOTHELIAL FUNCTION (FMD) POST EXERCSIE 
VERSUS PERCENTGAE CHANGE IN H2O2 POST EXERCISE. 
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3.17.3. Effect of post-pre exercise macro-vascular endothelial 
function on oxidative defence 
There was no correlation between percentage change in FMD post exercise and FORD: Pre- 
(Rs = 0.161, p = 0.497); post- (Rs = 0.268, p = 0.253) and percentage change post-exercise 
(Rs = 0.176, p = 0.458). 
 
3.17.4. Effect of post-pre exercise macro-vascular endothelial 
function on kidney injury 
There was no correlation between percentage change in FMD post exercise and NAG/ 
Creatinine ratio: Pre- (Rs = -0.277, p = 0.282); post- (Rs = -0.010, p = 0.970) 
 
There was a significant correlation between percentage change post exercise FMD and 
percent change NAG/ Creatinine ratio post exercise (Rs = 0.563, p = 0.019; Spearman’s rank 
correlation; Figure 3-30). 
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FIGURE 3-30. SCATTER GRAPH OF PERCENTAGE CHANGE IN ENDOTHEILA FUNCTION (FMD) POST EXERCSIE 
VERSUS PERCENTGAE CHANGE IN NAG/ CREATININE RATIO POST EXERCISE. 
 
 
 
 
 
3.17.5. Effect of post—pre exercise macro-vascular 
endothelial function on MCP-1 
There was no correlation between percentage change in FMD post exercise and MCP-1: Pre- 
(Rs = 0.251, p = 0.286); post- (Rs = 0.039, p = 0.870) and percentage change post-exercise 
(Rs = - 0.032, p = 0.895). 
 
 
 
 
 
 266 
 
3.18 Acute post-exercise rise in NAG/ Creatinine ratio as a 
differentiator of patients with intermittent claudication 
 
 
 
 
 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
FMD % change 
(post – pre-exercise) 
median, IQR, range 
0.09, -4.82 to 0.91, -
18.85 to 1.97  
2.56, 0.13 to 
3.698, -0.52 to 
14.10 
p = 0.027, Mann 
Whitney U test 
FIGURE 3-31. BOX PLOT DEMONSTRATING PERCENTAGE CHANGE IN ENDOTHELIAL FUNCTION (FMD) IN 
PATIENTS WITH AND WITHOUT RISE IN NAG/ CREATININE RATIO POST EXERCISE   
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 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
Maximum walking 
distance (m; 
median, IQR, range) 
170, 100 to 315, 90 
to 450  
 
415, 207.5 to 
908, 100 to 2400 
p = 0.043, Mann 
Whitney U test 
 
FIGURE 3-32. BOX PLOT DEMONSTRATING WALKING DISTANCE IN PATIENTS WITH AND WITHOUT RISE IN 
NAG/ CREATININE RATIO POST EXERCISE. THE SCALE HAS BEEN ADJUSTED TO OMIT OUTLIERS BUT ALL 
DATA HAS BEEN USED IN CALCULATIONS 
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 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
H2O2 (pre-exercise; 
mmol/l; median, 
IQR, range) 
2.74, 2.085 to 
3.295, 1.83 to 3.95 
1.85, 1.385 to 
2.268, 0.83 to 
4.56 
p = 0.043, Mann 
Whitney U test 
 
FIGURE 3-33. BOX PLOT DEMONSTRATING PRE-EXERCISE H2O2 IN PATIENTS WITH AND WITHOUT RISE IN 
NAG/ CREATININE RATIO POST EXERCISE 
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 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
H2O2 % change 
(post-pre; median, 
IQR, range) 
-7.72, -13.85 to -
1.97, -25.55 to 
39.02  
18.75, -1.53 to 
129.68, -45.83 to 
448.19 
p = 0.043, Mann 
Whitney U test 
 
FIGURE 3-34. BOX PLOT DEMONSTRATING PERCENTAGE CHANGE IN H2O2  POST EXERCISE IN PATIENTS WITH 
AND WITHOUT RISE IN NAG/ CREATININE RATIO POST EXERCISE. 
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3.19 Characteristics of claudicants with NAG/ Creatinine rise 
vs fall following exercise 
 
 
 
 
TABLE 14 DEMOGRAPHIC DATA OF PATIENTS WHO HAD A RISE/ NO RISE IN NAG/ CREATININE RATIO 
POST-EXERCISE 
 NAG/ Creatinine NO RISE NAG/ Creatinine RISE 
Number of participants 12 8 
Age (years)  (median, IQR) 74.5, 66 to 80.25 67.5, 63 to 73.25 
Male (n, %) 6, 50% 5, 62.5% 
Lowest ABPI (median, IQR) 0.71, 0.6225 to 0.8425 0.615, 0.5525 to 0.69 
Mean ABPI (median, IQR) 0.835, 0.72 to 0.8975 0.71, 0.6525 to 0.8325 
Maximum walking distance 
(metres) (median, IQR) 
195, 140 to 302.5 395, 282.5 to 716 
Height (m) (median, IQR) 1.685, 1.60 to 1.74 1.725, 1.5725 to 1.7525 
Weight (kg) (median, IQR) 69, 62 to 80.25 81, 67.75 to 92 
BMI (kg/ m2) (median, IQR) 23.85, 23.05 to 27.43 27.85, 26.925 to 30.325 
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TABLE 15 CHARACTERISTIC DATA OF PATIENTS WITH NO RISE IN NAG/ CREATININE RATIO POST EXERCISE 
 
N
A
G
/ C
r R
is
e 
Pa
rt
ic
ip
an
t	  n
o	  
Hy
pe
rt
en
sio
n	  
IH
D	  
DM
	  
Ch
ol
es
te
ro
l	  
Sm
ok
er
	  
O
th
er
	  P
M
H	  
st
at
in
	  
an
ti-­‐
pl
at
el
et
	  
M
ed
ic
at
io
n	  
✓ 1 Yes No No Yes ex BPH Atorvastatin Aspirin 
Lansoprazole, 
Tamsulosin, 
Finasteride, 
Amlodipine, 
Irbesartan 
✓ 4 Yes YES NO No no TIA, CABG Simvastatin Aspirin & Clopidogrel bisoprolol 
✓ 5 Yes Yes No Yes no  Simvastatin Aspirin  
✓ 6 Yes No No Yes ex IBS, Aortic Regurgitation Atorvastatin Aspirin  
✓ 7 Yes No Yes Yes no Type 2 diabetes, Hypothyroidism  Aspirin 
Metformin, , 
Insulin, 
Gliclazide, 
Enalapril, 
Amlodipine, and 
Bendrofluazide 
✓ 11 Yes No Yes No no    Metformin, BP medication 
✓ 12 No No No No ex no   none 
✓ 15 Yes No No Yes ex  Pravastatin Aspirin Amlodipine 
✖ 2 yes No No Yes yes COPD simvastatin Aspirin 
Spiriva inhaler, 
salbutamol 
inhaler 
✖ 3 No No No No no Ca colon, Ca bladder  Aspirin Tolterodine 
✖ 8 No yes No yes ex  Atovastin Aspirin Losec and Atenolol 
✖ 9 No No Yes No no AF   Amiodarone, Warfarin 
✖ 10 No No No Yes Ex Osteoarthritis Simvastatin  Simvastatin 
✖ 13 Yes Yes No Yes no  Rocuvastatin Aspirin Omeprazole, Carvedilol, , 
✖ 14 Yes No No Yes yes    Enalapril, Cilostasol 
✖ 16 Yes No Yes Yes no Primary biliary cirrhosis Simvastatin  
Bendrofluazide, 
Irbesartan, 
Metformin, 
Insulin, 
Omeprazole, 
Ursodeoxycholic 
acid 
✖ 17 Yes No Yes No yes    Bendrofluazide 
✖ 18 yes yes no no ex CABG Simvastatin Clopidogrel & Aspirin  
✖ 19 No Yes Yes Yes ex  Simvastatin Aspirin Metformin, 
✖ 20 Yes No No Yes ex Benign prostatic hypertrophy,Gastritis/duodenitis Simvastatin Aspirin 
Quinine, 
Bendrofluazide, 
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4. Discussion 
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4.1 Endothelial function changes in claudicants following 
exercise  
 
We initially investigated the effects of exercise on claudicants’ brachial artery diameter and 
Laser Doppler Flux as this may have increased due to increased blood flow associated with 
exercise. At rest, claudicants had a brachial artery diameter  (cm; median, IQR) of 4.49, 4.15 
to 5.03. Following exercise this was not significantly changed: 4.35, 3.94 to 4.99 (p = 0.147). 
Similarly, at rest, claudicants had a flux (AU; median, IQR) of 154.25, 154.25 to 265.05. 
Following exercise this was no significantly changed: 209.40, 142.83 to 768.03. These 
finding suggests that there was no significant contribution of exercise related sympathetic or 
flow mediated arterial dilatation. 
 
Brachial artery FMD in claudicants at rest (%; median, IQR) was 1.91; 3.55 to 3.87. 
Following maximal treadmill exercise, it was not significantly changed at 3.75; 1.29 to 7.45 
(p = 0.313). Interestingly, visually inspecting the paired data points as displayed in the slope 
graph (Figure 3-3), one can discern that there was clear heterogeneity in the direction of 
change in FMD post exercise. 
 
Resting brachial artery FMD in claudicants has been reported to be lower in claudicants than 
controls (5.1% vs 11.7%). Interestingly, asymptomatic patients with peripheral vascular 
disease had an intermediate FMD to the control and symptomatic groups (8.5%). The 
brachial artery response to sublingual nitroglycerine was similar indicating the effect was 
mediated by the endothelium rather than smooth muscle dysfunction (Silvestro et al., 2003). 
 
Others have reported a significant decrease in the percentage FMD of stable claudicants 
following maximal treadmill exercise (-1.5 ± 1; mean ± SD). (Gresele et al., 2007b).  
 
A similar lack of significant changes following exercise in endothelial function was measured 
in micro-vessels (%; median, IQR). Pre exercise values were 59, 25.74 to 260.43 and post 
were 11.2, -9.85 to 218.9 (p = 0.388). However, also similarly, there was heterogeneity in the 
direction of change in FMD responses post exercise. 
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Both these sets of results suggested to us that there may be heterogeneity in the macro- and 
micro-vascular endothelial function responses in claudicants following maximal treadmill 
exercise. 
 
4.2 Effect of resting FMD on post exercise endothelial function, 
oxidative stress and defense, kidney injury and MCP-1 
 
There was no correlation of pre- with post- or change following exercise post-exercise 
macro-vascular endotheial function (post: Rs = 0.143, p = 0.548; change post-exercise: R = 
0.247, p = 0.295). Similarly, there was no correlation between pre-exercise macro-vascular 
endothelial function with pre, post or change post exercise in micro-vascular function (pre: 
Rs = 0.035, p = 0.914, post Rs = -0.231, p =0.471, change post: Rs = -0.028, p = 0.907). 
 
There was no correlation between pre-exercise FMD with plasma oxidative stress measured 
by either FORT or H2O2 either pre, post or change post exercise. FORT – pre: Rs = 0.301, p 
= 0.198; post: Rs = 0.252, p = 0.285; change post: Rs = -0.003, p = 0.990.  H2O2 – pre: Rs = 
0.120, p = 0.613; post: Rs = 0.252, p = 0.285; change post: Rs = 0.071, p = 0.767.  
 
There was no correlation between pre-exercise FMD with pre, post or change post-exercise in 
oxidative defense (pre: Rs = -0.258, p = 0.272; post: Rs = 0.066, p = 0.781; change post: Rs = 
0.174, p = 0.462). 
 
There was no correlation between pre-exercise FMD with pre, post or change post-exercise in 
kidney injury (pre: Rs = 0.029, p = 0.911; post: Rs = 0.194, p = 0.456; change post: Rs = -
0.007, p = 0.978). 
 
 
There was no correlation between pre-exercise FMD with pre, post or change post-exercise in 
plasma MCP-1 (pre: Rs = 0.167, p = 0.482; post: Rs = 0.093, p = 0.696; change post: Rs = -
0.021, p =0.930). 
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4.3 Effect of post exercise FMD on oxidative stress and defense, 
kidney injury and MCP-1 
 
There was no correlation of post- with change post-exercise in macro-vascular endothelial 
function (post: Rs = -0.027, p = 0.910. Similarly, there was no correlation between post-
exercise macro-vascular endothelial function with change post exercise in micro-vascular 
function (Rs = 0.070, p =0.770). 
 
There was no correlation between post-exercise FMD with plasma oxidative stress measured 
by either FORT or H2O2 either pre, post or change post exercise. FORT – pre: Rs = R 
=0.259, p = 0.271; post: Rs = 0.063, p = 0.793; change post: Rs = --0.099, p = 0.677.  H2O2 
– pre: Rs = 0.044, p =0.855; post: Rs = 0.063, p = 0.793; change post: Rs = -0.099, p = 0.677.  
 
There was no correlation between post-exercise FMD with pre, post or change post-exercise 
in oxidative defense (pre: Rs = -0 .169, p = 0.475; post: Rs = 0.329, p =0.156; change post: 
Rs = 0.296, p =0.205). 
 
There was no correlation between post-exercise FMD with pre, post or change post-exercise 
in kidney injury (pre: Rs = 0.069, p =0.794; post: Rs = 0.363 p = 0.152; change post: Rs = -
0.199, p = 0.445). 
 
 
There was no correlation between post-exercise FMD with pre, post or change post-exercise 
in plasma MCP-1 (pre: Rs = 0.092, p = 0.701; post: Rs = -0.071, p =0.767; change post: Rs = 
-0.104, p = 0.663). 
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4.4 Effect of percent change post-exercise of macro-vascular 
endothelial function on micro-vascular endothelial function, 
oxidative stress, defense, kidney injury and MCP-1 
 
There was no correlation of change in macro-vascular endothelial function with pre, post- or 
change following exercise in micro-vascular endothelial function (pre: Rs = -0.238, p =0.457; 
post: Rs = 0.168, p = 0.602; change post-exercise: R = 0.178, p = 0.453).  
 
There was a significant correlation between percent change post exercise in macro-vascular 
endothelial function with plasma oxidative stress both pre (FORT: Rs = -0.468, p = 0.038; 
H2O2: Rs = -0.558, p = 0.011) and percentage change post-exercise (FORT: Rs = -0.0477, p 
= 0.034; H2O2: Rs = 0.522, p = 0.019). There was no correlation with post-exercise (FORT: 
Rs = -0.124, p = 0.6; H2O2: Rs = -0.124, p = 0.602)   
 
There was no correlation between change in macro-vascular endothelial function with pre, 
post or change post-exercise in oxidative defense (pre: Rs = 0.161, p = 0.497; post: Rs = 
0.268, p = 0.253; change post: Rs = 0.176, p = 0.458). 
 
There was significant correlation between percent change in macro-vascular endothelial 
function and percentage change post exercise in NAG/ Creatinine ratio (Rs = 0.563, p = 
0.019). There was no correlation between change in macro-vascular endothelial function with 
pre or post-exercise in kidney injury (pre: Rs = -0.277, p = 0.282; post: Rs = -0.010, p = 
0.970. 
 
There was no correlation between change in macro-vascular endothelial function post 
exercise with pre, post or change post-exercise in plasma MCP-1 (pre: Rs = 0.251, p = 0.286; 
post: Rs = 0.039, p = 0.870; change post: Rs = - 0.032, p = 0.895). 
 
4.5 Oxidative stress changes in claudicants following exercise 
 
 277 
 
Plasma oxidative stress as measured by the FORT test demonstrated that there was no 
significant change flowing exercise. Pre exercise levels were (FORT units; median, IQR) 
296.50, 243.25 to 425.50 and post were 303.5, 263 to 401.25 (p = 0.888). 
 
When the oxidative stress was measured in terms of H2O2, there was a similar picture of no 
significant difference. Pre (mmol/l; median; IQR): 2.19, 1.81 to 3.02 and post: 2.31, 2 – 3.1 
(p = 0.825). However, on inspecting the paired data points from the slope graphs (Figure 3-6 
and Figure 3-7), one can discern, again, heterogeneity in the response to exercise. 
4.6 Effects of resting oxidative stress on endothelial function, 
MCP-1 and kidney injury 
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FIGURE 4-1. FLOW CHART HIGHLIGHTING ASSOCIATIONS SEEN BETWEEN ABPI, MAXIMUM 
WALKING DISTANCE, PLASMA OXIDATIVE STRESS AND URINARY NAG/ CREATININE RATIO. 
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There was a negative correlation between the percent change post-exercise in plasma 
oxidative stress with pre-exercise macro-vascular endothelial function (FORT: Rs =  -0.468, 
p = 0.038; H2O2: Rs =  -0.537, p = 0.026). 
 
There was no association between macro-vascular endothelial function and pre (FORT: Rs = 
0.301, p = 0.198; H2O2: Rs = 0.120, p = 0.613) or post-exercise oxidative stress (FORT: Rs 
=0.259, p = 0.271; H2O2: Rs =0.044, p = 0.855) 
 
There was no association between micro-vascular endothelial function and pre (FORT: Rs =-
0.161, p = 0.618; H2O2: Rs = -0.161, p = 0.618), post-exercise oxidative stress (FORT: Rs =-
0.091, p = 0.779; H2O2: Rs =-0.091, p = 0.779) or percent change post exercise (FORT: Rs = 
0.049, p = 0.838; H2O2: Rs = -0.003, p = 0.990). 
 
There was a negative correlation between pre-exercise H2O2 and the percent change post-
exercise of NAG/ Creatinine ratio (Rs =  -0.468, p = 0.038). 
However, there was no association between pre-exercise FORT with NAG/ Creatinine ratio 
(Rs = -0.390, p = 0.122). In a murine model, it has been shown that tissues with higher levels 
of catalase (lung and vena cava c.f. aorta and myocardium) and hence low level of H2O2 had 
an attenuated up-regulation of eNOS in response to exercise. The dissimilarities were 
abolished by administration of a catalase inhibitor (Dao et al., 2011). Furthermore in another 
murine model, mice transfected with a gene to overexpress catalase in vascular tissue 
demonstrated no ability to up-regulate eNOS expression in response to exercise compared to 
wild type (Lauer et al., 2005). Our data provides further evidence of a protective role for 
endogenous H2O2 production. 
 
There was no association between pre-exercise plasma oxidative stress and NAG/creat ratio 
pre- (FORT: Rs = 0.002, p = 0.993; H2O2: Rs = 0.279, p = 0.277) or post-exercise (FORT: 
Rs =0.181, p = 0.486; H2O2: Rs =0.086, p = 0.743) 
 
There was no association between pre-exercise oxidative stress with pre (FORT: Rs = -0.271, 
p = 0.248; H2O2: Rs = -0.418, p = 0.067) post (FORT: Rs = -0.039, p = 0.870; H2O2: Rs = -
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0.080, p = 0.738), or percent change post-exercise (FORT: Rs = 0.232, p = 0.326; H2O2: Rs 
= 0.371, p = 0.107) of MCP-1. 
 
4.7 Effect of post exercise oxidative stress on endothelial 
function, kidney injury and MCP-1 
 
There was no association between post exercise oxidative stress (FORT: Rs = 0.252, p = 
0.285; H2O2: Rs = 0.252, p = 0.285) and pre-exercise macro-vascular endothelial function.  
 
Similarly there was no association between post exercise oxidative stress (FORT: Rs = 0.063, 
p = 0.793; H2O2: R =0.063, p = 0.793) with post-exercise macro-vascular endothelial 
function.  
 
There was no association between post-exercise oxidative stress and micro-vascular 
endothelial function pre (FORT: Rs = -0.165, p = 0.609; H2O2; Rs = -0.165, p = 0.609), post 
(FORT: Rs = 0.025, p = 0.940; H2O2: Rs = 0.025, p = 0.940) or percent change post-exercise 
(FORT: Rs = 0.215, p = 0.362; H2O2: Rs = 0.215, p = 0.362) 
 
There was no association between post-exercise oxidative stress with NAG/ Creatinine ratio 
pre (FORT: Rs = -0.229, p = 0.377; H2O2: Rs = -0.229, p = 0.377), post (FORT: R =-0.052, 
p = 0.844; H2O2: R =-0.052, p = 0.844) or percent change post exercise (FORT: Rs = -0.107, 
p = 0.683; H2O2: -0.107, p = 0.683) 
 
There was no association between post-exercise oxidative stress with MCP-1 pre- (FORT: Rs 
= -0.243, p = 0.303; H2O2; Rs = -0.243, p = 0.303), post- (FORT: Rs = -0.283, p = 0.226, 
H2O2: R = 0.283, p = 0.226) or percent change post-exercise (FORT: Rs = 0.156, p = 0.512; 
H2O2: Rs = 0.156, p = 0.512) 
 
 281 
 
4.8 Effect of change in oxidative stress post exercise on 
oxidative defense, endothelial function, kidney injury and 
MCP-1 
 
There was no association between percentage change post-exercise oxidative stress with 
oxidative defense pre- (FORT: Rs = -0.012, p = 0.960; H2O2: Rs = 0.071, p = 0.767), post- 
(FORT: Rs = -0.179, p = 0.449, H2O2: R = -0.024, p = 0.919) or percent change post-
exercise (FORT: Rs = -0.165, p = 0.486; H2O2: Rs = -0.046, p = 0.847) 
 
There was a significant correlation between percentage change post-exercise in oxidative 
stress with percentage change post-exercise in macro-vascular endothelial function (FORT: 
Rs = 0.477, p = 0.034; H2O2: Rs = 0.520, p = 0.019). However, there was no association 
between percentage change post-exercise oxidative stress with macro-vascular endothelial 
function pre- (FORT: Rs = -0.003, p = 0.990) or post-exercise (FORT: Rs = -0.099, p = 
0.677; H2O2: Rs =-0.003, p = 0.990). 
 
 
There was no association between percentage change post-exercise oxidative stress with 
micro-vascular endothelial function pre- (FORT: Rs = 0.217, p =0.499; H2O2: Rs = 0.224, p 
= 0.484), post- (FORT: Rs = 0.112, p = 0.729, H2O2: R = 0.119, p = 0.713) or percent 
change post-exercise (FORT: Rs = 0.098, p = 0.681; H2O2: Rs = 0.106, p = 0.658) 
 
There was a significant correlation between percent change post exercise in H2O2 and 
percent change in NAG/ Creatinine ratio post exercise (Rs = 0.507, p = 0.038), there was a 
tendency for significant also with FORT (Rs = 0.450, p = 0.07). However, there was no 
association between percentage change post-exercise oxidative stress with NAG/ Creatinine 
ratio pre- (FORT: Rs = -0.402, p = 0.109; H2O2: Rs = -0.422, p = 0.092) or post-exercise 
(FORT: Rs =-0.167, p = 0.522, H2O2: R = -0.074, p = 0.779). 
 
 
There was a significant correlation between the percent change post exercise of plasma 
oxidative stress with pre-exercise plasma MCP-1 levels in claudicants (FORT: Rs = 0.687, p 
= 0.000815; H2O2: Rs = 0.701, p = 0.000579). 
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There was no correlation between the percent change post-exercise of plasma oxidative stress 
with post- (FORT: R = 0.260, p = 0.268; H2O2: Rs = 0.256, p = 0.277) or percent change 
post-exercise MCP-1 (FORT: R = -0.301, p = 0.198; H2O2: R = -0.329, p = 0.156). 
 
4.9 Antioxidant defence in claudicants 
 
When comparing the plasma antioxidant defense reserve of claudicants, we found that there 
was no significant difference pre and post exercise. Pre (Trolox equivalents; median, IQR): 
0.96, 0.84 to 1.22 and post: 1, 0.43 to 1.32 (p = 0.575). Again when looking at paired 
individual data points in the slop graph (Figure 3-8), one can discern heterogeneity in the 
responses of individual claudicants to exercise. 
 
4.9.1. Effect of resting antioxidant defense on oxidative stress, 
endothelial function, kidney injury and MCP-1 
 
There was no correlation between pre-exercise plasma oxidative defense and pre- (FORT: -
0.090, p = 0.707; H2O2: Rs = 0.05, p = 0.818:), post- (FORT: -0.020, p = 0.932; H2O2: -
0.020, p = 0.932) or percent change post-exercise oxidative stress (FORT: Rs = -0.012, p = 
0.960; H2O2: Rs = -0.053, p = 0.823).  
 
There was no correlation between pre-exercise plasma oxidative defense and pre- (Rs = -
0.258, p = 0.272), post- (Rs = -0.169, p = 0.475) or percent change post-exercise macro-
vascular endothelial function (Rs = 0.161, p = 0.497). There was no correlation between pre-
exercise plasma oxidative defense and pre- (Rs = -0.245, p = 0.442), post- (Rs = 0.438, p = 
0.155) or percent change post-exercise micro-vascular endothelial function (Rs = 0.392, p = 
0.088).  
There was no correlation between pre-exercise plasma oxidative defense and pre- (Rs = -
0.206, p = 0.428), post- (Rs = -0.258, p = 0.318) or percent change post-exercise NAG/ 
Creatinine ratio (Rs = 0.260, p = 0.314).  
 
 283 
 
There was no correlation between pre-exercise plasma oxidative defense and pre- (Rs = 
0.061, p = 0.798), post- (Rs = -0.173, p = 0.465) or percent change post-exercise plasma 
MCP-1 (Rs = -0.152, p = 0.522).  
 
4.9.2. Effect of post-exercise antioxidant defense on oxidative 
stress, endothelial function, kidney injury and MCP-1 
 
There was no correlation between post-exercise plasma oxidative defense and pre- (FORT: 
0.285, p = 0.222; H2O2: Rs = 0.008, p = 0.972), post- (FORT: -0.024, p =0.919; H2O2: -
0.024, p = 0.919) or percent change post-exercise oxidative stress (FORT: Rs = -0.179, p = 
0.449; H2O2: Rs = -0.066, p = 0.784).  
 
There was no correlation between post-exercise plasma oxidative defense and pre- (Rs = 
0.066, p = 0.781), post- (Rs = 0.329, p = 0.156) or percent change post-exercise macro-
vascular endothelial function (Rs = 0.268, p = 0.253). There was no correlation between post-
exercise plasma oxidative defense and pre- (Rs = -0.417, p = 0.178), post- (Rs = 0.417, p = 
0.178) or percent change post-exercise micro-vascular endothelial function (Rs = 0.283, p = 
0.227).  
 
There was no correlation between post-exercise plasma oxidative defense and pre- (Rs = -
0.301, p = 0.240), post- (Rs = 0.144, p = 0.582) or percent change post-exercise NAG/ 
Creatinine ratio (Rs = -0.015, p = 0.955).  
 
There was a negative correlation between the post-exercise plasma oxidative defense and the 
post-exercise MCP-1 (Rs =  -0.481, p = 0.032). There was no correlation between post-
exercise plasma oxidative defense and pre- (Rs = -0.148, p = 0.532), percent change post-
exercise plasma MCP-1 (Rs = -0.314, p = 0.177). A case control study reports that free 
radical scavenging capacity is lower in claudicants as compared to controls (Edwards At Fau 
- Blann et al.). Although our data does not reproduce this finding, oxidative defense capacity 
correlated inversely with MCP-1 suggesting that oxidative defense is a factor in this complex 
process. 
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4.9.3. Effect of change in antioxidant defense post exercise on 
oxidative stress, endothelial function, kidney injury and MCP- 
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (FORT: 0.236, p = 0.316; H2O2: Rs = -0.032, p = 0.895), post- (FORT: -0.046, p = 
0.847; H2O2: -0.046, p = 0.847) or percent change post-exercise oxidative stress (FORT: Rs 
= -0.165, p = 0.486; H2O2: Rs = -0.068, p = 0.777).  
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (Rs = 0.174, p = 0.462), post- (Rs = 0.296, p = 0.205) or percent change post-exercise 
macro-vascular endothelial function (Rs = 0.176, p = 0.458). There was no correlation 
between percent change post-exercise plasma oxidative defense and pre- (Rs = -0.371, p = 
0.236), post- (Rs = 0.189, p = 0.557) or percent change post-exercise micro-vascular 
endothelial function (Rs = 0.098, p = 0.681).  
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (Rs = -0.086, p = 0.743), post- (Rs = 0.248, p = 0.338) or percent change post-exercise 
NAG/ Creatinine ratio (Rs = -0.233, p = 0.368).  
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (Rs = -0.247, p = 0.295), post- (Rs = -0.382, p = 0.097) or percent change post-exercise 
plasma MCP-1 (Rs = -0.161, p = 0.498).  
 
4.10 Kidney injury in claudicants following-exercise 
 
The plasma NAG/ Creatinine ratio was measured in claudicants pre and post exercise as a 
marker of acute kidney injury. Claudicants demonstrated a highly significant increase in 
NAG/ Creatinine ratio following exercise. Pre exercise levels were (µmol/L/mmol Cr; 
median, IQR): 8.94, 6.73 to 14.27 and post were: 12.90, 9.07 to 17.72 (p = 0.000293). Again, 
however, inspecting individual paired data points, one can discern heterogeneity in the 
responses to exercise (Figure 3-9). Similarly, Tisi et al., have demonstrated an increased in 
the albumin/ creatinine ratio following exercise in claudicants but not controls following 
maximal exercise (Tisi and Shearman, 1998b). However in a study comparing 20 patients 
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with intermittent claudication, stable for at least six month and 20 healthy controls, although 
claudicants had a higher level of plasma CRP and NAG/ Creatinine ratio than controls, 
exercise did not significantly increase either parameter (Collins et al., 2006). The seemingly 
discrepancy in findings may be a function of the ‘stable’ nature of the claudicants recruited in 
the work by Collins et al. Their chronic nature may represent an adaptation or a selection bias 
resulting from long-term survival. 
 
4.11 Plasma MCP-1 concentration in claudicants following-
exercise 
 
When comparing the effect of exercise on plasma MCP-1 levels pre and post exercise, no 
significant difference was found. The levels pre exercise were (pg/ ml; median; IQR): 88.41, 
69.34 to 119.43 and post were: 93.31, 70.6 to 48.49 (p = 0.601). Again, looking at individual 
paired data points in the slope graph (Figure 3-10), one can discern clear heterogeneity in the 
plasma MCP-1 response of individual claudicants to exercise. 
 
4.12 Effects of ABPI on oxidative stress and defense, 
endothelial function, kidney injury and plasma MCP-1 
 
4.12.1. Effect of ABPI on oxidative stress 
 
The lowest ABPI measured in the lower limbs of claudicants strongly correlated with the pre- 
exercise plasma oxidative stress measured in FORT units (Rs = 0.544, p = 0.013). 
 
However, there was a stronger correlation between the lowest ABPI versus post- exercise 
oxidative stress measured by FORT test (Rs = 0.736, p = 0.000218). 
 
This pattern was repeated when H2O2 was used as a measure of plasma oxidative stress 
(mm/L). Pre exercise plasma oxidative stress: Rs = 0.444, p = 0.05, post exercise oxidative 
stress: Rs = 0.736, p = 0.000218). 
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When correlating the average ABPI with pre- exercise plasma FORT, a significant but 
weaker association than  with lowest ABPI was found (Rs = 0.475, p = 0.043), similarly for 
post –exercise plasma FORT (Rs = 0.554, p = 0.011).  
 
Pre exercise plasma H2O2 did not correlate with average ABPI (Rs = 0.223, p = 0.346), 
however, post- exercise plasma H2O2 correlated with statistical significance but less strongly 
than the equivalent FORT correlation (Rs = 0.554, p = 0.011). 
 
There was, however, no association of lowest or average ABPI with change in oxidative 
stress by either measure following exercise (lowest ABPI: FORT; Rs = 0.164, p = 0.490, 
H2O2; Rs = 0.175, p = 0.462. Average ABPI: FORT; Rs = 0.220, p = 0.352, H2O2; Rs = 
0.283, p = 0.22). 
 
4.12.2. Effect of ABPI on anti-oxidant defense 
 
There was no correlation of lowest or average ABPI with plasma antioxidant defense 
capacity as measured by the FORD test (Trolox equivalents) . Correlations of lowest ABPI 
with pre, post and post – pre plasma FORD levels were: -0.3, p = 0.199; -0.124, p = 0.601; 
and 0.06, p = 0.801, respectively. Correlations of average ABPI with pre, post and post – pre 
plasma FORD levels were: -0.235, p = 0.319; 0.160, p = 0.501; and 0.220, p = 0.352, 
respectively. 
 
4.12.3. Effect of ABPI on endothelial function 
 
There was no correlation found between FMD (per cent change) pre exercise or percent 
change post – pre exercise. Pre (Lowest ABPI: Rs = 0.273, p = 0.244; Average ABPI: Rs = 
0.337, p = 0.146) or FMD per cent change (post – pre; Lowest ABPI: Rs = -0.181, p = 0.444; 
Average ABPI: -0.026, p = 0.915).  
 
However, although the lowest ABPI did not correlate with post exercise macro-vascular 
endothelial function (Rs = 0.286, p = 0.222), mean ABPI correlated well: Rs = 0.466, p = 
0.038. This may reflect that having a low average ABPI indicates a more systemic 
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manifestation of atherosclerosis, which may affect systemic endothelial function more 
obviously. 
 
There was no correlation in terms of micro-vascular endothelial function with lowest or 
average ABPI. Lowest ABPI: pre-exercise (Rs = -0.343, p = 0.275); post-exercise (Rs = 0.2, 
p = 0.534); % change following exercise (Rs = 0.173, p = 0.465. Average ABPI: pre-exercise 
(Rs = -0.364, p = 0.245); post-exercise (Rs = 0.301, p = 0.342); % change following exercise 
(Rs = 0.197, p = 0.406). 
 
4.12.4. Effect of ABPI on kidney injury 
 
There was no correlation of lowest or average ABPI with NAG/ Creatinine ratio. Lowest 
ABPI: Pre-exercise (Rs = -0.108, p = 0.680); post-exercise (Rs = -0.125, p = 0.633); % 
change post exercise (Rs = -0.326, p = 0.202). Average ABPI: Pre-exercise (Rs = -0.174, p = 
0.504); post-exercise (Rs = 0.015, p = 0.955); % change post exercise (Rs = -0.230, p = 
0.374). 
 
4.12.5. Effect of ABPI on plasma MCP-1 
 
There was no correlation of lowest or average ABPI with MCP-1. Lowest: pre-exercise (Rs = 
0.105, p = 0.661); post-exercise (Rs = 0.163, p = 0.494); % change post exercise (Rs = 0.167, 
p = 0.481). Average ABPI: pre-exercise (Rs = -0.174, p = 0.504); post-exercise (Rs = 0.015, 
p = 0.955); % change post exercise (Rs = -0.230, p = 0.374). 
 
4.13 Effect of maximum walking distance on endothelial 
function, oxidative stress and defense, kidney injury and 
MCP-1 
 
 
4.13.1. Effect of maximum walking distance on endothelial 
function 
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Maximum walking distance correlated significantly with percent change of endothelial 
function following exercise as measured by FMD (Rs = 0.515, p = 0.020). There was no 
correlation between distance travelled and pre- (R= 0.148, p = 0.533) or post-exercise (Rs = 
0.033, p = 0.890) macro-vascular endothelial function. 
 
Neither was there any correlation between maximum walking distance and micro-vascular 
endothelial function either pre- (Rs = -0.042, p = 0.897) or post-exercise (Rs = -0.182, p = 
0.57) or percent change post exercise (Rs = 0.128, p = 0.592) 
 
4.13.2. Effect of maximum walking distance on oxidative 
stress 
 
There was no correlation between maximum walking distance and pre, post, and percent 
change post exercise oxidative stress as measured by FORT (Pre-: Rs = 0.036, p = 0.880, 
Post-: Rs = -0.032, p = 0.892, and % change post- exercise: Rs = -0.115, p = 0.629) or H2O2 
(Pre-: Rs = -0.148, p = 0.533, Post-: Rs = -0.032, p = 0.892, p = 0.892, and % change post- 
exercise: Rs = -0.023, p = 0.925) 
 
4.13.3. Effect of maximum walking distance on oxidative 
defense 
 
There was no correlation between maximum walking distance and pre, post, and percent 
change post exercise anti-oxidant defense as measured by FORD (Pre-: Rs = 0.255, p = 
0.278, Post-: Rs = 0.152, p = 0.524, p = 0.892, and % change post- exercise: Rs = -0.110, p = 
0.645).  
 
4.13.4. Effect of maximum walking distance on kidney injury 
 
Maximum walking distance correlated with percent change in NAG/ Creatinine ratio, the 
association just fell short of significant at the 95% confidence level (Rs = 0.471, p = 0.056). 
There was a tendency for association of maximum walking distance with post-exercise NAG/ 
Creatinine ratio (Rs = -0.136, p = 0.062), whereas there was no correlation with post-exercise 
NAG/ Creatinine ratio (Rs = 0.153, p = 0.556). 
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4.13.5. Effect of maximum walking distance on MCP-1 
 
There was no correlation between maximum walking distance and pre, post, and percent 
change post exercise of plasma MCP-1 levels (Pre-: Rs = -0.273, p = 0.244, Post-: Rs = 
0.029, p = 0.905, p = 0.892, and % change post- exercise: Rs = 0.389, p = 0.09)  
4.14 Acute post-exercise rise in NAG/ Creatinine ratio as a 
differentiator of patients with intermittent claudication 
 
The claudicants cohort was segregated into those with a rise in NAG/ Creatinine ratio post 
exercise versus those who did not. It was found the group who had a rise in NAG/ Creatinine 
ratio had greater ability to increase endothelial reactivity (%; median, IQR; 0.09, -4.82 to 
0.91) than those without a rise (2.56, 0.13 to 3.698, p = 0.027). 
 
 
Similarly, the group with a rise in NAG/ Creatinine ratio post exercise were able to walk 
further (metres; median, IQR; 415, 207.5 to 908) compared to those without a rise (170, 100 
to 315, p = 0.043). 
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Also, the group with a rise in NAG/ Creatinine ratio post exercise had a significantly lower 
pre-exercise H2O2 (median, IQR; 1.85, 1.385 to 2.268 cf. 2.74, 2.085 to 3.295) as well as a 
significantly greater rise in H2O2 post exercise (18.75, -1.53 to 129.68 cf., -7.72, -13.85 to -
1.97, p = 0.043). Studies from transgenic mice over-expressing catalase have demonstrated a 
role for basal H2O2 expression in maintenance of arterial tone (Suvorava et al., 2005). 
 
 
 
 
 
⇧ NAG/ 
Creatinine ratio 
post exercise
⇧percent change 
macro-vascular 
endothelial 
function post-
exercise
⇧maximum 
walking distance
⇩pre-exercise 
H2O2
⇧percent change 
H2O2 post 
exercise
FIGURE 4-2. CHARACTERISTIC FEATURES OF THE GROUP OF CLAUDICANTS WITH A RISE IN 
NAG/ CREATININE RATIO FOLLOWING EXERCISE. 
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5. Conclusions 
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We have established that in the patients with intermittent lower limb claudication sampled in 
this study that a higher ABPI is associated with an increased resting plasma oxidative stress 
level. It has been previously reported that patients with peripheral vascular disease have an 
elevation in serum markers of oxidative stress, which can be improved with administration of 
antioxidants (Loffredo et al., 2007). However, we report that the basal level of oxidative 
stress level is associated with a decrease in the amount of increase in acute kidney injury as 
measured by urinary NAG/ Creatinine ratio.  
 
We have also established that the percentage change in oxidative stress post exercise from 
basal levels correlates with the percentage change in endothelial reactivity post exercise (i.e. 
absence of decrease). Both percentage change in oxidative stress and endothelial reactivity 
post-exercise are associated with increased acute kidney injury. Endothelial dysfunction has 
been reported to exist in young hypertensive and non-hypertensive men, suggesting that there 
may be phenotypic variation in the population rather than dysfunction being simply a 
consequence of oxidative stress (Doroszko et al., 2011). 
 
Others have previously shown that exercise in claudication is associated with an increase in 
renal endothelial permeability. (Tisi and Shearman, 1998b). We have established that there is 
a phenotypically distinct subgroup of claudicants who have an increase in kidney injury post 
exercise. Here, the basal oxidative stress levels are lower than claudicants without such a 
pattern of acute kidney injury. Also, these claudicants have a longer walking distance, and 
higher post-exercise increase in oxidative stress and macro-vascular endothelial function. 
 
This subgroup may be inducing acute kidney injury via an exaggerated generation of reactive 
oxygen species post exercise or via a decrease in production of anti-oxidant defense. Previous 
studies have reported a decrease in the activity of plasma glutathione peroxidase in 
claudicants compared to controls (Edwards At Fau - Blann et al.).  
 
Both arterial bypass surgery and angioplasty have been shown to reduce the exercise induced 
systemic inflammatory response associated with claudication (Hickey et al., 1990, Lewis et 
al., 2001, Husmann et al., 2008). Previously, hyper-homocyteinaemia has been purported as a 
potential mechanistic factor in the development of endothelial dysfunction and progression of 
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atherosclerosis. Recently data has emerged suggesting that antioxidants can reverse the 
systemic endothelial dysfunction seen in patients with coronary artery disease independently 
of homocyteine levels (Doshi et al., 2001, Bennett-Richards et al., 2002). A randomized 
controlled trial in claudicants has also demonstrated that vitamin C administration abolishes 
the exercised induced decrease in endothelial function caused by maximal exercise (Silvestro 
et al., 2002a). Endothelial dysfunction has previously been through to be largely related to 
nitric oxide availability (Joannides et al., 1995), however more recently it has been 
demonstrated that NOX-2 (catalytic subunit of NADPH oxidase) up-regulation is responsible 
for oxidative stress mediated endothelial dysfunction in claudicants. This effect was reversed 
by the administration of antioxidants (Loffredo et al., 2007). Increased levels of NOX-2 have 
been associated with increased anterograde/ retrograde and oscillatory shear stress across 
vascular endothelium, again an effect attenuated by antioxidants (Hwang et al., 2003, De 
Keulenaer et al., 1998). 
 
A possible overarching mechanism arises where a low resting oxidative stress relates to an 
attenuated ability to respond to the increased oxidative burden associated with maximal 
exercise. This ability may be mediated by NOS up-regulation (Lauer et al., 2005). Increasing 
production of reactive oxygen species leads to the oxidation of BH4 to BH3 radicals (Laursen 
et al., 2001, Landmesser et al., 2003). Low BH4 bioavailability uncouples eNOS thereby 
reducing eNOS function and augmenting eNOS superoxide production (Forstermann and 
Munzel, 2006). Others have reported that hydrogen peroxide increases the expression and 
activity of eNOS in endothelial cells and that increased eNOS activity is thought to be an 
acute cellular adaptation to an increase in oxidant stress(Suvorava and Kojda, 2009). This 
group also report that basal levels of hydrogen peroxide are required to produce essential 
vascular tone. A possible theoretical framework would involve ‘vulnerable’ claudicants not 
upregulating some anti-oxidant defeence mechanism by lack of basal hydrogen peroxide 
release. 
 
Recently much interest has been shown in the anti-oxidant response proteins including haem 
oxygenase-1 (Balla et al., 2003). Up regulation of haem oxygenase 1 has been seen in the 
endothelium in the early stage of progression of atherosclerotic lesions (Juckett et al., 1995) 
(Wang et al., 1998). Progression of atherosclerosis in those who develop worsening 
peripheral vascular disease may be a consequence of inadequacy or failure to up-regulate 
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these ant-oxidant/ anti-inflammatory mechanisms (Bauer et al., 2003). Upregulation of anti-
oxidant response proteins may be ameriliorate the effects of reactive oxygen species toxicity 
 
A previous study has shown that pre and post exercise endothelial dysfunction induced by 
maximal treadmill exercise improved following six weeks of supervised exercise (Andreozzi 
et al., 2007a). However there is as yet no data regarding end organ injury nor any 
consideration to the phenotypically distinct group identified in this study. 
 
According to Suvorava and Kojda repeated short terms bouts of oxidative stress may cause 
the up-regulation of anti-oxidant protein expression in the vascular wall eventually increasing 
its antioxidant capacity (Suvorava and Kojda, 2007). A case control study compared pro-
inflammatory cytokine levels in patients with moderate and severe intermittent claudication 
to healthy controls before and after exercise. This study demonstrated a rise in cytokine levels 
post exercise in all groups, also, most in the severe group and some in the moderate group 
exhibited a continued rise in cytokine levels in the resting period (Andreozzi et al., 2007b). 
This finding may support the notion that certain individuals may not be able to cope with 
increased oxidative stress and these people may be prone to worsening of atherosclerotic 
lesions. The previous dogma of treating claudication in five words “stop smoking and keep 
walking” (Housley) may not be the best management for all claudicants. Further phenotypic 
and genotypic characterization is required. 
 
Monocytes-macrohphages are crucial in the pathogensis of atherosclerosis (Mantovani et al., 
2004, Shalhoub et al., 2011). It has been reported that c-reactive peptide, a marker of 
systemic inflammation, is associated with a polarisation towards the pro-inflammatory (M1) 
monocyte phenotype (Devaraj and Jialal, 2011). Future work may investigate the association 
between oxidative stress, monocyte-macrophage phenotype and iscaemia reperfusion injury. 
 
With the increased uptake of ‘Best Medical Therapy’ for cardiovascular disease in patients 
with atherosclerosis, there seems to have been a decline in incidence of ischaemic strokes 
(Naylor, 2012). This reduction in incidence is thought to be mediated by plaque stabilisation. 
The effect of statins is thought to be modulated by anti-palatelet use in a complex manner (Ye 
et al., 2010). In a rat model, statins have been shown to increase tissue levels of the 
cytoprotective Haemoxygenase 1 and reduce renal ischaemia-reperfusion injury by 
upregulated production in infiltrating monocytes (Gueler et al., 2007). Although it is beyond 
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the scope of this study to formally investigate, there are similar prevalances of antiplatelet 
agent and statin usage in claudicants who suffered a NAG/ Creatinine ratio rise compated to 
those without a rise (Table 15). It has been shown that in a rat model, statin administration 
reduced the degree of renal ischaemia reperfusion injury following renal artery clipping 
(Gueler et al., 2002). However, it has been demonstrated that administration of either lipo- or 
hydro-philic statins do not modulate the effect of ischaemia reperfusion injury on brachial 
artery FMD in healthy volunteers (Wouters et al., 2012). Of additional note, reduction in 
infarct size may well be associated with short term use, and these protective effects may be 
lost in chronic use (Schulz, 2005). 
 
The identification of two distinct phenotypes in patietns with intermitted claudication offers a 
new prospect deciphering the complex associations between ischaemia-reperfusion injury, 
systemic cytokine release, endothelial function, monocyte-macrophage phenotype and end 
organ injury. Whole genome analysis using high throughput technology may help in 
revealing insight into this complex interplay(Fülöp and Falus, 2004). At the heart of the 
matter, so to speak, is the implication that repeated bouts of ischaemia-reperfusion are 
responsible for end organ injury. The data presented in this study support the setting up of a 
trial to establish if revascularisation of ‘vulnerable’ patients with intermitted claudication is 
protective against ischaemia-reperfusion mediated end organ injury and mortality. 
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FIGURE 5-1. SCHEMA DESSCRIBING POSSIBLE ROLE OF PRE-EXERCISE OXIDATIVE STRESS CAUSING 
ALTERATION IN CHANGE IN ENDOTHELIAL FUNCTION AND OXIDATIVE STRESS POST EXERCISE AND 
RESULTING IN INCREASED ACUTE KIDNEY INJURY. 
 
 
 297 
 
6. References 
 
AIKAWA, N., FUJISHIMA, S., SHINOZAWA, Y. & HORI, S. 1996. [Cytokine-mediated 
biological response to severe infections in surgical patients]. Nippon Geka Gakkai 
Zasshi, 97, 1054-1059. 
AKCAKOYUN, M., KARGIN, R., TANALP, A. C., PALA, S., OZVEREN, O., AKCAY, 
M., BARUTCU, I. & KIRMA, C. 2008. Predictive value of noninvasively determined 
endothelial dysfunction for long-term cardiovascular events and restenosis in patients 
undergoing coronary stent implantation: a prospective study. Coron.Artery Dis., 19, 
337-343. 
ALAM, T. A., SEIFALIAN, A. M. & BAKER, D. 2005. A review of methods currently used 
for assessment of in vivo endothelial function. Eur.J.Vasc.Endovasc.Surg., 29, 269-
276. 
ALDERTON, W. K., COOPER, C. E. & KNOWLES, R. G. 2001. Nitric oxide synthases: 
structure, function and inhibition. Biochem J, 357, 593-615. 
ALEXANDROVA, M., BOCHEV, P., MARKOVA, V., BECHEV, B., POPOVA, M., 
DANOVSKA, M. & SIMEONOVA, V. 2004. Dynamics of free radical processes in 
acute ischemic stroke: influence on neurological status and outcome. Journal of 
Clinical Neuroscience, 11, 501-506. 
ALLAN, P. D., PA; POZNIAK, MA 1997. Clinical Doppler Ultrasound. 1 ed. Churchill 
Livingstone. 
ALLISON, M. A., CRIQUI, M. H., MCCLELLAND, R. L., SCOTT, J. M., MCDERMOTT, 
M. M., LIU, K., FOLSOM, A. R., BERTONI, A. G., SHARRETT, A. R., HOMMA, 
S. & KORI, S. 2006. The effect of novel cardiovascular risk factors on the ethnic-
specific odds for peripheral arterial disease in the Multi-Ethnic Study of 
Atherosclerosis (MESA). J Am Coll Cardiol, 48, 1190-7. 
AMSTAD, P., CRAWFORD, D., MUEHLEMATTER, D., ZBINDEN, I., LARSSON, R. & 
CERUTTI, P. 1990. Oxidants stress induces the proto-oncogenes, C-fos and C-myc in 
mouse epidermal cells. Bull Cancer, 77, 501-2. 
ANDERSON, I. 2002. The effect of varying cuff position on recording ankle systolic blood 
pressure. J Wound Care, 11, 185-9. 
ANDREOZZI, G. M., LEONE, A., LAUDANI, R., DEINITE, G. & MARTINI, R. 2007a. 
Acute impairment of the endothelial function by maximal treadmill exercise in 
patients with intermittent claudication, and its improvement after supervised physical 
training. Int.Angiol., 26, 12-17. 
ANDREOZZI, G. M., MARTINI, R., CORDOVA, R., D'ERI, A., SALMISTRARO, G., 
MUSSAP, M. & PLEBANI, M. 2007b. Circulating levels of cytokines (IL-6 and IL-
1beta) in patients with intermittent claudication, at rest, after maximal exercise 
treadmill test and during restore phase. Could they be progression markers of the 
disease? Int.Angiol., 26, 245-252. 
ANGGARD, E. E. 1990. The endothelium--the body's largest endocrine gland? J Endocrinol, 
127, 371-5. 
ANNANE, D., BELLISSANT, E. & CAVAILLON, J.-M. 2005. Septic shock. Lancet, 365, 
63-78. 
ARUMUGAM, T. V., SHIELS, I. A., WOODRUFF, T. M., GRANGER, D. N. & TAYLOR, 
S. M. 2004. The role of the complement system in ischemia-reperfusion injury. Shock, 
21, 401-9. 
ASHIHARA, Y. K., Y; MAKAMURA, RM. Immunoassays an immunocytochemistry. . 
 298 
 
ASIMAKOPOULOS, G. 1999. Mechanisms of the systemic inflammatory response. 
Perfusion, 14, 269-77. 
AVERKIOU, M., POWERS, J., SKYBA, D., BRUCE, M. & JENSEN, S. 2003. Ultrasound 
contrast imaging research. Ultrasound Q, 19, 27-37. 
BALABAN, R. S., NEMOTO, S. & FINKEL, T. 2005. Mitochondria, oxidants, and aging. 
Cell, 120, 483-95. 
BALLA, J., VERCELLOTTI, G. M., NATH, K., YACHIE, A., NAGY, E., EATON, J. W. & 
BALLA, G. 2003. Haem, haem oxygenase and ferritin in vascular endothelial cell 
injury. Nephrol.Dial.Transplant., 18 Suppl 5, v8-12. 
BARCHOWSKY, A., MUNRO, S. R., MORANA, S. J., VINCENTI, M. P. & 
TREADWELL, M. 1995. Oxidant-sensitive and phosphorylation-dependent 
activation of NF-kappa B and AP-1 in endothelial cells. American Journal of 
Physiology - Lung Cellular and Molecular Physiology, 269, L829-L836. 
BARNES, P. J. & KARIN, M. 1997. Nuclear factor-kappaB: a pivotal transcription factor in 
chronic inflammatory diseases. N Engl J Med, 336, 1066-1071. 
BAUER, I., RENSING, H., FLORAX, A., ULRICH, C., PISTORIUS, G., REDL, H. & 
BAUER, M. 2003. Expression pattern and regulation of heme oxygenase-1/heat shock 
protein 32 in human liver cells. Shock, 20, 116-22. 
BAXTER, G. M. & POLAK, J. F. 1993. Lower limb colour flow imaging: a comparison with 
ankle: brachial measurements and angiography. Clin.Radiol., 47, 91-95. 
BEADLING, W. C., L; HENRY, JB. Immunohepatology. 
BEARD, J. D. 2000. ABC of arterial and venous disease: Chronic lower limb ischaemia. 
BMJ, 320, 854-7. 
BEARD, J. G., PA. 2004. Vascular and Endovascular Surgery, A Companion to Specialist 
Surgical Practice. 2 ed. Philadelphia: Elsevier. 
BECKER, B. F., KUPATT, C., MASSOUDY, P. & ZAHLER, S. 2000. Reactive oxygen 
species and nitric oxide in myocardial ischemia and reperfusion. Z Kardiol, 89 Suppl 
9, 88-91. 
BECKER, L. B. 2004. New concepts in reactive oxygen species and cardiovascular 
reperfusion physiology. Cardiovasc Res, 61, 461-70. 
BENDERMACHER BLW, W. E., TEIJINK JAW, PRINS MH 2006. Supervised exercise 
therapy versus non-supervised exercise therapy for intermittent claudication. 
Cochrane Database of Systematic Reviews. 
BENNETT-RICHARDS, K., KATTENHORN, M., DONALD, A., OAKLEY, G., 
VARGHESE, Z., REES, L. & DEANFIELD, J. E. 2002. Does oral folic acid lower 
total homocysteine levels and improve endothelial function in children with chronic 
renal failure? Circulation, 105, 1810-5. 
BHUNIA, A. K., HAN, H., SNOWDEN, A. & CHATTERJEE, S. 1997. Redox-regulated 
signaling by lactosylceramide in the proliferation of human aortic smooth muscle 
cells. J Biol Chem, 272, 15642-9. 
BLISS, M. R. 1998. Hyperaemia. J Tissue Viability, 8, 4-13. 
BLOMLEY, M. J., COOKE, J. C., UNGER, E. C., MONAGHAN, M. J. & COSGROVE, D. 
O. 2001. Microbubble contrast agents: a new era in ultrasound. BMJ, 322, 1222-1225. 
BOAZ, M., SMETANA, S., WEINSTEIN, T., MATAS, Z., GAFTER, U., IAINA, A., 
KNECHT, A., WEISSGARTEN, Y., BRUNNER, D., FAINARU, M. & GREEN, M. 
S. 2000. Secondary prevention with antioxidants of cardiovascular disease in endstage 
renal disease (SPACE): randomised placebo-controlled trial. Lancet, 356, 1213-8. 
BOGATCHEVA, N. V., GARCIA, J. G. N. & VERIN, A. D. 2002. Molecular mechanisms 
of thrombin-induced endothelial cell permeability. Biochemistry (Mosc), 67, 75-84. 
 299 
 
BOHRER, H., QIU, F., ZIMMERMANN, T., ZHANG, Y., JLLMER, T., MANNEL, D., 
BOTTIGER, B. W., STERN, D. M., WALDHERR, R., SAEGER, H. D., ZIEGLER, 
R., BIERHAUS, A., MARTIN, E. & NAWROTH, P. P. 1997. Role of NFkappaB in 
the mortality of sepsis. J.Clin.Invest, 100, 972-985. 
BONGARD, O. & FAGRELL, B. 1990. Discrepancies between total and nutritional skin 
microcirculation in patients with peripheral arterial occlusive disease (PAOD). Vasa, 
19, 105-11. 
BONVENTRE, J. V. & ZUK, A. 2004. Ischemic acute renal failure: an inflammatory 
disease? Kidney Int, 66, 480-485. 
BOSOMWORTH, M. P., APARICIO, S. R. & HAY, A. W. 1999. Urine N-acetyl-beta-D-
glucosaminidase--a marker of tubular damage? Nephrol Dial Transplant, 14, 620-6. 
BRAUNWALD, E. 1997. Shattuck lecture--cardiovascular medicine at the turn of the 
millennium: triumphs, concerns, and opportunities. N Engl J Med, 337, 1360-9. 
BRAVERMAN, I. M. 1989. Ultrastructure and organization of the cutaneous 
microvasculature in normal and pathologic states. J.Invest Dermatol., 93, 2S-9S. 
BRAVERMAN, I. M. 2000a. The cutaneous microcirculation. 
J.Investig.Dermatol.Symp.Proc., 5, 3-9. 
BRAVERMAN, I. M. 2000b. The cutaneous microcirculation. J Investig Dermatol Symp 
Proc, 5, 3-9. 
BRAVERMAN, I. M. & SCHECHNER, J. S. 1991. Contour mapping of the cutaneous 
microvasculature by computerized laser Doppler velocimetry. J Invest Dermatol, 97, 
1013-8. 
BRAVERMAN, I. M., SCHECHNER, J. S., SILVERMAN, D. G. & KEH-YEN, A. 1992. 
Topographic mapping of the cutaneous microcirculation using two outputs of laser-
Doppler flowmetry: flux and the concentration of moving blood cells. Microvasc Res, 
44, 33-48. 
BRAVERMAN, I. M. & YEN, A. 1977. Ultrastructure of the human dermal 
microcirculation. II. The capillary loops of the dermal papillae. J.Invest Dermatol., 
68, 44-52. 
BREALEY, D., BRAND, M., HARGREAVES, I., HEALES, S., LAND, J., SMOLENSKI, 
R., DAVIES, N. A., COOPER, C. E. & SINGER, M. 2002. Association between 
mitochondrial dysfunction and severity and outcome of septic shock. Lancet, 360, 
219-223. 
BULHAK AA FAU - SJOQUIST, P. O., SJOQUIST PO FAU - XU, C. B., XU CB FAU - 
EDVINSSON, L., EDVINSSON L FAU - PERNOW, J. & PERNOW, J. Protection 
against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related 
to production of nitric oxide and endothelin-1. 
BUND, S. J., WEST, K. P. & HEAGERTY, A. M. 1991. Effects of protection from pressure 
on resistance artery morphology and reactivity in spontaneously hypertensive and 
Wistar-Kyoto rats. Circ Res, 68, 1230-40. 
BUTLER, A. R., FLITNEY, F. W. & WILLIAMS, D. L. 1995. NO, nitrosonium ions, 
nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. 
Trends Pharmacol Sci, 16, 18-22. 
C, D. 1842. Über das farbige Licht der Doppelsterne und einiger anderer Gestirne des 
Himmels. Abhandlungen der k. bohm, 2, 465-482. 
C, M. 1983. The Cutaneous Arteries of the Human Body. New York: Springer-Verlag. 
CALVANO, J. E., UM, J. Y., AGNESE, D. M., HAHM, S. J., KUMAR, A., COYLE, S. M., 
CALVANO, S. E. & LOWRY, S. F. 2003. Influence of the TNF-alpha and TNF-beta 
polymorphisms upon infectious risk and outcome in surgical intensive care patients. 
Surg.Infect.(Larchmt.), 4, 163-169. 
 300 
 
CAO, G. & PRIOR, R. L. 1998. Comparison of different analytical methods for assessing 
total antioxidant capacity of human serum. Clinical Chemistry, 44, 1309-1315. 
CAO, Y., HONG, A., SCHULTEN, H. & POST, M. J. 2005. Update on therapeutic 
neovascularization. Cardiovasc Res, 65, 639-648. 
CARDEN, D. L. & GRANGER, D. N. 2000. Pathophysiology of ischaemia-reperfusion 
injury. J Pathol, 190, 255-266. 
CARLSEN, H., ALEXANDER, G., AUSTENAA, L. M., EBIHARA, K. & BLOMHOFF, R. 
2004. Molecular imaging of the transcription factor NF-kappaB, a primary regulator 
of stress response. Mutat Res, 551, 199-211. 
CARPENTER, A. Antibody-based methods. . 
CASPARY L, C. A., ALEXANDER K 1988. Biological zero in laser Doppler fluximetry. Int 
J Microcirc Clin Exp, 7, 367-371. 
CAVAILLON, J. M., DIB-CONQUY, M., CLOEZ-TAYARANI, I. & FITTING, C. 2001. 
Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not 
a generalized phenomenon: a review. J.Endotoxin.Res., 7, 85-93. 
CECONI, C., CARGNONI, A., PASINI, E., CONDORELLI, E., CURELLO, S. & 
FERRARI, R. 1991. Evaluation of phospholipid peroxidation as malondialdehyde 
during myocardial ischemia and reperfusion injury. Am J Physiol, 260, H1057-61. 
CESARI, M., PENNINX, B. W. J. H., NEWMAN, A. B., KRITCHEVSKY, S. B., 
NICKLAS, B. J., SUTTON-TYRRELL, K., TRACY, R. P., RUBIN, S. M., HARRIS, 
T. B. & PAHOR, M. 2003. Inflammatory markers and cardiovascular disease (The 
Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol, 92, 522-
528. 
CHAMOUN, F., BURNE, M., O'DONNELL, M. & RABB, H. 2000. Pathophysiologic role 
of selectins and their ligands in ischemia reperfusion injury. Front Biosci, 5, E103-9. 
CHARKOUDIAN, N. 2003. Skin blood flow in adult human thermoregulation: how it works, 
when it does not, and why. Mayo Clin Proc, 78, 603-12. 
CHEADLE, W. G., MERCER-JONES, M., HEINZELMANN, M. & POLK, H. C., JR. 1996. 
Sepsis and septic complications in the surgical patient: who is at risk? Shock, 6 Suppl 
1, S6-S9. 
CHEESEMAN, K. H. & SLATER, T. F. 1993. An introduction to free radical biochemistry. 
Br Med Bull, 49, 481-93. 
CHILD, N. J., YANG, I. A., PULLETZ, M. C., DE COURCY-GOLDER, K., ANDREWS, 
A. L., PAPPACHAN, V. J. & HOLLOWAY, J. W. 2003. Polymorphisms in Toll-like 
receptor 4 and the systemic inflammatory response syndrome. Biochem.Soc.Trans., 
31, 652-653. 
CHRIST, F., GAMBLE, J., GARTSIDE, I. B. & KOX, W. J. 1998. Increased microvascular 
water permeability in patients with septic shock, assessed with venous congestion 
plethysmography (VCP). Intensive Care Med, 24, 18-27. 
CHRISTMAN, J. W., LANCASTER, L. H. & BLACKWELL, T. S. 1998. Nuclear factor 
kappa B: a pivotal role in the systemic inflammatory response syndrome and new 
target for therapy. Intensive Care Med., 24, 1131-1138. 
CLARK, A. N., YOUKEY, R., LIU, X., JIA, L., BLATT, R., DAY, Y. J., SULLIVAN, G. 
W., LINDEN, J. & TUCKER, A. L. 2007. A1 adenosine receptor activation promotes 
angiogenesis and release of VEGF from monocytes. Circ Res, 101, 1130-8. 
CLEMENT, D. L. 2000. Medical treatment of peripheral artery occlusive disease (PAOD). 
Acta Chir Belg, 100, 190-3. 
COCHRANE T, S. S., BOULTON AJM, WARD JD, ATKINS RM 1986. Laser Doppler 
flowmetry: in the assessment of peripheral vascular disorders? A perliminary 
evaluation. Clin Physiol: Physiol Meas, 7, 31-42. 
 301 
 
COLANTUONI A, B. S., INTAGLIETTA M 1984. Quantitation of rhythmic diameter 
changes in arterial microcirculation. Am J Physiol, 246, H508-17. 
COLEMAN, H. A., TARE, M. & PARKINGTON, H. C. 2004. Endothelial potassium 
channels, endothelium-dependent hyperpolarization and the regulation of vascular 
tone in health and disease. Clin Exp Pharmacol Physiol, 31, 641-9. 
COLLINS, P., FORD, I., CROAL, B., BALL, D., GREAVES, M., MACAULAY, E. & 
BRITTENDEN, J. 2006. Haemostasis, inflammation and renal function following 
exercise in patients with intermittent claudication on statin and aspirin therapy. 
Thrombosis Journal, 4, 1-8. 
COMMONER, B., TOWNSEND, J. & PAKE, G. E. 1954. Free radicals in biological 
materials. Nature, 174, 689-91. 
COOLEN, S. A., WIJNEN, M. H., REIJENGA, J. C., VADER, H. L., ROUMEN, R. M. & 
HUF, F. A. 2002. A new method for measuring oxidative stress in claudicants during 
strenuous exercise using free radical derivatives of antipyrine as indicators: a pilot 
study. Ann Clin Lab Sci, 32, 181-7. 
COOPER, G. 2000. The Cell: A molecular Approach. . 2 ed. Sunderland: Sinauer Associates. 
COPPACK, S. W. 2001. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc, 60, 
349-356. 
CORRETTI, M. C., ANDERSON, T. J., BENJAMIN, E. J., CELERMAJER, D., 
CHARBONNEAU, F., CREAGER, M. A., DEANFIELD, J., DREXLER, H., 
GERHARD-HERMAN, M., HERRINGTON, D., VALLANCE, P., VITA, J. & 
VOGEL, R. 2002. Guidelines for the ultrasound assessment of endothelial-dependent 
flow-mediated vasodilation of the brachial artery: a report of the International 
Brachial Artery Reactivity Task Force. J.Am.Coll.Cardiol., 39, 257-265. 
CREUTZIG A, C. L., HERTEL RF, ALEXANDER K 1987. Temperature-dependent laser 
Doppler fluximetry in healthy and patients with peripheral arterial occlusive disease. 
Int J Microcirc Clin Exp, 6, 381-90. 
CRIQUI, M. H. 2001. Peripheral arterial disease--epidemiological aspects. Vasc Med, 6, 3-7. 
CUONG DV FAU - KIM, N., KIM N FAU - YOUM, J. B., YOUM JB FAU - JOO, H., JOO 
H FAU - WARDA, M., WARDA M FAU - LEE, J.-W., LEE JW FAU - PARK, W. 
S., PARK WS FAU - KIM, T., KIM T FAU - KANG, S., KANG S FAU - KIM, H., 
KIM H FAU - HAN, J. & HAN, J. Nitric oxide-cGMP-protein kinase G signaling 
pathway induces anoxic preconditioning through activation of ATP-sensitive K+ 
channels in rat hearts. 
DAGHER, P. C. 2004. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. 
Kidney Int, 66, 506-509. 
DAHLBACK, B. 2005. Blood coagulation and its regulation by anticoagulant pathways: 
genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med, 257, 209-
223. 
DAO, V. T., FLOEREN, M., KUMPF, S., BOTH, C., PETER, B., BALZ, V., SUVORAVA, 
T. & KOJDA, G. 2011. Catalase activity prevents exercise-induced up-regulation of 
vasoprotective proteins in venous tissue. J Cell Mol Med, 15, 2326-34. 
DE HARO, J., ACIN, F., LOPEZ-QUINTANA, A., MEDINA, F. J., MARTINEZ-
AGUILAR, E., FLOREZ, A. & MARCH, J. R. 2008. Direct association between C-
reactive protein serum levels and endothelial dysfunction in patients with 
claudication. Eur J Vasc Endovasc Surg, 35, 480-6. 
DE, H. J., ACIN, F., LOPEZ-QUINTANA, A., MEDINA, F. J., MARTINEZ-AGUILAR, E., 
FLOREZ, A. & MARCH, J. R. 2007. Direct Association between C-reactive Protein 
Serum Levels and Endothelial Dysfunction in Patients with Claudication. 
Eur.J.Vasc.Endovasc.Surg. 
 302 
 
DE KEULENAER, G. W., CHAPPELL, D. C., ISHIZAKA, N., NEREM, R. M., 
ALEXANDER, R. W. & GRIENDLING, K. K. 1998. Oscillatory and steady laminar 
shear stress differentially affect human endothelial redox state: role of a superoxide-
producing NADH oxidase. Circ Res, 82, 1094-101. 
DE WIT, C., BOLZ, S. S. & POHL, U. 2000. Interaction of endothelial autacoids in 
microvascular control. Z Kardiol, 89 Suppl 9, 113-116. 
DEL, G. R., LEONARDO, G. & ARPAIA, M. R. 1986. Evaluation of postischemic 
hyperemia on the skin using laser Doppler velocimetry: study on patients with 
claudicatio intermittens. Microvasc.Res., 32, 289-299. 
DEPALMA, R. G., HAYES, V. W., CAFFERATA, H. T., MOHAMMADPOUR, H. A., 
CHOW, B. K., ZACHARSKI, L. R. & HALL, M. R. 2003. Cytokine signatures in 
atherosclerotic claudicants. J Surg Res, 111, 215-21. 
DEVARAJ, S. & JIALAL, I. 2011. C-Reactive Protein Polarizes Human Macrophages to an 
M1 Phenotype and Inhibits Transformation to the M2 Phenotype. Arterioscler 
Thromb Vasc Biol, 31, 1397-1402. 
DEVASAGAYAM, T. P., TILAK, J. C., BOLOOR, K. K., SANE, K. S., GHASKADBI, S. 
S. & LELE, R. D. 2004. Free radicals and antioxidants in human health: current status 
and future prospects. J Assoc Physicians India, 52, 794-804. 
DINARELLO, C. A. 2005. Interleukin-1beta. Crit Care Med., 33, S460-S462. 
DJ, H. 1986. An overview of laser Doppler flowmetry. Biomed Sci Instrum, 22, 35-40. 
DORMANDY, J., MAHIR, M., ASCADY, G., BALSANO, F., DE, L. P., BLOMBERY, P., 
BOUSSER, M. G., CLEMENT, D., COFFMAN, J. & DEUTSHINOFF, A. 1989. Fate 
of the patient with chronic leg ischaemia. A review article. 
J.Cardiovasc.Surg.(Torino), 30, 50-57. 
DORMANDY, J. A. & RUTHERFORD, R. B. 2000. Management of peripheral arterial 
disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus 
(TASC). J Vasc Surg, 31, S1-S296. 
DOROSZKO, A., ANDRZEJAK, R. & SZUBA, A. 2011. Role of the nitric oxide metabolic 
pathway and prostanoids in the pathogenesis of endothelial dysfunction and essential 
hypertension in young men. Hypertens Res, 34, 79-86. 
DOSHI, S. N., MCDOWELL, I. F., MOAT, S. J., LANG, D., NEWCOMBE, R. G., 
KREDAN, M. B., LEWIS, M. J. & GOODFELLOW, J. 2001. Folate improves 
endothelial function in coronary artery disease: an effect mediated by reduction of 
intracellular superoxide? Arterioscler Thromb Vasc Biol, 21, 1196-202. 
DOUGNAC, A., RIQUELME, A., CALVO, M., ANDRESEN, M., MAGEDZO, A., 
EUGENIN, E., MARSHALL, G. & GUTIERREZ, M. 2001. [Study of cytokines 
kinetics in severe sepsis and its relationship with mortality and score of organic 
dysfunction]. Rev.Med.Chil., 129, 347-358. 
DROGE, W. 2002. Free radicals in the physiological control of cell function. Physiol Rev, 82, 
47-95. 
DRUMMOND, M. 1997. Socioeconomic impact of peripheral vascular disease. 
Atherosclerosis, 131 Suppl, S33-S34. 
DUCHEN, M. R. 2004a. Mitochondria in health and disease: perspectives on a new 
mitochondrial biology. Mol Aspects Med, 25, 365-451. 
DUCHEN, M. R. 2004b. Roles of mitochondria in health and disease. Diabetes, 53 Suppl 1, 
S96-102. 
DUMON, K., ROSSBACH, C., HARMS, B., GORELOV, V., GROSS-WEEGE, W., 
SCHNEIDER, E. M., GORETZKI, P. E. & ROHER, H. D. 1998. [Tumor necrosis 
factor-alpha (TNF-alpha) gene polymorphism in surgical intensive care patients with 
SIRS]. Langenbecks Arch.Chir Suppl Kongressbd., 115, 387-390. 
 303 
 
E, H. 1987. Optics Addison Wesley. 
EDWARDS AT FAU - BLANN, A. D., BLANN AD FAU - SUAREZ-MENDEZ, V. J., 
SUAREZ-MENDEZ VJ FAU - LARDI, A. M., LARDI AM FAU - MCCOLLUM, C. 
N. & MCCOLLUM, C. N. Systemic responses in patients with intermittent 
claudication after treadmill exercise. 
EEFTING, F., RENSING, B., WIGMAN, J., PANNEKOEK, W. J., LIU, W. M., CRAMER, 
M. J., LIPS, D. J. & DOEVENDANS, P. A. 2004. Role of apoptosis in reperfusion 
injury. Cardiovasc Res, 61, 414-426. 
EL-BARBARY, M. & KHABAR, K. S. 2002. Soluble tumor necrosis factor receptor p55 
predicts cytokinemia and systemic inflammatory response after cardiopulmonary 
bypass. Crit Care Med., 30, 1712-1716. 
ELENKOV, I. J., WILDER, R. L., CHROUSOS, G. P. & VIZI, E. S. 2000. The sympathetic 
nerve--an integrative interface between two supersystems: the brain and the immune 
system. Pharmacol Rev, 52, 595-638. 
ELLIOTT, W. 2001. Biochemisty and Molecular Biology. Oxford: Oxford university Press. 
ENGELHART M, K. J. 1986. Raynaud's phenomenon: blood supply to fingers during 
indirect cooling, evaluated by laser Doppler flowmetry. Clin Physiol, 6, 481-8. 
ESMON, C. T. 2004. Crosstalk between inflammation and thrombosis. Maturitas, 47, 305-
314. 
EUN, H. C. 1995. Evaluation of skin blood flow by laser Doppler flowmetry. Clin Dermatol, 
13, 337-47. 
FAN, C., PLAXCO, K. W. & HEEGER, A. J. 2005. Biosensors based on binding-modulated 
donor-acceptor distances. Trends Biotechnol, 23, 186-92. 
FEBBRAIO, M. A. & PEDERSEN, B. K. 2002. Muscle-derived interleukin-6: mechanisms 
for activation and possible biological roles. FASEB J, 16, 1335-47. 
FICHTLSCHERER, S., HEESCHEN, C. & ZEIHER, A. M. 2004. Inflammatory markers and 
coronary artery disease. Curr Opin Pharmacol, 4, 124-131. 
FIDLER, K. J., WILSON, P., DAVIES, J. C., TURNER, M. W., PETERS, M. J. & KLEIN, 
N. J. 2004. Increased incidence and severity of the systemic inflammatory response 
syndrome in patients deficient in mannose-binding lectin. Intensive Care Med., 30, 
1438-1445. 
FINK, M. P. 2002. Bench-to-bedside review: Cytopathic hypoxia. Crit Care, 6, 491-499. 
FIOTTI, N., GIANSANTE, C., PONTE, E., DELBELLO, C., CALABRESE, S., ZACCHI, 
T., DOBRINA, A. & GUARNIERI, G. 1999. Atherosclerosis and inflammation. 
Patterns of cytokine regulation in patients with peripheral arterial disease. 
Atherosclerosis, 145, 51-60. 
FLEMING, I., HECKER, M. & BUSSE, R. 1994. Intracellular alkalinization induced by 
bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial 
cells. Circ Res, 74, 1220-6. 
FORSTERMANN, U. & MUNZEL, T. 2006. Endothelial nitric oxide synthase in vascular 
disease: from marvel to menace. Circulation, 113, 1708-14. 
FORSTERMANN, U., POLLOCK, J. S., SCHMIDT, H. H., HELLER, M. & MURAD, F. 
1991. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide 
synthase activity is present in the particulate and cytosolic fractions of bovine aortic 
endothelial cells. Proc Natl Acad Sci U S A, 88, 1788-92. 
FORTINA, P., KRICKA, L. J., SURREY, S. & GRODZINSKI, P. 2005. Nanobiotechnology: 
the promise and reality of new approaches to molecular recognition. Trends 
Biotechnol, 23, 168-73. 
FOWKES, F. G. 1997. Epidemiology of peripheral vascular disease. Atherosclerosis, 131 
Suppl, S29-31. 
 304 
 
FOWKES, F. G., HOUSLEY, E., CAWOOD, E. H., MACINTYRE, C. C., RUCKLEY, C. 
V. & PRESCOTT, R. J. 1991. Edinburgh Artery Study: prevalence of asymptomatic 
and symptomatic peripheral arterial disease in the general population. 
Int.J.Epidemiol., 20, 384-392. 
FRIEDEWALD, J. J. & RABB, H. 2004. Inflammatory cells in ischemic acute renal failure. 
Kidney Int, 66, 486-491. 
FÜLÖP, A. K. & FALUS, A. 2004. Possibilities and results in the wide-scale genomic 
analysis of inflammation. Inflammation Research, 53, 517-522. 
G, L. 1926. The conservation of photons. Nature, 118, 874-875. 
GALLAGHER, P. M., LOWE, G., FITZGERALD, T., BELLA, A., GREENE, C. M., 
MCELVANEY, N. G. & O'NEILL, S. J. 2003. Association of IL-10 polymorphism 
with severity of illness in community acquired pneumonia. Thorax, 58, 154-156. 
GALLIN, J. S., R; FEARON, DT; HAYNES, BF; NATHAN,C. 1999. Inflammation: Basic 
Principles and Clinical Correlates. 3 ed. Lippincott Williams and Wilkins. 
GARRED, P., STROM, J., QUIST, L., TAANING, E. & MADSEN, H. O. 2003. Association 
of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients 
with systemic inflammatory response syndrome. J.Infect.Dis., 188, 1394-1403. 
GIANNOUDIS, P. V. 2003. Current concepts of the inflammatory response after major 
trauma: an update. Injury, 34, 397-404. 
GILLUM, R. F. 1990. Peripheral arterial occlusive disease of the extremities in the United 
States: hospitalization and mortality. Am.Heart J., 120, 1414-1418. 
GLANTZOUNIS, G. K., SALACINSKI, H. J., YANG, W., DAVIDSON, B. R. & 
SEIFALIAN, A. M. 2005. The contemporary role of antioxidant therapy in 
attenuating liver ischemia-reperfusion injury: a review. Liver Transpl, 11, 1031-47. 
GOLDSTEIN DS, B. R., ZIMLICKMAN R, ZAHN TP, CANNON RO III, ROSING DR, 
STULL R, KEISER HR 1986. Indices of sympathetic vascular innervation in 
sympathectomised patients. J Auton Nerv Syst, 15, 309-78. 
GOMEZ DEL ARCO P FAU - MARTINEZ-MARTINEZ, S., MARTINEZ-MARTINEZ S 
FAU - CALVO, V., CALVO V FAU - ARMESILLA, A. L., ARMESILLA AL FAU 
- REDONDO, J. M. & REDONDO, J. M. Antioxidants and AP-1 activation: a brief 
overview. 
GRACE PA, M. R. 1998. Ischaemia-Reperfusion injury. 1st Edition Oxford: Blackwell 
Science. 
GRANGER, D. N. 1999. Ischemia-reperfusion: mechanisms of microvascular dysfunction 
and the influence of risk factors for cardiovascular disease. Microcirculation, 6, 167-
78. 
GRANT RT, B. E. Observations on arteriovenous anastomoses in human skin and in the 
bird's foot with special reference to the reaction to cold. Heart, 15, 1931. 
GRESELE, P., MIGLIACCI, R., PROCACCI, A., DE MONTE, P. & BONIZZONI, E. 
2007a. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of 
the acute endothelial dysfunction induced by exercise in patients with intermittent 
claudication. Thromb Haemost, 97, 444-50. 
GRESELE, P., MIGLIACCI, R., PROCACCI, A., DE MONTE, P. & BONIZZONI, E. 
2007b. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, 
of the acute endothelial dysfunction induced by exercise in patients with intermittent 
claudication. Thromb Haemost, 97, 444-450. 
GRIFFITH, T. M. & EDWARDS, D. H. 1990. EDRF in intact vascular networks. Blood 
Vessels, 27, 230-7. 
 305 
 
GRIFFITH, T. M., EDWARDS, D. H., DAVIES, R. L., HARRISON, T. J. & EVANS, K. T. 
1987. EDRF coordinates the behaviour of vascular resistance vessels. Nature, 329, 
442-5. 
GUELER, F., PARK, J.-K., RONG, S., KIRSCH, T., LINDSCHAU, C., ZHENG, W., 
ELGER, M., FIEBELER, A., FLISER, D., LUFT, F. C. & HALLER, H. 2007. Statins 
Attenuate Ischemia-Reperfusion Injury by Inducing Heme Oxygenase-1 in Infiltrating 
Macrophages. The American Journal of Pathology, 170, 1192-1199. 
GUELER, F., RONG, S., PARK, J.-K., FIEBELER, A., MENNE, J., ELGER, M., 
MUELLER, D. N., HAMPICH, F., DECHEND, R., KUNTER, U., LUFT, F. C. & 
HALLER, H. 2002. Postischemic Acute Renal Failure Is Reduced by Short-Term 
Statin Treatment in a Rat Model. Journal of the American Society of Nephrology, 13, 
2288-2298. 
GUSTAFSSON H, M. M., NILSSON H 1993. Rhythmic contractions of isolated small 
arteries from rats- inﬂuence of endothelium. Acta Physiol Scand, 148, 153-63. 
HABAZETTL, H., HANUSCH, P. & KUPATT, C. 2000. Effects of 
endothelium/leukocytes/platelet interaction on myocardial ischemia--reperfusion 
injury. Z Kardiol, 89 Suppl 9, 92-95. 
HACK, C. E. & ZEERLEDER, S. 2001. The endothelium in sepsis: source of and a target for 
inflammation. Crit Care Med, 29, 21-27. 
HACKAM, D. G. & ANAND, S. S. 2003. Emerging risk factors for atherosclerotic vascular 
disease: a critical review of the evidence. JAMA, 290, 932-940. 
HADDOCK RE, H. G., HILL CE 2002. Voltage independence of vasomotion in isolated 
irideal arterioles of the rat. J Physiol, 540, 219-29. 
HADDY, N., SASS, C., DROESCH, S., ZAIOU, M., SIEST, G., PONTHIEUX, A., 
LAMBERT, D. & VISVIKIS, S. 2003. IL-6, TNF-alpha and atherosclerosis risk 
indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis, 
170, 277-83. 
HALTER, J., STEINBERG, J., FINK, G., LUTZ, C., PICONE, A., MAYBURY, R., 
FEDORS, N., DIROCCO, J., LEE, H. M. & NIEMAN, G. 2005. Evidence of 
systemic cytokine release in patients undergoing cardiopulmonary bypass. 
J.Extra.Corpor.Technol., 37, 272-277. 
HANSSON, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J 
Med, 352, 1685-95. 
HARRIS, A. G., STEINBAUER, M., LEIDERER, R. & MESSMER, K. 1997. Role of 
leukocyte plugging and edema in skeletal muscle ischemia-reperfusion injury. Am J 
Physiol, 273, 989-996. 
HASSETT, S., MOYNAGH, P. & REEN, D. 2006. TNF-alpha is a mediator of the anti-
inflammatory response in a human neonatal model of the non-septic shock syndrome. 
Pediatr.Surg.Int., 22, 24-30. 
HAUET, T., BAUMERT, H., GIBELIN, H., HAMEURY, F., GOUJON, J. M., 
CARRETIER, M. & EUGENE, M. 2000. Noninvasive monitoring of citrate, acetate, 
lactate, and renal medullary osmolyte excretion in urine as biomarkers of exposure to 
ischemic reperfusion injury. Cryobiology, 41, 280-291. 
HEINZEL, B., JOHN, M., KLATT, P., BOHME, E. & MAYER, B. 1992. Ca2+/calmodulin-
dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J, 
281 ( Pt 3), 627-30. 
HENRY, J. 2001. Clinical Diagnosis and Management by Laboratory Methods. 20 ed. W.B. 
Saunders. 
 306 
 
HICKEY, N. C., GOSLING, P., BAAR, S., SHEARMAN, C. P. & SIMMS, M. H. 1990. 
Effect of surgery on the systemic inflammatory response to intermittent claudication. 
Br J Surg, 77, 1121-4. 
HILDEBRAND, F., PAPE, H. C., GRIENSVEN, M., MEIER, S., HASENKAMP, S., 
KRETTEK, C. & STUHRMANN, M. 2005. Genetic predisposition for a 
compromised immune system after multiple trauma. Shock, 24, 518-522. 
HIRASAWA, F., KAWARADA, Y., SATO, M., SUZUKI, S., TERADA, K., MIURA, N., 
FUJII, M., KATO, K., TAKIZAWA, Y. & SUGIYAMA, T. 1997. The effect of silver 
administration on the biosynthesis and the molecular properties of rat ceruloplasmin. 
Biochim Biophys Acta, 1336, 195-201. 
HIROTA, M., SUGITA, H., MAEDA, K., ICHIBARA, A. & OGAWA, M. 2004. [Concept 
of SIRS and severe acute pancreatitis]. Nippon Rinsho, 62, 2128-2136. 
HIRSCH, A. T., HASKAL, Z. J., HERTZER, N. R., BAKAL, C. W., CREAGER, M. A., 
HALPERIN, J. L., HIRATZKA, L. F., MURPHY, W. R., OLIN, J. W., PUSCHETT, 
J. B., ROSENFIELD, K. A., SACKS, D., STANLEY, J. C., TAYLOR, L. M., JR., 
WHITE, C. J., WHITE, J., WHITE, R. A., ANTMAN, E. M., SMITH, S. C., JR., 
ADAMS, C. D., ANDERSON, J. L., FAXON, D. P., FUSTER, V., GIBBONS, R. J., 
HUNT, S. A., JACOBS, A. K., NISHIMURA, R., ORNATO, J. P., PAGE, R. L. & 
RIEGEL, B. 2006. ACC/AHA Guidelines for the Management of Patients with 
Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal 
aortic): a collaborative report from the American Associations for Vascular 
Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and 
Interventions, Society for Vascular Medicine and Biology, Society of Interventional 
Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee 
to develop guidelines for the management of patients with peripheral arterial disease)-
-summary of recommendations. J Vasc Interv Radiol, 17, 1383-97; quiz 1398. 
HIRSCH, A. T. & HIATT, W. R. 2001. PAD awareness, risk, and treatment: new resources 
for survival--the USA PARTNERS program. Vasc Med, 6, 9-12. 
HIRSCHI, K. K. & D'AMORE, P. A. 1996. Pericytes in the microvasculature. Cardiovasc 
Res, 32, 687-98. 
HOOGEVEEN, R. C., MORRISON, A., BOERWINKLE, E., MILES, J. S., RHODES, C. E., 
SHARRETT, A. R. & BALLANTYNE, C. M. 2005. Plasma MCP-1 level and risk for 
peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in 
Communities study. Atherosclerosis, 183, 301-7. 
HOUSLEY, E. Treating claudication in five words. 
HUANG, A. L. & VITA, J. A. 2006. Effects of systemic inflammation on endothelium-
dependent vasodilation. Trends Cardiovasc Med, 16, 15-20. 
HUETHER, S. E. 1983. The microcirculation. Nurse Pract, 8, 47, 49, 52. 
HUMEAU, A., SAUMET, J. L. & L'HUILLIER, J. P. 2000. Simplified model of laser 
Doppler signals during reactive hyperaemia. Med Biol Eng Comput, 38, 80-7. 
HUSMANN, M., DORFFLER-MELLY, J., KALKA, C., DIEHM, N., BAUMGARTNER, I. 
& SILVESTRO, A. 2008. Successful lower extremity angioplasty improves brachial 
artery flow-mediated dilation in patients with peripheral arterial disease. J Vasc Surg, 
48, 1211-6. 
HWANG, J., ING, M. H., SALAZAR, A., LASSEGUE, B., GRIENDLING, K., NAVAB, 
M., SEVANIAN, A. & HSIAI, T. K. 2003. Pulsatile versus oscillatory shear stress 
regulates NADPH oxidase subunit expression: implication for native LDL oxidation. 
Circ Res, 93, 1225-32. 
IWASAKA, H. & NOGUCHI, T. 2004. [Th1/Th2 balance in systemic inflammatory response 
syndrome (SIRS)]. Nippon Rinsho, 62, 2237-2243. 
 307 
 
J, R. 1988. The status of laser Doppler exam in patients with aterial occlusive disease. Herz, 
13, 382-91. 
JAFFER, U. & ASLAM, M. ECG Gating is Not Required for Brachial Artery Flow-Mediated 
Dilation Measurement. 
JAIN, K. K. 2005. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta, 358, 
37-54. 
JIANG, C., TING, A. T. & SEED, B. 1998. PPAR-gamma agonists inhibit production of 
monocyte inflammatory cytokines. Nature, 391, 82-6. 
JOANNIDES, R., HAEFELI, W. E., LINDER, L., RICHARD, V., BAKKALI, E. H., 
THUILLEZ, C. & LUSCHER, T. F. 1995. Nitric oxide is responsible for flow-
dependent dilatation of human peripheral conduit arteries in vivo. Circulation, 91, 
1314-9. 
JOHNSON, A. R., SCHULZ, W. W., NOGUIERA, L. A. & ERDOS, E. G. 1980. Kinins and 
angiotensins. Angiotensin I converting enzyme (kininase II) in endothelial cells 
cultured from human pulmonary arteries and veins. Clin Exp Hypertens, 2, 659-74. 
JOLLY, K. & GILL, P. 2008. Ethnicity and cardiovascular disease prevention: practical 
clinical considerations. Curr.Opin.Cardiol., 23, 465-470. 
JONES SP FAU - BOLLI, R. & BOLLI, R. The ubiquitous role of nitric oxide in 
cardioprotection. 
JORAS, M. & POREDOŠ, P. 2008. The association of acute exercise-induced ischaemia with 
systemic vasodilator function in patients with peripheral arterial disease. Vascular 
Medicine, 13, 255-262. 
JOYCE, D. E., NELSON, D. R. & GRINNELL, B. W. 2004. Leukocyte and endothelial cell 
interactions in sepsis: relevance of the protein C pathway. Crit Care Med, 32, 280-
286. 
JOYNER, W. L. & DAVIS, M. J. 1987. Pressure profile along the microvascular network 
and its control. Fed Proc, 46, 266-9. 
JUCKETT, M. B., BALLA, J., BALLA, G., JESSURUN, J., JACOB, H. S. & 
VERCELLOTTI, G. M. 1995. Ferritin protects endothelial cells from oxidized low 
density lipoprotein in vitro. Am.J.Pathol., 147, 782-789. 
KAMINSKI, K. A., BONDA, T. A., KORECKI, J. & MUSIAL, W. J. 2002. Oxidative stress 
and neutrophil activation--the two keystones of ischemia/reperfusion injury. Int J 
Cardiol, 86, 41-59. 
KAN, H., XIE, Z. & FINKEL, M. S. 1999. TNF-alpha enhances cardiac myocyte NO 
production through MAP kinase-mediated NF-kappaB activation. Am.J.Physiol, 277, 
H1641-H1646. 
KANANI, P. M., SINKEY, C. A., BROWNING, R. L., ALLAMAN, M., KNAPP, H. R. & 
HAYNES, W. G. 1999. Role of oxidant stress in endothelial dysfunction produced by 
experimental hyperhomocyst(e)inemia in humans. Circulation, 100, 1161-1168. 
KASTRUP J, B. J., LASSEN NA 1989. Vasomotion in humans skin before and after local 
heating recorded with laser Doppler ﬂowmetry. A method for induction of 
vasomotion. Int J Microcirc Clin Exp, 8, 205-15. 
KAWAI, S., SAKAYORI, S. & KOBAYASHI, H. 1995. [The role of IL-10 in patients with 
SIRS (systemic inflammatory response syndrome)--in relation to TNF activity]. 
Kansenshogaku Zasshi, 69, 765-771. 
KELLOGG, D. L., JR., CRANDALL, C. G., LIU, Y., CHARKOUDIAN, N. & JOHNSON, 
J. M. 1998. Nitric oxide and cutaneous active vasodilation during heat stress in 
humans. J Appl Physiol, 85, 824-9. 
KHAIRA, H. S., NASH, G. B., BAHRA, P. S., SANGHERA, K., GOSLING, P., CROW, A. 
J. & SHEARMAN, C. P. 1995. Thromboxane and neutrophil changes following 
 308 
 
intermittent claudication suggest ischaemia-reperfusion injury. Eur J Vasc Endovasc 
Surg, 10, 31-5. 
KIM, J.-S., OHSHIMA, S., PEDIADITAKIS, P. & LEMASTERS, J. J. 2004. Nitric oxide: a 
signaling molecule against mitochondrial permeability transition- and pH-dependent 
cell death after reperfusion. Free Radic Biol Med, 37, 1943-1950. 
KNOWLES, R. G. & MONCADA, S. 1994. Nitric oxide synthases in mammals. Biochem J, 
298 ( Pt 2), 249-58. 
KOJDA, G. & HAMBRECHT, R. 2005. Molecular mechanisms of vascular adaptations to 
exercise. Physical activity as an effective antioxidant therapy? Cardiovasc.Res., 67, 
187-197. 
KONSTANTOULAKI, M., KOUKLIS, P. & MALIK, A. B. 2003. Protein kinase C 
modifications of VE-cadherin, p120, and beta-catenin contribute to endothelial barrier 
dysregulation induced by thrombin. Am J Physiol Lung Cell Mol Physiol, 285, 434-
442. 
KREMER, J. P., JARRAR, D., STECKHOLZER, U. & ERTEL, W. 1996. Interleukin-1, -6 
and tumor necrosis factor-alpha release is down-regulated in whole blood from septic 
patients. Acta Haematol., 95, 268-273. 
KUNSCH, C. & MEDFORD, R. M. 1999a. Oxidative Stress as a Regulator of Gene 
Expression in the Vasculature. Circulation Research, 85, 753-766. 
KUNSCH, C. & MEDFORD, R. M. 1999b. Oxidative stress as a regulator of gene expression 
in the vasculature. Circ Res, 85, 753-66. 
KVERNEBO, K., SLAGSVOLD, C. E., STRANDEN, E., KROESE, A. & LARSEN, S. 
1988. Laser Doppler flowmetry in evaluation of lower limb resting skin circulation. A 
study in healthy controls and atherosclerotic patients. Scand.J.Clin.Lab Invest, 48, 
621-626. 
LABS, K. H., DORMANDY, J. A., JAEGER, K. A., STUERZEBECHER, C. S. & HIATT, 
W. R. 1999. Transatlantic Conference on Clinical Trial Guidelines in Peripheral 
Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology 
Group. Circulation, 100, 75-81. 
LAMAS, S., MICHEL, T., BRENNER, B. M. & MARSDEN, P. A. 1991. Nitric oxide 
synthesis in endothelial cells: evidence for a pathway inducible by TNF-alpha. Am J 
Physiol, 261, C634-41. 
LANDMESSER, U., DIKALOV, S., PRICE, S. R., MCCANN, L., FUKAI, T., HOLLAND, 
S. M., MITCH, W. E. & HARRISON, D. G. 2003. Oxidation of tetrahydrobiopterin 
leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin 
Invest, 111, 1201-9. 
LAUER, N., SUVORAVA, T., RUTHER, U., JACOB, R., MEYER, W., HARRISON, D. G. 
& KOJDA, G. 2005. Critical involvement of hydrogen peroxide in exercise-induced 
up-regulation of endothelial NO synthase. Cardiovasc Res, 65, 254-62. 
LAURSEN, J. B., SOMERS, M., KURZ, S., MCCANN, L., WARNHOLTZ, A., 
FREEMAN, B. A., TARPEY, M., FUKAI, T. & HARRISON, D. G. 2001. 
Endothelial regulation of vasomotion in apoE-deficient mice: implications for 
interactions between peroxynitrite and tetrahydrobiopterin. Circulation, 103, 1282-8. 
LE-CHONG P, Z. B. 1979. In vivo and in vitro velocity measurements of microvasculature 
with a laser. Microvasc Res, 17, 131-41. 
LEAHY MJ, D. M. F., NILSSON GE, MANIEWSKI R 1999. Principles and practice of  the  
laser-Doppler perfusion  technique. Technol Health Care, 7, 143-162. 
LENG, G. C., LEE, A. J., FOWKES, F. G., WHITEMAN, M., DUNBAR, J., HOUSLEY, E. 
& RUCKLEY, C. V. 1996. Incidence, natural history and cardiovascular events in 
 309 
 
symptomatic and asymptomatic peripheral arterial disease in the general population. 
Int J Epidemiol, 25, 1172-81. 
LENG, G. C., PAPACOSTA, O., WHINCUP, P., WANNAMETHEE, G., WALKER, M., 
EBRAHIM, S., NICOLAIDES, A. N., DHANJIL, S., GRIFFIN, M., BELCARO, G., 
RUMLEY, A. & LOWE, G. D. 2000. Femoral atherosclerosis in an older British 
population: prevalence and risk factors. Atherosclerosis, 152, 167-174. 
LEU, H. B., WU, C. C., WU, T. C., LIN, S. J. & CHEN, J. W. 2004. Fluvastatin reduces 
oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves 
endothelial function in patients with hypercholesterolemia. J Formos Med Assoc, 103, 
914-20. 
LEVICK, J. R. 1997. Fluid exchange across endothelium. Int J Microcirc Clin Exp, 17, 241-
7. 
LEVICK, J. R. 2003. An Introduction to Cardiovascular Physiology, Arnold. 
LEWIS, D. R., DAY, A., BAIRD, R. N., SMITH, F. C. & LAMONT, P. M. 1999. Vascular 
surgical society of great britain and ireland: angioplasty reverses the systemic effects 
of exercise in intermittent claudication. Br J Surg, 86, 709. 
LEWIS, D. R., DAY, A., JEREMY, J. Y., BAIRD, R. N., SMITH, F. C. & LAMONT, P. M. 
2001. The systemic effects of intermittent claudication are reversed by angioplasty. 
Eur J Vasc Endovasc Surg, 22, 326-30. 
LIBBY, P., SUKHOVA, G., LEE, R. T. & GALIS, Z. S. 1995. Cytokines regulate vascular 
functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol, 
25 Suppl 2, S9-12. 
LIND, L. 2003. Circulating markers of inflammation and atherosclerosis. Atherosclerosis, 
169, 203-214. 
LINDNER, J. R. 2002. Evolving applications for contrast ultrasound. Am J Cardiol, 90, 72J-
80J. 
LIPTON, S. A., CHOI, Y. B., PAN, Z. H., LEI, S. Z., CHEN, H. S., SUCHER, N. J., 
LOSCALZO, J., SINGEL, D. J. & STAMLER, J. S. 1993. A redox-based mechanism 
for the neuroprotective and neurodestructive effects of nitric oxide and related 
nitroso-compounds. Nature, 364, 626-32. 
LOFFREDO, L., MARCOCCIA, A., PIGNATELLI, P., ANDREOZZI, P., BORGIA, M. C., 
CANGEMI, R., CHIAROTTI, F. & VIOLI, F. 2007. Oxidative-stress-mediated 
arterial dysfunction in patients with peripheral arterial disease. Eur Heart J, 28, 608-
12. 
M, P. 1901. Über das Gesetz der Energieverteilung im Normalspectrum. Annalen der Physik, 
4, 553-563. 
M, S. 1988. Arteries of the skin. In: Taylor GI, Tempest M, eds. London: Churchill-
Livingstone. 
MAIER, J. 2005. Nanoionics: ion transport and electrochemical storage in confined systems. 
Nat Mater, 4, 805-815. 
MAIMAN, T. H. 1966. Biomedical lasers evolve toward clinical applications. Hosp Manage, 
101, 39-41. 
MALLICK, I. H., YANG, W., WINSLET, M. C. & SEIFALIAN, A. M. 2004. Ischemia-
reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci, 
49, 1359-1377. 
MANGELSDORF, D. J., THUMMEL, C., BEATO, M., HERRLICH, P., SCHUTZ, G., 
UMESONO, K., BLUMBERG, B., KASTNER, P., MARK, M., CHAMBON, P. & 
EVANS, R. M. 1995. The nuclear receptor superfamily: the second decade. Cell, 83, 
835-9. 
 310 
 
MANN, G. E., YUDILEVICH, D. L. & SOBREVIA, L. 2003. Regulation of amino acid and 
glucose transporters in endothelial and smooth muscle cells. Physiol Rev, 83, 183-
252. 
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A. & LOCATI, M. 
2004. The chemokine system in diverse forms of macrophage activation and 
polarization. Trends Immunol, 25, 677-86. 
MARX, N., BOURCIER, T., SUKHOVA, G. K., LIBBY, P. & PLUTZKY, J. 1999. 
PPARgamma activation in human endothelial cells increases plasminogen activator 
inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. 
Arterioscler Thromb Vasc Biol, 19, 546-51. 
MARX, N., SCHONBECK, U., LAZAR, M. A., LIBBY, P. & PLUTZKY, J. 1998. 
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression 
and migration in human vascular smooth muscle cells. Circ Res, 83, 1097-103. 
MASSEY, H. M., RA. Cytokines and adhesion molecules. 
MAUBAN JR, W. W. 2004. Essential role of EDHF in the initiation and maintenance of 
adrenergic vasomotion in rat mesenteric arteries. Am J Physiol Heart Circ Physiol, 
287, H608-16. 
MAZZONI, M. C., BORGSTROM, P., WARNKE, K. C., SKALAK, T. C., INTAGLIETTA, 
M. & ARFORS, K. E. 1995. Mechanisms and implications of capillary endothelial 
swelling and luminal narrowing in low-flow ischemias. Int J Microcirc Clin Exp, 15, 
265-70. 
MCCORD, J. M. & FRIDOVICH, I. 1968. The reduction of cytochrome c by milk xanthine 
oxidase. J Biol Chem, 243, 5753-60. 
MCDERMOTT, M. M., GURALNIK, J. M., CORSI, A., ALBAY, M., MACCHI, C., 
BANDINELLI, S. & FERRUCCI, L. 2005. Patterns of inflammation associated with 
peripheral arterial disease: the InCHIANTI study. Am Heart J, 150, 276-81. 
MCKENNA, M., WOLFSON, S. & KULLER, L. 1991. The ratio of ankle and arm arterial 
pressure as an independent predictor of mortality. Atherosclerosis, 87, 119-28. 
MICHIE, H. R., MANOGUE, K. R., SPRIGGS, D. R., REVHAUG, A., O'DWYER, S., 
DINARELLO, C. A., CERAMI, A., WOLFF, S. M. & WILMORE, D. W. 1988. 
Detection of circulating tumor necrosis factor after endotoxin administration. 
N.Engl.J.Med., 318, 1481-1486. 
MILLER, N. J. & RICE-EVANS, C. A. 1997. Factors Influencing the Antioxidant Activity 
Determined by the ABTS•+ Radical Cation Assay. Free Radical Research, 26, 195-
199. 
MOKART, D., CAPO, C., BLACHE, J. L., DELPERO, J. R., HOUVENAEGHEL, G., 
MARTIN, C. & MEGE, J. L. 2002. Early postoperative compensatory anti-
inflammatory response syndrome is associated with septic complications after major 
surgical trauma in patients with cancer. Br.J.Surg., 89, 1450-1456. 
MOLITORIS, B. A. & SUTTON, T. A. 2004. Endothelial injury and dysfunction: role in the 
extension phase of acute renal failure. Kidney Int, 66, 496-499. 
MONCADA, S. & PALMER, R. M. 1991. Biosynthesis and actions of nitric oxide. Semin 
Perinatol, 15, 16-9. 
MONCADA, S., PALMER, R. M. & HIGGS, E. A. 1991. Nitric oxide: physiology, 
pathophysiology, and pharmacology. Pharmacol Rev, 43, 109-42. 
MONSUEZ, J. J. 2001. [Mediators of reactive hyperemia]. Arch Mal Coeur Vaiss, 94, 591-9. 
MORALES, F., GRAAFF, R., SMIT, A. J., BERTUGLIA, S., PETOUKHOVA, A. L., 
STEENBERGEN, W., LEGER, P. & RAKHORST, G. 2005. How to assess post-
occlusive reactive hyperaemia by means of laser Doppler perfusion monitoring: 
 311 
 
application of a standardised protocol to patients with peripheral arterial obstructive 
disease. Microvasc Res, 69, 17-23. 
MORRIS, M. D., FR. 2001. Basic examination of blood. . 
MORSEY, H., ASLAM, M. & STANDFIELD, N. 2003. Patients with critical ischemia of the 
lower limb are at risk of developing kidney dysfunction. Am J Surg, 185, 360-3. 
MOSHFEGHI, A. A. & PEYMAN, G. A. 2005. Micro- and nanoparticulates. Adv Drug Deliv 
Rev, 57, 2047-2052. 
MULVANY, M. J. & AALKJAER, C. 1990. Structure and function of small arteries. Physiol 
Rev, 70, 921-61. 
MURABITO, J. M., EVANS, J. C., LARSON, M. G., NIETO, K., LEVY, D. & WILSON, P. 
W. 2003. The ankle-brachial index in the elderly and risk of stroke, coronary disease, 
and death: the Framingham Study. Arch Intern Med, 163, 1939-42. 
NAGY, L., TONTONOZ, P., ALVAREZ, J. G., CHEN, H. & EVANS, R. M. 1998. Oxidized 
LDL regulates macrophage gene expression through ligand activation of 
PPARgamma. Cell, 93, 229-40. 
NATARAJAN R FAU - SALLOUM, F. N., SALLOUM FN FAU - FISHER, B. J., FISHER 
BJ FAU - KUKREJA, R. C., KUKREJA RC FAU - FOWLER, A. A., 3RD & 
FOWLER, A. A., 3RD Hypoxia inducible factor-1 activation by prolyl 4-
hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. 
NAYLOR, A. R. 2012. Time to rethink management strategies in asymptomatic carotid 
artery disease. Nat Rev Cardiol, 9, 116-124. 
NICHOLS, W. W., O'ROURKE, M. F., AVOLIO, A. P., YAGINUMA, T., MURGO, J. P., 
PEPINE, C. J. & CONTI, C. R. 1985. Effects of age on ventricular-vascular coupling. 
Am J Cardiol, 55, 1179-84. 
NILSSON, H. & AALKJAER, C. 2003. Vasomotion: mechanisms and physiological 
importance. Mol Interv, 3, 79-89, 51. 
NORGREN L, H. W., DORMANDY JA, NEHLER MR, HARRIS KA, FOWKES FG, ET 
AL 2007; 33   2007. Inter-Society Consensus for the Management of Peripheral 
Arterial Disease (TASC II). . .Eur J Vasc Endovasc Surg, 33. 
NORWOOD, M. G., BOWN, M. J. & SAYERS, R. D. 2004. Ischaemia-reperfusion injury 
and regional inflammatory responses in abdominal aortic aneurysm repair. Eur J Vasc 
Endovasc Surg, 28, 234-45. 
NOSE, K., SHIBANUMA, M., KIKUCHI, K., KAGEYAMA, H., SAKIYAMA, S. & 
KUROKI, T. 1991. Transcriptional activation of early-response genes by hydrogen 
peroxide in a mouse osteoblastic cell line. Eur J Biochem, 201, 99-106. 
NYLAENDE, M., KROESE, A., STRANDEN, E., MORKEN, B., SANDBAEK, G., 
LINDAHL, A. K., ARNESEN, H. & SELJEFLOT, I. 2006. Markers of vascular 
inflammation are associated with the extent of atherosclerosis assessed as 
angiographic score and treadmill walking distances in patients with peripheral arterial 
occlusive disease. Vasc Med, 11, 21-8. 
O'DRISCOLL, G., GREEN, D. & TAYLOR, R. R. 1997. Simvastatin, an HMG-coenzyme A 
reductase inhibitor, improves endothelial function within 1 month. Circulation, 95, 
1126-31. 
OBERG, P. A. 1990. Laser-Doppler flowmetry. Crit Rev Biomed Eng, 18, 125-63. 
OLSSON, R. A. & PEARSON, J. D. 1990. Cardiovascular purinoceptors. Physiol Rev, 70, 
761-845. 
PALLUA, N., LOW, J. F. & VON, H. D. 2003. Pathogenic role of interleukin-6 in the 
development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble 
interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model. 
Crit Care Med., 31, 1495-1501. 
 312 
 
PARPART A, H. J. 1956. Flicker in erythrocytes - vibratory movements in the cytoplasm. J 
Cell Comp Physiol, 47, 295-303 
. 
PARUMS, D. V. 1990. Inflammatory mediators in atherosclerosis. Biochem Soc Trans, 18, 
1069-72. 
PEARSON, J. D. 1994. Endothelial cell function and thrombosis. Baillieres Clin Haematol, 
7, 441-52. 
PEDERSEN, B. K., STEENSBERG, A., FISCHER, C., KELLER, C., KELLER, P., 
PLOMGAARD, P., WOLSK-PETERSEN, E. & FEBBRAIO, M. 2004. The 
metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proc Nutr 
Soc, 63, 263-267. 
PEDERSEN, B. K., STEENSBERG, A. & SCHJERLING, P. 2001. Muscle-derived 
interleukin-6: possible biological effects. J Physiol, 536, 329-37. 
PENG H, M. V., IVARSEN A, AALKJÆR C, NILSSON H 2001. Hypothesis for the 
initiation of vasomotion. Circ Res, 88, 810-5. 
PETERSEN, A. M. & PEDERSEN, B. K. 2005. The anti-inflammatory effect of exercise. J 
Appl Physiol, 98, 1154-62. 
PETTY, R. G. & PEARSON, J. D. 1989. Endothelium--the axis of vascular health and 
disease. J R Coll Physicians Lond, 23, 92-102. 
PIANTADOSI, C. A. & ZHANG, J. 1996. Mitochondrial Generation of Reactive Oxygen 
Species After Brain Ischemia in the Rat. Stroke, 27, 327-332. 
PIERZGA, J. M., FRYMOYER, A. & KENNEY, W. L. 2003. Delayed distribution of active 
vasodilation and altered vascular conductance in aged skin. J Appl Physiol, 94, 1045-
53. 
PINDERSKI OSLUND, L. J., HEDRICK, C. C., OLVERA, T., HAGENBAUGH, A., 
TERRITO, M., BERLINER, J. A. & FYFE, A. I. 1999. Interleukin-10 blocks 
atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol, 19, 2847-
53. 
PINSKY, M. R., VINCENT, J. L., DEVIERE, J., ALEGRE, M., KAHN, R. J. & DUPONT, 
E. 1993. Serum cytokine levels in human septic shock. Relation to multiple-system 
organ failure and mortality. Chest, 103, 565-575. 
PIPER, H. M., ABDALLAH, Y. & SCHAFER, C. 2004. The first minutes of reperfusion: a 
window of opportunity for cardioprotection. Cardiovasc Res, 61, 365-371. 
POSTON, L. & TAYLOR, P. D. 1995. Glaxo/MRS Young Investigator Prize. Endothelium-
mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci (Lond), 
88, 245-55. 
PREIK, M., LAUER, T., HEISS, C., TABERY, S., STRAUER, B. E. & KELM, M. 2000. 
Automated ultrasonic measurement of human arteries for the determination of 
endothelial function. Ultraschall Med, 21, 195-8. 
PREISER, J. C., SCHMARTZ, D., VAN DER, L. P., CONTENT, J., VANDEN, B. P., 
BUURMAN, W., SEBALD, W., DUPONT, E., PINSKY, M. R. & VINCENT, J. L. 
1991. Interleukin-6 administration has no acute hemodynamic or hematologic effect 
in the dog. Cytokine, 3, 1-4. 
PRICE, R. G. 1992a. Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in 
urine methods and clinical applications. Eur J Clin Chem Clin Biochem, 30, 693-705. 
PRICE, R. G. 1992b. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of 
kidney disease including the monitoring of nephrotoxicity. Clin Nephrol, 38 Suppl 1, 
S14-9. 
 313 
 
PRICE, R. J. & SKALAK, T. C. 1994. Circumferential wall stress as a mechanism for 
arteriolar rarefaction and proliferation in a network model. Microvasc Res, 47, 188-
202. 
PRIES, A. R. & SECOMB, T. W. 2000. Microvascular adaptation--regulation, coordination 
and function. Z Kardiol, 89 Suppl 9, 117-120. 
PRYOR, W. A., CORNICELLI, J. A., DEVALL, L. J., TAIT, B., TRIVEDI, B. K., WITIAK, 
D. T. & WU, M. 1993. A rapid screening test to determine the antioxidant potencies 
of natural and synthetic antioxidants. The Journal of Organic Chemistry, 58, 3521-
3532. 
PUGSLEY, M. K. & TABRIZCHI, R. 2000. The vascular system. An overview of structure 
and function. J Pharmacol Toxicol Methods, 44, 333-40. 
PYKE, K. E. & TSCHAKOVSKY, M. E. 2005. The relationship between shear stress and 
flow-mediated dilatation: implications for the assessment of endothelial function. 
J.Physiol, 568, 357-369. 
R, B. 1828. A brief account of microscopical observations made in the months of June, July 
and August, 1827, on the particles contained in the pollen of plants; and on the 
general existence of active molecules in organic and inorganic bodies. Phil. Mag, 4, 
161-173. 
RABB, H. 1998. Evaluation of urinary markers in acute renal failure. Curr Opin Nephrol 
Hypertens, 7, 681-5. 
RAJAN, V., VARGHESE, B., VAN LEEUWEN, T. G. & STEENBERGEN, W. 2009. 
Review of methodological developments in laser Doppler flowmetry. Lasers Med Sci, 
24, 269-83. 
RAMANATHAN, A., CONAGHAN, P. J., JENKINSON, A. D. & BISHOP, C. R. 2003. 
Comparison of ankle-brachial pressure index measurements using an automated 
oscillometric device with the standard Doppler ultrasound technique. ANZ J Surg, 73, 
105-108. 
RASHED, R. 1990. A Pioneer in Anaclastics: Ibn Sahl on Burning Mirrors and Lenses. Isis, 
81, 464. 
RE, R., PELLEGRINI, N., PROTEGGENTE, A., PANNALA, A., YANG, M. & RICE-
EVANS, C. 1999. Antioxidant activity applying an improved ABTS radical cation 
decolorization assay. Free Radical Biology and Medicine, 26, 1231-1237. 
REDDY, R. C., CHEN, G. H., TEKCHANDANI, P. K. & STANDIFORD, T. J. 2001. 
Sepsis-induced immunosuppression: from bad to worse. Immunol.Res., 24, 273-287. 
REGENSTEINER, J. G. & HIATT, W. R. 2002. Treatment of peripheral arterial disease. 
Clin Cornerstone, 4, 26-40. 
REID, C. L., PERREY, C., PRAVICA, V., HUTCHINSON, I. V. & CAMPBELL, I. T. 2002. 
Genetic variation in proinflammatory and anti-inflammatory cytokine production in 
multiple organ dysfunction syndrome. Crit Care Med., 30, 2216-2221. 
REMICK, D. 2002. Protein analysis and bioassays of cytokines and cytokine receptors. . In: 
Rose 2002. 
RENDELL, M. S., FINNEGAN, M. F., HEALY, J. C., LIND, A., MILLIKEN, B. K., 
FINNEY, D. E. & BONNER, R. F. 1998. The relationship of laser-Doppler skin 
blood flow measurements to the cutaneous microvascular anatomy. Microvasc Res, 
55, 3-13. 
REYES, A. A., KARL, I. E. & KLAHR, S. 1994. Role of arginine in health and in renal 
disease. Am J Physiol, 267, F331-46. 
REZKALLA, S. H. & KLONER, R. A. 2002. No-reflow phenomenon. Circulation, 105, 656-
62. 
 314 
 
RICOTE M FAU - LI, A. C., LI AC FAU - WILLSON, T. M., WILLSON TM FAU - 
KELLY, C. J., KELLY CJ FAU - GLASS, C. K. & GLASS, C. K. The peroxisome 
proliferator-activated receptor-gamma is a negative regulator of macrophage 
activation. 
RIEDEMANN, N. C. & WARD, P. A. 2003. Complement in ischemia reperfusion injury. Am 
J Pathol, 162, 363-367. 
RIVA, C., ROSS, B. & BENEDEK, G. B. 1972. Laser Doppler measurements of blood flow 
in capillary tubes and retinal arteries. Invest Ophthalmol, 11, 936-44. 
ROBLESS P, M. D., STANSBY GP .  2008, 2008. Cilostazol for peripheral arterial disease. 
Cochrane Database of Systematic Reviews. 
ROBLESS, P., MIKHAILIDIS, D. P. & STANSBY, G. P. 2007. Cilostazol for peripheral 
arterial disease. Cochrane Database Syst Rev, CD003748. 
RODRIGUEZ-GASPAR, M., SANTOLARIA, F., JARQUE-LOPEZ, A., GONZALEZ-
REIMERS, E., MILENA, A., DE, L. V., RODRIGUEZ-RODRIGUEZ, E. & 
GOMEZ-SIRVENT, J. L. 2001. Prognostic value of cytokines in SIRS general 
medical patients. Cytokine, 15, 232-236. 
ROEBUCK, K. A., RAHMAN, A., LAKSHMINARAYANAN, V., JANAKIDEVI, K. & 
MALIK, A. B. 1995. H2O2 and tumor necrosis factor-alpha activate intercellular 
adhesion molecule 1 (ICAM-1) gene transcription through distinct cis-regulatory 
elements within the ICAM-1 promoter. J Biol Chem, 270, 18966-74. 
ROSE, N. D., B; HAMILTON, RG. 2002. Manual of Clinical Laboratory Immunology. 6 ed. 
Washington DC: American Society for Microbiology. 
ROSS, R. 1999. Atherosclerosis--an inflammatory disease. N Engl J Med, 340, 115-26. 
RUSSO, G., LEOPOLD, J. A. & LOSCALZO, J. 2002. Vasoactive substances: nitric oxide 
and endothelial dysfunction in atherosclerosis. Vascul.Pharmacol., 38, 259-269. 
S JADHAV, N. S., J R PETRIE, S M COBBE, W R FERRELL 2007. Reproducibility and 
repeatability of peripheral microvascular assessment using lontophoresis in 
conjunction with laser doppler imaging. Journal of Cardiovascular Pharmacology, 
50, 343 - 349. 
SALERUD EG, T. T., NILSSON GE, OEBERG PA 1983. Rhythmic variations in human 
skin blood flow. Int J Microcirc Clin Exp, 2, 91-102. 
SALOMONSSON, M., SORENSEN, C. M., ARENDSHORST, W. J., STEENDAHL, J. & 
HOLSTEIN-RATHLOU, N. H. 2004. Calcium handling in afferent arterioles. Acta 
Physiol Scand, 181, 421-429. 
SANDER, A., ARMBRUSTER, W., SANDER, B., DAUL, A. E., LANGE, R. & PETERS, J. 
1997. Hemofiltration increases IL-6 clearance in early systemic inflammatory 
response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. 
Intensive Care Med., 23, 878-884. 
SCHABAUER, A. M. & ROOKE, T. W. 1994. Cutaneous laser Doppler flowmetry: 
applications and findings. Mayo Clin Proc, 69, 564-74. 
SCHARTE, M., HAN, X., BERTGES, D. J., FINK, M. P. & DELUDE, R. L. 2003. 
Cytokines induce HIF-1 DNA binding and the expression of HIF-1-dependent genes 
in cultured rat enterocytes. Am.J.Physiol Gastrointest.Liver Physiol, 284, G373-G384. 
SCHMIDT-LUCKE C, B. M. P., SCHMIDT-LUCKE JA 2002. Low frequency 
ﬂowmotion/(vasomotion) during patho-physiological conditions. Life Sci, 71 
, 2713-28. 
SCHMITT, M., BLACKMAN, D. J., MIDDLETON, G. W., COCKCROFT, J. R. & 
FRENNEAUX, M. P. 2002. Assessment of venous capacitance. Radionuclide 
plethysmography: methodology and research applications. Br J Clin Pharmacol, 54, 
565-76. 
 315 
 
SCHNEIDER, E. M., LORENZ, I., MA, X. & WEISS, M. 2003. G-CSF modulates LPS-
induced apoptosis and IL-8 in human microvascular endothelial cells: involvement of 
calcium signaling. Ann.N.Y.Acad.Sci., 1010, 78-85. 
SCHRECK R FAU - ALBERMANN, K., ALBERMANN K FAU - BAEUERLE, P. A. & 
BAEUERLE, P. A. Nuclear factor kappa B: an oxidative stress-responsive 
transcription factor of eukaryotic cells (a review). 
SCHRECK R FAU - MEIER, B., MEIER B FAU - MANNEL, D. N., MANNEL DN FAU - 
DROGE, W., DROGE W FAU - BAEUERLE, P. A. & BAEUERLE, P. A. 
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact 
cells. 
SCHRECK R FAU - RIEBER, P., RIEBER P FAU - BAEUERLE, P. A. & BAEUERLE, P. 
A. Reactive oxygen intermediates as apparently widely used messengers in the 
activation of the NF-kappa B transcription factor and HIV-1. 
SCHRODER, O., SCHULTE, K. M., OSTERMANN, P., ROHER, H. D., EKKERNKAMP, 
A. & LAUN, R. A. 2003. Heat shock protein 70 genotypes HSPA1B and HSPA1L 
influence cytokine concentrations and interfere with outcome after major injury. Crit 
Care Med., 31, 73-79. 
SCHROEDER, S., BORGER, N., WRIGGE, H., WELZ, A., PUTENSEN, C., HOEFT, A. & 
STUBER, F. 2003. A tumor necrosis factor gene polymorphism influences the 
inflammatory response after cardiac operation. Ann.Thorac.Surg., 75, 534-537. 
SCHULZ, R. 2005. Pleiotropic effects of statinsAcutely good, but chronically bad?*. Journal 
of the American College of Cardiology, 45, 1292-1294. 
SEAL, J. B. & GEWERTZ, B. L. 2005. Vascular dysfunction in ischemia-reperfusion injury. 
Ann Vasc Surg, 19, 572-84. 
SEGAL, S. S. 1994. Cell-to-cell communication coordinates blood flow control. 
Hypertension, 23, 1113-20. 
SERRANO HERNANDO, F. A. C., A 2007. Peripheral Artery Disease: Pathophysiology, 
Diagnosis, 
and Treatment. Rev Esp Cardiol., 60, 969-82. 
SESSA, W. C. 1994. The nitric oxide synthase family of proteins. J Vasc Res, 31, 131-43. 
SHALHOUB, J., FALCK-HANSEN, M. A., DAVIES, A. H. & MONACO, C. 2011. Innate 
immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond), 
8, 9. 
SHASTRY, S., MINSON, C. T., WILSON, S. A., DIETZ, N. M. & JOYNER, M. J. 2000. 
Effects of atropine and L-NAME on cutaneous blood flow during body heating in 
humans. J Appl Physiol, 88, 467-72. 
SHEARMAN, C. P. & SIMMS, M. H. 1988. Limb salvage surgery in a district general 
hospital: factors affecting outcome. Ann R Coll Surg Engl, 70, 262-3. 
SHEPHERD , A. Ö., PÅ 1990. Laser Doppler Blood Flowmetry. Hingham, Boston: Kluwer, 
57-72. 
SHIBANUMA, M., KUROKI, T. & NOSE, K. 1990. Stimulation by hydrogen peroxide of 
DNA synthesis, competence family gene expression and phosphorylation of a specific 
protein in quiescent Balb/3T3 cells. Oncogene, 5, 1025-32. 
SHIN, W. S., SZUBA, A. & ROCKSON, S. G. 2002. The role of chemokines in human 
cardiovascular pathology: enhanced biological insights. Atherosclerosis, 160, 91-102. 
SIEMIONOW, M. & ARSLAN, E. 2004. Ischemia/reperfusion injury: a review in relation to 
free tissue transfers. Microsurgery, 24, 468-475. 
SILVESTRO, A., SCOPACASA, F., OLIVA, G., DE CRISTOFARO, T., IULIANO, L. & 
BREVETTI, G. 2002a. Vitamin C prevents endothelial dysfunction induced by acute 
exercise in patients with intermittent claudication. Atherosclerosis, 165, 277-83. 
 316 
 
SILVESTRO, A., SCOPACASA, F., OLIVA, G., DE CRISTOFARO, T., IULIANO, L. & 
BREVETTI, G. 2002b. Vitamin C prevents endothelial dysfunction induced by acute 
exercise in patients with intermittent claudication. Atherosclerosis, 165, 277-283. 
SILVESTRO, A., SCOPACASA, F., RUOCCO, A., OLIVA, G., SCHIANO, V., 
ZINCARELLI, C. & BREVETTI, G. 2003. Inflammatory status and endothelial 
function in asymptomatic and symptomatic peripheral arterial disease. Vascular 
Medicine, 8, 225-232. 
SIMS, D. E. 1986. The pericyte--a review. Tissue Cell, 18, 153-74. 
SLADE, M. S., SIMMONS, R. L., YUNIS, E. & GREENBERG, L. J. 1975. 
Immunodepression after major surgery in normal patients. Surgery, 78, 363-372. 
SMITH, F. B., LOWE, G. D., LEE, A. J., RUMLEY, A., LENG, G. C. & FOWKES, F. G. 
1998. Smoking, hemorheologic factors, and progression of peripheral arterial disease 
in patients with claudication. J Vasc Surg, 28, 129-35. 
SOCHA, L. A., GOWARDMAN, J., SILVA, D., CORRECHA, M. & PETROSKY, N. 2006. 
Elevation in interleukin 13 levels in patients diagnosed with systemic inflammatory 
response syndrome. Intensive Care Med., 32, 244-250. 
SORENSEN, K. E., KRISTENSEN, I. B. & CELERMAJER, D. S. 1997. Atherosclerosis in 
the human brachial artery. J.Am.Coll.Cardiol., 29, 318-322. 
SPRIGGS, D. R., SHERMAN, M. L., FREI, E., III & KUFE, D. W. 1987. Clinical studies 
with tumour necrosis factor. Ciba Found.Symp., 131, 206-227. 
SRINIVAS, P. R., KRAMER, B. S. & SRIVASTAVA, S. 2001. Trends in biomarker 
research for cancer detection. Lancet Oncol, 2, 698-704. 
STEFANOVSKA A, B. M., KVERNMO K 1999. Wavelet analysis of oscillations in the 
peripheral blood circulation measured by laser Doppler technique. IEEE Trans 
Biomed Eng, 46, 1230-9. 
STEHOUWER, C. D., FISCHER, H. R., VAN KUIJK, A. W., POLAK, B. C. & DONKER, 
A. J. 1995. Endothelial dysfunction precedes development of microalbuminuria in 
IDDM. Diabetes, 44, 561-4. 
STERN, M. D. 1975a. In vivo evaluation of microcirculation by coherent light scattering. 
Nature, 254, 56-8. 
STERN, M. D. 1975b. In vivo evaluation of microcirculation with coherent light scattering. 
Nature (London), 254, 56-8. 
STERN, M. D., LAPPE, D. L., BOWEN, P. D., CHIMOSKY, J. E., HOLLOWAY, G. A., 
JR., KEISER, H. R. & BOWMAN, R. L. 1977. Continuous measurement of tissue 
blood flow by laser-Doppler spectroscopy. Am.J.Physiol, 232, H441-H448. 
STERNBERG, E. M. 2001. Neuroendocrine regulation of autoimmune/inflammatory disease. 
J Endocrinol, 169, 429-35. 
STEVENS, T., GARCIA, J. G., SHASBY, D. M., BHATTACHARYA, J. & MALIK, A. B. 
2000. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung 
Cell Mol Physiol, 279, 419-422. 
STEVENS, T., ROSENBERG, R., AIRD, W., QUERTERMOUS, T., JOHNSON, F. L., 
GARCIA, J. G., HEBBEL, R. P., TUDER, R. M. & GARFINKEL, S. 2001. NHLBI 
workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am J 
Physiol Cell Physiol, 281, 1422-1433. 
STRACHAN, F. E. & WEBB, D. J. 2002. Local forearm vasoconstriction to endothelin-1 
measured by venous occlusion plethysmography in vivo. Methods Mol Biol, 206, 229-
37. 
SUFFREDINI, A. F., FROMM, R. E., PARKER, M. M., BRENNER, M., KOVACS, J. A., 
WESLEY, R. A. & PARRILLO, J. E. 1989. The cardiovascular response of normal 
humans to the administration of endotoxin. N.Engl.J.Med., 321, 280-287. 
 317 
 
SUTHERLAND, A. M., WALLEY, K. R., MANOCHA, S. & RUSSELL, J. A. 2005a. The 
association of interleukin 6 haplotype clades with mortality in critically ill adults. 
Arch.Intern.Med., 165, 75-82. 
SUTHERLAND, A. M., WALLEY, K. R. & RUSSELL, J. A. 2005b. Polymorphisms in 
CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased 
prevalence of infection in critically ill adults. Crit Care Med., 33, 638-644. 
SUVORAVA, T. & KOJDA, G. 2007. Prevention of transient endothelial dysfunction in 
acute exercise: a friendly fire? Thromb.Haemost., 97, 331-333. 
SUVORAVA, T. & KOJDA, G. 2009. Reactive oxygen species as cardiovascular mediators: 
Lessons from endothelial-specific protein overexpression mouse models. Biochimica 
et Biophysica Acta (BBA) - Bioenergetics, 1787, 802-810. 
SUVORAVA, T., LAUER, N., KUMPF, S., JACOB, R., MEYER, W. & KOJDA, G. 2005. 
Endogenous vascular hydrogen peroxide regulates arteriolar tension in vivo. 
Circulation, 112, 2487-95. 
SUZUKI, Y. J. & PACKER, L. 1993. Inhibition of NF-kappa B activation by vitamin E 
derivatives. Biochem Biophys Res Commun, 193, 277-83. 
TABRIZCHI, R. & PUGSLEY, M. K. 2000. Methods of blood flow measurement in the 
arterial circulatory system. J Pharmacol Toxicol Methods, 44, 375-84. 
TANG XQ FAU - YU, H.-M., YU HM FAU - ZHI, J.-L., ZHI JL FAU - CUI, Y., CUI Y 
FAU - TANG, E.-H., TANG EH FAU - FENG, J.-Q., FENG JQ FAU - CHEN, P.-X. 
& CHEN, P. X. Inducible nitric oxide synthase and cyclooxgenase-2 mediate 
protection of hydrogen peroxide preconditioning against apoptosis induced by 
oxidative stress in PC12 cells. 
TEDESCO, F., FISCHETTI, F., PAUSA, M., DOBRINA, A., SIM, R. B. & DAHA, M. R. 
1999. Complement-endothelial cell interactions: pathophysiological implications. Mol 
Immunol, 36, 261-268. 
TENLAND T, S. E., NIELSSON GE, OBERG PA 1983a. Spatial and temporal variations in 
human skin blood flow. Int J Microcirc Clin Exp, 2, 81-90. 
TENLAND T, S. E., NIELSSON GE, OBERG PA 1983b. Spatial and temporal variations in 
human skin blood flow. Int J Microcirc Clin Exp, 2, 81-90. 
TEOH, N. C. & FARRELL, G. C. 2003. Hepatic ischemia reperfusion injury: pathogenic 
mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol, 18, 891-902. 
THADHANI, R., PASCUAL, M. & BONVENTRE, J. V. 1996. Acute renal failure. N Engl J 
Med, 334, 1448-1460. 
THOMPSON, E. B. 1998. Special topic: apoptosis. Annu Rev Physiol, 60, 525-32. 
THRUSH, A. H., T 2004. Peripheral Vascular Ultrasound: How, Why and When. 2 ed. 
Elsevier Health Sciences. 
TISI, P. V., HULSE, M., CHULAKADABBA, A., GOSLING, P. & SHEARMAN, C. P. 
1997. Exercise training for intermittent claudication: does it adversely affect 
biochemical markers of the exercise-induced inflammatory response? Eur J Vasc 
Endovasc Surg, 14, 344-50. 
TISI, P. V. & SHEARMAN, C. P. 1998a. Biochemical and inflammatory changes in the 
exercising claudicant. Vasc Med, 3, 189-98. 
TISI, P. V. & SHEARMAN, C. P. 1998b. Biochemical and inflammatory changes in the 
exercising claudicant. Vasc Med, 3, 189-198. 
TOUYZ, R. M. 2004. Reactive oxygen species and angiotensin II signaling in vascular cells -
- implications in cardiovascular disease. Braz J Med Biol Res, 37, 1263-73. 
TOUYZ, R. M. & SCHIFFRIN, E. L. 2000. Signal transduction mechanisms mediating the 
physiological and pathophysiological actions of angiotensin II in vascular smooth 
muscle cells. Pharmacol Rev, 52, 639-672. 
 318 
 
TUBARO, F., MICOSSI, E. & URSINI, F. 1996. The antioxidant capacity of complex 
mixtures by kinetic analysis of crocin bleaching inhibition. Journal of the American 
Oil Chemists’ Society, 73, 173-179. 
TZOULAKI, I., MURRAY, G. D., LEE, A. J., RUMLEY, A., LOWE, G. D. & FOWKES, F. 
G. 2005. C-reactive protein, interleukin-6, and soluble adhesion molecules as 
predictors of progressive peripheral atherosclerosis in the general population: 
Edinburgh Artery Study. Circulation, 112, 976-83. 
URBAN, T., HURBAIN, I., URBAN, M., CLEMENT, A. & HOUSSET, B. 1995. [Oxidants 
and antioxidants. Biological effects and therapeutic perspectives]. Ann Chir, 49, 427-
34. 
URSINO M, C. A., BERTUGLIA S 1998. Vasomotion and blood ﬂow regulation in hamster 
skeletal muscle microcirculation: a theoretical and experimental study. Microvasc 
Res, 56, 233-52. 
URSINO M, C. S., BERTUGLIA S, COLANTUONI A 1996. Theoretical analysis of 
complex oscillations in multibranched microvascular networks. Microvasc Res, 23, 
229-49. 
URSINO M, F. G. 1992. Role of the myogenic mechanism in the genesis of microvascular 
oscillation (vasomotion): analysis with a mathematical model. Microvasc Res, 43, 
156-77. 
VALLANCE, P., COLLIER, J. & MONCADA, S. 1989. Effects of endothelium-derived 
nitric oxide on peripheral arteriolar tone in man. Lancet, 2, 997-1000. 
VERBEUREN, T. J., JORDAENS, F. H., ZONNEKEYN, L. L., VAN HOVE, C. E., 
COENE, M. C. & HERMAN, A. G. 1986. Effect of hypercholesterolemia on vascular 
reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent 
contractions and relaxations in isolated arteries of control and hypercholesterolemic 
rabbits. Circ.Res., 58, 552-564. 
W, S. 1893. Die vertheilung der blutgefasse in der haut. Arch Anat. 
WAGNER, D. A., YOUNG, V. R. & TANNENBAUM, S. R. 1983. Mammalian nitrate 
biosynthesis: incorporation of 15NH3 into nitrate is enhanced by endotoxin treatment. 
Proc Natl Acad Sci U S A, 80, 4518-21. 
WAHLBERG, E. & FAGRELL, B. 1994. Spatial and temporal variation in laser Doppler flux 
values in healthy lower limbs: comparison between the standard and the multiprobe. 
Int J Microcirc Clin Exp, 14, 343-6. 
WAHLBERG, E., JORNESKOG, G., OLOFSSON, P., SWEDENBORG, J. & FAGRELL, B. 
1990. The influence of reactive hyperemia and leg dependency on skin 
microcirculation in patients with peripheral arterial occlusive disease (PAOD), with 
and without diabetes. Vasa, 19, 301-306. 
WAHLBERG, E., LINE, P. D., OLOFSSON, P. & SWEDENBORG, J. 1994. Correlation 
between peripheral vascular resistance and time to peak flow during reactive 
hyperaemia. Eur J Vasc Surg, 8, 320-5. 
WANG, L. J., LEE, T. S., LEE, F. Y., PAI, R. C. & CHAU, L. Y. 1998. Expression of heme 
oxygenase-1 in atherosclerotic lesions. Am.J.Pathol., 152, 711-720. 
WARD, B. J. & MCCARTHY, A. 1995. Endothelial cell "swelling" in ischaemia and 
reperfusion. J Mol Cell Cardiol, 27, 1293-300. 
WASCHER, T. C., BAMMER, R., STOLLBERGER, R., BAHADORI, B., WALLNER, S. 
& TOPLAK, H. 1998. Forearm composition contributes to differences in reactive 
hyperaemia between healthy men and women. Eur J Clin Invest, 28, 243-8. 
WATANABE, E., HIRASAWA, H., ODA, S., MATSUDA, K., HATANO, M. & 
TOKUHISA, T. 2005. Extremely high interleukin-6 blood levels and outcome in the 
 319 
 
critically ill are associated with tumor necrosis factor- and interleukin-1-related gene 
polymorphisms. Crit Care Med., 33, 89-97. 
WATERER, G. W., QUASNEY, M. W., CANTOR, R. M. & WUNDERINK, R. G. 2001. 
Septic shock and respiratory failure in community-acquired pneumonia have different 
TNF polymorphism associations. Am.J.Respir.Crit Care Med., 163, 1599-1604. 
WAYNER, D. D. M., BURTON, G. W., INGOLD, K. U., BARCLAY, L. R. C. & LOCKE, 
S. J. 1987. The relative contributions of vitamin E, urate, ascorbate and proteins to the 
total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochimica 
et Biophysica Acta (BBA) - General Subjects, 924, 408-419. 
WEBSTER, J. I., TONELLI, L. & STERNBERG, E. M. 2002. Neuroendocrine regulation of 
immunity. Annu Rev Immunol, 20, 125-163. 
WEITZ, J. I., BYRNE, J., CLAGETT, G. P., FARKOUH, M. E., PORTER, J. M., 
SACKETT, D. L., STRANDNESS, D. E., JR. & TAYLOR, L. M. 1996. Diagnosis 
and treatment of chronic arterial insufficiency of the lower extremities: a critical 
review. Circulation, 94, 3026-49. 
WERNLY, J. A. 2004. Ischemia, reperfusion, and the role of surgery in the treatment of 
cardiogenic shock secondary to acute myocardial infarction: an interpretative review. 
J Surg Res, 117, 6-21. 
WHITTON, J. T. & EVERALL, J. D. 1973. The thickness of the epidermis. Br J Dermatol, 
89, 467-76. 
WIJNEN, M. H., COOLEN, S. A., VADER, H. L., REIJENGA, J. C., HUF, F. A. & 
ROUMEN, R. M. 2001. Antioxidants reduce oxidative stress in claudicants. J Surg 
Res, 96, 183-7. 
WINTERS, J. P., AA Hemapheresis. In (Henry, 2001). 
WOOD, R. E., SANDERSON, B. E., ASKEW, C. D., WALKER, P. J., GREEN, S. & 
STEWART, I. B. 2006. Effect of training on the response of plasma vascular 
endothelial growth factor to exercise in patients with peripheral arterial disease. 
Clin.Sci.(Lond), 111, 401-409. 
WOOLF, N. 1998. Pathology: Basic and Systemic. 1 ed. Philadelphia: Elsevier. 
WOUTERS, C. W., WEVER, K. E., BRONCKERS, I., HOPMAN, M. T., SMITS, P., 
THIJSSEN, D. H. & RONGEN, G. A. 2012. Short-term statin treatment does not 
prevent ischemia and reperfusion-induced endothelial dysfunction in humans. J 
Cardiovasc Pharmacol, 59, 22-8. 
WUNG, B. S., CHENG, J. J., CHAO, Y. J., LIN, J., SHYY, Y. J. & WANG, D. L. 1996. 
Cyclical strain increases monocyte chemotactic protein-1 secretion in human 
endothelial cells. Am J Physiol, 270, H1462-8. 
YE, Y., PEREZ-POLO, J. R. & BIRNBAUM, Y. 2010. Protecting against ischemia-
reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Ann N Y 
Acad Sci, 1207, 76-82. 
YEH H, C. H. 1964. Localised fluid flow measurements with a He-Ne laser spectrometer. 
Appl Phys Lett, 4, 176-8. 
YEUM, K. J., RUSSELL, R. M., KRINSKY, N. I. & ALDINI, G. 2004. Biomarkers of 
antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. 
Arch Biochem Biophys, 430, 97-103. 
YSEBAERT, D. K., DE GREEF, K. E., DE BEUF, A., VAN ROMPAY, A. R., 
VERCAUTEREN, S., PERSY, V. P. & DE BROE, M. E. 2004. T cells as mediators 
in renal ischemia/reperfusion injury. Kidney Int, 66, 491-496. 
YUEN, C. T., KIND, P. R., PRICE, R. G., PRAILL, P. F. & RICHARDSON, A. C. 1984. 
Colorimetric assay for N-acetyl-beta-D-glucosaminidase (NAG) in pathological urine 
using the omega-nitrostyryl substrate: the development of a kit and the comparison of 
 320 
 
manual procedure with the automated fluorimetric method. Ann Clin Biochem, 21 ( Pt 
4), 295-300. 
ZIEGLER, S., KUDLACEK, S., LUGER, A. & MINAR, E. 2005. Osteoprotegerin plasma 
concentrations correlate with severity of peripheral artery disease. Atherosclerosis, 
182, 175-80. 
ZORATTI M, S. I., DE MU 2005. Mitochondrial permeability transitions: How many doors 
to the house? Biochem Biophys Res Commun, 1706, 40-52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Appendix 
 
Appendix A: ELISA technique for plasma level of MCP-1  
Preparation before entering step 1:  
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 a all agent from the refrigerator were bring to be at room 
temperature(RT) as well as sample plasma was bring 
from the freezer to be thawing at RT. 
 
 b buffer were prepared:  
  b1 Coating buffer 1.59 g Na2CO3, 2.93 g NaCO3, 
0.2 g NaN3 making up to 1 litre distilled water 
(dH2O) store a 40C for 2 weeks 
 
  b2 Washing buffer PBS (pH7.4): 8 g NaCl, 0.2 g 
KH2PO4, 2.9 g NaHPO4. 12H2O, and 0.2 g KCl 
making up to 1 litre distilled water (dH2O) 
 
  b3 Washing buffer PBS-T (PBS-Tween 20): 0.5 ml 
of tween 20 to 1 litre of prepared PBS as 
described above 
 
 c Sets of cytokines standard (TNF-α standard, IL-6 
standard and IL-10 standard) were prepared at an interval 
of concentration as a control series known concentration 
at 0---0.156---0.312---0.625---1.25---2.5---5---10---15---
25---50---100 pg/ml 
 
 d Mapping well plate to identify what each well will 
contain 
 
Step 1 Capture antibody  
 a monoclonal antibody specific to each studied cytokines 
was applied for pre-coating micro plate following the 
plate map  
 
 b all the microplate was left at RT for half an hour  
 c all the microplate was inverted to pour out its content  
Step 2 Cytokine adding  
 a 100 µl of standard and samples containing the studies 
cytokines were pipetted into each well by the 
concentration following to the previous mark of platemap 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
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 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by buffer six times to remove 
the unbounds 
 
Step 3 Enzyme-conjugated antibody adding  
 a 200 µl of Enzyme-conjugated antibody [Alkaline 
phosphatase (ALP) (enzyme)=cytokine specific 
polyclonal antibody (conjugate)] was add to each well 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
 
 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by buffer six times to remove 
the unbounds 
 
Step 4 Color development   
 a 50 µl of Substrate (Naphthyl phosphate) was 
immediately added to each well in order to release of 
colorless Naphthol and Phosphoric Acid (H3PO4) 
 
 b The microplates were cover with cling film and left on 
the bench to incubate at room temperature for one hour 
 
 c 50 µl of Amplifier solution (Nitryl phenyl phosphate) 
was added to make color 
 
 d The microplates were cover with cling film and left on 
the bench to incubate at room temperature for 10 minutes 
 
 e Stop solution was added  
     
Step 5 Spectrophotometrical calibration  
  The purple solution in the well-plate were calibrated by 
filter set at wavelength 405 nm and between 492 and 620 
nm and read by spectrophotometer. The result of 
cytokines concentration was reported in unit of pg/ml.  
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Appendix B: ELISA technique of Urine concentration of NAG 
 
Preparation before entering step 1:  
 a all agent from the refrigerator were bring to be at room 
temperature(RT) as well as sample plasma was bring 
from the freezer to be thawing at RT. 
 
 b buffer were prepared:   
  b1 Coating buffer 1.59 g Na2CO3, 2.93 g NaCO3, 
0.2 g NaN3 making up to 1 litre distilled water 
(dH2O) store a 40C for 2 weeks 
 
  b2 Incubation buffer: a mixture of citric acid 
monohydrate and dipotassium hydrogen 
phosphate 
 
  b3 Washing buffer PBS (pH7.4): 8 g NaCl, 0.2 g 
KH2PO4, 2.9 g NaHPO4. 12H2O, and 0.2 g KCl 
making up to 1 litre distilled water (dH2O) and 
/ or  
 
  b4 Washing buffer PBS-T (PBS-Tween 20): 0.5 
ml of tween 20 to 1 litre of prepared PBS as 
described above 
 
  b5 Color development buffer: a solution of 
potassium carbonate and potassium hydrogen 
carbonate at pH 9.5 (alkaline buffer or 
amplifier solution) 
 
 c Sets of sodio-m-cresolsulfonphthaleinyl N-acetyl-β-D-
glucosaminase standard were prepared at an interval of 
concentration as a control series known concentration at 
0---0.156---0.312---0.625---1.25---2.5---5---10---15---
25---50---100---200 pg/ml 
 
 d Mapping well plate to identify what each well will 
contain 
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Step 1 Cytokine adding  
 a 100 µl of standard and samples containing the studied    
sodio-m-cresolsulfonphthaleinyl-N-acetyl-β-D-
glucosaminase were pipetted into each well by the 
concentration following to the previous mark of 
platemap 
 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
 
 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by washing buffer six times to 
remove the unbounds 
 
Step 2 Enzyme-conjugated antibody adding  
 a 200 µl of Enzyme-conjugated antibody [sodio-m-
cresolsulfonphthaleinyl N-acetyl-β-D-glucosaminase 
(enzyme)=specific polyclonal antibody of NAG 
(conjugate)] was added to each well 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
 
 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by buffer six times to remove 
the unbounds 
 
Step 3 Color development   
 a 50 µl of substrate [2-methoxy-4-(2’-nitrovinyl) phenyl-
2acentamido-2-deoxy-β-D-glucopyranoside (MNP-Glc 
NAC) in 0.005M HCL (yellow solution)] was 
immediately added to each well in order to release of 2-
Methoxy-4(2’nitrovinyl)-phenol 
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 b The microplates were cover with cling film and left on 
the bench to incubate at room temperature for one hour 
 
 c 50 µl of alkaline buffer (amplifier solution) was added to 
make  red color 
 
 d The microplates were cover with cling film and left on 
the bench to incubate at room temperature for 10 minutes 
 
 e Stop solution was added  
    
    
Step 4 Spectrophotometrical calibration  
  The intensity of red color was measured by 
spectrophotometer at 505 nm wavelength 
 
     
Factoring with creatinine concentration  
 a Urine creatinine concentration is measured by using 
automated urinalysis machine 
 
 b Each value of urine NAG obtained from step 4 needs to 
be factored with the concentration of creatinine since 
each subject has produced a different amount of urine 
volume at the time of collection. 
 
 c The unit of urine NAG is then presented as µmol / mMol 
creatinine 
 
 
 
 
 
 
 
Appendix C: FORT test for plasma level of free radicals  
Preparation before entering step 1:  
 a 20µl of capillary blood or venous blood was drawn up 
into a heparinized capillary tube. 
 
 b Reagents:  
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  R1 chromogen  
  R2 pH 5.0 buffer solution and stabilizer.  
 c Blood was stored on ice after phlebotomy and all tests 
were completed within one hour of taking samples. R1 
and R2 were stored at room temperature in foil blister 
pack as per manufacturers instructions. 
 
 Test procedure  
 a Place the capillary tube with the whole blood sample 
(20µl) into the FORT R2 reagent tube. 
 
 b Gently rock up and down a few times until the capillary 
has been emptied of the blood. 
 
 c Pour the contents into the FORT R1 reagent cuvette and 
rock gently for a matter of seconds. 
 
 d Centrifuge for 1 minute at approx. 3500rpm1. Once the 
centrifugation is over, make sure that the supernatant is 
clear. 
 
 e Place the activated cuvette into the reading cell and 
testing begins automatically. The result is available after 
6 minutes. 
 
 
Appendix D: FORD test for plasma level of antioxidants 
 
 
Preparation before entering step 1:  
 a 50µl of capillary blood or venous blood was drawn up 
into a heparinized capillary tube. 
 
 b Reagents:  
  S1 Hyperosmolar buffer  
  S2 pH 5.2 acetate buffer.  
  S3 Iron solution  
  C1 chromogen.  
 c Blood was stored on ice after phlebotomy and all tests 
were completed within one hour of taking samples. 
Reagents were stored at room temperature in foil blister 
 
 327 
 
pack as per manufacturers instructions. 
 Test procedure  
 a Pour the content of the S2 (BLUE labeled tube) into a 
new C1 square cuvette. 
 
 b Add 50µl of the S3 reagent using the pipette 
supplied1; close the cap tightly and rock gently until the 
reagent has dissolved completely. Place the cuvette into 
the reading cell. The first reading is performed after 4 
minutes. 
 
 c In the meantime, place the collected blood (50µl) into the 
S1 reagent tube (WHITE tube) and gently rock up and 
down a few times. 
 
 d Centrifuge for 1 minute at approx. 3500rpm to obtain the 
supernatant. 
 
 e At the end of the phase 2, remove the cuvette and pipette 
50µl of the supernatant sample twice (therefore 100µl) 
using the pipette supplied. 
 
 f Place the activated cuvette into the reading cell for the 
second reading. The result is available after 2 minutes. 
 
 
 
 
 
 
 
 
Appendix E: Demographic data for individual participants 
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 Age Sex Height 
(m) 
Weight 
(kg) 
BMI 
(kg/m
2) 
Blood 
pressure 
(mmHg) 
Pulse 
(beats 
per 
minute) 
High 
BP 
IHD DM High 
cholesterol 
Smoker Medication 
1 80 M 
1.81 91 27.8 136/67 68 Yes No No Yes Ex 
Aspirin ,Lansoprazole, Tamsulosin, , Atorvastatin, Finasteride, 
Amlodipine, Irbesartan 
2 84 F 1.5 54 24 128/78 72 Yes No No Yes Yes Aspirin, Spiriva inhaler, salbutamol inhaler, simvastatin 
3 80 M 1.8 68 21 138/64 60 No No No No No Aspirin, Tolterodine 
4 80 F 1.55 67 27.9 187/96 68 Yes Yes No Yes No Aspirin,Clopidogrel,simvastatin, bisoprolol 
5 69 M 1.75 110 35.9 142/80 83 Yes Yes No Yes No Aspirin , Simvastatin 
6 57 F 1.58 68 27.2 171/73 73 Yes No No No ex Aspirin, Atorvastatin, ramipril 
7 71 F 
1.53 61 26.1 158/60 78 Yes No Yes Yes No 
Aspirin , simvastatin, Metformin, , Insulin, Gliclazide, 
Enalapril, Amlodipine, and Bendrofluazide 
8 78 M 1.8 81 25 148/76 53 No Yes No Yes ex Aspirin, Atovastin, omeprazole and Atenolol 
9 61 F 1.62 117 44.6 130/80 62 No No Yes No No Amiodarone, Warfarin 
10 64 F 1.72 70 23.7 114/70 72 No No No Yes Ex Simvastatin 
11 65 M 1.75 95 31 120/72 104 Yes No Yes No No Metformin, Ramipril 
12 66 M 1.7 87 30.1 145/91 94 No No No No ex None 
13 66 F 1.69 55 19.2 159/77 55 Yes Yes No Yes No Aspirin , Omeprazole, Carvedilol,  Rosuvastatin 
14 83 M 1.85 80 23.4 135/87 111 Yes No No Yes Yes Enalapril, Cilostasol 
15 55 M 1.76 75 24.2 111/78 88 Yes No No Yes Ex Aspirin , Amlodipine, Pravastatin 
16 76 F 
1.55 64 26.6 165/72 84 Yes No Yes Yes No 
Bendrofluazide, Simvastatin, Irbesartan, Metformin, Insulin, 
Omeprazole, Ursodeoxycholic acid 
17 73 M 1.68 62 22 166/77 101 Yes No Yes No Yes Bendrofluazide 
18 72 F 1.53 70 29.9 128/78 78 Yes Yes No No Ex Aspirin , Clopidogrel and simvastatin 
19 66 M 1.72 100 33.8 142/72 78 No Yes Yes Yes Ex  Metformin, Simvastatin 
20 81 M 1.62 62 23.6 173/76 89 Yes No No Yes Ex Aspirin , Simvastatin, Quinine, Bendrofluazide 
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TABLE 5. PUBLISHED LITERATURE REGARDING GENETIC FACTORS AFFECTING SIRS. 
Author, date 
and country 
Patient group 
Study type 
(level of 
evidence) 
Outcomes Key results 
(Watanabe et 
al., 2005) 
113 ICU patients with sequential 
organ failure score of ≥ 5 
Prospective 
cohort study 
IL-6 max, survival, and septic 
complications were compared between 
carriers and non-carriers of less frequent 
alleles 
Carriers of less frequent alleles in IL-1-related 
polymorphisms appear to have significant 
vulnerability to production of excessive IL-6 blood 
levels and to deterioration in septic shock 
(Hildebrand et 
al., 2005) 
97 injured patients. Injury 
Severity Score >16, age 18 to 60 
years, and a survival >48 h after 
injury 
Prospective 
cohort study 
Four different polymorphisms (TNF-
Nco1, IL-1-Taq1, IL-6-174G/C, and IL-
8-251A/T) were determined in patients 
who did and did not develop SIRS 
The IL-6-174G/C polymorphism was associated 
with the severity of posttraumatic SIRS 
(Sutherland et 
al., 2005b) 
252 patients with SIRS 
Prospective 
cohort study 
C-159T CD14, the X/Y and B, C, and D 
polymorphisms of mannose-binding 
lectin, and T-16933A Toll-like receptor-
2 were genotyped. tested for association 
Mannose-binding lectin haplotype pairs XO/O and 
O/O were also associated with increased 
prevalence of positive bacterial cultures. Toll-like 
receptor-2 -16933AA was associated with 
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of genotype with prevalence of positive 
bacterial cultures, type of organism 
(Gram-positive, Gram-negative, other), 
sepsis and septic shock at admission to 
the intensive care unit, and 28-day 
survival. 
increased prevalence of sepsis and with Gram-
positive bacteria. 
(Watanabe et 
al., 2005) 
150 ICU patients with IL-6 
levels > or =10,000 pg/mL and 
150 healthy subjects 
Case control 
Allelic frequencies of polmorphisms of  
IL6, IL1β and TNF of patients with IL-6 
peak levels of > or =10,000 pg/mL 
(group A) were compared with those of 
patients with IL-6 peak levels of 
<10,000 pg/mL (group B) 
The IL-6 peak levels were significantly correlated 
with simultaneously measured TNF. 
TNF-308*A, IL1RN*2, and IL1RN*3 alleles were 
associated with the prevalence of the extremely 
high IL-6 blood level in the critically ill, their 
uncontrollable blood IL-6 kinetics, and outcome 
(Sutherland et 
al., 2005a) 
228 critically ill white patients 
who met at least 2 of 4 SIRS 
criteria 
Cohort study 
28-day mortality and multi-organ 
dysfunction 
Patients who had 2 copies of haplotypes from 
within the IL6 haplotype clades -
174C/1753C/2954G (C/C/G), G/G/G, or G/C/C 
had a greater 28-day mortality compared with 
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patients who carried 1 or no copies of these 
haplotypes (40.0% vs 26.0%; P = .02) 
(Fidler et al., 
2004) 
One hundred consecutive 
admissions to a PICU with at 
least one organ system failure 
longer than 12 h 
Cohort study Development of SIRS 
Variant Mannose Binding Lectin (MBL) alleles 
were significantly over-represented amongst the 
59 patients that developed SIRS 
(Garred et al., 
2003) 
272 patients with systemic 
inflammatory response 
syndrome 
Prospective 
cohort 
different MBL genotypes were 
compared, with respect to microbiology, 
sepsis development, and survival 
MBL variant alleles was associated with the 
development of sepsis, severe sepsis, and septic 
shock. An increased risk of fatal outcome was 
observed in patients carrying variant alleles 
(Dumon et al., 
1998) 
Surgical ITU patients with SIRS 
and sepsis 
Cohort 
 
determined the TNFA polymorphism 
(position--308) and related these data to 
plasma cytokine levels of TNF alpha, 
IL6, IL6R and IL8 
clear risk group could not be determined 
(Calvano et al., 
2003) 
44 surgical ITU patients 
Prospective 
cohort 
incidence of sepsis, septic shock, or 
mortality between patients bearing the 
There was no difference in the  
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various alleles 
     
(Child et al., 
2003) 
 cohort severity of SIRS 
A trend between the minor allele of TLR4 and 
mortality in SIRS (odds ratio of 4.3; P =0.076),  
(Schroeder et 
al., 2003) 
Cardiac patients, 47 with CPB 
and 36 without 
Case control 
 
TNF alpha plasma level and TNF 
genotype 
Patients homozygous for the TNF-B2 allele 
showed significantly higher TNF-alpha plasma 
levels after termination of CPB compared with 
non-CPB patients 
(Gallagher et 
al., 2003) 
Patient with community 
acquired pneumonia (CAP) 
Cohort study 
TNF alpha and IL-10 gene 
polymorphisms and SIRS score (1-4) 
There was a higher frequency of the GG genotype 
of IL-10 with increasing severity from non-SIRS 
through to SIRS 4. IL-10 G allele frequency was 
also increased in patients who died as a result of 
CAP (n=11) compared with CAP survivors (n=82) 
(p=0.01) 
(Schroder et 
al., 2003) 
80 consecutive severe trauma 
patients 
cohort 
Plasma concentrations of interleukin-6 
and tumour necrosis factor-alpha were 
Patients carrying the genotypes HSPA1B AG or 
HSPA1L CT had significantly higher plasma 
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measured over a 5 days. The genotypes 
of the polymorphisms HSPA1B (HSP70-
2) G1538A and HSPA1L (HSP70-Hom) 
C2437T were determined. 
concentrations of tumour necrosis factor-alpha and 
interleukin-6 compared with those with genotype 
GG or TT 
(Reid et al., 
2002) 
83 patients with MODS  
prevalence of genetic variation for 
cytokine production (tumour necrosis 
factor [TNF]-alpha, interleukin-10, 
transforming growth factor-beta1 
compared to clinical outcome. 
A genetic predisposition to high interleukin-10 
production or intermediate TNF-alpha production 
may be protective of admission to the intensive 
care unit, although once admitted, any protection 
provided by these genotypes seems to be lost. 
TNF-beta genotype conferred no advantage to 
patients with multiple organ dysfunction 
syndrome, the TNFB2 allele being associated with 
increased mortality 
(Waterer et al., 
2001) 
280 patients with CAP cohort 
LTalpha+250 (TNFbeta+250) and 
TNFalpha-308 gene polymorphisms and 
development of septic shock and 
Carrying at least one AA (tumour necrosis factor 
[TNF] high secretor) genotype had an 18.0% risk 
of SS versus 6.8% (p = 0.006). GG homozygotes 
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respiratory failure. (TNF low secretors) at both loci had only a 2.9% 
risk of SS. Septic shock was associated with the 
LTalpha+250:TNFalpha-308 A:G haplotype but 
not the A:A haplotype, suggesting that 
LTalpha+250 is a marker, rather than a causative 
polymorphism. Carriage of the G:G haplotype had 
a significant protective effect against the 
development of septic shock (p = 0.011). T1RF 
was not associated with LTalpha+250 AA 
genotype. In the absence of septic shock, there was 
a significant trend to greater T1RF in patients with 
LTalpha+250 GG (TNFα hyposecretor) genotype 
(p = 0.03). 
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1.7 Peripheral vascular disease and systemic inflammation 
1.7.1. Introduction  
Cardiovascular disease (CVD) associated with atherosclerosis is a common condition 
particularly in older patients. The lower limbs are among the most common sites for 
atheroma development or plaque obstructive lesions. By the nature of atherogenesis, it is 
believed that patients with PAOD have a prolong period of chronic inflammation in the 
arterial wall preceding the presence of ischaemic symptoms like claudication. Investigators 
found evidence of chronic inflammation associated with an elevation of circulatory pro-
inflammatory cytokines.  (Petersen and Pedersen, 2005) have suggested the term “chronic 
low-grade systemic inflammation” for conditions in which a typically two- to threefold 
increase in the systemic concentrations of TNF-α, IL-1β, IL-6, IL-10, IL-1ra, sTNF-R, and 
CRP are present in individuals with obese, aging, smokers, insulin resistance, type 2 diabetes 
mellitus and atherosclerosis. 
 
Ischaemia reperfusion injury is one of the main problems encountered in the management of 
CVD, which is one of the most common and debilitating modern illnesses. New approaches 
to the management of CVD have been developed, reperfusion therapeutic strategies including 
percutaneous transluminal angioplasty (PTA) and bypass surgery have become widely 
available both for CAD and PAOD and reduce morbidity and mortality for CVD patients. 
Presently, reperfusion therapy (revascularisation) has been accepted to benefit patients and 
effectively decrease the rate of mortality and morbidity for CVD disease. However, 
revascularisation that has achieved restoration of blood flow into ischaemic area, may also 
create an ischaemia reperfusion injury (IRI). Restoration of blood supply to previously 
ischaemic tissue can paradoxically injure these tissues by means of oxidative stress and acute 
inflammation. ROSs toxicity and neutrophil hypersensitivity have been suggested as the two 
keystones mediating the pathophysiological mechanisms of IRI (Kaminski et al., 2002). The 
ischaemic condition contributes to a low flow haemodynamic state and inadequate tissue 
oxygen supply, these lead to activation of PMN by means of parenchymal cells necrosis, 
haemoconcentration, blood cell packing. Once the ischaemic condition is relieved, the 
reperfusion increases oxygen supply to the previously ischaemic tissues which may result in 
oxidative stress. ROSs can further exacerbate PMN activation which are recruited to the 
tissue by restoration of blood flow which in turn amplifies oxidative stress by generating 
ROSs through their NADPH activity.  
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Another distinctive feature of IRI is a possible relationship between local IRI events and a 
systemic response, which can if unchecked lead to multi-organ pathologies and in some 
cases, even death. The immuno-reactive activities in the inflammatory processes are 
supposed to take place in the local region, however, local intense inflammation is presently 
accepted to be able to generate systemic immunoreactions due to the generation of circulating 
inflammatory mediators. Propagated through a number of molecular and cellular mediators, 
this local IRI can result in a systemic condition known as systemic immune responses (SIRs) 
(Grace PA, 1998). Evidence suggests that pro-inflammatory cytokines such as IL-1, IL-6, IL-
8, TNF, eicasanoids, complement and cell-adhesion-molecules (CAMs) are responsible for 
the global effects. The details of common proinflammatory mediators implicated in IRI are 
shown in Table 6. 
 
TABLE 6. BROAD GROUPINGS OF INFLAMMATORY MEDIATORS (WOOLF, 1998) 
Source  Mediators  
   
Activated plasma protein cascades Complement system 
Kinin system 
  Blood clotting activation 
  Fibrinolytic system such as plasmin 
   
Stored within cells and released on 
demand 
Histamine  
5- Hydroxytryptamine (seratonin) 
  Lysosomal components  such as MPO 
   
Newly synthesized in and released 
from cells on demand 
Eicasanoids such as prostaglandins, 
thromboxane and leukotriens 
  Platelet-activating factor 
  Cytokines such as IL-l, IL-6 and TNF 
   
 
The common source of the common proinflammatory cytokine IL-1 is produced by 
macrophage, endothelial cells, and activated PMN while the major sources of IL-6 are 
macrophage, endothelial cells as well as IL-8. The major sources of TNF are macrophage and 
PMN but not endothelial cells while the sources of IL-10 are macrophage and lymphocyte (as 
shown in Table 7) (Gallin, 1999). 
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TABLE 7. THE MAJOR SOURCES OF COMMON CYTOKINES (ADAPTED FROM (NORWOOD ET AL., 2004)) 
   
Cytokines Main sources and Cells of 
origin 
Effects 
   
IL-1β Macrophages, Neutrophil, 
Endothelium 
Endothelial activation, fever 
and neutrophil release 
  
   
TNF-α Macrophage, Neutrophil Endothelial activation, 
interfering endothelial nitric 
oxide synthesis, fever,  
neutrophil and macrophage 
activation and 
chemoattraction 
  
  
   
IL-6  Macrophage, Neutrophil,  
Endothelium and Monocytes 
Endothelial activation, Fever, 
neutrophil release and  acute 
phase protein synthesis 
   
IL-8 Macrophage, Neutrophil and 
Endothelium 
Neutrophil chemoattraction 
and activation 
   
IL-10 Macrophage and T-cells Inhibition of macrophage and 
T-cell function (anti-
inflammatory) 
  
 
It is accepted that the local tissue I/R condition is a resource of these inflammatory mediators, 
produced in large volumes and then secreted into the circulation. Therefore, IRI can lead to 
remote organs injury by a mechanism similar to SIRs seen in sepsis, burns and other kinds of 
severe injuries. 
 
Obviously, the derivative molecules of ROSs and RNSs have been suggested as a cause of 
oxidative injury. However, there are several inflammatory mediators responsible for 
generating the local and global effects and it is not possible to definitely identify one of those 
mediators as a single responsible cause. The aims of this study were to investigate IRI 
mechanisms and elucidated the progression of the pathophysiological consequences of IRI at 
the cellular level, in the microcirculation and to investigate the relationship between 
microcirculation of locally injured tissues and microcirculation of distant organs. 
Furthermore, it is an aim of this study to determine the relationship between mediators of IRI 
and the clinical outcome. 
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1.8 Molecular mechanisms of cytokines in ischaemia reperfusion 
injury 
1.8.1. Redox responsive transcriptional pathways 
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FIGURE 1-39. DIAGRAMMATIC REPRESENTATION OF THE ROLE OF NF-κB IN INFLAMMATORY PATHWAY 
SIGNALLING 
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1.8.2. Redox sensitive transcription factors 
 
Transcription factors are the nuclear components that are modulated by upstream signaling 
events. They interact with transcription factor specific DNA in the regulatory regions of 
genes, transcription factors to modulate the magnitude of gene expression. Redox-sensitive 
modulation of transcription factor activity may occur via direct oxidative modification of the 
transcription factor itself by intracellular ROS or by post-translational modifications (ie, 
phosphorylation/dephosphorylation), as a result of redox- regulated intracellular signaling 
cascades. 
 
Hypoxia inducible factor-1 (HIF-1) 
 
HIF-1 is a nuclear transcription factor important in the cellular response to ischaemia. It may 
confer protection against IR injury by triggering the activation of specific protective genes. 
iNOS is a known downstream target of HIF-1, and has been shown to be cardioprotective in 
acute and chronic heart disease (Tang Xq Fau - Yu et al., Bulhak Aa Fau - Sjoquist et al., 
Cuong Dv Fau - Kim et al., Jones Sp Fau - Bolli and Bolli). In murine microvascular 
endothelial cells, induction of HIF-1 expression produced a time- and dose-dependent 
increase in iNOS mRNA. These mice experienced a decrease in infarct size and cardiac 
dysfunction following global myocardial IR. The improved functional recovery was lost in 
iNOS knockout mice (Natarajan R Fau - Salloum et al.). 
 
Its expression and activation in cultured human intestinal type epithelial cells was compared 
in response to hypoxia and also a cytomix, (IFNγ, TNF, and IL-1β). Incubation of normoxic 
cells with cytomix, as well as hypoxia for 48 h both markedly increased HIF-1 DNA binding 
(Fink, 2002, Scharte et al., 2003). 
 
NFκB 
 
NFκB is a DNA binding protein, which is thought to play a pivotal role in activation of 
inflammatory pathways (Figure 1-39). In septic patients, NFκB activation in peripheral 
monocytes was shown to correlate well with mortality (Bohrer et al., 1997). Its mechanism of 
activation has recently been elucidated and is well reviewed elsewhere (Christman et al., 
1998). TNFα activates NFκB via binding to the type 1 TNF receptor (TNFR1), which then 
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through a series of signal transducing proteins activates NFκB inducing kinase (NIK). 
Activation of NIK results in phosphorylation of IκB kinases (IKK) which binds to and 
phosphorylates IκBα at serines 32 and 36. Phosphorylation of IκBα is targeted for destruction 
by the ubiquitinisation/ proteosome (26S) degradation pathway, allowing translocation of 
NFκB to the nucleus. 
 
IL-1β binding to the type 1 IL-1 receptor (IL-1R1) and IL-1 receptor accessory protein (IL-
1RacP), which facilitates an interaction between IL-1 receptor associated kinase (IRAK) and 
TNF receptor associated factor 6 (TRAF-6), which subsequently results in NIK, IKK and 
NFκB.  
 
Studies on neonatal rat cardiac cells have demonstrated that TNF α enhances the IL-2 
induced expression of iNOS mRNA, iNOS proteins and increased production of NO. The 
TNF α effects also included enhancement of the transcription factor NFκB activity. Both 
effects was blocked by a selective inhibitor of mitogen activated protein kinase (Kan et al., 
1999). Thus there is evidence to support elevation of NFκB activity and upregulation of NO 
production may be important pathways in the cytokine response in SIRS. 
 
Common to all of the activation mechanisms that lead to IκB degradation and NF-κB nuclear 
translocation has been suggested to involve ROS. The evidence for this is that inhibition of 
NF-kB activation is achieved by several chemically distinct antioxidants (Schreck R Fau - 
Rieber et al., Schreck R Fau - Albermann et al., Schreck R Fau - Meier et al.) (Suzuki and 
Packer, 1993). 
 
AP-1 
 
AP-1 behaves as a redox- sensitive transcription factor in several cell types and is 
activated, to different extents, under pro-oxidant conditions generated by treatment 
with agents such as superoxide, H2O2, and cytokines (Amstad et al., 1990, Shibanuma 
et al., 1990, Nose et al., 1991).  
 
In endothelial cells, agents such as H2O2  LDL, and oxLDL have been found to activate AP-1 
DNA binding activity. In smooth muscle cells, oxLDL, H2O2, and the lipid peroxidation 
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product 4-hydroxy-2-nonenal have been shown to increase AP-1 expression or DNA binding 
activity (Kunsch and Medford, 1999a).  
 
Interestingly, regulation of the vascular inflammatory genes MCP-1 and ICAM-1 by H2O2 is 
mediated by AP-1 binding elements in the promoters of these genes (Wung et al., 1996, 
Roebuck et al., 1995). 
 
In terms of the mechanism of redox mediated activation of AP-1; H2O2-induced AP-1 
activation requires both tyrosine and serine/threonine phosphorylation (Barchowsky et al., 
1995), and it has been suggested that AP-1 activation under oxidative conditions may be, at 
least in part, mediated by phosphorylation of Jun proteins (Gomez del Arco P Fau - Martinez-
Martinez et al.).Therefore, it appears that posttranslational modifications after oxidative stress 
may modulate AP-1 activity. 
 
Peroxisome Proliferator-Activated Receptors 
 
The PPARs are composed of members of the nuclear hormone receptor superfamily of 
transcription factors. This large and diverse group of proteins, mediate ligand-dependent 
transcriptional activation and repression (Mangelsdorf et al., 1995). PPARs are key control 
elements in lipid and glucose metabolism. Reports suggest that PPARs may play a role in 
inflammatory processes involved in the pathogenesis of atherosclerosis and restenosis due to 
their ability to modulate monocyte gene expression(Nagy et al., 1998, Jiang et al., 1998, 
Ricote M Fau - Li et al.). Also, PPAR expression and functional activity have recently been 
observed in endothelial cells (Marx et al., 1999) and smooth muscle cells (Marx et al., 1998). 
These studies suggest that PPARs may have a role as redox- sensitive transcription factors in 
the vasculature by being selectively activated by oxidised fatty acids. 
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2. Methods  
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2.1 Methods Used To Measure Blood Flow And Vessel Function 
 
2.1.1. Introduction 
 
Advancement in medical imaging and biotechnology has made it possible to undertake 
detailed investigation of the anatomy, physiology, cellular, molecular and metabolic 
processes of the circulatory system. 
 
The imaging technologies in the radiological field has been technically improved leading to 
an ability to display anatomy of the blood vessels in three dimensional view and physiology 
of the blood flow as an animated motion. In addition, using well-advanced contrast media in 
nanotechnology such as micro-bubbles, microspheres and nanoparticles, it is possible to 
acquire precise detail of molecular and metabolic detail of the elementary cells in the 
microcirculation (Maier, 2005) (Fan et al., 2005). It also provides a novel avenue of 
delivering drug for treatment at the cellular level (Blomley et al., 2001) (Lindner, 2002) 
(Averkiou et al., 2003) (Jain, 2005) (Moshfeghi and Peyman, 2005) (Fortina et al., 2005). 
 
The advancement in vascular imaging technology has broadened and has been integrated with 
intelligent computer software programs to emerge as a powerful technique such as spiral CT 
and high frequency cutting plane MRI, which are capable of providing real-time trimensional 
images of the vascular structure. Digital subtraction angiography can display vascular images 
without interference from the surrounding tissue while echocardiogram and color Doppler 
imaging ultrasound can assess physiology of the blood flow and displays the information as a 
real time motion-animation show. 
 
A major advancement in the field of circulatory assessment has been the development of flow 
probes for blood flow assessment. The flow probes or sensors are non invasive and therefore 
are commonly employed techniques in vivo for the measurement of arterial blood flow in 
several organs. Two of the commercially available systems for blood flow assessment include 
ultrasound (1-50 MHz) and electromagnetic flow probes (Figure 2-1). The ultrasound and 
Doppler ultrasound techniques are basically noninvasive tools while the electromagnetic 
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probe is invasive as it is necessary to dissect the vessels and apply the probe directly over the 
blood vessels. 
 
audible range ultrasound
20 Hz 20 kHz
1MHz 50 MHz
vascular: 4 to 10 MHz  
 
FIGURE 2-1. RANGE OF ULTRASOUND FREQUENCIES USED IN MEDICAL IMAGING (ALLAN, 1997) 
 
 
There are two types of ultrasonic modalities, conventional ultrasound and Doppler 
ultrasound. The Doppler ultrasound is an extension of conventional grey scale ultrasound. 
The Doppler ultrasound was established in 1960s and it is one of the dominant tools in 
vascular assessment. The Doppler principle has been well known for many years. Christian 
Doppler (1842) formulated his theory in regard to light. He was the first to observe that the 
frequency of a wave signal change, depending on the relative velocity of the source and the 
detector: the so called “Doppler shift”. His theory later can applied to both light and sound 
waves (Tabrizchi and Pugsley, 2000).  
 
The Doppler ultrasound probe measures the blood flow by calculating the “transit time” of 
the emitted ultrasound wave to traverse the vessel. The transducers emit higher than normal 
frequency sound (ultrasonic waves) traversing the blood vessel, which are then reflected by a 
fixed acoustic reflector and subsequently detected by a sensor in the body of the probe 
(Tabrizchi and Pugsley, 2000). The Doppler ultrasound basically measures RBC movement 
as an object creating the “Doppler shifts” signals. For advanced and accurate measurement of 
blood flow, microbubbles, microspheres and nanoparticles are used as a contrast to enhance 
the image information. 
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The principle of Doppler shift has been used with both ultrasound and light. Laser light from 
an optic fibre is used as a photodetector which can measure and translate the scatter effect 
transmitted back from the vessel of interest. Laser Doppler technique is capable of resolving 
images of very small/micoscopic scale objects, whereas Doppler ultrasound is used for 
imaging larger structures. And therefore the laser Doppler is frequently used for assessing 
microcirculation while Doppler ultrasound is generally reserved for medium to large arteries 
(Tabrizchi and Pugsley, 2000).  
 
Common techniques for the assessment of the cardiovascular system are demonstrated in the 
Table 8 below 
 
TABLE 8. COMMON TECHNIQUES FOR THE ASSESSMENT OF THE CARDIOVASCULAR SYSTEM (PUGSLEY AND 
TABRIZCHI, 2000) 
In vivo tools and modalities In vitro tools and modalities 
• Vascular imaging  • Dissected tissue preparations 
Arteries   
Veins 
• Angiography  • Isolated cell and cultured methods  
Smooth muscle cells 
Cultured endothelial cells 
• Flow probes or sensors  
Conventional ultrasound 
Doppler-ultrasound / laser 
Electromagnetic 
Sonomicrometry – Microbubles, 
Microspheres and 
Nanoparticles 
Intravascular ultrasound 
• Biochemical and Molecular 
• Sphygmomanometer 
     Plethysmography  
• Genetic recombinant 
 § Immunohistochemical (IHC) 
 § ELISA 
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Currently, the application of molecular biology, usually in vitro, is the way forward to study 
the cardiovascular system (Table 8). Using molecular biology technologies, arterial or venous 
tissue can be examined at molecular level, while the microvascular cells such as endothelium 
or vascular smooth muscle cell (VSMC) can be isolated, cultured and replicated. The modern 
development in molecular biomedical technologies for the assessment of circulatory system, 
have been integrated into preexisting basic methodologies such as microscopy, to produce 
ideal investigative tools.  
 
Sub-cellular fractionation and centrifugation have long been utilized for separating the cells 
from the secretions and tissues while the techniques of fluorescence facilitate cell sorting 
(FACS) and flow cytometry can detect and purify the cells with the specific phenotypes 
(Rose, 2002). As well as the methods to retrieve specific cells for study, a variety of methods 
to extract the biomolecules have been crafted. Column chromatography and electrophoresis 
are commonly used for protein separation by using the fundamental of the different molecular 
mass of the substances for extracting the protein. These two techniques have evolved into 
sophisticated technologies of electro-blotting for separating protein, DNA and RNA (Rose, 
2002). 
 
One of the major innovations has been the development of the immunochemistry technique 
based on a simple principle of specific binding between antigen and its specific antibody. 
Enzyme-linked immunosorbent assay (ELISA) was initially a tool for diagnosing infectious 
diseases by using either polyclonal or monoclonal antibodies in immunological methods 
(Rose, 2002). Advances in ELISA technique has made it possible to show gene-protein 
expression or the phenotype of the cell in the body secretions and tissues. Advances in 
immunocytochemistry, staining the antigen-antibody with coloring substances like DAB, has 
expanded to the technique of radioimmunoassay (RIA) method (Rose, 2002) in which the 
binding of antigens-antibody complexes can be seen by tagging the samples with radioactive 
substance such as I131. The integration of chromatography, electrophoresis and 
immunochemistry have resulted in the development of immunoprecipitation techniques 
which use chromatography-electrophoresis to extract the  proteins by  their electric charges 
and molecular mass, and then can be retrieved with a high specificity by using the 
antigenicity properties of  these proteins for separation. This method of specific proteins 
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separation is known as Western blotting, immunoblotting or enzyme-assisted 
immunoelectroblotting (Rose, 2002). 
 
Another major advancement in the field of molecular biology has been the development of 
genetic recombinants technology. These techniques include gene cloning and DNA 
sequencing, polymerase chain reaction (PCR) for amplifying the DNA and RNA, and 
Southern blotting for DNA separation (Rose, 2002). In addition, genetic engineering together 
with immunochemistry have become power tools to study gene expression, including 
Northern blotting for separation of  active RNA, Quantitative PCR- Reverse Transcriptase 
PCR (RT-PCR: the most sensitive tool for detection of mRNA) and in-situ hybridization 
(Rose, 2002). Ankle Brachial Pressure Index (ABPI) 
 
A distinguished German physiologist and physician, and a pioneer in finding method to 
record the blood pressure, Otto Frank (1865–1944) is well known to circulatory physiologists 
as one of the discoverers of the Frank-Starling law (Levick, 2003). In medicine, physician 
routinely compare right and left to detect abnormalities. Blood pressure is the simplest 
method that is still used. Therefore, in PAOD, ABPI test uses this principle to detect a decline 
of blood flow in the lower limb by comparing blood pressure in the ankle to the forearms. 
Sphygmomanometer is the universal tool used for measuring blood pressure. The 
measurement is done by applying the cuff and measuring the blood pressure from the brachial 
arteries in the arm. The ankle brachial pressure index (ABPI) is the formula for the 
comparison of ankle systolic blood pressure to the forearm (brachial) pressure. For the 
measurement of ankle blood pressure, Doppler ultrasound probe and sphygmomanometer are 
used to record the value of blood pressure. 
 
ABPI is chiefly employed in the lower extremities in patients with the symptom of leg pain 
on walking and clinical signs of arterial occlusion in the lower extremities. To grade the 
severity of the atherosclerosis lesion, ABPI ratio of more than 0.95 is considered to be normal 
while the range 0.5-0.95 indicates mild to moderate lesion classified as intermittent 
claudication (IC), a value of less than 0.5 is classified as severe obstructive lesion and termed 
as critical ischaemia (CI). (Table 9) 
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TABLE 9 ABPI GRADING AND CLINICAL PROGRESSION OF THE PATIENTS WITH PAOD 
ABPI Range Clinical Grouping 
More than 0.95 Normal 
0.5 - 0.95 Intermittent Claudication (IC) 
Less than 0.5 Critical Ischaemia (CI) 
 
ABPI is also the tool used for assessing the success of the revascularisation operation in the 
PAOD patients. Continuous wave Doppler ultrasound is a basic tool used to provide the early 
assessment of ABPI postoperatively. An increase of ABPI by 0.15 following 
revascularisation indicates successful procedure (Anderson, 2002) (Murabito et al., 2003) 
(Ramanathan et al., 2003). 
2.1.2. Continuous Wave Doppler Ultrasound 
 
The ultrasound devices for vascular testing are equipped with various facilities including 
continuous wave Doppler (CWD), pulse wave Doppler (PWD), duplex Doppler (DD), colour 
Doppler imaging (CDI) and power Doppler imaging (PDI) ultrasound (Allan, 1997). All 
these functions are usually present in the expensive laboratory based machines whereas 
smaller devices have only one or two functions. CWD ultrasound is a small common 
inexpensive basic bedside device capable of displaying the sound and the Doppler wave of a 
blood vessel being examined.  
 
CWD ultrasound is commonly used for testing peripheral arterial occlusive disease as it can 
reveal the early pathology by detecting attenuation of triphasic Doppler signal, which 
deteriorates, to biphasic and monophasic waves representing the progression of 
atherosclerosis lesion. The early plaque lesion is difficult to detect with angiography, as there 
is a reflex vasodilatation, which does not allow narrowing of the arterial lumen in early 
atherosclerosis. However, the stiffness of the arterial wall can cause changes in the normal 
laminar flow and the resulting changes in the parabolic velocity can be detected with CWD 
ultrasound. This modality is sensitive enough to detect small changes in velocity thereby 
providing information about the early phase of the occlusive disease.   
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The tri-phasic velocity graph is the normal graph illustrating the systolic blood pressure with 
the highest average velocity during cardiac contraction shown as a first phase, while the 
second phase shown as the negative velocity are produced due to the cardiac relaxation 
during the diastolic period. Finally the third phase is the compliance without the stiffness of 
normal arteries which generate a small increase of velocity. (Figure 2-2) 
 
 
The atherosclerosis causing a stiffness of arterial wall leads to the change of blood flow to 
become biphasic feature. When the atherosclerosis disease progresses with a partial or nearly 
complete obstruction, the velocity profile will change to monophasic and attenuated 
monophasic, respectively. This is because of the massive reflex vasodilatation and the blood 
flow of collateral circulation distal to the obstructive point (Thrush, 2004). The highlight of 
the early pathology of atheroma or plaques by continuous wave ultrasound is the support 
velocity
systole diastole
normal triphasic flow profile
biphasic monophasic attenuated monophasic
FIGURE 2-2 TRI-PHASIC, BI-PHASIC, MONO-PHASIC AND ATTENUATED (DAMPED) MONO-PHASIC GRAPH OF 
THE VELOCITY GRAPH DISPLAYED BY CWD U/S 
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confirmation of the diagnosis of the unseen plaque lesion and also proclaims the possible 
concurrence of the lesion in the other arteries and the risk of forthcoming atheromatous 
complications. 
 
2.1.3. Imaging Duplex Doppler Ultrasound  
 
Although the CWD ultrasound can measure the velocity of the blood flow and show as a 
wave sign, it has limitations as it reveals only the average of blood flow and can not identify 
the true variation of velocity termed as a parabolic laminar flow as shown in Figure 2-3. 
 
 
plaque
plaque
 
FIGURE 2-3 NORMAL LAMINAR FLOW (AS A PARABOLIC CURVE) AND ABNORMAL DISTURBED FLOW 
 
Both CWD and PWD ultrasound cannot show blood flow as an animated image. The 
combination of CWD and PWD ultrasound leads to the Duplex Doppler (DD) ultrasound.  
 
The DD ultrasound is the technology that transforms the information of blood flow and vessel 
structure into image (Allan, 1997). The mode of imaging Doppler ultrasound, therefore, 
includes  
• Simple duplex Doppler (DD) mode 
• Colour Doppler imaging (CDI) mode  
• Power Doppler imaging (PDI) mode.  
 
And these modes are presently combined into the single one device. 
 
The sonographer can select mode of Duplex Doppler ultrasound combination instrument 
which can display the information obtained either from mode of simple DD, CDI and PDI 
ultrasound. By inserting the different colour fixed to the direction of blood flow, the CDI 
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ultrasound can discriminate basically the artery and vein as the blood flow usually travel in 
the opposite direction in one anatomical area. In addition, by the same principal, it can 
demonstrate the turbulence effect. The PDI ultrasound is the mode of duplex Doppler 
imaging designed for detecting the flow that is very low and difficult for other modes to 
sense. 
 
Imaging with duplex Doppler ultrasound is superior to CWD ultrasound, it can demonstrate 
different velocities (parabolic wave) from the highest in the center of arterial lumen to the 
lowest in the tangential area nearest to the wall as a display of Doppler spectra. 
 
2.1.4. Angiography  
 
Angiography is the technique that is performed by inserting a catheter into blood vessel and 
then injecting radio opaque contrast media into blood circulation. Afterwards, the X-ray is 
shot and an image is obtained. Generally, there are two modes of angiography, conventional 
and digital subtraction which is conducted by taking X-ray as a background firstly and then 
after the injection the contrast media (Beard, 2004). Thereafter, subtracting the image of the 
background will display only contrast media in the examined arteries. Nonetheless, the 
contrast media used in angiography vascular imaging carries the acceptable risk of allergic 
anaphylaxis and there is contraindication of this technique in renal failure patients 
predisposing them to renal tubule toxicity. The high dose of contrast media used in digital 
subtraction angiography has to be weighed between a clearer image and unfavourable risks 
(Beard, 2004). 
 
Angiography is a standard intra-operative assessment for evaluating successful  operation not 
only in the revascularisation of the coronary arteries in CAOD and lower limb arteries in 
PAOD but also in the reanastomosis of arteries in the field of traumatic surgery and in the 
procedures regarding thrombolytic therapy (Beard, 2004). Their displays of the contrast 
media refilling distal to previous obstruction confirms the successful reperfusion as shown in 
Figure 2-4. 
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FIGURE 2-4 A) PRE PROCEDURE AND B) POST REVASCULARISATION ANGIOGRAPHY AS A CONFIRMATIVE 
ASSESSMENT OF SUCCESSFUL REVASCULARISATION 
 
Although the intraoperative assessment indicates the success of the operation, there may be 
secondary causes of the obstruction due to certain factors regarding non-reflow phenomenon 
which may progress to complete blockage by the development of thrombo-embolic events. 
 
In the heart, it is important to make sure the success of a reperfusion therapy. Therefore, 
many centers have certain guidelines for intra-operative measurement of certain physiological 
responses such as 12-lead ECGs etc where in coronary angioplasties, the ST-segment 
elevation should gradually return to baseline (Rezkalla and Kloner, 2002). The monitoring of 
the successful tissue perfusion after revascularisation, have been integrated as an aid for the 
diagnosis and an early detection of the failure of  PTA and CABG interventions and the 
identification of non-reflow phenomenon (Rezkalla and Kloner, 2002). With the advances of 
radio-imaging technology, the techniques including coronary Doppler flow wire, digital 
coronary angiography, nuclear imaging, contrast-enhanced magnetic resonance, and positron 
emission tomography (PET) scan can confirmed the non-reflow phenomenon that may occur 
immediately after reperfusion or shortly thereafter (Rezkalla and Kloner, 2002). 
Nevertheless, the availability of these techniques is varied in each center. 
 
On the other hand, in the lower limbs of PAOD patients, ABPI is accepted as the initial 
assessment for the post-operative evaluation for the outcome of the revascularisation and the 
increase of ABPI of more than 0.15 is accepted to be an indicator of successful 
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revascularisation. In case the symptoms are not relieved and the ABPI is not increased, 
further investigation using simple DD, CDI and PDI ultrasound and repeated angiography are 
performed. 
2.1.5. Non Invasive Measurement of Endothelial Function – Macro-
circulation 
 
Brachial Artery Flow mediated dilation (FMD) 
 
Flow mediated dilatation is well established as a technique to assess endothelial function in 
human arteries. The technique relies on the creation of increased flow in the vessel being 
assessed and the resulting changes in vessel size measured with duplex ultrasound. Ischaemia 
in the distal vascular bed caused by tourniquet inflation is often used to cause increased flow 
in the vessel being assessed (Pyke and Tschakovsky, 2005). 
 
As discussed previously, blood vessels have the ability to self-regulate vasomotor tone. An 
increase in blood flow will result in an increase in ‘shear stress’ to the local endothelium. The 
vessel responds to this by dilating – flow mediated dilation (FMD; Figure 2-5). 
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FIGURE 2-5 DIAGRAM ILLUSTRATING PRINCIPLE OF FLOW MEDIATED DILATION 
 
Recently, increasing effort has been made assessing brachial artery vasodilator response in 
order to establish a correlation with presence of atherosclerotic disease in coronary and 
carotid vascular beds as well as predicting the risk of restenosis following coronary artery 
restenosis (Akcakoyun et al., 2008).  
 
Furthermore it has been found in an autopsy study (Sorensen et al., 1997) that the grade of 
atherosclerotic lesion in the brachial, carotid and coronary arteries are significantly 
correlated, as was severity in the brachial and carotid arteries and the carotid and coronary 
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arteries. This provides morphological corroboration to the findings from non-invasive studies 
of endothelial function.  
 
Technique for Flow mediated dilation (FMD) for endothelial function assessment. 
Flow mediated dilatation is well established as a technique to assess endothelial function in 
human arteries. The technique relies on the creation of increased flow in the vessel being 
assessed and the resulting changes in vessel size measured with duplex ultrasound. Ischaemia 
in the distal vascular bed caused by tourniquet inflation is often used to cause increased flow 
in the vessel being assessed (Pyke and Tschakovsky, 2005). Duplex ultrasound quantified 
flow mediated dilation (FMD) has been used to quantify endothelial function in patients with 
intermittent claudication. A cross sectional study has shown that reduced FMD was 
associated with an increased serum concentration of the serum inflammatory marker highly 
sensitive c-reactive protein (hs-crp) (De Haro et al., 2008). 
A study has shown that maximal exercise on a treadmill causes a worsening in the FMD 
assessed endothelial function. Interestingly, the both pre and post exercise endothelial 
function were found to be improved following six weeks of supervised exercise (Andreozzi et 
al., 2007a).  
A single blinded trial of 28 days of aspirin versus a nitric oxide releasing aspirin treatment 
showed that nitroaspirin was able to abolish the exercise induced FMD assessed endothelial 
dysfunction seen in the aspirin group. There was no basal effect on endothelial function and 
the effect was mirrored in exercise induced levels of serum elastase and VCAM-1 levels 
(Gresele et al., 2007a). A study examining the effect of both acute and 6 weeks of exercise 
training on VEGF levels did not find any differential expression (Wood et al., 2006). 
Using a high resolution ultrasound scanner it is possible to monitor changes in vessel 
diameter resulting from FMD and thus non-invasively determine endothelial function (Alam 
et al., 2005).  
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The acquisition of images whilst maintaining the anatomical location of the transducer is 
technically difficult and some investigators insist on a stereo tactic probe holding device 
(Corretti et al., 2002). Also the necessity of gating image acquisition to the R-wave of the 
ECG recording has been discussed. Some authors suggest that ECG gating is essential to the 
accurate acquisition of brachial artery images (Alam et al., 2005). R-wave gating will ensure 
that all images are acquired in the end diastole phase of the cardiac cycle.  
 
Previously it was thought that ECG gating of the brachial artery measurements was essential 
to accurate measurement of brachial artery diameter for FMD assessment (Alam et al., 2005, 
Corretti et al., 2002). Such gating relies on the R-wave of the ECG coinciding with the end-
diastolic phase of the cardiac cycle.  
 
Vessel diameter is larger at peak diastole compared to end-diastole, and the degree of this 
difference may be related to vessel compliance which itself may be related to availability of 
NO. Thus R wave gating may act to mask the effects of endothelial dysfunction, potentially 
resulting in reduced sensitivity. Also, automated computer based analysis of brachial artery 
size has been shown to reduce variability in measurement (Preik et al., 2000). 
ECG R-waves
pre-distal ischaemia post distal ischaemia
brachial artery
diameter
ECG trace
time time
A
B C
FIGURE 2-6 EXPLANATION OF ECG R-WAVE GATING OF BRACHIAL ARTERY DIAMETER MEASUREMENT FOR 
FMD. A) B MODE US IMAGE OF BRACHIAL ARTERY SHOWING EDGE DETECTION OF INTIMA-MEDIA 
INTERFACE. B) PRE-ISCHAEMIA CONTINUOUS RECORDING OF BRACHIAL ARTERY DIAMETER WITH 
CONCOMITANT RECORDING OF ECG TRACE BELOW. R WAVES ARE INDICATED BY ARROWS. C) POST-
ISCHAEMIA RECORDING SHOWING INCREASED BRACHIAL ARTERY DIAMETERS. 
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We have previously demonstrated that with automated image registering software, there is 
good correlation and good agreement between R-wave gated and non-gated ultrasound 
brachial artery measurements. (Jaffer and Aslam) (Figure 2-7and Figure 2-8). 
 
 
 
FIGURE 2-7 SCATTER PLOT OF R-WAVE GATED VERSUS NON-GATED BRACHIAL ARTERY DIAMETER SHOWING 
CORRELATION LINE. 
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FIGURE 2-8 BLAND AND ALTMAN PLOT OF DIFFERENCE IN R-WAVE GATED AND UN-GATED BRACHIAL ARTERY 
DIAMETERS AND MEAN OF TWO DIAMETERS. SOLID LINES DENOTED MEAN DIFFERENCE ± TWO STANDARD 
DEVIATIONS. 
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FMD patient testing protocol 
 
1) Following taking informed consent from a participant, the participant was asked to lie 
down on a couch for a period of approximately 45 minutes. 
 
2) A blood pressure cuff was placed around the participant’s upper right arm after confirming 
that this site was not painful or tender.  
 
3) The participant’s right brachial artery was scanned in longitudinal section approximately 2 
to 3 cm above the elbow joint. The arm was positioned on an arm board attached to the 
examination couch. The arm was stabilised using a vacuum beanbag attached to the arm 
board (Figure 2-9). 
 
 
FIGURE 2-9 PHOTOGRAPHS OF A) PROBE HOLDER ATTACHED TO COUCH AND B) ARM HELD IN POSITION ON 
VACUUM BEANBAG ON ARM BOARD. 
 
4) The blood pressure cuff will be inflated to 30 mmHg above the systolic blood pressure. 
Inflation was maintained for a period of three minutes. 
 
5) Following release of the blood pressure cuff, the brachial artery scan was repeated. 
 
6) The participant was then asked to walk briskly on a treadmill (10 per cent incline; 4 miles/ 
hour) until they could not tolerate their typical claudication pain.  
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7) Steps 3, 4 and 5 were then repeated following exercise in order to assess endothelial 
function again. 
 
Image Analysis 
 
Images were acquired using the M7 portable ultrasound machine (Shenzhen, China) using a 
40mm 5-10 MHz broadband linear array transducer. 
 
Images were transferred from the S-video output via a digital image recording device to a 
personal computer, Dazzle video creator (Pinnacle Systems GMBH, Braunschweig, 
Germany). Images were stored as AVI files and analysed off line. 
 
Brachial artery diameter and carotid intima-media thickness measurements were performed 
using automated edge detection software, Vascular Research Tools 5 (Medical Imaging 
Applications, Coralville, Iowa, USA; Figure 2-10).  
 
ECG R-wave gated measurements were obtained by frame by frame examination of the 
captured video clips and recording those which corresponded to the simultaneously recorded 
ECG R-wave at the bottom of the ultrasound scanner display.   
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2.1.6. Non Invasive Measurement of Endothelial Function - 
Microcirculation 
2.1.6.1. Introduction 
The use of techniques to monitor the microcirculation or the blood flow through small vessels 
at the capillary level is a more recent development of the last two decades. The various 
options that are available for monitoring the microcirculation are included in table 5.1 with a 
brief description about each one. The technique employed in this work is Laser Doppler 
flowmetry. 
Propelled by the work of Stern (Stern, 1975b) who first demonstrated the use of Doppler 
shifted light to quantify red blood cell movement in the skin, the laser Doppler technique has 
since become the focus of numerous studies, particularly in the fields of dermatology and 
microvascular surgery. Growing use of this technique was facilitated by linking the laser 
Doppler flowmeter (LDF) to a computer in order to store and analyze the acquired data. 
Although given credit for its ability to make non-invasive and continuous measurements, the 
laser Doppler has yet to gain universal acceptance for any one of its many potential 
applications as it will be explained further in this document. 
FIGURE 2-10 AUTOMATED IMAGE ANALYSIS OF BRACHIAL ARTERY NEAR TO FAR INTIMAL DIAMETER IN 
DEFINED REGION OF INTEREST. RESULTS PANE ON RIGHT OF IMAGE RECORDS INDIVIDUAL 
MEASUREMENTS. 
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2.1.6.2. Optics 
 
Light is a form electromagnetic radiation. Electromagnetic radiation has a sinusoidal 
waveform and is capable of travelling in a vacuum. White light is composed of many 
different wavelengths both visible and invisible to the human eye; when broken down, each 
component of white light has it’s own unique properties which we perceive as colour. In 
1901, Max Planck showed that light exists in small packets or units and he termed these 
“quanta”(M, 1901). The word photon (γ) derives from the Greek for light and was coined by 
Gilbert Lewis 1926(G, 1926). Einstein and others demonstrate that photons exhibit both 
wave-like and particle-like properties. Photons have wave-like properties because they may 
be refracted, reflected, dispersed, diffracted, polarised and be subject to interference. Photons 
also have particle-like properties because they interact with other elementary particles by 
being absorbed and emitted as a whole: it is this theory of photons reacting in discrete units 
or as a whole, which gives the photon its particle-like property. Photon are thus said to have 
wave-particle duality. The study of light is known as optics. 
 
The main properties of photons can be described in terms of: 
• Intensity 
• Frequency (f) 
• Energy (E) 
• Wavelength (λ) 
• Phase 
• Speed (c) 
• Polarisation 
 
Intensity 
In optics, light intensity refers to the timed-average energy flux, per unit volume and may be 
denoted by many symbols and calculated in many ways which are irrelevant to this book. 
Intensity of light can be broadly found by taking the energy per unit volume of light and 
multiplying it by the velocity, to give vector of intensity per unit volume. It describes the 
energy transferred by a population of photons, within a given volume. Medical lasers may be 
of high or low intensity depending on their purpose. Diagnostic lasers are normally of low 
intensity because they aim to leave tissues intact. The intensity (I) of light can be calculated 
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from the speed of light (c), the energy of the light (E), refractive index (RI) of the medium 
and the electric constant E0: 
 
 I = E2 [(cE0 RI) / 2] 
 
Frequency (f) 
In optics, frequency refers to the number of cycles of a wave, per unit time. The unit of time 
is usually 1 second and often measured in Hertz (Hz). For reasons of pragmatism, we will 
denote frequency by the letter (f) but normally, in optics, the frequency of a photon is denoted 
by the Greek letter nu (ν). Of note, the frequency of any given photon never changes. 
 
Energy 
A photon has a constant energy which is proportional to the frequency (f) multiplied by 
Planck’s constant (h). Planck’s constant is simply the numerical relationship between the 
energy of a photon and its frequency. The energy of a photon is also inversely proportional to 
the wavelength (λ), whereby: 
 
 E = hf= hc / λ 
 
Wavelength (λ) 
The wavelength of a sinusoidal wave is a measure of the special period over which it repeats. 
The point of repetition is usually taken as a peak, trough or zero crossing. The wavelength of 
a sinusoidal wave of light is equal to the speed (c) divided, by the frequency (f) and so given 
by the equation: 
 
λ = c / f 
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Phase 
Phase is a function of frequency and refers to the relative time taken for a sinusoidal wave to 
be formed and complete a single cycle. In optics, phase is an important term which conveys 
information about the timing of wave production. For example, photons are said to have the 
same phase if they have been produced at the same time or complete a cycle at the same time. 
If photons are produced at different time points then are said to have different phases, or have 
under gone a phase-shift. Figure 2-11 shows two identical waveforms for a photon of light; 
one produced at t = 0 and the other at t > 0; therefore, the photons have a different phase. If 
both were produced or to cross the x-axis at the same value of t, they would be said to have 
the same phase.  
 
 
t
FIGURE 2-11 SHOWS THE 2 PHASES OF 2 IDENTICAL WAVES 
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The idea of phase becomes important when we superimpose 2 (or more) waves upon each 
other. Consider 2 photons with the same frequency; they will always have the same phase if 
produced at the same time but never be in phase if produced at different times (as in Figure 
2-12). Now consider 2 photons with different frequencies (and therefore wavelengths); one 
with wavelength λ1 and the other with wavelength λ2. If these photons are produced at the 
same time, then they will have the same phase at creation but fall out of phase thereafter. 
They will travel in unison, and cancel/add with one-another until they (if at all) come back 
into phase again. The overall frequency of these 2 waves can then be calculated, based on the 
principle of phase and give a measure known as “beats”, which will be covered in the 
Doppler effect section. 
 
Speed 
Light has a constant speed in a vacuum of 299 792 458 metres/second and is denoted by the 
letter c (“the speed of light in a vacuum”). The speed of light varies depending on the 
medium in which the photon travels (e.g., in a vacuum it is faster than in a solid) due to 
alterations in wavelength. The speed of a photon(c) can be calculated from the wavelength (λ) 
and frequency (f), with the formula: 
 
 c =λ f 
 
Light travelling in a medium may be slower that c because photons are continuously absorbed 
and re-emitted from elementary particles within the medium. Some photons (of specific 
t
FIGURE 2-12 SHOWS 2 DIFFERENT WAVES (OF WAVELENGTH Λ1 
AND Λ2) COMING IN AND OUT OF PHASE. 
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wavelengths) may also be absorbed & re-emitted more than others and thus, emerge from the 
medium at different times; this is known as dispersion and occurs when light is split into its 
component colours by a prism. For this reason, in optics, the discussion of the speed of light 
in a medium, is often described in terms of phase velocity (v).  
 
Phase velocity (v) describes the effect of a given medium, on the relative speed of light. The 
degree to which photons are absorbed & re-emitted in a medium dictates the “speed” of 
conduction because this process takes time. This absorption and re-emission phenomenon is 
also termed refraction because of the macroscipc effect that this process has on bending light 
and slowing portions of it. So, if a material is highly refractive (e.g., plastic) it is less 
“permeable” to light and so, will slow the passage of light: it is slowed because the matrial is 
more dense, therefore absorbs and re-emits more photons. If a material (e.g., air) is highly 
permeable to light, it will not slow its passage because there are few particles to absorb & re-
emit photons. It is the “permeability” of a substance to light which determines how refractive 
it is, and this property is quantified by the refractive index (RI).  
 
 
 
 
 
 
 
photon photon
time
FIGURE 2-13 PHASE VELOCITY – PHOTON A 
TRAVELLING THROUGH A SUBSTANCE WITH LOW 
REFRACTIVE INDEX WILL EMERGE SOONER THAN 
PHOTON B, BECAUSE IT HAS TRAVELLED LESS 
DISTANCE AND THE SPEED OF LIGHT IS CONSTANT. 
THUS, THE PHASE VELOCITY OF A > B. 
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Refraction occurs because when a photon interacts with an atom (i.e. it is absorbed), the 
electron fields are energised and disturbed, causing them to oscillate. The wavelength of the 
oscillating electrons is generally slightly out of sync (phase) with the wavelength of the 
photon. Therefore, when the photon is re-emitted (as the electron is de-energised and falls to 
a lower shell) it too becomes disturbed; more specifically, the wavelength is reduced and so, 
the velocity reduces in the medium. The photon is now said to have undergone a phase shift.  
 
To relate refraction to velocity: if the RI of a medium is high, light travels slowly through the 
material and vice versa. Photons travelling an equal distance through a substance with a high 
refractive index will emerge at a relatively later time than photons travelling through a 
substance of low refractive index. It is this relative velocity which we term phase velocity and 
is shown pictorially in Figure 2-13. This relationship between phase velocity of a photon (v) 
and the refractive index (RI) of a medium, is given by the equation: 
 
v = c / RI 
 
Sometimes it is more practical to talk in terms of the velocity of groups of photons (vg) in a 
medium and the affect of a refractive index on the passage of grouped light (RIg). This 
relationship between the phase velocity for grouped photons and the RI is inferred from the 
equation above but still based on a velocity of a single photon. The equation is: 
 
RIg = c / vg 
  
The importance being that the grouped refractive index (RIg) can now be related to the 
wavelength of a particular photon in a vacuum (λ), by differentiation/ integration: 
 
 RIg = RI – λ [dRI / dλ] 
 
Or the  group velocity (vg) may be calculated for a known refractive index of a homologous 
medium: 
 
vg = 1 / c [RI – λ (dRI / dλ)] 
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In summary, the speed of photons (c) in a vacuum is proportional to the frequency (f) 
multiplied by the wavelength (λ). However, the velocity of a photon is not constant and 
depends upon the RI of the medium in which it is travelling or the velocity of a moving object 
which it encounters. The wavelength (therefore velocity) of a photon decreases when it 
travels in a medium. The relationship between the original velocity and the new velocity 
(phase velocity), when a photon is slowed by a medium or moving object, is known as a 
phase shift. This relationship is given by the formula: 
 
λ = c / RI f 
 
This pivotal principle linking the velocity of a photon in a medium with wavelength and 
frequency, is the basis of the Doppler effect in laser technology. 
 
Polarisation 
The polarity of a wave describes the plane in which a wave travels. In general, light (as an 
electromagnetic wave), is made up of mutually perpendicular, fluctuating electric and 
magnetic fields; thus, the photons are travelling in the same direction but in any and all 
number of planes. White light is made up of many waves of different polarity. When waves 
are travelling perpendicular to one another, they cancel out, otherwise, they add. Diagnostic 
medical lasers may or may not have a polarising filter to allow the passage of selected 
photons, of parallel waveforms. 
 
2.1.6.3. Lasers 
 
The first working laser was demonstrated by Maiman et al (Maiman, 1966) and four years 
after this, a laser was used to measure the velocity of particles in solution by interpreting the 
Doppler frequency-shifted light which was backscattered (Yeh H, 1964). Some years later  
(Riva et al., 1972) used the principle of the Doppler shift to measure the velocities of red 
blood cells using lasers, in a glass tube. The birth of laser Doppler blood perfusion 
measurement however, is attributed to  (Stern, 1975a) for his description of ‘In vivo 
evaluation of microcirculation by coherent light scattering’: He postulated that when 
coherent light impinges on the skin, some of it will be backscattered by moving red blood 
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cells and some by static tissue. If the reflected light is brought to the surface of a sensitive 
photodetector, optical beating will produce an audio-frequency photocurrent output.  
 
A laser (light amplification by stimulated emission of radiation) is a mechanism for emitting 
light from the electromagnetic radiation region of the spectrum. Light emitted from a laser is 
spatially coherent and has narrow low-divergence, but can be manipulated by a lens. Most 
lasers are “coherent” which means that all the light produced is of the same frequency & 
phase; however, some can be configured to produce a broad beam of light, with varying 
wavelengths and differing phases (“incoherent”). In medicine, most lasers are monochromatic 
and thus, coherent. 
 
A laser can emit light of any frequency from gamma waves to radio waves. A laser is 
constructed from three principle parts and sometimes may also have a lens (the 4th part) 
(Figure 2-14): 
1. The pump (energy source) 
2. The gain/laser medium 
3. Two or more mirrors that form an “optical resonator” 
4. Lens 
 
  
 
 
 
FIGURE 2-14 LASER CONSTRUCT SHOWING THAT LIGHT PRODUCED FROM THE PUMP ENTERS THE MEDIUM 
TO ENERGISE IT. PHOTONS OF VARYING FREQUENCIES ARE LIBERATED. PHOTONS OF UNDESIRED FREQUENCY 
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ARE REFLECTED BACK INTO THE MEDIUM FROM THE HIGHLY OF PARTIALLY REFLECTIVE MIRRORS (TO 
“GAIN” FURTHER PHOTON EMISSION). PHOTONS OF DESIRED FREQUENCY PASS THROUGH THE PARTIALLY 
REFLECTIVE MIRROR, FOCUSED BY A LENS AND THUS, A LASER IS PRODUCED. 
 
 
The Pump 
This part produces the energy for the laser system. The energy (photons( may be produced 
from electrical discharges, flash-lamps, arc lamps, chemical reactions or even another laser. 
A historic energy source is a Helium-Neon (HeNe) gas mixture which emits light of 
wavelength of 632 nm, when a charge is applied to it. The most commonly used pump in 
current medical laser systems is a laser diode, because it is small, safe, energy efficient and 
cheap to produce. A laser diode is a semiconductor which converts alternating current into 
direct current (rectification), and passes this current across a specific and microscopic gap-
junction, with the aid a carrier substance (e.g., gallium arsenide). When the carrier substance 
delivers the charge to the other side of the gap-junction, a photon is produced. The frequency 
of the photon corresponds to the composition of the semiconductor. Laser diodes produce 
incoherent photons, therefore, modulation is required (by the gain medium and optical 
resonator) to make the laser coherent. 
 
The Gain/Laser Medium 
A gain medium is a substance designed to absorbed and re-emit photons of specific 
frequencies. It may be principally composed of: 
• Gases:  these lasers normally use electricity from the pump to discharge light  
from gases such as: HeNe, CO2 and Krypton 
• Liquids: normally composed of a solvent and a dye, these lasers use a variety of 
energy sources. 
• Solids (such as crystals or glasses). Solid mediums are usually laced with an 
impurity (e.g., Neodymium) and the pump/energy source is often a laser diode or 
flash lamp. 
• Semiconductors: formed from a conductor and an insulator, which allows 
direction of current through pores. They can be configured to produce photons of 
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different frequencies according to the concentration of ‘impurities’ or crystals 
(dopant level), when electrons pass through the micro gap-junctions. 
 
When light from the pump interacts with the gain medium, the molecules become excited and 
undergo population inversion. Population inversion describes the situation where groups of 
atoms (N), in ground energy state (E1), absorbs light energy and thus become energised to a 
higher energy state (E2). This ascension of atoms to a higher state of energy occurs through 
the promotion of electrons to an outer and higher order shell. When an electron(s) ascends 
shells it absorbs energy and when it returns/falls back to its original shell, it emits a photon of 
light. Some atoms within the molecule will be energised (N2) whilst others will not (N1), 
giving the relationship:  
 
N = N1 + N2 
 
The difference between the ground energy state (E1) and the new higher energy state (E2) of 
atoms, is denoted by the symbol (ΔE) and given by the equation: 
 
ΔE = E2 – E1 = hfχ 
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Where h is Planck’s constant, describing the relationship between the frequency and energy 
of a photon and fχ is the characteristic frequency of light which will interact maximally with 
an atom. Any number of photons of any frequency can promote an electron (in many steps or 
one) to a higher energy state, as shown in Figure 2-15. However, the frequency of light 
proportional to the energy gap ΔE is determine by the chemical composition of the gain 
medium and so χ can take many values. It is this value of χ which determines the frequency 
of light emitted from the gain medium and therefore, the frequency of the laser light 
produced, when an electron falls back down to its original shell and the atom returns to 
ground energy state (E1).  
 
When atoms in the gain medium (N) are saturated with energy, some groups of atoms will 
become energised and decompose to emit photons of light: these photons are randomly 
generated and are of differing frequencies, hence incoherent. This is known as spontaneous 
emission. If an atom is in a higher energy state (E2), then it may be disturbed by another 
photon of light with a frequency equal to the energy gap ΔE. In this case, if another photon of 
frequency fχ interacts with the atom in energy state E2, then the atom relaxes back to the 
ground energy state (E1) and emits a photon of identical frequency (fχ) and phase to the 
disturbing photon. Interestingly, the disturbing photon is not absorbed and thus escapes the 
medium. This has the effect of producing 2 photons of identical phase & frequency; the 
hf = E
E2; higher energy state
E1; ground energy state
FIGURE 2-15 WHEN A PHOTON (OF FΧ) IS 
ABSORBED BY A GROUND ENERGY STATE ATOM 
(E1) AND ASCENDS TO A HIGHER ENERGY STATE 
(E2) 
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output photon from the relaxing atom and the original photon. This is the process of 
stimulated emission and illustrated in Figure 2-16. 
 
It follows then, that to produce more laser light than one puts in (through the pump), the ratio 
of atoms in the ground energy state (N1) and higher energy state (N2) cannot be equal, 
because then the photons would simply be reabsorbed into the medium. In order to ensure net 
output of laser light, the population of atoms must be N2>N1. 
 
The Optical Resonator 
In order to attain more atoms in a higher energy state (E2) than ground energy state (E1), 
photons of undesired frequency can be recycled. Recall that the photons emerging from the 
decomposing gain medium are of multiple frequencies and phases. These photons can either 
be allowed to escape out of the system (if they are of the desired frequency) or they can 
otherwise be redirected into the medium, and thus reabsorbed.  The reabsorbed photons of 
unwanted frequency aid the promotion of other atoms in a ground energy state (E1) to a 
higher energy state (E2). Therefore, by inputting light (from the pump) of the desired 
frequency & phase, more identical light is produced than input. This phenomenon is known 
as optical gain or amplification, and is the crux of laser production. 
 
hf = E
E2; higher energy state
E1; ground energy state
in: 1 photon (hf)
out: two photons of 
identical frequency 
(hf) and phase 
FIGURE 2-16. WHEN A PHOTON (OF FΧ) PASSES AN ATOM IN A HIGHER ENERGY STATE 
(E2) WITH AN EQUIVOCAL ΔE, THE PASSING PHOTON CAUSES THE ATOM TO RELAX 
BACK TO GROUND ENERGY STATE (E1) AND EMIT A PHOTON OF IDENTICAL FREQUENCY 
& PHASE 
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The optical resonator is a system of mirrors within the device, which reflects light of 
unwanted frequencies back into the gain medium. Traditionally, the optical resonator is 
composed of multiple mirrors flanking the gain medium; one mirror is a partial reflector and 
the other(s) high reflector(s). High reflectors reflect all light and partial reflectors only 
permits photons of the desired frequency through to form the output laser beam, while 
reflecting all other frequencies back into the gain medium, in order to drive the production of 
more photons. 
 
Lens 
 
According to Snell’s Law (Rashed, 1990), when a wave (or photon in this case) passes from 
one medium to another, it undergoes refraction. This means that the normal wave’s direction 
of travel is altered (because the wavelength changes) and the incident wave takes a new 
direction of travel. This is relationship is given by the equation: 
 
 RI1 sin θ1 = RI2 sin θ2 
 
Where RI1 and RI2 are the refractive indices of the two mediums, and θ1 and θ2 are the angles 
between the normal and incident wave respectively (Figure 2-17). This phenomenon is also 
associated with the change in the speed of light (as the RI of a medium affects the wavelength 
and speed) and so, based on the equation linking the velocity of a photon wave in a medium 
(v) and the RI, we can infer: 
v1
v2
1
2
medium with RI1 medium with RI2
FIGURE 2-17 SNELL’S LAW OF THE CASE OF A 
WAVE MOVING FROM AIR (RI1) TO A MEDIUM 
(E.G., SKIN) WITH RI2. 
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 V1 sin θ2 = v2 sin θ1 
 
This principle of refraction holds strong for uniformly dens medium, with a constant RI. Lens 
can either focus (converge) light to a narrow beam with a convex lens or disperse (diverge) 
light with a concave lens. Lenses of medical lasers normally to converge laser light and use 
the Lensmaker’s equation (E, 1987) (Figure 2-18) to determine the focal length and required 
properties of the lens. This is given by the equation: 
 
(1 / S1) + (1 / S2) = 1 / FL 
 
Where FL is the desired focal length, S1 is the object difference and S2 is the virtual image. 
 
Lenses also have many other properties which can be exploited (such as chromatic 
aberration) but they are not pertinent to LDV. 
 
photon B
photon A
object
image
S1
S2
F
FIGURE 2-18 THE LENSMAKER’S EQUATION APPLIED TO TWO PHOTONS, 
ONE BEING REFRACTED BY A CONVERGING LENS (A), THE OTHER NOT. THE 
OBJECT IS WHERE THE INCIDENT BEAMS MEET AND IS MOST INTENSE. 
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In LDV, it is not just the mechanisms behind laser production which are important, but also 
the focussing of the beam and measurement of what is reflected back. Diagnostic medical 
also have a: 
1. Photodetector 
2. HP filter 
3. Nomaliser 
4. Differential Amplitude Detector 
 
Photodetector 
Photons returning from the illuminated tissue interact with each other (adding or cancelling) 
and strike the surface of the photodetector attached to the surface of the skin. The 
photodetector measures the difference in frequency between the interacting photons in Hz 
and converts this into a DC current with a fast Fourier Transformation. The range of Hz 
detected is proportional to the intensity of light striking the detector and thus, DC amplitude. 
The DC current, defining the flow rate, is then passed through a filter. 
 
Laser
skin
photodetector HP filter Normaliser
Differential 
aplitude 
detector
photodetector HP filter Normaliser
processing 
unit
output 
graph
 
FIGURE 2-19 SHOWS A MULTI-CHANNEL SETUP FOR A LDF, MEASURING THE BACK SCATTERED LIGHT FROM 
MULTIPLE LOCATIONS TO REDUCE THE SIGNAL-TO-NOISE RATIO AND GAIN A HIGHER QUALITY RECORDING 
 
Low Pass (LP) High Pass (HP) filter 
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Filters only allow DC photocurrents corresponding to a specific Hz range to continue through 
the system. A LP filter cuts of frequencies below a certain value whilst a HP filter removes 
high frequencies. For example, low frequency lasers (~633nm) have a tight HP filter which 
permits only 0~12Hz current through, compared to HP filters of high frequency lasers 
(~780nm) which permit a range of 0~30Hz through. The range permissible depends on the 
depth of measurement the investigators wants because higher frequencies will penetrate into 
deeper tissue and thus undergo a greater Doppler shift, which must be allowed for the 
measurement. The HP filter differs between machines and is sometimes changeable, but 
dictates the range of flux detectable. This range of detectable flux is often termed the 
“Bandwidth” and some authors advise that higher bandwidths should be used, in order to 
measure as deeply as possible and detect higher average velocities of red blood cells. The 
filtered DC current is then passed to the Normaliser. 
 
Normaliser 
DC charge passed into the normaliser can be plotted in a graphical form. At this point, the 
distribution of DC charge is exponential and only useful to a skin depth of 0.6mm9-10. The 
distribution of the DC photocurrent should be normal (Gaussian) because Brownian motion  
and tissue light scattering is random, therefore, the distribution of the residuals should also be 
normal. For this reason, the photocurrent and thus, LDF flux trace can be considered to have 
2 main portions; The heterodyne signal (iS) and homodyne signal (iR) as shown in Figure 
homodyne
‘noise’
heterodyne
‘signal ’
I
0 f∆f
FIGURE 2-20 SHOWS THE HOMODYNE TRACE (“NOISE”) OF 
BACKSCATTERED LIGHT FROM STATIC TISSUES AND THE 
HETERODYNE TRACE (“SIGNAL”) ARISING FROM DOPPLER SHIFTED 
PHOTONS FROM MOVING OBJECTS, PLOT AGAINST INTENSITY (I) 
AND IN FREQUENCY (F). 
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2-20. 
The heterodyne trace (iS) arises from photons backscattered from moving objects (“signal”) 
and shows the only true variation in measured flux which is due to flowing blood cells. The 
heterodyne signal is often simply termed “signal” an is the portion of the LDF trace which we 
are interested in. The homodyne trace (iR) arises from photons backscattered from static 
tissue and/or the reference beam: due to the fact that scattering from static tissue is random 
and constant (provided there is no motion artefact and experimental conditions eg. 
temperature, TcO2 etc are kept constant), we can disregard this trace as background noise. 
The ratio heterodyne to homodyne signal is termed “signal-to-noise ratio”. 
 
The signal-to-noise ratio is determined by the number of channels in the device and their 
mathematical algorithms. Each channel measures backscattered light from a separate area of 
skin, allowing assimilation and comparison. Usually there are multiple channels arranged 
around a central laser which identify homodyne patterns signifying background noise and 
remove them from the trace. Some noise patterns however cannot be removed, despite 
improving hardware and software, therefore, the resultant DC photocurrent is still expressed 
in terms of signal (iS) and irrevocable noise (iR): 
 
DC photocurrent = iR + iS  
 
As described, the distribution of the photocurrent is exponential, therefore to normalise it the 
DC photocurrent is often squared – [DC]2. Due to this transformation, the flow measurement 
is now defined in arbitrary units of flux and given by the formula: 
 
Flux = [iR + iS]2  
 
Newer LDF machines can measure flux relative to overall flow and alter the output signal by 
using the root-mean-square (RMS) of the DC current which is more contextualised and offers 
some advantages for measuring flow continuously in one specific location, because it better 
removes the effect of tissue light scattering. It is given by the formula: 
Relative flux = [√µDC]2  
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We advise authors to express reported LDF measurements in flux units and define which 
normalising algorithm was used. 
 
Differential Amplitude Detector 
This portion of the detector measures the difference in DC photocurrent and simply plots it 
on a graph against time (x-axis). The output of more recent machines is digital and can be to 
PC software, for keeping and later statistical analysis. 
2.1.6.4. The Doppler Effect: Lasers 
 
Johan Christian Doppler originally described the Doppler effect in 1842 (C, 1842), as a 
change in the frequency of a wave for an observer moving relative to the source wave. In 
other words, the frequency of a wave changes depending on the relative velocities of the 
source and the detector. It occurs because the waves emitted by the source are either 
compressed (if the source and detector are moving towards each other) or dispersed if the 
source and detector are moving in opposite directions. This principle allows us to calculate 
the velocity of a moving object, based on the frequency (Doppler; Figure 2-21) shift which it 
produces.  
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epidermis
dermis
blood vessel wall
red blood cells
non Doppler shifted laser light
Doppler shifted laser light
 
FIGURE 2-21 DOPPLER EFFECT. 
 
 
To understand how LDV is clinically applicable, 3 particular facts are of importance: 
1. If a photon is absorbed and re-emitted it is refracted but continues travelling away 
from the source 
2. If a photon is reflected from a static tissue, it’s wavelength is unchanged and so its 
phase velocity remains constant 
3. If a photon is reflected from a moving object, it’s wavelength is reduced and so is 
its phase velocity: ie. the wave undergoes a Doppler shift. 
 
Most photons are either absorbed & re-emitted by static tissues or reflected back unchanged 
[Nilsson GE. Perimed's LDV flowmeter.  In: (Shepherd 1990)]. Only a very small number of 
photons undergo a Doppler shift and are backscattered for measurement, but it is this small 
sample of photons from which we can discern the speed and concentration of blood flow 
(Leahy MJ, 1999) (Figure 2-22). 
 
Over time, the term “Doppler Effect” has become synonymous with “velocity measurement” 
in medicine, however, the methods by which velocity is inferred in the field of medical lasers 
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is different. Unlike sound waves, photons have very high frequencies which are difficult to 
measure directly. As previously eluded to, the issue of measuring a photon’s frequency can 
be circumvented by using the phenomenon of ‘beats’.  
 
When photons come in and out of phase, their frequencies synchronously add (if the 
polarities is the same) or cancel (if the polarities are different), respectively. Therefore, when 
two photons of slightly different frequencies are superimposed, we can simply measure the 
difference in frequency between them as this value will be much smaller and more readily 
quantifiable. Take a photon of frequency=3 and one of frequency=2: the maximum range of 
difference is -1 to 5 units. Again, take a photon of frequency 10,000 and one of frequency 
20,000. The maximum range of difference is -10,000 to +30,000. When a photon undergoes a 
Doppler shift, the frequency drops (because the wavelength is reduced), therefore, we are not 
interested in the high end of the range of differences, but only the lower end. This 
conveniently makes measuring the frequency of Doppler shifted photons much easier. The 
difference in frequency between 2 photons is measured in terms of amplitude and called a 
‘beat’(Yeh H, 1964). The frequency of each ‘beat’ is exactly proportional to the frequency 
shift produced by the Doppler effect and therefore, allows us to calculate velocity.  
 
First, consider these scenarios to explain how the Doppler effect is applied to lasers: 
1. Two identical photons are produced from a source and reflected directly back 
from a mirror, to the detector.  The difference in frequencies is nothing because 
they had the same phase at emission and detection. The measured amplitude 
therefore is zero. 
2. Now make the 2 photons of slightly different frequency but keep all other 
conditions the same. As the photons travel to the mirror they come in and out of 
phase slightly, before returning to the detector in a different relative phase to that 
which they left. The difference in frequencies will be small and so the measure 
amplitude will be small also. 
3. Finally, take 2 photons of different frequencies and emit them from the source, 
and make the mirror static human tissue. Call one photon the reference wave (R) 
and the other, the effector wave (Z). Allow the reference photon (Z) to be 
reflected directly back from static tissue to the detector, but the other photon (R) 
to be affected by a moving object e.g., a red blood cell. The frequency of the 2nd 
photon (Z) will be reduced, because the movement of a photon in a medium is 
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relatively slowed due to absorption and re-emission, therefore its wavelength is 
reduced and so is its frequency. This means that the effecter photon (Z) will have 
undergone a Doppler shift and strike the detector well after the reference photon 
(R). The difference in frequencies between the reference photon (R) and the 
effected photon (Z) will now be greater than the when they were emitted, so the 
difference measured amplitude will be large.  
 
 
 
 
 
 
By mixing a Doppler-shifted wave with a reference wave, a ‘beat’ is produced. The 
frequency of each beat is much lower than either of the two constituent waves and is thus 
much easier to measure.  
 
In simplicity, the relationship between the frequency change (a ‘beat’) between a reference 
wave and Doppler shifted wave can now be expressed in the equation: 
 
 f ' – f = f [v(c – v)] 
 
FIGURE 2-22. SHOWS	  A	  PHOTON	  TRAVELLING	  IN	  DIRECTION	  K1	  AT	  ANGLE	  TO	  THE	  
NORMAL	  AND	  COLLIDING	  WITH	  A	  RED	  BLOOD	  CELL.	  THE	  INCIDENT	  PHOTON	  THEN	  
TRAVELS	  IN	  DIRECTION	  (K2)	  AT	  ANGLE	  AFTER	  UNDERGOING	  A	  DOPPLER	  SHIFT.	  NOTE:	  
THE	  ANGLES	  ARE	  HIGHLY	  EXAGGERATED.	  SCATTERING	  IS	  USUALLY	  IN	  THE	  FORWARD	  
DIRECTION	  WITH	  THE	  MEAN	  ANGLE	  BEING	  5.4O 
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Where f ' is the Doppler shifted frequency, f is the reference frequency, v is the relative 
velocity of the source/detector and c is the velocity of the photon. In the case of laser 
Doppler, the velocity of light (c) is usually much larger than the velocities we are interested 
in and so the subtraction of measured velocities would make no difference to the observed f ’, 
therefore, we ignore it and simply the equation to: 
 
f ' – f = f (v/c) 
 
To express this in terms of change in frequency (Δf) we have the equation: 
 
 Δf = f – f ‘ = 2v / λ 
 
These equations hold true only for the detection of photons travelling perpendicular to the 
source and do not consider the angulations of the normal beam (θ) and moving objects. 
Therefore, a more practical equation in common use is: 
 
 Δf = 2v sin θ / λ 
 
If the returning photon is detected after a single Doppler shift and without further scattering 
from moving objects, then the resultant Δf can be considered in terms of the angle of 
incidence (φ) also: 
 
 Δf = cos φ (2v sin θ / λ) 
 
This is still impractical because in a system of moving particles such as skin, it is clear that 
photons will interact with more than just one single structure (moving or static) and so 
undergo more than one Doppler shift. Therefore, the detected frequency is written in terms of 
the sum (Σ) of individual events (i): 
 
 Δf = Σi cos φi (2vi sin θi / λ) 
 
Now that we can measure the Doppler shift of a laser by calculating the difference in 
frequencies, which produce a ‘beat’, we can translate this into a useful measurement to 
quantify flow. This value of frequency change is an arbitrary figure and usually termed ‘flux’. 
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2.1.6.5. Biological Zero 
 
Measurement of flow with Laser Doppler flux is still not perfect; even after total vessel 
occlusion, tissues can remain metabolically active for several hours and the contained 
molecules will continue to move in space & time. Therefore, in the absence of flow and even 
in death, tissues have a detectable Doppler signal (Tenland T, 1983b, Caspary L, 1988).  This 
signals primarily seems to originate from Brownian movement of the interstitium (Tenland T, 
1983b, Caspary L, 1988) and movement of red blood cells in the vascular compartment 
(Parpart A, 1956). Brownian movement is the mathematical model which describes the 
seemingly random movement of particles suspended in a liquid/gas (R, 1828). In relationship 
to laser Doppler measurements, it is particularly the movements of macromolecules within 
the interstitium of skin that generates measurable Doppler shift on photons and therefore, a 
flux signal. It is this measurable baseline signal, which is always present and independent of 
regional flow, which was termed “Biological Zero” (BZ) by Tenland et al (Tenland T, 
1983b). 
 
Many authors believe that the BZ signal should be subtracted from measurements, in order to 
get the “true” flux value and thus, the “true” flow (ref). Although BZ is clinically only 
influenced by temperature, the value for BZ is very small and usually consistent between and 
within subjects, therefore, it rarely (if ever) changes the results of any study. Furthermore, 
subtracting BZ from measured results has been shown to be detrimental to the reproducibility 
of measurements (S Jadhav, 2007). 
 
The question still remains, does BZ change in normal versus disease tissue and during 
occlusion? Until this question is answered, it is advised that experimental conditions be kept 
constant, the BZ is not subtracted from flux measurements but all factors and readings clearly 
stated in the write up; (Rajan et al., 2009). 
 
2.1.6.6. Types of Laser Doppler measuring devices 
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There are two main types of laser Doppler measuring devices: the probe and the 
scanner/imager. The first to be developed was the conventional laser Doppler probe or 
flowmeter (LDF). After LDF, the laser Doppler imager (LDI) emerged predictably in 
response to several limitations of the conventional flowmeter. One complaint about the probe, 
which is applied directly to the skin, was that it restricted measurements to an area of 1 mm2 
at a time. A single reading could misrepresent the spatial heterogeneity of blood perfusion in 
the surrounding area of interest. The probe was also found to be extremely sensitive to 
motion and vibration and it was considered to have poor reproducibility of readings. Finally, 
it was suggested that direct contact of the probe with the skin surface could itself alter skin 
blood flow.  
 
Laser Doppler imaging is based on the same principle of measuring blood flow as 
conventional laser Doppler flowmetry, except that a system of mirrors and light- collecting 
lenses performs the function of the fiber optics in the probe device. The laser beam is focused 
on the skin by a mirror that is maneuvered by microprocessor-controlled stepping motors. 
The instrument scans the given area (from 5 5 cm up to 50 50 cm) in a systematic, 
rectilinear manner. Light reflected back from the skin is detected by a photodetector, which is 
positioned approximately 200 mm above the skin surface. Unlike the laser Doppler probe, the 
photodetector is not placed in contact with the skin. Measurements are made sequentially at 
65,536 points and are processed and stored. Once scanning is complete, a color-coded 
perfusion image can be displayed on a connected computer screen along-side a corresponding 
"photo image". This research used the laser Doppler flowmeter technique.  
2.1.6.7. Laser Doppler Flowmeter 
The laser Doppler technique measures blood flow in the very small blood vessels of the 
microvasculature, such as the low-speed flows associated with nutritional blood flow in 
capillaries close to the skin surface and flow in the underlying arterioles and venules involved 
in regulation of skin temperature. It consists of a 2-mW helium-neon gas laser, which 
transmits light (usually of visible red wavelength=632.8 nm) to the skin surface via optical 
fibers running through a probe head; the probe head is placed directly on the skin. Once the 
transmitted incident light is reflected and scattered from both stationary structures and 
moving red blood cells, a portion of this backscattered light is collected by another optical 
fiber at the skin surface. This blended sample of nonshifted and Doppler shifted components 
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is transferred to a photodetector for processing and conversion to a voltage output. Normal 
fibre separations in the probe head are a few tenths of a mm so consequently blood flow is 
measured in a tissue volume of typically 1mm3 or smaller. The tissue thickness sampled is 
typically 1mm, the capillary diameters 10 microns and the velocity spectrum measurement 
typically 0.01 to 10mm/s. This depth reaches the arterioles, capillaries, and postcapillary 
venules of the upper horizontal plexus but does not extend beyond these vessels to the deep 
horizontal plexus below the dermis, so the capillary blood supply to the sweat glands and hair 
follicles does not contribute to the LDF signal because these structures are 3-5 mm below the 
skin surface.  Ultimately, however, the depth of tissue penetrated by the laser is dependent on 
factors such as laser light wavelength, skin pigmentation, and probe type. 
 
As it was said before the technique depends on the Doppler principle whereby low power 
light from a monochromatic stable laser; e.g. a Helium Neon gas laser or a single mode near 
infra-red laser diode, incident on tissue is scattered by moving red blood cells and as a 
consequence is frequency broadened. The frequency broadened light, together with laser light 
scattered from static tissue, is photodetected and the resulting photocurrent processed to 
provide a blood flow measurement. Doppler shift frequency range is typically 20Hz to 20 
KHz for a well perfused region of the microcirculation. e.g. finger tips. 
 
(Braverman, 2000b) constructed a topographic map of the skin areas using Laser Doppler 
flowmetry and correlative skin biopsies and defined whether these areas were predominantly 
arteriolar in composition, venular in composition or essentially devoid of all microvascular 
elements. He recorded simultaneously by laser Doppler flowmetry red cell flux and the 
concentration of moving red blood cells (CMRBC). He found that high amplitude red cell 
flux waves exhibiting vasomotion correspond to an underlying ascending arteriole and low 
amplitude waves without vasomotor activity corresponded to venular predominance under the 
1 mm diameter LDF detecting probe (Table 10). 
 
These LDF studies have demonstrated that the ascending arterioles are randomly spaced at 
intervals of 1.5-7 mm (Braverman and Schechner, 1991), thus explaining the basis for the 
spatial heterogeneity of LDF measurements (Tenland T, 1983a). Each ascending arteriole 
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divides into 4-5 branches to form a portion of the upper horizontal plexus. The ascending 
arteriole is accompanied by a post-capillary venule that is formed from the confluence of 8-
10 branches within the upper plexus. Each vascular unit is attached to its neighbours along a 
portion of their respective peripheries. In three dimensions, the vascular unit resembles an 
umbrella: the handle is represented by the paired ascending arteriole and descending venule. 
The umbrella proper is formed by the arteriolar and venular branches, with the arterioles 
being predominant in the center and the venules predominant in the periphery. The phasic 
(vasomotor) variation in red cell flux amplitude is greatest over the ascending arteriole and its 
immediate branches, suggesting that these vessels are the morphologic site for the generation 
of vasomotor activity detected by LDF in the skin. The putative sphincter, formed by a single 
encircling smooth muscle cell at the site where the elastic containing arteriole branches to 
form the arterioles of the upper plexus, may be the origin of the vasomotion detected by LDF. 
When a single arteriolar site is continuously monitored for 1-2 h, the red cell flux changes 
from minimum to maximum and vice versa at intervals of 12-20 min at some sites and 70-90 
min at other sites, thus explaining in part the temporal heterogeneity of LDF measurements. 
 
TABLE 10 TOPOGRAPHIC MAPPING OF THE CUTANEOUS MICROCIRCULATION BY MEANS OF LASER-DOPPLER 
FLOWMETRY. ((BRAVERMAN, 2000A, BRAVERMAN ET AL., 1992) 
 
 
The strategy based on LDF-morphologic correlation provides a way to determine the 
approximate mixture o microvascular elements beneath the 1 mm diameter probe. Density of 
ascending arterioles in a defined area of skin can be determined  
FLUX CMRBC* STRUCTURE 
High High Ascending arteriole + descending venule 
High High to Medium Ascending arteriole entering upper plexus 
High Low Arteriolar predominance 
Medium/Low Medium 
Medium to low 
Peripheral part of the vascular unit that was 
fed by the ascending arteriole 
Low High Venular predominance 
Low Low Avascular Areas 
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as well as the areas of capillary and postcapillary predominance between the arterioles may 
be defined, and the areas of relative avascularity in both experimental designs and pathologic 
states. The vascular islands with attachments at their peripheries coupled with intervening 
avascular spaces explains the livedo pattern in skin following heat stress and impaired blood 
flow for other reasons  (Braverman, 2000b). 
 
          *CMRBC= Concentration of moving red blood cells. 
. 
 
The pattern of LDF oscillations is peculiar for each type of vessels, and the total power is 
greater in larger arterioles than in venules. In other words, the flux motion is fundamentally 
dependent on the type of vessel from which it originates and is directly related to the 
vasomotion of the arterioles (Colantuoni A, 1984). 
 
As it was demonstrated by (Wahlberg and Fagrell, 1994) the time to reach peak hyperaemic 
flux recorded with laser Doppler is a simple and accurate method of evaluating ischaemic 
limbs since it does reflect limb vascular resistance in an experimental model. Thus, LDF may 
be used as a quantitative indicator of overall blood flow impairment and it may be useful in 
patients with lower-limb atherosclerosis. Laser Doppler flowmetry has a list of applications 
in experimental medicine but also in clinical medicine measuring certain inflammatory 
reactions, monitoring inflammation, monitoring flaps and monitoring burn depth (Eun, 1995). 
In experimental medicine, laser-Doppler flowmetry has been used in the study of 
spontaneous rhythmical variations as well as in the study of spatial and temporal fluctuations 
in human skin blood flow and in a variety of tissues (Oberg, 1990). Rhytmic variations in 
blood flow are called oscillatory flow activity and are due to variations in the myogenics 
activity of the smooth muscle cells of the arteries and arterioles. Oscillatory flow patterns are 
composed of waves with several different frequencies (Colantuoni A, 1984). Although early 
studies suggested that LDF had substantial difficulties with sampling, stability, and 
reproducibility, subsequent refinements in equipment and application have led to technical 
acceptability (Schabauer and Rooke, 1994). 
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2.1.6.8. Post-occlusive Reactive Hyperaemia  
The smooth muscle of distal vascular networks displays an inherent property of periodical 
contraction and relaxation. This is known as rhythmical vasomotion, a process thought to be 
part of active microvascular autoregulation (reviewed by (Nilsson and Aalkjaer, 2003)).  
Laser Doppler flowmetry (LDF) is a non-invasive measure of tissue perfusion and reliably 
assesses cutaneous blood flow (Stern, 1975a). LDF measurements have been shown to 
reliably differentiate patients with peripheral arterial occlusive disease from controls 
(Morales et al., 2005). 
Laser Doppler perfusion monitoring is a well know technique for assessing tissue 
microcirculation in a continuous and non-invasive way (Stern et al., 1977). A typical Laser 
Doppler flowmeter makes use of two optical fibres, the illuminating or source fibre and a 
detecting or collecting fibre. Diode laser light of wavelength 780 nm is commonly used as the 
illuminating light source. The degree of the Doppler shift n frequency from the reflected light 
represents the degree of flux of the moving elements in the sample volume. 
 
A number of studies have shown that resting flux measurements are of questionable value 
(Kvernebo et al., 1988).  However the use of provocative tests such as the post-occlusive 
reactive hyperaemia test as described for brachial artery flow mediated dilation has been 
shown to differentiate between patients with peripheral vascular disease and normal controls 
(Del et al., 1986) (Wahlberg et al., 1990). 
 
One of the most well-known tests in clinical practice for evaluating the functional aspects of 
the arterial blood flow in a limb is the reactive hyperaemic response to a certain period of 
arterial occlusion, also called postocclusive reactive hyperemia (PORH; Table 11 and Figure 
2-23).  
TABLE 11 PARAMETERS FOR LDF EVALUATION OF SKIN MICROCIRCULATION DURING POSTOCCLUSIVE 
REACTIVE HYPERAEMIA (PRH). 
PARAMETERS DEFINITION 
rLDF Resting LD flux value 
pLDF (peak flow) Highest LD value after occlusion 
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tpLDF Time to peak flow 
FRT (time of 
latency) 
Time after occlusion until start of hyperaemic response 
Time of recovery Time after occlusion until rest LD flux value is reached 
Time of hyperaemia Time to total duration of the hyperaemic response 
 
FIGURE 2-23 SCHEMATIC TRACING OF AN LD FLUX RECORDING IN PRH 
 
This test is based on the response to an ischaemic insult. If the blood flow to a tissue is 
stopped for a while by compressing the supplying artery, or is slowed to the point where it is 
inadequate for tissue nutrition (a state called “ischaemia”), the blood flow immediately after 
releasing the compression is much higher than normal, and then decays exponentially. The 
table 5.2 shows the various parameters used for LDF evaluation of skin circulation during 
postocclusive reactive hyperaemia (PRH) (Bongard and Fagrell, 1990).  
 
2.1.6.9. Problems Of Evaluating The LDF Signal Measurements 
Of The Skin 
 
Signal composition 
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It is still uncertain what actually generates the signal recorded from the skin because all 
moving objects of a certain structure within the measuring volume are recorded, and in the 
skin of healthy subjects most of the signal is made up by the movement of red blood cells. 
However, during pathological conditions, e.g., in patients with leukaemia or 
thrombocythemia, a portion of the signal could possibly be produced also by the movements 
of white cells and platelets, respectively. Consequently, in order to be accurate, it can only be 
stated that the major part of the signal is produced by the movements of all blood cells in the 
vascular bed of the measuring volume (Bongard and Fagrell, 1990). 
Penetration depth and measuring volume 
 
The penetration depth has been said to be approximately 1.5 mm, but this value cannot be 
fixed since it must vary with factors like the amount of blood and the composition of the skin 
in the region investigated. Also, the measuring volume must change with these factors. 
Consequently, a quantification of flow in ml min -1 100 g -1 can be obtained only if certain 
specific considerations are fulfilled, which is not the case for the human skin (Bongard and 
Fagrell, 1990). 
 
Instrumental and biological zero values 
 
According to the instructions of the manufacturer, the zero value for the instrument is 
obtained by applying the flow probe to a white surface. This zero value has been found to be 
reasonably stable and can be referred to as the instrument zero. However, it cannot be used as 
zero value for a biological tissue, since marked variations in this value, i.e., the biological 
zero, can be seen from one tissue, and from one area to another (Bongard and Fagrell, 1990). 
 
2.1.6.10. Protocol for Laser Doppler Flowmetry Measurement  
 
A laser-Doppler blood flow monitor DRT4 (Moor Instruments Limited Axminster, Devon) 
with compatible DRTSOFT V3.5 hardware (copyright Moors Instruments Ltd) was used for 
this study (Figure 2-24) and two optical probes previously calibrated were adhered onto the 
forearm skin surface and hand skin surface using double sided adhesive discs (PAD) to 
transmit and collect the light.  The probes were DP1T of a dual fibre design with a fibre 
separation of 0.5 mm (centre to centre) and fibre total diameter of 500 µm which is a dual 
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channel system capable of measuring flux from two different areas simultaneously. A cuff 
was placed in the same arm. The optic connectors from the glass fibres were attached to the 
front panel of the laser Doppler instrument. 
Initially baseline blood flow was recorded for 3 minutes and reactive hyperaemic response 
was obtained after a 3 minutes occlusion period blocking the circulation into the arm by 
having inflated the cuff over systolic pressure and after that exact period time measured by 
the computer the cuff was released. The cuff pressure was reached using air pumps to achieve 
the maximum cuff pressure in a very short time (within 0.1 second). The flow (flux) was 
recorded then continuously until it reached baseline again or for a minimum 3 minutes 
period. 
 
Definition Of Parameters Of Measurements 
 
FLUX: This parameter is related to the product of average speed and concentration of moving 
red blood cells in the tissue sample volume.  
CONCENTRATION: This parameter gives an indication of the number of moving red blood 
cells in the tissue sample volume. 
 
SPEED: This parameter gives an indication of the average speed of red blood cells moving in 
the tissue sample volume. 
 
FIGURE 2-24 DRT4 LASER DOPPLER BLOOD FLOW 
MONITOR (MOOR INSTRUMENTS LIMITED, UK). OPTICAL 
FIBRES TRANSMIT LASER LIGHT TO THE TISSUE. 
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DC: This parameter gives an indication of the backscattered laser light intensity. It can be 
used to check the efficiency of light collection by the laser Doppler probes. 
 
TEMPERATURE: This is measured by probe and where there is good thermal conduction 
between probe and tissue it reaches tissue temperature. 
 
FLOW UNITS: It is generally agreed by researchers and manufacturers that because of the 
nature of the flow in capillaries and connecting small blood vessels, and the effect of varying 
skin colour and structure, it is not appropriate to use absolute flow units such as ml/100 
gm/minute. So, flux was measured in arbitrary units (AU). 
 
Optical Probe Calibration 
 
Probes were calibrated individually in a room with stable temperature (20-22 degrees 
centigrade) and on a surface free from oscillation. Five ml of Flux standard was poured into 
the calibration pot after shaking it. Using a clamp, the probe head was positioned in the 
calibration pot making sure that the surface of the probe was near the centre of the fluid 
volume and finally a stable reading was checked on the screen in run mode. 
 
Laser-Doppler Flowmetry Measurements 
 
For all measurements performed, the probe on the forearm was identified with the number 1 
and the one on the hand was identified with the number two. The following measurements 
were performed in all groups of subjects: 
Baseline flux 1 (BL Flux 1) 
Baseline flux 2 (BL Flux 2) 
Baseline red cells concentration 1 (BL conc. 1) 
Baseline red cells concentration 2 (BL conc. 2) 
Baseline dc 1 (BL dc 1) 
Baseline temperature 1 (BL temp. 1) 
Baseline temperature 2 (BL temp. 2) 
Maximum flux 1 (Max. Flux 1) 
Maximum flux 2 (Max. Flux 2) 
Maximum concentration 1 (Max. conc. 1) 
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Maximum concentration 2 (Max. conc. 2) 
Maximum dc 1 (Max. dc 1) 
Maximum dc 2 (Max. dc 2) 
Maximum temperature 1 (Max. temp. 1) 
Maximum temperature 2 (Max. temp. 2) 
Minimum flux 1 (Min. Flux 1) 
Minimum flux 2 (Min. Flux 2) 
Minimum concentration 1 (Min. conc. 1) 
Minimum concentration 2 (Min. conc. 2) 
Minimum dc 1 (Min. dc 1) 
Minimum dc 2 (Min. dc 2) 
Minimum temperature 1 (Min. temp. 1) 
Minimum temperature 2 (Min. temp. 2) 
Time from the peak to baseline flux 1 (seconds) (Peak-BL1) 
Time from the peak to baseline flux 2 (seconds) (Peak-BL2) 
Time to reach maximum hyperaemic response 1 (seconds) (time-MHR1) 
Time to reach maximum hyperaemic response 2 (seconds) (time-MHR2) 
Time from baseline to minimum flux 1 (seconds) (time BL-Min.Flux1) 
Time from baseline to minimum flux 2 (seconds) (time BL-Min. Flux 2) 
Percentage of increase on baseline flux 1 during maximum hyperaemic response (% MHR1) 
Percentage of increase on baseline flux 2 during maximum hyperaemic response (% MHR2) 
Delta Flux (Δ Flux): Difference between peak at maximum hyperaemic response and baseline 
flux. 
 
 
Laser Doppler flowmetry traces were analysed using the Moorsoft/ DRT4 version 2 software 
(Axminster, UK). Basal, blood pressure cuff inflation and maximal post deflation 
measurements were recorded. 
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FIGURE 2-25 SCREEN SHOT OF MOOR/ DRT4 ANALYSIS SOFTWARE FOR LASER DOPPLER FLOWMETER. 
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2.2 Methods for Cellular and Molecular Analysis 
 
2.2.1. Circulatory Inflammatory Biomarkers 
 
Biomarkers are the tools that have arisen from the technology of the new genetics. Abnormal 
genes and their respective products, and other organic chemicals made by these abnormal or 
pathological cells are identifiers that make up the molecular signals of a cell. Biomarkers are 
cellular indicators of the physiological state and of changes during a pathogenesis of certain 
chronic diseases. For instance, researchers have saught to indetify biomarkers indicating the 
presence of the risk of CVD, and to pursuit early detection or prognosis (Fichtlscherer et al., 
2004) (Srinivas et al., 2001) (Lind, 2003).  
 
Blood testing which encompasses analyses of the haematocrit, platelet counting, erythrocyte 
sedimentation rate (ESR), function of blood cells and their precursors in bone marrow (e.g. 
staining blood films), and chemical constituents of blood serum and plasma (e.g. 
coagulation), are basically biochemical markers (Henry, 2001)[(Morris, 2001) cited in  
(Henry, 2001)]. In addition, the inflammatory markers are currently become promising 
predictor as biochemical markers of atherosclerosis and its complications.  
 
The plasma CRP, fibrinogen and IL-6 are important as they both are used as systemic 
markers of inflammation and these markers provide satisfactory correlation between analysis 
of their level and incidence of thrombo-embolic events. This might be because the high 
inflammation in the vascular wall is associated to the high possibility of fibrous cap rupture 
of the plaques. Furthermore, the onset of myocardial infarction (MI) is sudden and can be a 
fatal event. The initial diagnosis of MI is performed by serial measurement of the cardiac 
enzymes as biomarkers, namely troponin and CK-MB. These biomarkers have become a 
reliable indicator to support the diagnosis of MI and assist the management of these patients 
(Fichtlscherer et al., 2004) (Srinivas et al., 2001) (Lind, 2003).  
 
In IRI, blood test can identify the presence of inflammatory mediators like cytokines and the 
other inflammatory mediators, deriving from the injured parenchymal cells, endothelial cells, 
infiltrated immune cells and the reactions of complement and hemostatic processes on the BE 
interface. The studies of biomarkers of inflammation is essential in the field of  IRI  because 
the pathophysiological consequences of IRI start to occur from the cell injury within the 
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locally affected microcirculation of the tissue causing generation of inflammatory mediators 
which are subsequently released into the circulation and eventually have effects on the 
microcirculation of the remote organs. 
 
Immuno-hematology basically refers to hematology regarding the immunological properties 
and reactions of all blood components and its constituents (Henry, 2001, Beadling, 
Immunohepatology). It plays an integral part in transfusion medicine (since the testing 
reactions of the antigen on RBC surface and the antibody in plasma is necessary for blood 
grouping) and in the transplantation medicine (since the testing of the major 
histocompatibility complex (MHC) on the WBC surface is required for the compatibility 
between the donor and the recipient).  
 
Hormones, cytokines and other inflammatory mediators represent less than 1% of blood 
plasma. Although the amount of these substances in blood is small, their influences on the 
whole body are massive. 
 
Haemapheresis is the process of separating blood serum into its constituent components, 
generally by centrifugation. It includes cytapheresis and plasmapheresis, which aim to take 
blood cells and to use plasma component of serum, respectively (Henry, 2001) (Winters). It is 
widely used in transfusion medicine to prepare blood component for transfusion purposes, 
but is also useful in the study of cytokine concentration in plasma. 
 
Assays for the cytokines quantification / characterization fall into two categories (Remick, 
2002) :  
 
• Bioassay  
• Immunoassay  
 
The purpose of the bioassay is to validate the biological functions of the cytokines typified 
into four areas: i) measuring their cytotoxicity, ii) measuring the cell proliferation they induce 
iii) measuring their action in regard to specific cell function, iv) measuring the amount of 
cellular protein production they induce. On the other hand, immunoassay is mainly used to 
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monitor the level of cytokines in plasma regardless of their biological actions (Remick, 
2002).  
 
Although bioassays are the best way to assess the cytokine activity, they are time-consuming, 
as cells have to be cultured before the cytokines can be inserted into them. The technique is 
usually unmanageable for clinical purposes in a hospital setting (Massey) in (Henry, 2001). 
 
The concept of biological ligand is interesting in immuno-hematology as it is based on the 
affinity between a two specific molecules such as an enzyme and substrate, a hormone and 
receptor, or an antigen and antibody. Immunoassay is an analytical tool, which estimates the 
frequency of specific binding between an antibody and an antigen. There are at least six well-
recognised immunoassays: i) radioimmunoassay (RIA), ii) enzyme-linked immunosorbent 
assay (ELISA), iii) precipitation immunoassays iv) particles immunoassays, v) fluorescent 
immunoassays and vi) chemi-luminescent immunoassays (Ashihara) in (Henry, 2001).  
 
2.2.2. Enzyme-linked Immunosorbent Assay (ELISA) 
 
Immunoassays can be devided into liquid phase and solid phase, also sometimes termed 
homogeneous and heterogeneous (Remick, 2002). First, in the homogeneous immunoassay, 
all stages are conducted in the liquid phase, which means that the studied substance is 
homogeneously mixed in the solution all the time, so no washing is required. In contrast, the 
solid phase or heterogeneous methods necessitate washing an unbound antibody out at some 
stages of the procedure.  
 
The solid-phase immunoassay is ubiquitous in the modern biological laboratory providing 
decisive information for use in both clinical medicine and basic molecular biological science 
(Carpenter) in (Rose, 2002). There are a variety of matching sets of the immunoassay 
technique available to appropriately quantify each of the circulating inflammatory mediators 
in the plasma, for instance cytokines, cellular adhesion molecules (CAMs), complements and 
coagulation factors. 
 
The radioimmunoassay RIA and ELISA are the two commonest methodologies employed in 
clinical practice to quantitatively measure the plasma level of cytokines. The former uses 
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radioisotope and proton counting (e.g. 125I, 3H) while the latter uses an enzyme as a label, 
which can be quantified by a variety of spectrophotometries, which measure the absorption of 
light by color created by the enzyme label (Henry, 2001) (Remick, 2002) [(Ashihara) in 
(Henry, 2001)] 
They are both of the heterogeneous or solid phase type. Although RIA is superior in its 
rapidity and high sensitivity, the radioactive agents used to label the immune complex 
possess a certain amount of radio-toxicity. ELISA, which was initially introduced in the 
1970s, has largely replaced earlier techniques, such as immuno-fluorescence and 
agglutination. This technique has outstanding efficiency, objectivity and capability to run 
large numbers of samples with less hands-on technician time. It has been acknowledged to be 
the most appropriate tool for the assessment of circulating cytokines in plasma. 
 
Enzyme-linked immunosorbent assay (ELISA) is the immunochemistry technique based on 
the principle of specific binding of the antigen and the antibody. 
 
The antigen and its associated antibody are conjugated to an enzyme, and then deposited on a 
substrate to form a coloured product (labelling step). Commonly used enzymes are 
horseradish peroxidase (HRP) and alkaline phosphatase (AP). Substrates used for HRP 
include o-phenlenediamine (OPD), 5-aminosalicylic acid, 2,2-azino-di (3-ethyl-
benzthiazoline sulfonate-6 (ABTS) and 3,3’,5,5’-tetramethylbenzidine (TMB) while ρ-
nitrophenyl phosphate (NPP) is commonly used with AP (Carpenter) in (Rose, 2002).  
 
The technique can be divided into two major methodological categories: direct and indirect 
(or sandwich). Both methods are illustrated in Figure 2-26.  
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FIGURE 2-26 DIRECT AND INDIRECT CONJUGATION OF AG-AB AND ENZYME IN ELISA (ADAPTED FROM 
(REMICK, 2002)) 
 
ELISA is routinely performed in 96-well-plate and in both direct and indirect procedures, the 
initial step (step 1) is to fix the cytokine (antigen) or the antibody to the well plate base. The 
antigen (cytokine) is titrated and prepared by diluting in coating buffer. In the direct method, 
the second step involves adding antibody to form immune complex, which is then incubated 
and washing out the unbounds, successively. In the indirect method, there is an additional 
step. The sandwiched antibody is added, incubated and washed out. The following steps 
involve conjugation which is performed by adding enzyme to conjugate the immune complex 
and afterward the pouring of the substrate to generate a color. 
 
Washing requires the use of the different buffers at each step of washing out; the buffer 
commonly employed for cytokine assessment is phosphate buffer solution (PBS). Incubation 
is important to bind antigen-antibody securely to form the immune complex and to bind the 
complex to the conjugated enzyme. Normally, the incubation period is 1-2 hour, at room 
temperature (250c).  
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In the final step, the measurement of the cytokine concentration is calibrated by 
spectrophotometer, measuring the optical density of the color created by the enzyme. The 
optical density (color intensity) is done first at one wavelength (492 nm) and then at another 
wavelength (620 nm). By subtracting these two values, the concentration of cytokine apart 
from other substances can be estimated. The spectrophotometer is interfaced with a dedicated 
computer which processes the results. 
 
The degree of intensity of the color reaction is directly proportional to i) the ability of Ag or 
Ab to bind well with the well plate, ii) the amount of the binding of the Ag-Ab which 
subsequently determines iii) the quantity of the combination of enzyme to the Ag-Ab 
complex. In the direct method, the accuracy is sometimes low because it binding with the 
plastic plate is poor due to competition by several other proteins in plasma (other cytokines). 
Therefore, indirect method claims to overcome this problem and was chosen for this study. 
 
Indirect ELISA has been modified into two types: competitive and noncompetitive. The 
advantage of the competitive method is cost as it uses less expensive antibody commercial 
kit. The non-competitive indirect method is lower in specificity but higher in sensitivity. 
 
In this study, venous blood was taken from PAOD patients undergoing revascularisation 
preoperatively and postoperatively at one hour and one day. Blood samples taken from the 
patients were centrifuged at 10,000 rounds (revolutions) per minute for 15 minutes. The 
plasma in the sample tube was subsequently separated from blood cells and kept frozen at -
700C until the sample size was sufficient to be analysed in a statistically significant way. The 
technique for quantifying the mediators was an indirect non-competitive ELISA technique 
using an available commercial kit. The detail of this technique is detailed in Appendix A.   
 
 
2.2.3. Assessment the Remote Organ Injury: Urine NAG (N-acetyl-
β-D-glucosaminidase) 
 
Normally, 25% of cardiac output passes through the kidneys every minute, amounting to, 
around 180 litre of blood filtrate, of which only 1-2 litre/day is excreted as urine through 
renal glomeruli (Henry, 2001)]. Urinalysis basically investigates urine by three approaches: 
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the examination of its physical properties; the qualitative and quantitative assessment of its 
chemical components and the microscopic examination of urine sediment. 
 
The physical examination of urine inspects the colour, clarity, odor, osmolarity and volume 
(urine output). The chemical analysis includes the measurement of urine pH and electrolytes 
and the identification of a wide range of bioorganic components, including proteins, glucose 
and other sugars, ketones, hemoglobin, myoglobin, bilirubin, urobilinogen, using a variety of 
biomedical laboratory techniques.  
 
The examination of the urine sediment uses centrifugation to retrieve insoluble constituents. 
Microscopic examination of the solid constituents is carried out, which includes cells 
(desquamated/exfoliated epithelial lining cell of urinary tract, hematogneous origin:WBC, 
RBC and neoplastic cells), casts (cellular element originated from kidney), crystals and 
microorganisms (Henry, 2001)]. Nowadays, automated urinalysis is widely available. 
 
The investigation of proteins in the urine has been refined over the years in order to diagnose 
pathologies in the body. The biomarker for renal tubule impairment can be identified in this 
way. Urine enzyme activity has been acknowledged as a reliable indicator of renal tubule 
damage (Bosomworth et al., 1999). IRI is a major mechanism causing acute renal failure 
(Hauet et al., 2000), and several urine enzymes, such as  urine N-acetyl-b-D-glucosaminidase 
(NAG),  trimethylamine-N-oxide (TMAO), dimethylamine (DMA) and acetate have been 
used as biomarkers of renal tubule exposure to it. 
 
Urine N-acetyl-b-D-glucosaminidase (NAG) is an enzyme protein and is one of 200 kinds of 
proteins that can be found in urine. It is one of the most commonly used diagnostic markers 
for early indication of renal tubular damage and dysfunction due to insults by nephrotoxic 
substances or renal diseases (Hauet et al., 2000) (Price, 1992b). The ELISA of urinary N-
acetyl-beta-D-glucosaminidase (NAG) is a reliable test with few false positives since the 
NAG level remains high during active disease or a sustained insult and it falls to normal 
levels quickly during the period of recovery or the removal of toxic substances (Bosomworth 
et al., 1999) (Hauet et al., 2000) (Price, 1992b) (Rabb, 1998) (Price, 1992a). The ELISA 
method used for qualitative analysis urine NAG has been previously described (Yuen et al., 
1984) and its use in this study is detailed in Appendix B.   
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2.3 Assays of Oxidative Stress and Anti-oxidant defence (FORT 
and FORD) 
 
 
2.3.1. Oxidative Stress 
 
The FORT test (Callegari, Parma, Italy) is a colourimetric test based on the ability of 
transition metals, such as iron, to catalyse the breakdown of hydroperoxides into derivative 
radicals (ROOH), according to Fenton’s reaction. Once they are formed in cells, ROOH 
maintain their chemical reactivity and oxidative capacity to generate proportional amounts of 
alkoxyl (RO·) and peroxyl (ROO·) radicals (Figure 2-29, reactions A and B).  
 
These derivative radicals are then preferentially trapped by a suitably buffered chromogen (an 
amine derivative, reagents R1 of the FORT kit; CrNH2) and develop, in a linear kinetic based 
reaction at 37°C, a coloured fairly long-lived cation photometrically detectable radical (fig. 5, 
reaction C).  
FIGURE 2-27 THE CR3000 ANALYSER (CALLEGARI, PARMA, ITALY) FOR USE 
WITH FORT AND FORD TESTS. 
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The intensity of the colour correlates directly with the quantity of radical compounds, 
according to the Lambert-Beer’s law, and it can be related to the oxidative status of the 
sample. 
 
R-OOH Fe2+ R-O OH- Fe3+
R-OOH Fe3+ R-OO H+ Fe2+
R-O ROO 2CrNH2 RO- ROO-
+ + +
+ + +
+ + +
A
B
C
 
FIGURE 2-28 REACTIONS CHARACTERISING THE FORT TEST (FENTON’S EQUATIONS). A: ALKOXYL RADICAL 
FORMATION; B: PEROXYL RADICAL FORMATION; C: COLOURED COMPOUND FORMATION 
 
Interpretation of FORT test results 
Due to the chemical heterogeneity of the secondary radical species deriving from the iron-
dependent breakdown of ROOH during the FORT test (RO· and ROO·), the 
spectrophotometer absorbency readings are converted into arbitrary units (FORT units). The 
transformation is automatically performed by the instrument. Results are also expressed as 
equivalent concentrations of H2O2 as reference hydroperoxide. One FORT unit corresponds 
to approx.7.6 mmol/l equivalent to 0.26 mg/l of H2O2. 
 
The higher the result obtained, the higher the level of oxidative stress. Normal values are up 
to 310 FORT units. 
 
Reagents 
All reagents are ready to use, and stored at room temperature. 
The test kit contains: 
 
• R1 reagent: a solid chromogen contained in disposable square based cuvettes. 
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• R2 reagent: a buffer stabilised and preserved in disposable conical tubes. 
• 20 ml heparinised capillaries. 
 
The testing procedure is described in Appendix C. 
2.3.2. Antioxidant Defence 
 
The FORD (Callegari, Parma, Italy) test is a near patient plasma antioxidant capacity test. 
The assay measures the combined effect of the overall plasma water-soluble antioxidant 
defenses in blood thus enabling assessment of the integrated antioxidant system which 
encompasses biological components with antioxidant activity.  
 
Antioxidants measured by FORD test include: 
 
• Vitamin C  
• Vitamin E (water soluble part) 
• Plasma proteins (albumin, ferritin, metallothionine, transferrin)  
• Thiol group containing compounds (Glutatione, cysteine, lipoic acid, N-acetyl-cysteine, 
mercaptopropionylglycine (MPG)).  
• Bilirubin  
• Polyphenolic compounds (ie flavonoids and tannins).  
 
FORD is a colourimetric test based on the ability of antioxidants present in plasma to reduce 
a preformed radical cation. A stable coloured cation (photometrically detectable at 505 nm) is 
formed in the presence of an acidic buffer (pH 5.2) and an oxidant (FeCl3). Antioxidant 
compounds (AO) present in the sample analysed, reduce the radical cation of the chromogen 
quenching the color and producing a decolouration of the solution, which is proportional to 
their amount in the sample (Figure 2-29).  
 
chomogen+ 
(purple)
AOH chromogen
+ 
uncoloured) AO+ +
 
FIGURE 2-29. COLOURIMETRIC REACTION USED IN THE FORD TEST 
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The UV-visible spectrum of the FORD chromogen radical cation shows a maximum of 
absorbance at 505nm.  Absorbance reading between 0.80 and 1.00 is reached after 3-4 
minutes when a stable coloured solution is formed. This provides an assay based on the 
extent of radical reduction at a fixed time point, namely 4 minutes, and not on the rate of 
reduction. This feature rules out complications owing to monitoring the time course of colour 
inhibition, which is common to other methods such a crocin based assays ((Pryor et al., 1993, 
Tubaro et al., 1996)and ABTS based assays (Miller and Rice-Evans, 1997). 
 
Colour quenching is determined especially by contribution of antioxidants like proteins such 
as albumin, reduced glutathione, Vitamin C, Trolox (water soluble analogue of Vitamin E). 
These antioxidants (together with uric acid which is purposely not detected by the FORD test, 
see later) are among the most important contributors to plasma antioxidant function. FORD 
results are obtained from the capacity of plasmatic antioxidants to inhibit the chromogen 
radical, relative to Trolox. 
 
Results are expressed as Trolox equivalents (mmol/l). A calibration curve is performed using 
a Trolox standard solution. 
 
Interpretation of FORD test results 
Based on a preliminary number (Unpublished data; Callegari, Italy) of 70 human blood 
donors (male/female ratio, 37/33; aged 20-70 years, mean age 36 years) and the values cited 
in scientific literature (Miller and Rice-Evans, 1997, Re et al., 1999, Wayner et al., 1987, 
Yeum et al., 2004, Cao and Prior, 1998), the reference values of FORD were established to 
be within the 1.07-1.53 mmol/l Trolox range (mean value = 1.23 mmol/l Trolox). 
 
Reagents 
All reagents are ready to use, and stored at room temperature. 
 
C1 reagent: a solid chromogen contained in disposable square based cuvettes. 
S1 reagent: a NaCl solution preserved in disposable conical tubes. 
S2 reagent: a buffer stabilised and preserved in disposable conical tubes. 
S3 solution (FeCl3). 
 
The testing process is described in Appendix D. 
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2.4 Hypothesis, Aims and Objectives 
2.4.1. Hypotheses 
 
There is a relationship between plasma oxidative stress, endothelial function and kidney 
injury in claudicants undergoing maximal walking exercise. 
 
There is a subgroup of patients with intermittent claudication who are more susceptible to 
acute kidney injury when undergoing maximal walking exercise. 
 
2.4.2. Aims 
 
§ To investigate relationship between endothelial function, oxidative stress, oxidative 
defence and acute kidney injury in patients with intermittent claudication in response 
to maximal walking exercise. 
§ To identify a potential screening strategy to identify claudicants who are vulnerable to 
acute kidney injury when undergoing maximal walking exercise.  
§ To investigate the relationship between the cytokine MCP-1 with oxidative stress, 
endothelial function and acute kidney injury. 
2.5 Participant Recruitment 
Potential participants were identified from the arterial database maintained at the vascular 
laboratory at the Hammersmith Hospital, London. All patients with intermittent claudication 
were invited to participate. Patients with leg pain when at rest and/or skin ulceration were 
excluded. 
Inclusion criteria:  
§ Patients with peripheral vascular disease experiencing intermittent claudication. 
 
Exclusion criteria: Concomitant disease precluding treadmill exercise: 
§ Active heart disease 
§ Active renal failure 
§ Active lung disease 
§ Musculoskeletal pain 
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2.6 Study Design 
 
The study design is shown in the following flow diagram (Figure 2-30). 
 
Testing protocol for claudicant patient 
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Patients with intermittent 
claudication
Arrive, empty bladder and rest 
for 90 mins
Treadmill stress test till 
maximum walking distance 
achieved (4km/h, 10% incline)
Post exercise FMD and blood 
sample
Free radicals and anti-
oxidative capacity (near 
patient test)
Urinary NAG test
Free radicals and anti-
oxidative capacity (near 
patient test)
Urinary NAG test
plasma MCP-1
plasma MCP-1
FIGURE 2-30 STUDY DESIGN FOR INVESTIGATION OF SYSTEMIC INFLUENCE OF EXERCISE IN 
PATIENT WITH INTERMITTENT CLAUDICATION 
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2.7 Data Analysis 
Data was analysed using Microsoft Excel (2010 edition) and SPSS (version 20). Data will be 
plotted and parametric or non-parametric tests were used appropriately.  
 
2.8 Study Administration; Ethical Issues; Dissemination And 
Outcomes 
 
Patients’ interests were safeguarded by providing contact points for clarification or 
complaints. All contact details were provided in the Patient Information Leaflet. 
 
Supervision and sponsorship for the study was provided by Imperial College London, with Dr 
Aslam (Hammersmith Hospital) being responsible.  
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3. Results 
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3.1 Demographic data 
 
 
 
 
 
 
 
 
 
 
 
2250 patients identified from 
vascular lab database with 
lower limb ABPI 
measurements between 
2004 and 2011 
114 patients identified 
with ABPI % 0.9 and 
invited to participate
20 patients agreed to 
partipate
No records not found for 
3 patients
Vascular lab reports 
reviewed to identify 
patients with intermittent 
claudication
9 female 11 male
94 patients not available 
for study or with very 
limited mobility
FIGURE 3-1 FLOW CHART DEMONSTRATING RECRUITMENT OF PATIENTS FROM VASCULAR 
LABORATORY DATABASE. 
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Demographic data is summarised in the Table 12 below. Details of individual participants are 
included in Appendix E 
 
TABLE 12. DEMOGRAPHIC DATA OF ALL PARTICPANTS. 
Number of participants 20 
Age (years)  (median, IQR) 71.5, 65.75 to 80 
Male (n, %) 11 (55%) 
Lowest ABPI (median, IQR) 0.7, 0.6 to 0.8 
Mean ABPI (median, IQR) 0.8, 0.66 to 0.9 
Maximum walking distance (m; median, IQR) 265, 155 to 450 
Height (m) (median, IQR) 1.695, 1.5725 to 1.7525 
Weight (kg) (median, IQR) 70, 63.5 to 88 
BMI (kg/ m2) (median, IQR) 26.35, 23.675 to 29.95 
 
TABLE 13. MEDICATION USAGE IN PARTICIPANTS 
Particpant 
number 
Statin Antiplatelet Other drugs 
1 Atorvastatin Aspirin Lansoprazole, Tamsulosin, 
Finasteride, Amlodipine, Irbesartan 
2 simvastatin Aspirin Spiriva inhaler, salbutamol inhaler,  
3  Aspirin Tolterodine 
4 simvastatin Aspirin,Clopidogrel Bisoprolol 
5 Simvastatin Aspirin  
6  Aspirin Ramipril 
7 simvastatin Aspirin Metformin, , Insulin, Gliclazide, 
Enalapril, Amlodipine, and 
Bendrofluazide 
8 Atorvastin Aspirin Omeprazole and Atenolol 
9   Amiodarone, Warfarin 
10 Simvastatin   
11   Metformin, Ramipril 
12   None 
13 Rosuvastatin Aspirin Omeprazole, Carvedilol 
14   Enalapril, Cilostasol 
15 Pravastatin Aspirin Amlodipine 
16 Simvastatin  Bendrofluazide, Irbesartan, Metformin, 
Insulin, Omeprazole, Ursodeoxycholic acid 
17   Bendrofluazide 
18 Simvastatin Aspirin , Clopidogrel  
19 Simvastatin Aspirin Metformin,  
20 Simvastatin Aspirin Quinine, Bendrofluazide 
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3.2 Endothelial function changes in claudicants following 
exercise  
 
 
3.2.1. Comparison of Brachial artery diameter in claudicants pre- 
and post-exercise 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
Brachial artery 
diameter (cm; 
median, IQR, range) 
4.49; 4.15 to 5.03, 
2.86 to 5.80 
4.35; 3.94 to 
4.99, 2.86 to 5.22 
p = 0.147, Mann 
Whitney U test 
 
 
FIGURE 3-2. A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
BRACHIAL ARTERY DIAMETER IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.2.2. Comparison of FMD in claudicants pre- and post-exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
FMD (% change; 
median, IQR, range) 
1.91; 3.55 to 3.87,  -
17.48 to 13.39  
3.75; 1.29 to 
7.45, -17.43 to 
13.99 
p = 0.313, Mann 
Whitney U test 
 
FIGURE 3-3. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING ENDOTHELIAL FUNCTION (FMD) IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.2.3. Comparison of resting LDF in claudicants pre- and post-
exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 12 12  
Resting LDF 
(median, IQR, 
range) 
154.25, 154.25 to 
265.05, 24 to 887 
209.40, 142.83 to 
768.03, 115 to 
945 
p = 0.06, Mann 
Whitney U test 
 
FIGURE 3-4. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING LASER DOPPLER FLOWMETRY FLUX IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.2.4. Post occlusion reactive hyperaemia (LDF) for claudicants 
pre- and post-exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 12 12  
PORH - LDF 
(median, IQR, 
range) 
59, 25.74 to 260.43, 
-70 to 786 
11.2, -9.85 to 
218.9, -64 to 303 
p = 0.388, Mann 
Whitney U test 
 
FIGURE 3-5. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING LASER DOPPLER FLOWMETRY POST OCCLUSION HYPERAEMIA RESPONSE IN 
CLAUDICANTS PRE AND POST EXERCISE. 
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3.3 Oxidative stress in claudicants 
 
3.3.1. Plasma oxidative stress in claudicants pre- and post exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
FORT (FORT units; 
median, IQR, range) 
296.50, 243.25 to 
425.50, 160 to 600 
303.5, 263 to 
401.25, 160 to 
600 
p = 0.888, Mann 
Whitney U test 
 
FIGURE 3-6. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING PLASMA OXIDATIVE STRESS (FORT) IN CLAUDICANTS PRE AND POST EXERCISE. 
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 Pre-exercise Post-exercise p value 
n 20 20  
H2O2 (mmol/l; 
median, IQR, range) 
2.19, 1.81 to 3.02, 
0.83 to 4.56 
2.31, 2 – 3.1, 
1.22 to 1.56 
p = 0.825, Mann 
Whitney U test 
 
FIGURE 3-7. . A) BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE 
DEMONSTRATING PLASMA OXIDATIVE STRESS (H2O2) IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.3.2. Antioxidant defence in claudicants pre- and post-exercise 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
FORD (Trolox 
equivalents; median, 
IQR, range) 
0.96, 0.84 
 to 1.22, 0.25 to 
1.53 
1, 0.43 to 1.32, 
0.25 to 4.55 
p = 0.575, Mann 
Whitney U test 
 
FIGURE 3-8. BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
PLASMA OXIDATIVE DEFENCE (FORD) IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.4 Urinary N-acetyl-β-D-glucosaminase/ Creatinine ratio in 
claudicants pre- and post-exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 17 17  
Urinary NAG/ 
creatinine; 
µmol/L/mmol Cr, 
median, IQR, range) 
8.94, 6.73 to 14.27, 
4.4 to 23.25 
 
12.90, 9.07 to 
17.72, 7.16 to 
36.98 
p = 0.000293, Mann 
Whitney U test 
 
FIGURE 3-9. BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
URINARY NAG/ CREATININE RATIO IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.5 Plasma MCP-1 concentration in claudicants pre- and post-
exercise 
 
 
 
 
 
 Pre-exercise Post-exercise p value 
n 20 20  
Plasma MCP-1; 
pg/ml, median, IQR, 
range) 
88.41, 69.34 to 
119.43, 47.45 to 
178.84 
 
93.31, 70.6 to 
48.49, 70.6 to 
126.41 
p = 0.601, Mann 
Whitney U test 
 
FIGURE 3-10. BOX PLOT, B) SLOPE GRPAH SHOWING PAIRED DATA POINTS AND C) TABLE DEMONSTRATING 
PLASMA MCP-1 IN CLAUDICANTS PRE AND POST EXERCISE. 
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3.6 Effects of lowest ABPI on oxidative stress and defence, 
endothelial function, MCP-1 and kidney injury 
 
3.6.1. Correlation of lowest ABPI with oxidative stress in 
claudicants 
 
 
FIGURE 3-11. SCATTER GRAPH OF LOWEST ABPI VERSUS PRE- EXERCISE PLASMA OXIDATIVE STRESS 
MEASURED BY FORT TEST (FORT UNITS) 
 
 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
pre-exercise plasma oxidative stress as measured by the FORT test (Rs = 0.544, p = 0.013; 
Spearman’s rank correlation; Figure 3-11). 
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FIGURE 3-12. SCATTER GRAPH OF LOWEST ABPI VERSUS POST- EXERCISE OXIDATIVE STRESS MEASURED BY 
FORT TEST (FORT UNITS) 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
post-exercise plasma oxidative stress as measured by the FORT test (Rs = 0.736, p = 
0.000218; Spearman’s rank correlation; Figure 3-12). 
 
There was no association between lowest ABPI with percentage change (post-pre) of FORT 
(Rs = 0.164, p = 0.490)   
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FIGURE 3-13. SCATTER GRAPH OF LOWEST ABPI VERSUS PLASMA OXIDATIVE STRESS AS MEASURED IN H2O2 
(MMOL/L). 
 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
pre-exercise plasma H2O2 (Rs = 0.444, p = 0.05; Spearman’s rank correlation; Figure 3-13). 
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FIGURE 3-14. SCATTER GRAPH OF LOWEST ABPI VERSUS POST- EXERCISE PLASMA OXIDATIVE STRESS AS 
MEASURED IN H2O2 (MMOL/ L).  
 
 
There was a strong correlation between the lowest ABPI measured in claudicants with the 
post-exercise plasma H2O2 (Rs = 0.736, p = 0.000218; Spearman’s rank correlation; Figure 
3-14). 
 
There was no association between lowest ABPI with percentage change (post-pre) of H2O2 
(Rs = 0.175, p = 0.462)   
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3.6.2. Correlation of lowest ABPI with anti-oxidant defense 
 
There was no correlation between lowest ABPI and the antioxidant defense as measured by 
FORD (pre: Rs = -0.3, p = 0.199; post: Rs = -0.124, p = 0.601; percent change post exercise: 
Rs = 0.06, p = 0.801). 
 
3.6.3. Correlation of lowest ABPI with macro-vascular endothelial 
function 
There was no correlation found between FMD (per cent change) either pre (Rs = 0.273, p = 
0.244) or post exercise (Rs = 0.286, p = 0.222) nor FMD per cent change (post – pre; Rs = -
0.181, p = 0.444) exercise with lowest ABPI. 
 
3.6.4. Correlation of lowest ABPI With micro-vascular endothelial 
function 
There was no correlation of LDF PORH response (per cent change) either pre (Rs = -0.343, p 
= 0.275) or post (Rs = 0.2, p = 0.534) nor per cent change (post – pre; Rs = 0.173, p = 0.465) 
with lowest ABPI. 
 
3.6.5. Correlation of lowest ABPI with kidney injury 
Similarly there was no correlation of NAG/ Creatinine ratio neither pre (Rs = -0.108, p = 
0.680) or post (Rs = -0.125, p = 0.633) nor per cent change (post – pre; Rs = -0.326, p = 
0.202) with lowest ABPI. 
 
3.6.6. Correlation of lowest ABPI with plasma MCP-1 
There was no correlation of lowest ABPI with MCP-1 pre- (Rs = 0.105, p = 0.661); post-: Rs 
= 0.163, p = 0.494; or percent change post-exercise: Rs = 0.167, p = 0.481). 
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3.7 Effect of average ABPI on oxidative stress and defence, 
endothelial function, MCP-1 and kidney injury 
3.7.1. Correlation of average ABPI with oxidative stress 
There was a significant correlation between average ABPI with the plasma FORT pre-
exercise (Rs = 0.475, p = 0.043; Spearman’s rank correlation; Figure 3-15). 
 
 
 
 
There was a significant correlation between average ABPI and plasma FORT post-exercise 
(Rs = 0.554, p = 0.011; Spearman’s rank correlation; Figure 3-16). 
 
FIGURE 3-15. SCATTER GRAPH OF AVERAGE ABPI VERSUS PRE- EXERCISE OXIDATIVE STRESS AS MEASURED 
BY FORT (FORT UNITS) 
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There was no significant correlation between average ABPI and plasma FORT change post 
exercise (Rs = 0.220, p = 0.352) 
 
There was no correlation between average ABPI and plasma H2O2 pre-exercise (Rs = 0.223, 
p = 0.346). 
 
There was a significant correlation between average ABPI and plasma H2O2 post-exercise 
(Rs = 0.554, p = 0.011; Spearman’s rank correlation; Figure 3-16). 
 
 
FIGURE 3-16. SCATTER GRAPH OF AVERAGE ABPI VERSUS POST- EXERCISE PLASMA OXIDATIVE STRESS AS 
MEASURED IN FORT UNITS. 
 234 
 
 
 
 
There was no significant correlation between average ABPI and plasma H2O2 percentage 
change post exercise (Rs = 0.283, p = 0.227). 
 
3.7.2. Correlation of average ABPI with oxidative defence 
There was no significant correlation between average ABPI and FORD: pre (Rs = -0.235, p = 
0.319); post (Rs = 0.160, p = 0.501); and percent change, post – pre (Rs = 0.220, p = 0.352). 
 
 
 
 
 
 
FIGURE 3-17. SCATTER GRAPH OF AVERAGE ABPI VERSUS POST-EXERCISE PLASMA OXIDATIVE STRESS AS 
MEASURED BY H2O2 
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3.7.3. Correlation of average ABPI with macro-vascular endothelial 
function 
 
 
There was a significant correlation between average ABPI And FMD post-exercise (Rs = 
0.466, p = 0.038; Spearman’s rank correlation; Figure 3-18). There was no correlation 
between average ABPI and pre-exercise FMD (Rs = 0.337, p = 0.146). There was no 
association between average ABPI and percent change (post – pre) FMD (Rs = -0.026, p = 
0.915). 
 
 
 
FIGURE 3-18. SCATTER GRAPH OF AVEAGE ABPI VERSUS POST EXERCISE ENDOTHELIAL FUNCTION. 
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3.7.4. Correlation of average ABPI with micro-vascular endothelial 
function 
 
There was no correlation between average ABPI and LDF: Pre- (Rs = -0.364, p = 0.245); 
post- (Rs = 0.301, p = 0.342) or percent change post – pre LDF (Rs = 0.197, p = 0.406). 
 
3.7.5. Correlation of average ABPI with kidney injury 
 
There was no correlation between average ABPI and kidney injury (NAG/ Creatinine ratio): 
Pre- (Rs = -0.174, p = 0.504); post- (Rs = 0.015, p = 0.955) or percent change post – pre LDF 
(Rs = -0.230, p = 0.374). 
3.7.6. Correlation of average ABPI with MCP-1 
 
There was no correlation between average ABPI and MCP-1: Pre- (Rs = 0.232, p = 0.326); 
post- (Rs = 0.155, p = 0.514) or percent change post – pre LDF (Rs = 0.026, p = 0.915). 
 
3.8 Effects of resting oxidative stress on endothelial function, 
MCP-1 and kidney injury 
 
3.8.1. Correlation of pre exercise oxidative stress with macro-
vascular endothelial function in claudicants 
 
There was no association between FORT (pre) and FMD (% change) pre exercise (Rs = 
0.301, p = 0.198). Similarly, there was no association between FORT (pre-exercise) and 
FMD % change (post exercise) R =0.259, p = 0.271. 
 
 237 
 
 
FIGURE 3-19. SCATTER GRAPH OF PRE EXERCISE OXIDATIVE STRESS (FORT) VERSUS PERCENTAGE CHANGE 
IN ENDOTHEIAL FUNCTION (FMD) POST EXERCISE. 
 
There was a negative correlation between the post – pre change in FMD with pre-exercise 
FORT test in claudicants (Rs =  -0.468, p = 0.038; Spearman’s rank correlation; Figure 3-19). 
There was no association between H2O2 (pre) and FMD % change pre exercise (Rs = 0.120, 
p = 0.613).  
 
Similarly there was no association between H2O2 (pre) and FMD % change post exercise R 
=0.044, p = 0.855. 
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There was a negative correlation between the post – pre change in FMD with pre-exercise 
H2O2 in claudicants (Rs =  -0.537, p = 0.026; Spearman’s rank correlation; Figure 3-20). 
 
3.8.2. Correlation of pre exercise oxidative stress with micro-
vascular endothelial function in claudicants 
There was no correlation between pre-exercise FORT with the LDF post-occlusion 
hyperaemia response: Pre- (Rs = -0.161, p = 0.618); post- (Rs = -0.091, p = 0.779) or percent 
change post-exercise (Rs = 0.049, p = 0.838). 
 
There was no correlation between pre-exercise H2O2 with the LDF post-occlusion 
hyperaemia response: Pre- (Rs = -0.161, p = 0.618); post- (Rs = -0.091, p = 0.779) or percent 
change post-exercise (Rs = -0.003, p = 0.990). 
FIGURE 3-20. SCATTER GRAPH OF PRE-EXERCISE OXIDATIVE STRESS (H2O2) VERSUS PERCENTAGE CHANGE 
IN ENDOTHELIAL FUNCTION (FMD) POST EXERCISE. 
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3.8.3. Correlation of pre exercise oxidative stress with kidney 
injury in claudicants 
There was no association between FORT (pre) and NAG/creat ratio pre exercise (Rs = 0.002, 
p = 0.993). Similarly there was no association between FORT (pre) Nag/creat (post) R 
=0.181, p = 0.486. There was no association between FORT  (pre) with NAG/creat ratio (post 
– pre) Rs = -0.390, p = 0.122 
 
There was no association between H2O2 (pre) and NAG/creat ratio pre exercise (Rs = 0.279, 
p = 0.277). Similarly there was no association between H2O2 (pre) and Nag/creat (post) R 
=0.086, p = 0.743. There was a negative correlation between the per cent change (post – pre) 
of NAG/ Creatinine with pre-exercise H2O2 in claudicants (Rs =  -0.468, p = 0.038; 
Spearman’s rank correlation; Figure 3-21). 
 
 
 
FIGURE 3-21. SCATTER GRAPH OF PRE-EXERCISE OXIDATIVE STRESS (H2O2) VERSUS PERCENTAGE CHANGE 
IN NAG/ CREATININE RATIO POST EXERCISE. 
 240 
 
3.8.4. Correlation of pre exercise oxidative stress with MCP-1 
 
There was no association between pre exercise FORT with pre exercise MCP-1 (R = -0.271, 
p = 0.248). There was no association between pre exercise FORT with post exercise MCP-1 
(R = -0.039, p = 0.870). There was no association between pre exercise FORT with % change 
post- pre exercise MCP-1 (R = 0.232, p = 0.326). 
 
There was no association between pre exercise H2O2 with pre exercise MCP-1 (R = -0.418, p 
= 0.067). There was no association between pre exercise H2O2 with post exercise MCP-1 (R 
= -0.080, p = 0.738). There was no association between pre exercise H2O2 with % change 
post- pre exercise MCP-1 (R = 0.371, p = 0.107). 
 
3.9 Effect of post exercise oxidative stress on endothelial 
function, kidney injury and MCP-1 
 
3.9.1. Correlation of post exercise oxidative stress with macro-
vascular endothelial function in claudicants 
 
There was no association between FORT (post) and FMD % change pre exercise (Rs = 0.252, 
p = 0.285). Similarly there was no association between FORT (post) with FMD % change 
(post) R =0.063, p = 0.793. 
 
There was no association between H2O2 (post) and FMD % change pre exercise (Rs = 0.252, 
p = 0.285). Similarly there was no association between H2O2 (post) and FMD % change 
(post) R =0.063, p = 0.793. 
 
3.9.2. Correlation of post exercise oxidative stress with micro-
vascular endothelial function in claudicants 
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There was no correlation between the post exercise FORT with the post-occlusion 
hyperaemia response pre- (Rs = -0.165, p = 0.609), post- (Rs = 0.025, p = 0.940) or 
percentage change post-exercise (Rs = 0.215, p = 0.362). 
 
There was no correlation between the post exercise H2O2 with the post-occlusion 
hyperaemia response pre- (Rs = -0.165, p = 0.609), post- (Rs = 0.025, p = 0.940) or 
percentage change post-exercise (Rs = 0.215, p = 0.362). 
 
3.9.3. Correlation of post exercise oxidative stress with kidney 
injury in claudicants 
There was no association between FORT (post) and NaG/creat pre exercise (Rs = -0.229, p = 
0.377). Similarly there was no association between FORT (post) with NaG/creat (post) R =-
0.052, p = 0.844. 
 
There was no association between H2O2 (post) and NaG/creat pre exercise (Rs = -0.229, p = 
0.377). Similarly there was no association between H2O2 (post) with NaG/creat (post) R =-
0.052, p = 0.844. 
 
3.9.4. Correlation of post exercise oxidative stress with MCP-1 
There was no association between post exercise FORT with pre exercise MCP-1 (R = -0.243, 
p = 0.303). There was no association between post exercise FORT with post exercise MCP-1 
(R = -0.283, p = 0.226). There was no association between post exercise FORT with % 
change post- pre exercise MCP-1 (R = 0.156, p = 0.512). 
 
There was no association between post exercise H2O2 with pre exercise MCP-1 (R = -0.243, 
p = 0.303). There was no association between post exercise H2O2 with post exercise MCP-1 
(R = 0.283, p = 0.226). There was no association between post exercise H2O2 with % change 
post- pre exercise MCP-1 (R = 0.156, p = 0.512). 
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3.10 Effect of change in oxidative stress post exercise on 
endothelial function, kidney injury and MCP-1 
3.10.1. Correlation of post-pre exercise change in oxidative 
stress with antioxidant defence 
There was no association between percentage change post exercise FORT with FORD: Pre 
(Rs = -0.012, p = 0.960); post- (Rs = -0.179, p = 0.449); or percentage change post-exercise 
(Rs = -0.165, p = 0.486). 
 
There was no association between percentage change post exercise H2O2 with FORD: Pre 
(Rs = -0.020, p = 0.932); post- (Rs = -0.024, p = 0.919); or percentage change post-exercise 
(Rs = -0.046, p = 0.847). 
 
3.10.2. Correlation of post – pre exercise oxidative stress with 
macro-vascular endothelial function in claudicants 
There was no association between FORT percent change (post - pre) and FMD % change pre 
exercise (Rs = -0.003, p = 0.990). Similarly there was no association between FORT (post - 
pre) with FMD % change (post) R =-0.099, p = 0.677.  
 
Also, there was association between FORT (post - pre) with FMD % change (post - pre) (Rs 
= 0.477, p = 0.034; Spearman’s rank correlation; Figure 3-22). 
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FIGURE 3-22. SCATTER GRAPH OF PERCETNAGE CHANGE IN OXIDATIVE STRESS (FORT) POST EXERCISE 
VERSUS PERCENTGAE CHANGE IN ENDOTHELIAL FUNCTION (FMD) POST EXERCISE. 
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There was a correlation between the percent change (post – pre) of plasma oxidative stress as 
measured by the FORT test with per cent change (post – pre) in FMD in claudicants (Rs = 
0.477, p = 0.034; Spearman’s rank correlation). 
 
 
 
There was no association between H2O2 (post - pre) and FMD % change pre exercise (Rs = 
0.071, p = 0.767). Similarly there was no association between H2O2 (post - pre) and FMD % 
change (post) R =-0.003, p = 0.990. 
 
Also, there was association between H2O2 (post - pre) with FMD % change (post - pre) R 
=0.520, p = 0.019; Spearman’s rank correlation; Figure 3-23).  
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FIGURE 3-23. SCATTER GRAPH OF PERCENTGAE CHANGE IN OXIDATIVE STRESS (H2O2) POST EXERCISE 
VERSUS PERCENTAGE CHANGE IN ENDOTHEIAL FUNCTION (FMD) POST EXERCISE. 
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3.10.3. Correlation of post – pre oxidative stress with micro-
vascular endothelial function in claudicants 
 
There was no association between the percentage change FORT post – pre with the post 
occlusion reactive hyperaemia test pre- (Rs = 0.217, p =0.499), post- (Rs = 0.112, p = 0.729) 
or percent change post exercise (Rs = 0.098, p = 0.681). 
 
There was no association between the percentage change H2O2 post – pre with the post 
occlusion reactive hyperaemia test pre- (Rs = 0.224, p = 0.484), post- (Rs = 0.119, p = 0.713) 
or percent change post exercise (Rs = 0.106, p = 0.658). 
 
3.10.4. Correlation of post – pre exercise oxidative stress with 
kidney injury in claudicants 
 
There was no association between FORT percent change (post - pre) and NAG/ creat ratio 
pre exercise (Rs = -0.402, p = 0.109). Similarly there was no association between FORT (post 
- pre) with NAG/ creat ratio (post) R =-0.167, p = 0.522.  
 
Also, there was no association between FORT (post - pre) with NAG/ creat ratio (post - pre) 
Rs =0.450, p = 0.070. 
 
 
There was no association between H2O2 percent change (post - pre) and NAG/ creat ratio pre 
exercise (Rs = -0.422, p = 0.092). Similarly there was no association between H2O2 (post - 
pre) with NAG/ creat ratio (post) R =-0.074, p = 0.779.  
 
Also, there was a significant association between H2O2 (post - pre) with NAG/ creat ratio 
(post - pre) R =0.507, p = 0.038; Spearman’s rank correlation; Figure 3-24). 
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3.10.5. Correlation of post - pre exercise oxidative stress with 
MCP-1 
 
There was a correlation between the per cent change (post – pre) of plasma oxidative stress as 
measured by the FORT test with pre-exercise plasma MCP-1 levels in claudicants (Rs = 
0.687, p = 0.000815; Spearman’s rank correlation; Figure 3-25). 
 
FIGURE 3-24. SCATTER GRAPH OF PERCENTAGE CHANGE IN OXIDATIVE STRESS (H2O2) POST EXERCISE 
VERSUS PERCENTAGE CHANGE IN NAG/ CREATININE RATIO POST EXERCISE. 
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There was no association between post - pre exercise FORT with post exercise MCP-1 (R = 
0.260, p = 0.268). 
 
 
There was no association between post - pre exercise FORT with % change post- pre exercise 
MCP-1 (R = -0.301, p = 0.198). 
 
 
There was an association between post - pre exercise H2O2 with pre exercise MCP-1 (R = 
0.701, p = 0.000579; Figure 3-26). 
 
 
 
 
FIGURE 3-25. SCATTER GRAPH OF PERCENTGAE CHANGE IN OXIDATIVE STRESS (FORT) POST EXERCISE 
VERSUS MCP-1 PRE EXERCISE. 
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FIGURE 3-26. SCATTER GRAPH OF PERCENTAGE CHANGE IN OXIDATIVE SRTESS (H2O2) POST EXERCISE 
VERSUS MCP-1 PRE EXERCISE. 
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There was no association between post - pre exercise H2O2 with post exercise MCP-1 (R = 
0.256, p = 0.277). 
 
There was no association between post - pre exercise H2O2 with % change post- pre exercise 
MCP-1 (R = -0.329, p = 0.156). 
 
3.11 Effect of resting antioxidant defense on oxidative stress, 
endothelial function, kidney injury and MCP-1 
3.11.1. Correlation resting antioxidant defense with oxidative 
stress 
There was no correlation between resting FORD and FORT: pre- (Rs = -0.090, p = 0.707); 
post- (Rs = -0.020, p = 0.932) and percentage change post-exercise (Rs = -0.012, p = 0.960). 
 
There was no correlation between resting FORD and H2O2: pre- (Rs = 0.05, p = 0.818); post- 
(Rs = -0.020, p = 0.932) and percentage change post-exercise (Rs = -0.053, p = 0.823). 
 
3.11.2. Correlation of resting antioxidant defence with macro-
vascular endothelial function 
There was no correlation between resting FORD and FMD: pre- (Rs = -0.258, p = 0.272); 
post- (Rs = -0.169, p = 0.475) and percentage change post-exercise (Rs = -0.161, p = 0.497). 
 
 
3.11.3. Correlation of resting antioxidant defence with micro-
vascular endothelial function 
There was no correlation between resting FORD and LDF: pre- (Rs = -0.245, p = 0.442); 
post- (Rs = 0.438, p = 0.155) and percentage change post-exercise (Rs = 0.392, p = 0.088). 
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3.11.4. Correlation of resting antioxidant defence with kidney 
injury 
 
There was no correlation between resting FORD and NAG/ Creatinine ratio: pre- (Rs = -
0.206, p = 0.428); post- (Rs = 0.392, p = 0.088) and percentage change post-exercise (Rs = 
0.260, p = 0.314). 
 
3.11.5. Correlation of resting antioxidant defence with MCP-1 
There was no correlation between resting FORD and MCP-1: pre- (Rs = 0.061, p = 0.798); 
post- (Rs = -0.173, p = 0.465) and percentage change post-exercise (Rs = -0.152, p = 0.522). 
 
3.12 Effect of post-exercise antioxidant defense on oxidative 
stress, endothelial function, kidney injury and MCP-1 
3.12.1. Correlation of post-exercise antioxidant defense with 
oxidative stress 
There was no correlation between post-exercise FORD and FORT: pre- (Rs = 0.285, p = 
0.222); post- (Rs = -0.024, p =0.919) and percentage change post-exercise (Rs = -0.179, p = 
0.449). 
 
There was no correlation between post-exercise FORD and H2O2: pre- (Rs = 0.008, p = 
0.972); post- (Rs = -0.024, p = 0.919) and percentage change post-exercise (Rs = -0.066, p = 
0.784). 
 
3.12.2. Correlation of post exercise antioxidant defence with 
macro-vascular endothelial function 
There was no correlation between post-exercise FORD and FMD: pre- (Rs = 0.066, p = 
0.781); post- (Rs = 0.329, p = 0.156) and percentage change post-exercise (Rs = 0.268, p = 
0.253). 
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3.12.3. Correlation of post exercise antioxidant defence with 
micro-vascular endothelial function 
There was no correlation between post-exercise FORD and LDF: pre- (Rs = -0.417, p = 
0.178); post- (Rs = 0.417, p = 0.178) and percentage change post-exercise (Rs = 0.283, p = 
0.227). 
 
3.12.4. Correlation of post exercise antioxidant defence with 
kidney injury 
There was no correlation between post-exercise FORD and NAG/ Creatinine ratio: pre- (Rs = 
-0.301, p = 0.240); post- (Rs = 0.144, p = 0.582) and percentage change post-exercise (Rs = -
0.015, p = 0.955). 
 
3.12.5. Correlation of post exercise antioxidant defence with 
MCP-1 
There was no significant correlation between post-exercise FORD and pre-exercise (Rs = -
0.148, p = 0.532) or percentage change MCP-1 post exercise (Rs = -0.314, p = 0.177). 
However, there was a significant correlation between post-exercise FORD and post-exercise 
MCP-1 (Rs = -0.481, p = 0.032; Spearman’s rank correlation; Figure 3-27).  
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FIGURE 3-27. SCATTER GRAPH OF OXIDATIVE DEFENSE POST EXERCISE VERSUS MCP-1 POST EXERCISE. 
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3.13 Effect of change in antioxidant defense post exercise on 
oxidative stress, endothelial function, kidney injury and MCP-
1 
3.13.1. Correlation of percent change post-exercise in 
antioxidant defense with oxidative stress 
There was no correlation between percentage change post-exercise FORD and FORT: pre- 
(Rs = 0.236, p = 0.316); post- (Rs = -0.046, p = 0.847) and percentage change post-exercise 
(Rs = -0.165, p = 0.486). 
 
There was no correlation between percentage change post-exercise FORD and H2O2: pre- 
(Rs = -0.032, p = 0.895); post- (Rs = -0.046, p = 0.847) and percentage change post-exercise 
(Rs = -0.068, p = 0.777). 
 
3.13.2. Correlation of post exercise change in antioxidant 
defence with macro-vascular endothelial function 
There was no correlation between percentage change post-exercise FORD and FMD: pre- (Rs 
= 0.174, p = 0.462); post- (Rs = 0.296, p = 0.205) and percentage change post-exercise (Rs = 
0.176, p = 0.458). 
 
3.13.3. Correlation of post exercise change in antioxidant 
defence with micro-vascular endothelial function 
There was no correlation between percentage change post-exercise FORD and LDF: pre- (Rs 
= -0.371, p = 0.236); post- (Rs = 0.189, p = 0.557) and percentage change post-exercise (Rs = 
0.098, p = 0.681). 
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3.13.4. Correlation of post exercise change in antioxidant 
defence with kidney injury 
There was no correlation between percentage change post-exercise FORD and NAG/ 
Creatinine ratio: pre- (Rs = -0.086, p = 0.743); post- (Rs = 0.248, p = 0.338) and percentage 
change post-exercise (Rs = -0.233, p = 0.368). 
 
3.13.5. Correlation of post-exercise antioxidant defence with 
MCP-1 
There was no correlation between percentage change post-exercise FORD and MCP-1: pre- 
(Rs = -0.247, p = 0.295); post- (Rs = -0.382, p = 0.097) and percentage change post-exercise 
(Rs = -0.161, p = 0.498). 
 
3.14 Effect of maximum walking distance on endothelial 
function, oxidative stress and defense, kidney injury and 
MCP-1 
3.14.1. Correlation of maximal walking distance with macro-
vascular endothelial function in claudicants  
There was a significant association between the maximum walking distance and the percent 
change in endothelial function post exercise in FMD (Rs = 0.515, p = 0.020; Spearman’s rank 
correlation; Figure 3-28). There was no correlation between distance traveled and pre-
exercise FMD (0.148, p = 0.533). There was no association between distance travelled and 
post-exercise FMD (0.033, p = 0.890). 
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FIGURE 3-28. SCATTER GRAPH OF MAXIMUM WALKING DISTANCE VERSUS PERCENTGAE CHANGE IN 
ENDOTHEILA FUNCTION (FMD) POST EXERCISE. 
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3.14.2. Correlation of maximal walking distance with micro-
vascular endothelial function in claudicants  
There was no correlation between maximum walking distance and post occlusion hyperaemia 
response of LDF: pre- (Rs = -0.042, p = 0.897); post- (Rs = -0.182, p = 0.570) and percentage 
change post-exercise (Rs = 0.128, p = 0.592). 
 
3.14.3. Correlation of maximal walking distance with oxidative 
stress in claudicants 
There was no correlation between maximum walking distance and FORT: pre- (Rs = 0.036, p 
= 0.880); post- (Rs = -0.032, p = 0.892) and percentage change post-exercise (Rs = -0.115, p 
= 0.629). 
 
There was no correlation between maximum walking distance and H2O2: pre- (Rs = -0.148, 
p = 0.533); post- (Rs = -0.032, p = 0.892) and percentage change post-exercise (Rs = -0.023, 
p = 0.925). 
 
3.14.4. Correlation of maximal walking distance with 
antioxidant defense in claudicants  
There was no correlation between maximum walking distance and FORD: pre- (Rs = 0.255, p 
= 0.278); post- (Rs = 0.152, p = 0.524) and percentage change post-exercise (Rs = -0.110, p = 
0.645). 
 
3.14.5. Correlation of maximal walking distance with kidney 
injury in claudicants  
There was no correlation between maximum walking distance and NAG/ Creatinine ratio: 
pre- (Rs = -0.136, p = 0.062); post- (Rs = 0.153, p = 0.556) and percentage change post-
exercise (Rs = 0.471, p = 0.056). 
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3.14.6. Correlation of maximal walking distance with MCP-1 in 
claudicants  
There was no correlation between maximum walking distance and MCP-1: pre- (Rs = -0.273, 
p = 0.244); post- (Rs = 0.029, p = 0.905) and percentage change post-exercise (Rs = 0.389, p 
= 0.090). 
 
3.15 Effect of resting FMD on post exercise endothelial 
function, oxidative stress and defence, kidney injury and 
MCP-1 
3.15.1. Correlation of resting macro-vascular endothelial 
function with post exercise and percent change in macro-
vascular endothelial function 
There was no correlation between resting FMD and FMD: post- (Rs = 0.143, p = 0.548); and 
percentage change post-exercise (Rs = 0.247, p = 0.295). 
 
3.15.2. Effect of resting macro-vascular endothelial function 
on resting, post exercise and percent change in microvacular 
endothelial function following exercise 
There was no correlation between resting FMD and LDF post occlusion hyperaemia 
response: pre- (Rs = 0.035, p = 0.914); post- (Rs = -0.231, p =0.471) and percentage change 
post-exercise (Rs = -0.028, p = 0.907). 
 
3.15.3. Effect of resting macro-vascular endothelial function 
on oxidative stress 
There was no correlation between resting FMD and FORT: pre- (Rs = 0.301, p = 0.198); 
post- (Rs = 0.252, p = 0.285) and percentage change post-exercise (Rs = -0.003, p = 0.990). 
 
There was no correlation between resting FMD and H2O2: pre- (Rs = 0.120, p = 0.613); post- 
(Rs = 0.252, p = 0.285) and percentage change post-exercise (Rs = 0.071, p = 0.767). 
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3.15.4. Effect of resting macro-vascular endothelial function 
on oxidative defence 
There was no correlation between resting FMD and FORD: pre- (Rs = -0.258, p = 0.272); 
post- (Rs = 0.066, p = 0.781) and percentage change post-exercise (Rs = 0.174, p =0.462). 
 
3.15.5. Effect of resting macro-vascular endothelial function 
on kidney injury 
There was no correlation between resting FMD and NAG/ Creatinine ratio: pre- (Rs = 0.029, 
p = 0.911); post- (Rs = 0.194, p = 0.456) and percentage change post-exercise (Rs = -0.007, p 
= 0.978). 
 
3.15.6. Effect of resting macro-vascular endothelial function 
on MCP-1 
There was no correlation between resting FMD and MCP-1: pre- (Rs = 0.167, p = 0.482); 
post- (Rs = 0.093, p = 0.696) and percentage change post-exercise (Rs = -0.021, p =0.930). 
 
3.16 Effect of post exercise FMD on oxidative stress and 
defence, kidney injury and MCP-1 
3.16.1. Correlation of post-exercise macro-vascular 
endothelial function with percent change in macro-vascular 
endothelial function 
There was no correlation between post exercise FMD and percent change in FMD post-
exercise (Rs = -0.027, p = 0.910). 
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3.16.2. Effect of post-exercise macro-vascular endothelial 
function on percent change in micro-vacular endothelial 
function following exercise 
There was no correlation between post exercise FMD and percent change in LDF post 
occlusion hyperaemia response (Rs = 0.070, p =0.770). 
 
3.16.3. Effect of post-exercise macro-vascular endothelial 
function on oxidative stress 
There was no correlation between post exercise FMD and FORT: pre- (Rs = 0.259, p = 
0.271); post- (Rs = 0.063, p = 0.793) and percentage change post-exercise (Rs = -0.099, p = 
0.677). 
 
There was no correlation between post exercise FMD and H2O2: pre- (Rs = 0.044, p =0.855); 
post- (Rs = 0.063, p = 0.793) and percentage change post-exercise (Rs = -0.099, p = 0.677). 
 
3.16.4. Effect of post-exercise macro-vascular endothelial 
function on oxidative defence 
There was no correlation between post exercise FMD and FORD: pre- (Rs = -0 .169, p = 
0.475); post- (Rs = 0.329, p =0.156) and percentage change post-exercise (Rs = 0.296, p 
=0.205). 
 
3.16.5. Effect of post-exercise macro-vascular endothelial 
function on kidney injury 
There was no correlation between post exercise FMD and NAG/ Creatinine ratio: pre- (Rs = 
0.069, p =0.794); post- (Rs = 0.363 p = 0.152) and percentage change post-exercise (Rs = -
0.199, p = 0.445). 
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3.16.6. Effect of post-exercise macro-vascular endothelial 
function on MCP-1 
There was no correlation between post exercise FMD and MCP-1: pre- (Rs = 0.092, p = 
0.701); post- (Rs = -0.071, p =0.767) and percentage change post-exercise (Rs = -0.104, p = 
0.663). 
 
3.17 Effect of post – pre exercise FMD on micro-vascular 
FMD, oxidative stress and defence, kidney injury and MCP-1 
 
3.17.1. Effect of post-exercise macro-vascular endothelial 
function on percent change in micro-vascular endothelial 
function following exercise 
There was no correlation between percentage change in FMD post exercise and LDF post-
occlusion hyperaemia response: Pre- (Rs = -0.238, p =0.457); post- (Rs = 0.168, p = 0.602) 
and percentage change post-exercise (Rs = 0.178, p = 0.453). 
 
3.17.2. Effect of post- pre-exercise macro-vascular endothelial 
function on oxidative stress 
There were significant correlations between percentage change in FMD post exercise and 
FORT: Pre- (Rs = -0.468, p = 0.038); and percentage change post-exercise (Rs = 0.477, p 
=0.034). There was no correlation between percentage change in FMD post exercise and 
FORT post-exercise (Rs = -0.0124, p =0.062). 
 
There were significant correlations between percentage change in FMD post exercise and 
H2O2: Pre- (Rs = -0.558, p = 0.011; Spearman’s rank correlation; Figure 3-29); and 
percentage change post-exercise (Rs = 0.520, p = 0.019). There was no correlation between 
percentage change in FMD post exercise and H2O2 post-exercise (Rs = -0.124, p = 0.602). 
 263 
 
 
FIGURE 3-29. SCATTER GRAPH OF PERCENTAGE CHANGE IN ENDOTHELIAL FUNCTION (FMD) POST EXERCSIE 
VERSUS PERCENTGAE CHANGE IN H2O2 POST EXERCISE. 
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3.17.3. Effect of post-pre exercise macro-vascular endothelial 
function on oxidative defence 
There was no correlation between percentage change in FMD post exercise and FORD: Pre- 
(Rs = 0.161, p = 0.497); post- (Rs = 0.268, p = 0.253) and percentage change post-exercise 
(Rs = 0.176, p = 0.458). 
 
3.17.4. Effect of post-pre exercise macro-vascular endothelial 
function on kidney injury 
There was no correlation between percentage change in FMD post exercise and NAG/ 
Creatinine ratio: Pre- (Rs = -0.277, p = 0.282); post- (Rs = -0.010, p = 0.970) 
 
There was a significant correlation between percentage change post exercise FMD and 
percent change NAG/ Creatinine ratio post exercise (Rs = 0.563, p = 0.019; Spearman’s rank 
correlation; Figure 3-30). 
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FIGURE 3-30. SCATTER GRAPH OF PERCENTAGE CHANGE IN ENDOTHEILA FUNCTION (FMD) POST EXERCSIE 
VERSUS PERCENTGAE CHANGE IN NAG/ CREATININE RATIO POST EXERCISE. 
 
 
 
 
 
3.17.5. Effect of post—pre exercise macro-vascular 
endothelial function on MCP-1 
There was no correlation between percentage change in FMD post exercise and MCP-1: Pre- 
(Rs = 0.251, p = 0.286); post- (Rs = 0.039, p = 0.870) and percentage change post-exercise 
(Rs = - 0.032, p = 0.895). 
 
 
 
 
 
 266 
 
3.18 Acute post-exercise rise in NAG/ Creatinine ratio as a 
differentiator of patients with intermittent claudication 
 
 
 
 
 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
FMD % change 
(post – pre-exercise) 
median, IQR, range 
0.09, -4.82 to 0.91, -
18.85 to 1.97  
2.56, 0.13 to 
3.698, -0.52 to 
14.10 
p = 0.027, Mann 
Whitney U test 
FIGURE 3-31. BOX PLOT DEMONSTRATING PERCENTAGE CHANGE IN ENDOTHELIAL FUNCTION (FMD) IN 
PATIENTS WITH AND WITHOUT RISE IN NAG/ CREATININE RATIO POST EXERCISE   
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 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
Maximum walking 
distance (m; 
median, IQR, range) 
170, 100 to 315, 90 
to 450  
 
415, 207.5 to 
908, 100 to 2400 
p = 0.043, Mann 
Whitney U test 
 
FIGURE 3-32. BOX PLOT DEMONSTRATING WALKING DISTANCE IN PATIENTS WITH AND WITHOUT RISE IN 
NAG/ CREATININE RATIO POST EXERCISE. THE SCALE HAS BEEN ADJUSTED TO OMIT OUTLIERS BUT ALL 
DATA HAS BEEN USED IN CALCULATIONS 
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 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
H2O2 (pre-exercise; 
mmol/l; median, 
IQR, range) 
2.74, 2.085 to 
3.295, 1.83 to 3.95 
1.85, 1.385 to 
2.268, 0.83 to 
4.56 
p = 0.043, Mann 
Whitney U test 
 
FIGURE 3-33. BOX PLOT DEMONSTRATING PRE-EXERCISE H2O2 IN PATIENTS WITH AND WITHOUT RISE IN 
NAG/ CREATININE RATIO POST EXERCISE 
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 NAG/ Creatinine 
Fall 
NAG/ Creatinine 
Rise 
p value 
n 9 8  
H2O2 % change 
(post-pre; median, 
IQR, range) 
-7.72, -13.85 to -
1.97, -25.55 to 
39.02  
18.75, -1.53 to 
129.68, -45.83 to 
448.19 
p = 0.043, Mann 
Whitney U test 
 
FIGURE 3-34. BOX PLOT DEMONSTRATING PERCENTAGE CHANGE IN H2O2  POST EXERCISE IN PATIENTS WITH 
AND WITHOUT RISE IN NAG/ CREATININE RATIO POST EXERCISE. 
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3.19 Characteristics of claudicants with NAG/ Creatinine rise 
vs fall following exercise 
 
 
 
 
TABLE 14 DEMOGRAPHIC DATA OF PATIENTS WHO HAD A RISE/ NO RISE IN NAG/ CREATININE RATIO 
POST-EXERCISE 
 NAG/ Creatinine NO RISE NAG/ Creatinine RISE 
Number of participants 12 8 
Age (years)  (median, IQR) 74.5, 66 to 80.25 67.5, 63 to 73.25 
Male (n, %) 6, 50% 5, 62.5% 
Lowest ABPI (median, IQR) 0.71, 0.6225 to 0.8425 0.615, 0.5525 to 0.69 
Mean ABPI (median, IQR) 0.835, 0.72 to 0.8975 0.71, 0.6525 to 0.8325 
Maximum walking distance 
(metres) (median, IQR) 
195, 140 to 302.5 395, 282.5 to 716 
Height (m) (median, IQR) 1.685, 1.60 to 1.74 1.725, 1.5725 to 1.7525 
Weight (kg) (median, IQR) 69, 62 to 80.25 81, 67.75 to 92 
BMI (kg/ m2) (median, IQR) 23.85, 23.05 to 27.43 27.85, 26.925 to 30.325 
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TABLE 15 CHARACTERISTIC DATA OF PATIENTS WITH NO RISE IN NAG/ CREATININE RATIO POST EXERCISE 
 
N
A
G
/ C
r R
is
e 
Pa
rt
ic
ip
an
t	  n
o	  
Hy
pe
rt
en
sio
n	  
IH
D	  
DM
	  
Ch
ol
es
te
ro
l	  
Sm
ok
er
	  
O
th
er
	  P
M
H	  
st
at
in
	  
an
ti-­‐
pl
at
el
et
	  
M
ed
ic
at
io
n	  
✓ 1 Yes No No Yes ex BPH Atorvastatin Aspirin 
Lansoprazole, 
Tamsulosin, 
Finasteride, 
Amlodipine, 
Irbesartan 
✓ 4 Yes YES NO No no TIA, CABG Simvastatin Aspirin & Clopidogrel bisoprolol 
✓ 5 Yes Yes No Yes no  Simvastatin Aspirin  
✓ 6 Yes No No Yes ex IBS, Aortic Regurgitation Atorvastatin Aspirin  
✓ 7 Yes No Yes Yes no Type 2 diabetes, Hypothyroidism  Aspirin 
Metformin, , 
Insulin, 
Gliclazide, 
Enalapril, 
Amlodipine, and 
Bendrofluazide 
✓ 11 Yes No Yes No no    Metformin, BP medication 
✓ 12 No No No No ex no   none 
✓ 15 Yes No No Yes ex  Pravastatin Aspirin Amlodipine 
✖ 2 yes No No Yes yes COPD simvastatin Aspirin 
Spiriva inhaler, 
salbutamol 
inhaler 
✖ 3 No No No No no Ca colon, Ca bladder  Aspirin Tolterodine 
✖ 8 No yes No yes ex  Atovastin Aspirin Losec and Atenolol 
✖ 9 No No Yes No no AF   Amiodarone, Warfarin 
✖ 10 No No No Yes Ex Osteoarthritis Simvastatin  Simvastatin 
✖ 13 Yes Yes No Yes no  Rocuvastatin Aspirin Omeprazole, Carvedilol, , 
✖ 14 Yes No No Yes yes    Enalapril, Cilostasol 
✖ 16 Yes No Yes Yes no Primary biliary cirrhosis Simvastatin  
Bendrofluazide, 
Irbesartan, 
Metformin, 
Insulin, 
Omeprazole, 
Ursodeoxycholic 
acid 
✖ 17 Yes No Yes No yes    Bendrofluazide 
✖ 18 yes yes no no ex CABG Simvastatin Clopidogrel & Aspirin  
✖ 19 No Yes Yes Yes ex  Simvastatin Aspirin Metformin, 
✖ 20 Yes No No Yes ex Benign prostatic hypertrophy,Gastritis/duodenitis Simvastatin Aspirin 
Quinine, 
Bendrofluazide, 
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4. Discussion 
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4.1 Endothelial function changes in claudicants following 
exercise  
 
We initially investigated the effects of exercise on claudicants’ brachial artery diameter and 
Laser Doppler Flux as this may have increased due to increased blood flow associated with 
exercise. At rest, claudicants had a brachial artery diameter  (cm; median, IQR) of 4.49, 4.15 
to 5.03. Following exercise this was not significantly changed: 4.35, 3.94 to 4.99 (p = 0.147). 
Similarly, at rest, claudicants had a flux (AU; median, IQR) of 154.25, 154.25 to 265.05. 
Following exercise this was no significantly changed: 209.40, 142.83 to 768.03. These 
finding suggests that there was no significant contribution of exercise related sympathetic or 
flow mediated arterial dilatation. 
 
Brachial artery FMD in claudicants at rest (%; median, IQR) was 1.91; 3.55 to 3.87. 
Following maximal treadmill exercise, it was not significantly changed at 3.75; 1.29 to 7.45 
(p = 0.313). Interestingly, visually inspecting the paired data points as displayed in the slope 
graph (Figure 3-3), one can discern that there was clear heterogeneity in the direction of 
change in FMD post exercise. 
 
Resting brachial artery FMD in claudicants has been reported to be lower in claudicants than 
controls (5.1% vs 11.7%). Interestingly, asymptomatic patients with peripheral vascular 
disease had an intermediate FMD to the control and symptomatic groups (8.5%). The 
brachial artery response to sublingual nitroglycerine was similar indicating the effect was 
mediated by the endothelium rather than smooth muscle dysfunction (Silvestro et al., 2003). 
 
Others have reported a significant decrease in the percentage FMD of stable claudicants 
following maximal treadmill exercise (-1.5 ± 1; mean ± SD). (Gresele et al., 2007b).  
 
A similar lack of significant changes following exercise in endothelial function was measured 
in micro-vessels (%; median, IQR). Pre exercise values were 59, 25.74 to 260.43 and post 
were 11.2, -9.85 to 218.9 (p = 0.388). However, also similarly, there was heterogeneity in the 
direction of change in FMD responses post exercise. 
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Both these sets of results suggested to us that there may be heterogeneity in the macro- and 
micro-vascular endothelial function responses in claudicants following maximal treadmill 
exercise. 
 
4.2 Effect of resting FMD on post exercise endothelial function, 
oxidative stress and defense, kidney injury and MCP-1 
 
There was no correlation of pre- with post- or change following exercise post-exercise 
macro-vascular endotheial function (post: Rs = 0.143, p = 0.548; change post-exercise: R = 
0.247, p = 0.295). Similarly, there was no correlation between pre-exercise macro-vascular 
endothelial function with pre, post or change post exercise in micro-vascular function (pre: 
Rs = 0.035, p = 0.914, post Rs = -0.231, p =0.471, change post: Rs = -0.028, p = 0.907). 
 
There was no correlation between pre-exercise FMD with plasma oxidative stress measured 
by either FORT or H2O2 either pre, post or change post exercise. FORT – pre: Rs = 0.301, p 
= 0.198; post: Rs = 0.252, p = 0.285; change post: Rs = -0.003, p = 0.990.  H2O2 – pre: Rs = 
0.120, p = 0.613; post: Rs = 0.252, p = 0.285; change post: Rs = 0.071, p = 0.767.  
 
There was no correlation between pre-exercise FMD with pre, post or change post-exercise in 
oxidative defense (pre: Rs = -0.258, p = 0.272; post: Rs = 0.066, p = 0.781; change post: Rs = 
0.174, p = 0.462). 
 
There was no correlation between pre-exercise FMD with pre, post or change post-exercise in 
kidney injury (pre: Rs = 0.029, p = 0.911; post: Rs = 0.194, p = 0.456; change post: Rs = -
0.007, p = 0.978). 
 
 
There was no correlation between pre-exercise FMD with pre, post or change post-exercise in 
plasma MCP-1 (pre: Rs = 0.167, p = 0.482; post: Rs = 0.093, p = 0.696; change post: Rs = -
0.021, p =0.930). 
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4.3 Effect of post exercise FMD on oxidative stress and defense, 
kidney injury and MCP-1 
 
There was no correlation of post- with change post-exercise in macro-vascular endothelial 
function (post: Rs = -0.027, p = 0.910. Similarly, there was no correlation between post-
exercise macro-vascular endothelial function with change post exercise in micro-vascular 
function (Rs = 0.070, p =0.770). 
 
There was no correlation between post-exercise FMD with plasma oxidative stress measured 
by either FORT or H2O2 either pre, post or change post exercise. FORT – pre: Rs = R 
=0.259, p = 0.271; post: Rs = 0.063, p = 0.793; change post: Rs = --0.099, p = 0.677.  H2O2 
– pre: Rs = 0.044, p =0.855; post: Rs = 0.063, p = 0.793; change post: Rs = -0.099, p = 0.677.  
 
There was no correlation between post-exercise FMD with pre, post or change post-exercise 
in oxidative defense (pre: Rs = -0 .169, p = 0.475; post: Rs = 0.329, p =0.156; change post: 
Rs = 0.296, p =0.205). 
 
There was no correlation between post-exercise FMD with pre, post or change post-exercise 
in kidney injury (pre: Rs = 0.069, p =0.794; post: Rs = 0.363 p = 0.152; change post: Rs = -
0.199, p = 0.445). 
 
 
There was no correlation between post-exercise FMD with pre, post or change post-exercise 
in plasma MCP-1 (pre: Rs = 0.092, p = 0.701; post: Rs = -0.071, p =0.767; change post: Rs = 
-0.104, p = 0.663). 
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4.4 Effect of percent change post-exercise of macro-vascular 
endothelial function on micro-vascular endothelial function, 
oxidative stress, defense, kidney injury and MCP-1 
 
There was no correlation of change in macro-vascular endothelial function with pre, post- or 
change following exercise in micro-vascular endothelial function (pre: Rs = -0.238, p =0.457; 
post: Rs = 0.168, p = 0.602; change post-exercise: R = 0.178, p = 0.453).  
 
There was a significant correlation between percent change post exercise in macro-vascular 
endothelial function with plasma oxidative stress both pre (FORT: Rs = -0.468, p = 0.038; 
H2O2: Rs = -0.558, p = 0.011) and percentage change post-exercise (FORT: Rs = -0.0477, p 
= 0.034; H2O2: Rs = 0.522, p = 0.019). There was no correlation with post-exercise (FORT: 
Rs = -0.124, p = 0.6; H2O2: Rs = -0.124, p = 0.602)   
 
There was no correlation between change in macro-vascular endothelial function with pre, 
post or change post-exercise in oxidative defense (pre: Rs = 0.161, p = 0.497; post: Rs = 
0.268, p = 0.253; change post: Rs = 0.176, p = 0.458). 
 
There was significant correlation between percent change in macro-vascular endothelial 
function and percentage change post exercise in NAG/ Creatinine ratio (Rs = 0.563, p = 
0.019). There was no correlation between change in macro-vascular endothelial function with 
pre or post-exercise in kidney injury (pre: Rs = -0.277, p = 0.282; post: Rs = -0.010, p = 
0.970. 
 
There was no correlation between change in macro-vascular endothelial function post 
exercise with pre, post or change post-exercise in plasma MCP-1 (pre: Rs = 0.251, p = 0.286; 
post: Rs = 0.039, p = 0.870; change post: Rs = - 0.032, p = 0.895). 
 
4.5 Oxidative stress changes in claudicants following exercise 
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Plasma oxidative stress as measured by the FORT test demonstrated that there was no 
significant change flowing exercise. Pre exercise levels were (FORT units; median, IQR) 
296.50, 243.25 to 425.50 and post were 303.5, 263 to 401.25 (p = 0.888). 
 
When the oxidative stress was measured in terms of H2O2, there was a similar picture of no 
significant difference. Pre (mmol/l; median; IQR): 2.19, 1.81 to 3.02 and post: 2.31, 2 – 3.1 
(p = 0.825). However, on inspecting the paired data points from the slope graphs (Figure 3-6 
and Figure 3-7), one can discern, again, heterogeneity in the response to exercise. 
4.6 Effects of resting oxidative stress on endothelial function, 
MCP-1 and kidney injury 
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FIGURE 4-1. FLOW CHART HIGHLIGHTING ASSOCIATIONS SEEN BETWEEN ABPI, MAXIMUM 
WALKING DISTANCE, PLASMA OXIDATIVE STRESS AND URINARY NAG/ CREATININE RATIO. 
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There was a negative correlation between the percent change post-exercise in plasma 
oxidative stress with pre-exercise macro-vascular endothelial function (FORT: Rs =  -0.468, 
p = 0.038; H2O2: Rs =  -0.537, p = 0.026). 
 
There was no association between macro-vascular endothelial function and pre (FORT: Rs = 
0.301, p = 0.198; H2O2: Rs = 0.120, p = 0.613) or post-exercise oxidative stress (FORT: Rs 
=0.259, p = 0.271; H2O2: Rs =0.044, p = 0.855) 
 
There was no association between micro-vascular endothelial function and pre (FORT: Rs =-
0.161, p = 0.618; H2O2: Rs = -0.161, p = 0.618), post-exercise oxidative stress (FORT: Rs =-
0.091, p = 0.779; H2O2: Rs =-0.091, p = 0.779) or percent change post exercise (FORT: Rs = 
0.049, p = 0.838; H2O2: Rs = -0.003, p = 0.990). 
 
There was a negative correlation between pre-exercise H2O2 and the percent change post-
exercise of NAG/ Creatinine ratio (Rs =  -0.468, p = 0.038). 
However, there was no association between pre-exercise FORT with NAG/ Creatinine ratio 
(Rs = -0.390, p = 0.122). In a murine model, it has been shown that tissues with higher levels 
of catalase (lung and vena cava c.f. aorta and myocardium) and hence low level of H2O2 had 
an attenuated up-regulation of eNOS in response to exercise. The dissimilarities were 
abolished by administration of a catalase inhibitor (Dao et al., 2011). Furthermore in another 
murine model, mice transfected with a gene to overexpress catalase in vascular tissue 
demonstrated no ability to up-regulate eNOS expression in response to exercise compared to 
wild type (Lauer et al., 2005). Our data provides further evidence of a protective role for 
endogenous H2O2 production. 
 
There was no association between pre-exercise plasma oxidative stress and NAG/creat ratio 
pre- (FORT: Rs = 0.002, p = 0.993; H2O2: Rs = 0.279, p = 0.277) or post-exercise (FORT: 
Rs =0.181, p = 0.486; H2O2: Rs =0.086, p = 0.743) 
 
There was no association between pre-exercise oxidative stress with pre (FORT: Rs = -0.271, 
p = 0.248; H2O2: Rs = -0.418, p = 0.067) post (FORT: Rs = -0.039, p = 0.870; H2O2: Rs = -
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0.080, p = 0.738), or percent change post-exercise (FORT: Rs = 0.232, p = 0.326; H2O2: Rs 
= 0.371, p = 0.107) of MCP-1. 
 
4.7 Effect of post exercise oxidative stress on endothelial 
function, kidney injury and MCP-1 
 
There was no association between post exercise oxidative stress (FORT: Rs = 0.252, p = 
0.285; H2O2: Rs = 0.252, p = 0.285) and pre-exercise macro-vascular endothelial function.  
 
Similarly there was no association between post exercise oxidative stress (FORT: Rs = 0.063, 
p = 0.793; H2O2: R =0.063, p = 0.793) with post-exercise macro-vascular endothelial 
function.  
 
There was no association between post-exercise oxidative stress and micro-vascular 
endothelial function pre (FORT: Rs = -0.165, p = 0.609; H2O2; Rs = -0.165, p = 0.609), post 
(FORT: Rs = 0.025, p = 0.940; H2O2: Rs = 0.025, p = 0.940) or percent change post-exercise 
(FORT: Rs = 0.215, p = 0.362; H2O2: Rs = 0.215, p = 0.362) 
 
There was no association between post-exercise oxidative stress with NAG/ Creatinine ratio 
pre (FORT: Rs = -0.229, p = 0.377; H2O2: Rs = -0.229, p = 0.377), post (FORT: R =-0.052, 
p = 0.844; H2O2: R =-0.052, p = 0.844) or percent change post exercise (FORT: Rs = -0.107, 
p = 0.683; H2O2: -0.107, p = 0.683) 
 
There was no association between post-exercise oxidative stress with MCP-1 pre- (FORT: Rs 
= -0.243, p = 0.303; H2O2; Rs = -0.243, p = 0.303), post- (FORT: Rs = -0.283, p = 0.226, 
H2O2: R = 0.283, p = 0.226) or percent change post-exercise (FORT: Rs = 0.156, p = 0.512; 
H2O2: Rs = 0.156, p = 0.512) 
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4.8 Effect of change in oxidative stress post exercise on 
oxidative defense, endothelial function, kidney injury and 
MCP-1 
 
There was no association between percentage change post-exercise oxidative stress with 
oxidative defense pre- (FORT: Rs = -0.012, p = 0.960; H2O2: Rs = 0.071, p = 0.767), post- 
(FORT: Rs = -0.179, p = 0.449, H2O2: R = -0.024, p = 0.919) or percent change post-
exercise (FORT: Rs = -0.165, p = 0.486; H2O2: Rs = -0.046, p = 0.847) 
 
There was a significant correlation between percentage change post-exercise in oxidative 
stress with percentage change post-exercise in macro-vascular endothelial function (FORT: 
Rs = 0.477, p = 0.034; H2O2: Rs = 0.520, p = 0.019). However, there was no association 
between percentage change post-exercise oxidative stress with macro-vascular endothelial 
function pre- (FORT: Rs = -0.003, p = 0.990) or post-exercise (FORT: Rs = -0.099, p = 
0.677; H2O2: Rs =-0.003, p = 0.990). 
 
 
There was no association between percentage change post-exercise oxidative stress with 
micro-vascular endothelial function pre- (FORT: Rs = 0.217, p =0.499; H2O2: Rs = 0.224, p 
= 0.484), post- (FORT: Rs = 0.112, p = 0.729, H2O2: R = 0.119, p = 0.713) or percent 
change post-exercise (FORT: Rs = 0.098, p = 0.681; H2O2: Rs = 0.106, p = 0.658) 
 
There was a significant correlation between percent change post exercise in H2O2 and 
percent change in NAG/ Creatinine ratio post exercise (Rs = 0.507, p = 0.038), there was a 
tendency for significant also with FORT (Rs = 0.450, p = 0.07). However, there was no 
association between percentage change post-exercise oxidative stress with NAG/ Creatinine 
ratio pre- (FORT: Rs = -0.402, p = 0.109; H2O2: Rs = -0.422, p = 0.092) or post-exercise 
(FORT: Rs =-0.167, p = 0.522, H2O2: R = -0.074, p = 0.779). 
 
 
There was a significant correlation between the percent change post exercise of plasma 
oxidative stress with pre-exercise plasma MCP-1 levels in claudicants (FORT: Rs = 0.687, p 
= 0.000815; H2O2: Rs = 0.701, p = 0.000579). 
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There was no correlation between the percent change post-exercise of plasma oxidative stress 
with post- (FORT: R = 0.260, p = 0.268; H2O2: Rs = 0.256, p = 0.277) or percent change 
post-exercise MCP-1 (FORT: R = -0.301, p = 0.198; H2O2: R = -0.329, p = 0.156). 
 
4.9 Antioxidant defence in claudicants 
 
When comparing the plasma antioxidant defense reserve of claudicants, we found that there 
was no significant difference pre and post exercise. Pre (Trolox equivalents; median, IQR): 
0.96, 0.84 to 1.22 and post: 1, 0.43 to 1.32 (p = 0.575). Again when looking at paired 
individual data points in the slop graph (Figure 3-8), one can discern heterogeneity in the 
responses of individual claudicants to exercise. 
 
4.9.1. Effect of resting antioxidant defense on oxidative stress, 
endothelial function, kidney injury and MCP-1 
 
There was no correlation between pre-exercise plasma oxidative defense and pre- (FORT: -
0.090, p = 0.707; H2O2: Rs = 0.05, p = 0.818:), post- (FORT: -0.020, p = 0.932; H2O2: -
0.020, p = 0.932) or percent change post-exercise oxidative stress (FORT: Rs = -0.012, p = 
0.960; H2O2: Rs = -0.053, p = 0.823).  
 
There was no correlation between pre-exercise plasma oxidative defense and pre- (Rs = -
0.258, p = 0.272), post- (Rs = -0.169, p = 0.475) or percent change post-exercise macro-
vascular endothelial function (Rs = 0.161, p = 0.497). There was no correlation between pre-
exercise plasma oxidative defense and pre- (Rs = -0.245, p = 0.442), post- (Rs = 0.438, p = 
0.155) or percent change post-exercise micro-vascular endothelial function (Rs = 0.392, p = 
0.088).  
There was no correlation between pre-exercise plasma oxidative defense and pre- (Rs = -
0.206, p = 0.428), post- (Rs = -0.258, p = 0.318) or percent change post-exercise NAG/ 
Creatinine ratio (Rs = 0.260, p = 0.314).  
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There was no correlation between pre-exercise plasma oxidative defense and pre- (Rs = 
0.061, p = 0.798), post- (Rs = -0.173, p = 0.465) or percent change post-exercise plasma 
MCP-1 (Rs = -0.152, p = 0.522).  
 
4.9.2. Effect of post-exercise antioxidant defense on oxidative 
stress, endothelial function, kidney injury and MCP-1 
 
There was no correlation between post-exercise plasma oxidative defense and pre- (FORT: 
0.285, p = 0.222; H2O2: Rs = 0.008, p = 0.972), post- (FORT: -0.024, p =0.919; H2O2: -
0.024, p = 0.919) or percent change post-exercise oxidative stress (FORT: Rs = -0.179, p = 
0.449; H2O2: Rs = -0.066, p = 0.784).  
 
There was no correlation between post-exercise plasma oxidative defense and pre- (Rs = 
0.066, p = 0.781), post- (Rs = 0.329, p = 0.156) or percent change post-exercise macro-
vascular endothelial function (Rs = 0.268, p = 0.253). There was no correlation between post-
exercise plasma oxidative defense and pre- (Rs = -0.417, p = 0.178), post- (Rs = 0.417, p = 
0.178) or percent change post-exercise micro-vascular endothelial function (Rs = 0.283, p = 
0.227).  
 
There was no correlation between post-exercise plasma oxidative defense and pre- (Rs = -
0.301, p = 0.240), post- (Rs = 0.144, p = 0.582) or percent change post-exercise NAG/ 
Creatinine ratio (Rs = -0.015, p = 0.955).  
 
There was a negative correlation between the post-exercise plasma oxidative defense and the 
post-exercise MCP-1 (Rs =  -0.481, p = 0.032). There was no correlation between post-
exercise plasma oxidative defense and pre- (Rs = -0.148, p = 0.532), percent change post-
exercise plasma MCP-1 (Rs = -0.314, p = 0.177). A case control study reports that free 
radical scavenging capacity is lower in claudicants as compared to controls (Edwards At Fau 
- Blann et al.). Although our data does not reproduce this finding, oxidative defense capacity 
correlated inversely with MCP-1 suggesting that oxidative defense is a factor in this complex 
process. 
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4.9.3. Effect of change in antioxidant defense post exercise on 
oxidative stress, endothelial function, kidney injury and MCP- 
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (FORT: 0.236, p = 0.316; H2O2: Rs = -0.032, p = 0.895), post- (FORT: -0.046, p = 
0.847; H2O2: -0.046, p = 0.847) or percent change post-exercise oxidative stress (FORT: Rs 
= -0.165, p = 0.486; H2O2: Rs = -0.068, p = 0.777).  
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (Rs = 0.174, p = 0.462), post- (Rs = 0.296, p = 0.205) or percent change post-exercise 
macro-vascular endothelial function (Rs = 0.176, p = 0.458). There was no correlation 
between percent change post-exercise plasma oxidative defense and pre- (Rs = -0.371, p = 
0.236), post- (Rs = 0.189, p = 0.557) or percent change post-exercise micro-vascular 
endothelial function (Rs = 0.098, p = 0.681).  
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (Rs = -0.086, p = 0.743), post- (Rs = 0.248, p = 0.338) or percent change post-exercise 
NAG/ Creatinine ratio (Rs = -0.233, p = 0.368).  
 
There was no correlation between percent change post-exercise plasma oxidative defense and 
pre- (Rs = -0.247, p = 0.295), post- (Rs = -0.382, p = 0.097) or percent change post-exercise 
plasma MCP-1 (Rs = -0.161, p = 0.498).  
 
4.10 Kidney injury in claudicants following-exercise 
 
The plasma NAG/ Creatinine ratio was measured in claudicants pre and post exercise as a 
marker of acute kidney injury. Claudicants demonstrated a highly significant increase in 
NAG/ Creatinine ratio following exercise. Pre exercise levels were (µmol/L/mmol Cr; 
median, IQR): 8.94, 6.73 to 14.27 and post were: 12.90, 9.07 to 17.72 (p = 0.000293). Again, 
however, inspecting individual paired data points, one can discern heterogeneity in the 
responses to exercise (Figure 3-9). Similarly, Tisi et al., have demonstrated an increased in 
the albumin/ creatinine ratio following exercise in claudicants but not controls following 
maximal exercise (Tisi and Shearman, 1998b). However in a study comparing 20 patients 
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with intermittent claudication, stable for at least six month and 20 healthy controls, although 
claudicants had a higher level of plasma CRP and NAG/ Creatinine ratio than controls, 
exercise did not significantly increase either parameter (Collins et al., 2006). The seemingly 
discrepancy in findings may be a function of the ‘stable’ nature of the claudicants recruited in 
the work by Collins et al. Their chronic nature may represent an adaptation or a selection bias 
resulting from long-term survival. 
 
4.11 Plasma MCP-1 concentration in claudicants following-
exercise 
 
When comparing the effect of exercise on plasma MCP-1 levels pre and post exercise, no 
significant difference was found. The levels pre exercise were (pg/ ml; median; IQR): 88.41, 
69.34 to 119.43 and post were: 93.31, 70.6 to 48.49 (p = 0.601). Again, looking at individual 
paired data points in the slope graph (Figure 3-10), one can discern clear heterogeneity in the 
plasma MCP-1 response of individual claudicants to exercise. 
 
4.12 Effects of ABPI on oxidative stress and defense, 
endothelial function, kidney injury and plasma MCP-1 
 
4.12.1. Effect of ABPI on oxidative stress 
 
The lowest ABPI measured in the lower limbs of claudicants strongly correlated with the pre- 
exercise plasma oxidative stress measured in FORT units (Rs = 0.544, p = 0.013). 
 
However, there was a stronger correlation between the lowest ABPI versus post- exercise 
oxidative stress measured by FORT test (Rs = 0.736, p = 0.000218). 
 
This pattern was repeated when H2O2 was used as a measure of plasma oxidative stress 
(mm/L). Pre exercise plasma oxidative stress: Rs = 0.444, p = 0.05, post exercise oxidative 
stress: Rs = 0.736, p = 0.000218). 
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When correlating the average ABPI with pre- exercise plasma FORT, a significant but 
weaker association than  with lowest ABPI was found (Rs = 0.475, p = 0.043), similarly for 
post –exercise plasma FORT (Rs = 0.554, p = 0.011).  
 
Pre exercise plasma H2O2 did not correlate with average ABPI (Rs = 0.223, p = 0.346), 
however, post- exercise plasma H2O2 correlated with statistical significance but less strongly 
than the equivalent FORT correlation (Rs = 0.554, p = 0.011). 
 
There was, however, no association of lowest or average ABPI with change in oxidative 
stress by either measure following exercise (lowest ABPI: FORT; Rs = 0.164, p = 0.490, 
H2O2; Rs = 0.175, p = 0.462. Average ABPI: FORT; Rs = 0.220, p = 0.352, H2O2; Rs = 
0.283, p = 0.22). 
 
4.12.2. Effect of ABPI on anti-oxidant defense 
 
There was no correlation of lowest or average ABPI with plasma antioxidant defense 
capacity as measured by the FORD test (Trolox equivalents) . Correlations of lowest ABPI 
with pre, post and post – pre plasma FORD levels were: -0.3, p = 0.199; -0.124, p = 0.601; 
and 0.06, p = 0.801, respectively. Correlations of average ABPI with pre, post and post – pre 
plasma FORD levels were: -0.235, p = 0.319; 0.160, p = 0.501; and 0.220, p = 0.352, 
respectively. 
 
4.12.3. Effect of ABPI on endothelial function 
 
There was no correlation found between FMD (per cent change) pre exercise or percent 
change post – pre exercise. Pre (Lowest ABPI: Rs = 0.273, p = 0.244; Average ABPI: Rs = 
0.337, p = 0.146) or FMD per cent change (post – pre; Lowest ABPI: Rs = -0.181, p = 0.444; 
Average ABPI: -0.026, p = 0.915).  
 
However, although the lowest ABPI did not correlate with post exercise macro-vascular 
endothelial function (Rs = 0.286, p = 0.222), mean ABPI correlated well: Rs = 0.466, p = 
0.038. This may reflect that having a low average ABPI indicates a more systemic 
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manifestation of atherosclerosis, which may affect systemic endothelial function more 
obviously. 
 
There was no correlation in terms of micro-vascular endothelial function with lowest or 
average ABPI. Lowest ABPI: pre-exercise (Rs = -0.343, p = 0.275); post-exercise (Rs = 0.2, 
p = 0.534); % change following exercise (Rs = 0.173, p = 0.465. Average ABPI: pre-exercise 
(Rs = -0.364, p = 0.245); post-exercise (Rs = 0.301, p = 0.342); % change following exercise 
(Rs = 0.197, p = 0.406). 
 
4.12.4. Effect of ABPI on kidney injury 
 
There was no correlation of lowest or average ABPI with NAG/ Creatinine ratio. Lowest 
ABPI: Pre-exercise (Rs = -0.108, p = 0.680); post-exercise (Rs = -0.125, p = 0.633); % 
change post exercise (Rs = -0.326, p = 0.202). Average ABPI: Pre-exercise (Rs = -0.174, p = 
0.504); post-exercise (Rs = 0.015, p = 0.955); % change post exercise (Rs = -0.230, p = 
0.374). 
 
4.12.5. Effect of ABPI on plasma MCP-1 
 
There was no correlation of lowest or average ABPI with MCP-1. Lowest: pre-exercise (Rs = 
0.105, p = 0.661); post-exercise (Rs = 0.163, p = 0.494); % change post exercise (Rs = 0.167, 
p = 0.481). Average ABPI: pre-exercise (Rs = -0.174, p = 0.504); post-exercise (Rs = 0.015, 
p = 0.955); % change post exercise (Rs = -0.230, p = 0.374). 
 
4.13 Effect of maximum walking distance on endothelial 
function, oxidative stress and defense, kidney injury and 
MCP-1 
 
 
4.13.1. Effect of maximum walking distance on endothelial 
function 
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Maximum walking distance correlated significantly with percent change of endothelial 
function following exercise as measured by FMD (Rs = 0.515, p = 0.020). There was no 
correlation between distance travelled and pre- (R= 0.148, p = 0.533) or post-exercise (Rs = 
0.033, p = 0.890) macro-vascular endothelial function. 
 
Neither was there any correlation between maximum walking distance and micro-vascular 
endothelial function either pre- (Rs = -0.042, p = 0.897) or post-exercise (Rs = -0.182, p = 
0.57) or percent change post exercise (Rs = 0.128, p = 0.592) 
 
4.13.2. Effect of maximum walking distance on oxidative 
stress 
 
There was no correlation between maximum walking distance and pre, post, and percent 
change post exercise oxidative stress as measured by FORT (Pre-: Rs = 0.036, p = 0.880, 
Post-: Rs = -0.032, p = 0.892, and % change post- exercise: Rs = -0.115, p = 0.629) or H2O2 
(Pre-: Rs = -0.148, p = 0.533, Post-: Rs = -0.032, p = 0.892, p = 0.892, and % change post- 
exercise: Rs = -0.023, p = 0.925) 
 
4.13.3. Effect of maximum walking distance on oxidative 
defense 
 
There was no correlation between maximum walking distance and pre, post, and percent 
change post exercise anti-oxidant defense as measured by FORD (Pre-: Rs = 0.255, p = 
0.278, Post-: Rs = 0.152, p = 0.524, p = 0.892, and % change post- exercise: Rs = -0.110, p = 
0.645).  
 
4.13.4. Effect of maximum walking distance on kidney injury 
 
Maximum walking distance correlated with percent change in NAG/ Creatinine ratio, the 
association just fell short of significant at the 95% confidence level (Rs = 0.471, p = 0.056). 
There was a tendency for association of maximum walking distance with post-exercise NAG/ 
Creatinine ratio (Rs = -0.136, p = 0.062), whereas there was no correlation with post-exercise 
NAG/ Creatinine ratio (Rs = 0.153, p = 0.556). 
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4.13.5. Effect of maximum walking distance on MCP-1 
 
There was no correlation between maximum walking distance and pre, post, and percent 
change post exercise of plasma MCP-1 levels (Pre-: Rs = -0.273, p = 0.244, Post-: Rs = 
0.029, p = 0.905, p = 0.892, and % change post- exercise: Rs = 0.389, p = 0.09)  
4.14 Acute post-exercise rise in NAG/ Creatinine ratio as a 
differentiator of patients with intermittent claudication 
 
The claudicants cohort was segregated into those with a rise in NAG/ Creatinine ratio post 
exercise versus those who did not. It was found the group who had a rise in NAG/ Creatinine 
ratio had greater ability to increase endothelial reactivity (%; median, IQR; 0.09, -4.82 to 
0.91) than those without a rise (2.56, 0.13 to 3.698, p = 0.027). 
 
 
Similarly, the group with a rise in NAG/ Creatinine ratio post exercise were able to walk 
further (metres; median, IQR; 415, 207.5 to 908) compared to those without a rise (170, 100 
to 315, p = 0.043). 
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Also, the group with a rise in NAG/ Creatinine ratio post exercise had a significantly lower 
pre-exercise H2O2 (median, IQR; 1.85, 1.385 to 2.268 cf. 2.74, 2.085 to 3.295) as well as a 
significantly greater rise in H2O2 post exercise (18.75, -1.53 to 129.68 cf., -7.72, -13.85 to -
1.97, p = 0.043). Studies from transgenic mice over-expressing catalase have demonstrated a 
role for basal H2O2 expression in maintenance of arterial tone (Suvorava et al., 2005). 
 
 
 
 
 
⇧ NAG/ 
Creatinine ratio 
post exercise
⇧percent change 
macro-vascular 
endothelial 
function post-
exercise
⇧maximum 
walking distance
⇩pre-exercise 
H2O2
⇧percent change 
H2O2 post 
exercise
FIGURE 4-2. CHARACTERISTIC FEATURES OF THE GROUP OF CLAUDICANTS WITH A RISE IN 
NAG/ CREATININE RATIO FOLLOWING EXERCISE. 
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5. Conclusions 
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We have established that in the patients with intermittent lower limb claudication sampled in 
this study that a higher ABPI is associated with an increased resting plasma oxidative stress 
level. It has been previously reported that patients with peripheral vascular disease have an 
elevation in serum markers of oxidative stress, which can be improved with administration of 
antioxidants (Loffredo et al., 2007). However, we report that the basal level of oxidative 
stress level is associated with a decrease in the amount of increase in acute kidney injury as 
measured by urinary NAG/ Creatinine ratio.  
 
We have also established that the percentage change in oxidative stress post exercise from 
basal levels correlates with the percentage change in endothelial reactivity post exercise (i.e. 
absence of decrease). Both percentage change in oxidative stress and endothelial reactivity 
post-exercise are associated with increased acute kidney injury. Endothelial dysfunction has 
been reported to exist in young hypertensive and non-hypertensive men, suggesting that there 
may be phenotypic variation in the population rather than dysfunction being simply a 
consequence of oxidative stress (Doroszko et al., 2011). 
 
Others have previously shown that exercise in claudication is associated with an increase in 
renal endothelial permeability. (Tisi and Shearman, 1998b). We have established that there is 
a phenotypically distinct subgroup of claudicants who have an increase in kidney injury post 
exercise. Here, the basal oxidative stress levels are lower than claudicants without such a 
pattern of acute kidney injury. Also, these claudicants have a longer walking distance, and 
higher post-exercise increase in oxidative stress and macro-vascular endothelial function. 
 
This subgroup may be inducing acute kidney injury via an exaggerated generation of reactive 
oxygen species post exercise or via a decrease in production of anti-oxidant defense. Previous 
studies have reported a decrease in the activity of plasma glutathione peroxidase in 
claudicants compared to controls (Edwards At Fau - Blann et al.).  
 
Both arterial bypass surgery and angioplasty have been shown to reduce the exercise induced 
systemic inflammatory response associated with claudication (Hickey et al., 1990, Lewis et 
al., 2001, Husmann et al., 2008). Previously, hyper-homocyteinaemia has been purported as a 
potential mechanistic factor in the development of endothelial dysfunction and progression of 
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atherosclerosis. Recently data has emerged suggesting that antioxidants can reverse the 
systemic endothelial dysfunction seen in patients with coronary artery disease independently 
of homocyteine levels (Doshi et al., 2001, Bennett-Richards et al., 2002). A randomized 
controlled trial in claudicants has also demonstrated that vitamin C administration abolishes 
the exercised induced decrease in endothelial function caused by maximal exercise (Silvestro 
et al., 2002a). Endothelial dysfunction has previously been through to be largely related to 
nitric oxide availability (Joannides et al., 1995), however more recently it has been 
demonstrated that NOX-2 (catalytic subunit of NADPH oxidase) up-regulation is responsible 
for oxidative stress mediated endothelial dysfunction in claudicants. This effect was reversed 
by the administration of antioxidants (Loffredo et al., 2007). Increased levels of NOX-2 have 
been associated with increased anterograde/ retrograde and oscillatory shear stress across 
vascular endothelium, again an effect attenuated by antioxidants (Hwang et al., 2003, De 
Keulenaer et al., 1998). 
 
A possible overarching mechanism arises where a low resting oxidative stress relates to an 
attenuated ability to respond to the increased oxidative burden associated with maximal 
exercise. This ability may be mediated by NOS up-regulation (Lauer et al., 2005). Increasing 
production of reactive oxygen species leads to the oxidation of BH4 to BH3 radicals (Laursen 
et al., 2001, Landmesser et al., 2003). Low BH4 bioavailability uncouples eNOS thereby 
reducing eNOS function and augmenting eNOS superoxide production (Forstermann and 
Munzel, 2006). Others have reported that hydrogen peroxide increases the expression and 
activity of eNOS in endothelial cells and that increased eNOS activity is thought to be an 
acute cellular adaptation to an increase in oxidant stress(Suvorava and Kojda, 2009). This 
group also report that basal levels of hydrogen peroxide are required to produce essential 
vascular tone. A possible theoretical framework would involve ‘vulnerable’ claudicants not 
upregulating some anti-oxidant defeence mechanism by lack of basal hydrogen peroxide 
release. 
 
Recently much interest has been shown in the anti-oxidant response proteins including haem 
oxygenase-1 (Balla et al., 2003). Up regulation of haem oxygenase 1 has been seen in the 
endothelium in the early stage of progression of atherosclerotic lesions (Juckett et al., 1995) 
(Wang et al., 1998). Progression of atherosclerosis in those who develop worsening 
peripheral vascular disease may be a consequence of inadequacy or failure to up-regulate 
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these ant-oxidant/ anti-inflammatory mechanisms (Bauer et al., 2003). Upregulation of anti-
oxidant response proteins may be ameriliorate the effects of reactive oxygen species toxicity 
 
A previous study has shown that pre and post exercise endothelial dysfunction induced by 
maximal treadmill exercise improved following six weeks of supervised exercise (Andreozzi 
et al., 2007a). However there is as yet no data regarding end organ injury nor any 
consideration to the phenotypically distinct group identified in this study. 
 
According to Suvorava and Kojda repeated short terms bouts of oxidative stress may cause 
the up-regulation of anti-oxidant protein expression in the vascular wall eventually increasing 
its antioxidant capacity (Suvorava and Kojda, 2007). A case control study compared pro-
inflammatory cytokine levels in patients with moderate and severe intermittent claudication 
to healthy controls before and after exercise. This study demonstrated a rise in cytokine levels 
post exercise in all groups, also, most in the severe group and some in the moderate group 
exhibited a continued rise in cytokine levels in the resting period (Andreozzi et al., 2007b). 
This finding may support the notion that certain individuals may not be able to cope with 
increased oxidative stress and these people may be prone to worsening of atherosclerotic 
lesions. The previous dogma of treating claudication in five words “stop smoking and keep 
walking” (Housley) may not be the best management for all claudicants. Further phenotypic 
and genotypic characterization is required. 
 
Monocytes-macrohphages are crucial in the pathogensis of atherosclerosis (Mantovani et al., 
2004, Shalhoub et al., 2011). It has been reported that c-reactive peptide, a marker of 
systemic inflammation, is associated with a polarisation towards the pro-inflammatory (M1) 
monocyte phenotype (Devaraj and Jialal, 2011). Future work may investigate the association 
between oxidative stress, monocyte-macrophage phenotype and iscaemia reperfusion injury. 
 
With the increased uptake of ‘Best Medical Therapy’ for cardiovascular disease in patients 
with atherosclerosis, there seems to have been a decline in incidence of ischaemic strokes 
(Naylor, 2012). This reduction in incidence is thought to be mediated by plaque stabilisation. 
The effect of statins is thought to be modulated by anti-palatelet use in a complex manner (Ye 
et al., 2010). In a rat model, statins have been shown to increase tissue levels of the 
cytoprotective Haemoxygenase 1 and reduce renal ischaemia-reperfusion injury by 
upregulated production in infiltrating monocytes (Gueler et al., 2007). Although it is beyond 
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the scope of this study to formally investigate, there are similar prevalances of antiplatelet 
agent and statin usage in claudicants who suffered a NAG/ Creatinine ratio rise compated to 
those without a rise (Table 15). It has been shown that in a rat model, statin administration 
reduced the degree of renal ischaemia reperfusion injury following renal artery clipping 
(Gueler et al., 2002). However, it has been demonstrated that administration of either lipo- or 
hydro-philic statins do not modulate the effect of ischaemia reperfusion injury on brachial 
artery FMD in healthy volunteers (Wouters et al., 2012). Of additional note, reduction in 
infarct size may well be associated with short term use, and these protective effects may be 
lost in chronic use (Schulz, 2005). 
 
The identification of two distinct phenotypes in patietns with intermitted claudication offers a 
new prospect deciphering the complex associations between ischaemia-reperfusion injury, 
systemic cytokine release, endothelial function, monocyte-macrophage phenotype and end 
organ injury. Whole genome analysis using high throughput technology may help in 
revealing insight into this complex interplay(Fülöp and Falus, 2004). At the heart of the 
matter, so to speak, is the implication that repeated bouts of ischaemia-reperfusion are 
responsible for end organ injury. The data presented in this study support the setting up of a 
trial to establish if revascularisation of ‘vulnerable’ patients with intermitted claudication is 
protective against ischaemia-reperfusion mediated end organ injury and mortality. 
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FIGURE 5-1. SCHEMA DESSCRIBING POSSIBLE ROLE OF PRE-EXERCISE OXIDATIVE STRESS CAUSING 
ALTERATION IN CHANGE IN ENDOTHELIAL FUNCTION AND OXIDATIVE STRESS POST EXERCISE AND 
RESULTING IN INCREASED ACUTE KIDNEY INJURY. 
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7. Appendix 
 
Appendix A: ELISA technique for plasma level of MCP-1  
Preparation before entering step 1:  
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 a all agent from the refrigerator were bring to be at room 
temperature(RT) as well as sample plasma was bring 
from the freezer to be thawing at RT. 
 
 b buffer were prepared:  
  b1 Coating buffer 1.59 g Na2CO3, 2.93 g NaCO3, 
0.2 g NaN3 making up to 1 litre distilled water 
(dH2O) store a 40C for 2 weeks 
 
  b2 Washing buffer PBS (pH7.4): 8 g NaCl, 0.2 g 
KH2PO4, 2.9 g NaHPO4. 12H2O, and 0.2 g KCl 
making up to 1 litre distilled water (dH2O) 
 
  b3 Washing buffer PBS-T (PBS-Tween 20): 0.5 ml 
of tween 20 to 1 litre of prepared PBS as 
described above 
 
 c Sets of cytokines standard (TNF-α standard, IL-6 
standard and IL-10 standard) were prepared at an interval 
of concentration as a control series known concentration 
at 0---0.156---0.312---0.625---1.25---2.5---5---10---15---
25---50---100 pg/ml 
 
 d Mapping well plate to identify what each well will 
contain 
 
Step 1 Capture antibody  
 a monoclonal antibody specific to each studied cytokines 
was applied for pre-coating micro plate following the 
plate map  
 
 b all the microplate was left at RT for half an hour  
 c all the microplate was inverted to pour out its content  
Step 2 Cytokine adding  
 a 100 µl of standard and samples containing the studies 
cytokines were pipetted into each well by the 
concentration following to the previous mark of platemap 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
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 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by buffer six times to remove 
the unbounds 
 
Step 3 Enzyme-conjugated antibody adding  
 a 200 µl of Enzyme-conjugated antibody [Alkaline 
phosphatase (ALP) (enzyme)=cytokine specific 
polyclonal antibody (conjugate)] was add to each well 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
 
 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by buffer six times to remove 
the unbounds 
 
Step 4 Color development   
 a 50 µl of Substrate (Naphthyl phosphate) was 
immediately added to each well in order to release of 
colorless Naphthol and Phosphoric Acid (H3PO4) 
 
 b The microplates were cover with cling film and left on 
the bench to incubate at room temperature for one hour 
 
 c 50 µl of Amplifier solution (Nitryl phenyl phosphate) 
was added to make color 
 
 d The microplates were cover with cling film and left on 
the bench to incubate at room temperature for 10 minutes 
 
 e Stop solution was added  
     
Step 5 Spectrophotometrical calibration  
  The purple solution in the well-plate were calibrated by 
filter set at wavelength 405 nm and between 492 and 620 
nm and read by spectrophotometer. The result of 
cytokines concentration was reported in unit of pg/ml.  
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Appendix B: ELISA technique of Urine concentration of NAG 
 
Preparation before entering step 1:  
 a all agent from the refrigerator were bring to be at room 
temperature(RT) as well as sample plasma was bring 
from the freezer to be thawing at RT. 
 
 b buffer were prepared:   
  b1 Coating buffer 1.59 g Na2CO3, 2.93 g NaCO3, 
0.2 g NaN3 making up to 1 litre distilled water 
(dH2O) store a 40C for 2 weeks 
 
  b2 Incubation buffer: a mixture of citric acid 
monohydrate and dipotassium hydrogen 
phosphate 
 
  b3 Washing buffer PBS (pH7.4): 8 g NaCl, 0.2 g 
KH2PO4, 2.9 g NaHPO4. 12H2O, and 0.2 g KCl 
making up to 1 litre distilled water (dH2O) and 
/ or  
 
  b4 Washing buffer PBS-T (PBS-Tween 20): 0.5 
ml of tween 20 to 1 litre of prepared PBS as 
described above 
 
  b5 Color development buffer: a solution of 
potassium carbonate and potassium hydrogen 
carbonate at pH 9.5 (alkaline buffer or 
amplifier solution) 
 
 c Sets of sodio-m-cresolsulfonphthaleinyl N-acetyl-β-D-
glucosaminase standard were prepared at an interval of 
concentration as a control series known concentration at 
0---0.156---0.312---0.625---1.25---2.5---5---10---15---
25---50---100---200 pg/ml 
 
 d Mapping well plate to identify what each well will 
contain 
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Step 1 Cytokine adding  
 a 100 µl of standard and samples containing the studied    
sodio-m-cresolsulfonphthaleinyl-N-acetyl-β-D-
glucosaminase were pipetted into each well by the 
concentration following to the previous mark of 
platemap 
 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
 
 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by washing buffer six times to 
remove the unbounds 
 
Step 2 Enzyme-conjugated antibody adding  
 a 200 µl of Enzyme-conjugated antibody [sodio-m-
cresolsulfonphthaleinyl N-acetyl-β-D-glucosaminase 
(enzyme)=specific polyclonal antibody of NAG 
(conjugate)] was added to each well 
 
 b The microplates were cover with cling film and left on 
the moving horizontal orbital shaker to incubate at room 
temperature for two hours 
 
 c Following incubation, all the microplate was inverted to 
pour out its content 
 
 d all the well were washed by buffer six times to remove 
the unbounds 
 
Step 3 Color development   
 a 50 µl of substrate [2-methoxy-4-(2’-nitrovinyl) phenyl-
2acentamido-2-deoxy-β-D-glucopyranoside (MNP-Glc 
NAC) in 0.005M HCL (yellow solution)] was 
immediately added to each well in order to release of 2-
Methoxy-4(2’nitrovinyl)-phenol 
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 b The microplates were cover with cling film and left on 
the bench to incubate at room temperature for one hour 
 
 c 50 µl of alkaline buffer (amplifier solution) was added to 
make  red color 
 
 d The microplates were cover with cling film and left on 
the bench to incubate at room temperature for 10 minutes 
 
 e Stop solution was added  
    
    
Step 4 Spectrophotometrical calibration  
  The intensity of red color was measured by 
spectrophotometer at 505 nm wavelength 
 
     
Factoring with creatinine concentration  
 a Urine creatinine concentration is measured by using 
automated urinalysis machine 
 
 b Each value of urine NAG obtained from step 4 needs to 
be factored with the concentration of creatinine since 
each subject has produced a different amount of urine 
volume at the time of collection. 
 
 c The unit of urine NAG is then presented as µmol / mMol 
creatinine 
 
 
 
 
 
 
 
Appendix C: FORT test for plasma level of free radicals  
Preparation before entering step 1:  
 a 20µl of capillary blood or venous blood was drawn up 
into a heparinized capillary tube. 
 
 b Reagents:  
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  R1 chromogen  
  R2 pH 5.0 buffer solution and stabilizer.  
 c Blood was stored on ice after phlebotomy and all tests 
were completed within one hour of taking samples. R1 
and R2 were stored at room temperature in foil blister 
pack as per manufacturers instructions. 
 
 Test procedure  
 a Place the capillary tube with the whole blood sample 
(20µl) into the FORT R2 reagent tube. 
 
 b Gently rock up and down a few times until the capillary 
has been emptied of the blood. 
 
 c Pour the contents into the FORT R1 reagent cuvette and 
rock gently for a matter of seconds. 
 
 d Centrifuge for 1 minute at approx. 3500rpm1. Once the 
centrifugation is over, make sure that the supernatant is 
clear. 
 
 e Place the activated cuvette into the reading cell and 
testing begins automatically. The result is available after 
6 minutes. 
 
 
Appendix D: FORD test for plasma level of antioxidants 
 
 
Preparation before entering step 1:  
 a 50µl of capillary blood or venous blood was drawn up 
into a heparinized capillary tube. 
 
 b Reagents:  
  S1 Hyperosmolar buffer  
  S2 pH 5.2 acetate buffer.  
  S3 Iron solution  
  C1 chromogen.  
 c Blood was stored on ice after phlebotomy and all tests 
were completed within one hour of taking samples. 
Reagents were stored at room temperature in foil blister 
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pack as per manufacturers instructions. 
 Test procedure  
 a Pour the content of the S2 (BLUE labeled tube) into a 
new C1 square cuvette. 
 
 b Add 50µl of the S3 reagent using the pipette 
supplied1; close the cap tightly and rock gently until the 
reagent has dissolved completely. Place the cuvette into 
the reading cell. The first reading is performed after 4 
minutes. 
 
 c In the meantime, place the collected blood (50µl) into the 
S1 reagent tube (WHITE tube) and gently rock up and 
down a few times. 
 
 d Centrifuge for 1 minute at approx. 3500rpm to obtain the 
supernatant. 
 
 e At the end of the phase 2, remove the cuvette and pipette 
50µl of the supernatant sample twice (therefore 100µl) 
using the pipette supplied. 
 
 f Place the activated cuvette into the reading cell for the 
second reading. The result is available after 2 minutes. 
 
 
 
 
 
 
 
 
Appendix E: Demographic data for individual participants 
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 Age Sex Height 
(m) 
Weight 
(kg) 
BMI 
(kg/m
2) 
Blood 
pressure 
(mmHg) 
Pulse 
(beats 
per 
minute) 
High 
BP 
IHD DM High 
cholesterol 
Smoker Medication 
1 80 M 
1.81 91 27.8 136/67 68 Yes No No Yes Ex 
Aspirin ,Lansoprazole, Tamsulosin, , Atorvastatin, Finasteride, 
Amlodipine, Irbesartan 
2 84 F 1.5 54 24 128/78 72 Yes No No Yes Yes Aspirin, Spiriva inhaler, salbutamol inhaler, simvastatin 
3 80 M 1.8 68 21 138/64 60 No No No No No Aspirin, Tolterodine 
4 80 F 1.55 67 27.9 187/96 68 Yes Yes No Yes No Aspirin,Clopidogrel,simvastatin, bisoprolol 
5 69 M 1.75 110 35.9 142/80 83 Yes Yes No Yes No Aspirin , Simvastatin 
6 57 F 1.58 68 27.2 171/73 73 Yes No No No ex Aspirin, Atorvastatin, ramipril 
7 71 F 
1.53 61 26.1 158/60 78 Yes No Yes Yes No 
Aspirin , simvastatin, Metformin, , Insulin, Gliclazide, 
Enalapril, Amlodipine, and Bendrofluazide 
8 78 M 1.8 81 25 148/76 53 No Yes No Yes ex Aspirin, Atovastin, omeprazole and Atenolol 
9 61 F 1.62 117 44.6 130/80 62 No No Yes No No Amiodarone, Warfarin 
10 64 F 1.72 70 23.7 114/70 72 No No No Yes Ex Simvastatin 
11 65 M 1.75 95 31 120/72 104 Yes No Yes No No Metformin, Ramipril 
12 66 M 1.7 87 30.1 145/91 94 No No No No ex None 
13 66 F 1.69 55 19.2 159/77 55 Yes Yes No Yes No Aspirin , Omeprazole, Carvedilol,  Rosuvastatin 
14 83 M 1.85 80 23.4 135/87 111 Yes No No Yes Yes Enalapril, Cilostasol 
15 55 M 1.76 75 24.2 111/78 88 Yes No No Yes Ex Aspirin , Amlodipine, Pravastatin 
16 76 F 
1.55 64 26.6 165/72 84 Yes No Yes Yes No 
Bendrofluazide, Simvastatin, Irbesartan, Metformin, Insulin, 
Omeprazole, Ursodeoxycholic acid 
17 73 M 1.68 62 22 166/77 101 Yes No Yes No Yes Bendrofluazide 
18 72 F 1.53 70 29.9 128/78 78 Yes Yes No No Ex Aspirin , Clopidogrel and simvastatin 
19 66 M 1.72 100 33.8 142/72 78 No Yes Yes Yes Ex  Metformin, Simvastatin 
20 81 M 1.62 62 23.6 173/76 89 Yes No No Yes Ex Aspirin , Simvastatin, Quinine, Bendrofluazide 
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